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An instrumental aspect of cancer progression is the acquired deregulation of the 
cellular processes that regulate growth and proliferation. Most of these processes are, at 
some level, controlled by a kinase-catalyzed change in the phosphorylation status of key 
signaling intermediates. Given the role of kinases in regulating every key cellular process, 
kinase inhibitors have emerged as an important class of anticancer therapeutics. 
However, as our knowledge of the phosphoproteome grows, our understanding of the 
identified phosphorylation sites remains limited. However, the ability to fully deconvolute 
kinase signaling networks is hampered by the transient nature of kinase-substrate 
interactions, a property that renders traditional methods of identifying novel protein-
protein interactions ineffectual. Thus, new tools are needed with which to identify kinases 
that act on phosphorylation sites known to contribute to the pathophysiology of cancer.  
Cap-dependent translation (CDT) is a critical cellular process that enables the 
expression of mRNA transcripts encoding for growth and survival proteins, many of which 
contribute to malignancy. Consequently, regulation of CDT is typically maintained at 
different levels by numerous signaling cascades. However, these pathways ultimately 
converge to alter the phosphorylation status of the translational suppressor eukaryotic 
initiation factor 4E binding protein (4E-BP1). 4E-BP1 serves as a gate-keeper of CDT by 
competing with translation initiation factors for binding to the m7G-cap-binding protein 
eIF4E. In cancers, oncogenic signaling results in hyperphosphorylation of 4E-BP1, 
eliminating the negative repression on eIF4E, leading to constitutive CDT. This has 
provided rationale for the development of mechanistic Target Of Rapamycin (mTOR) 
inhibitors as cancer therapeutics, as mTOR complex 1 (mTORC1) is thought to be 
responsible for the ultimate regulation of 4E-BP1 phosphorylation. However, resistance 
to allosteric and active site mTOR inhibitors is a hallmark of many cancers, which has 
decreased the clinical efficacy of mTOR-targeted therapeutics. Moreover, 4E-BP1 
contains several uncharacterized phosphorylation sites, the function and regulation of 
which are unknown. These findings have resulted in speculation about the possibility of 
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uncharacterized 4E-BP1 kinases that promote 4E-BP1 hyperphosphorylation, CDT, and 
tumorigenesis.  
To facilitate the identification of kinases capable of acting on phosphorylation sites 
of interest, a kinase crosslinking assay (termed PhAXA) was developed. When coupled 
to LC-MS/MS analysis, PhAXA yields high confidence kinase-substrate interactions with 
phosphosite specificity. Proof-of-concept studies demonstrated the broad applicability of 
this approach by validating known relationships for three distinct kinase-substrate pairs. 
This chemoproteomic pipeline was then used to uncover the role of CDK4 in regulating 
4E-BP1 phosphorylation. Dissection of this relationship revealed that CDK4 activity 
maintains CDT under conditions of mTORC1 inhibition in CDK4/6 inhibitor-sensitive cell 
lines. Moreover, Ser101, an orphan, understudied 4E-BP1 phosphorylation site, was 
identified and validated as a CDK4 substrate. Evaluation of this event provided a 
mechanism by which inhibition of CDK4 regulates translation of the oncoprotein c-Myc, 
which drives a host of known cancers. The discovery of this signaling axis has uncovered 
a novel function of clinically approved CDK4/6 inhibitors, and sheds light on the 
mechanism by which these drugs synergize with mTORC1-targeted therapies. The 
successful implementation of this approach to uncover new biology should result in wide-
spread adaptation of the PhAXA platform for elucidating novel drug targets for the 
treatment of cancers and other kinase-driven diseases. 
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Chapter 1  
  
Kinases and Activity Based Probes 
 
 
1.1  Abstract 
 Kinase-catalyzed addition of a phosphate to a substrate serine, threonine or tyrosine 
is the most ubiquitous post-translational modification in eukaryotes, serving as a robust 
mechanism for intracellular information transfer. Aberrant kinase signaling contributes to 
the pathophysiology of many diseases such as cancer, lung fibrosis and rheumatoid 
disorders.1-3 However, despite the important role protein phosphorylation plays in 
mediating important cellular processes, most of identified phosphorylation sites remain 
uncharacterized. Elucidation of the kinases responsible for mediating the modification of 
clinically relevant phosphorylation sites would lead to new targets for modulation with 
therapeutics. 
Because of the transient nature of kinase-substrate interactions, traditional affinity 
purification followed by mass spectrometry approaches for mapping protein-protein 
interactions have been ineffective for solving this problem.4,5 Thus, tools such as yeast-
two hybrid assays, promiscuous crosslinkers, and proximity labeling techniques have 
been implemented to directly identify novel substrates for a kinase-of-interest; however, 
these methods provide little information about phospho-site specificity.6-12 Identifying 
kinases capable of phosphorylating a specific residue has proven difficult; very few 
methods are available to answer this question and each has considerable limitations.13 
Given the limitations of currently available technology, new tools are needed to assign 
kinases to site-specific phosphorylation sites, allowing for a better understanding of the 
interplay between signaling networks and the identification of therapeutically relevant 
protein targets. 
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1.2  Signal Transduction, Kinases and the Phosphoproteome 
 Cells are capable of responding to a diverse set of environmental stimuli, including 
nutrient availability, stress and a variety of small molecule effectors, using many different 
methods of signal transduction. These extracellular stimuli are recognized by intra- or 
extra-cellular receptors, which activate or inactivate signaling cascades required to elicit 
the appropriate cellular response. Following activation of a surface receptor, the signal is 
transduced through an ordered list of intermediary proteins until an end result, such as 
increased/decreased translation or transcription, is achieved. These intermediary 
proteins propagate and amplify the appropriate signal upon modulation of their activity by 
post-translational modifications (PTMs). PTMs that modify protein activity include 
phosphorylation, glycosylation, hydroxylation, acetylation, lipidation and ubiquitylation14 
(Table 1.1). Accounting for these modifications yields an estimated 1,000,000 distinct 
proteins in the human proteome,15 each of which may perform a diverse array of 
functions.  
Modification Type Amino Acid Enzyme Class Review 
Phosphorylation Ser/Thr/Tyr Kinase 16 
Glycosylation Asn/Ser/Thr Glycosidase & Glycosyltransferase 
17 
Acetylation Lys/Nterm* Acetyltransferase 18 
Amidation Cterm**  19 
Hydroxylation Pro/Asn Hydroxylase 20 
Methylation Lys/Arg Methyltransferase 21 
Lipidation Cys/N-Gly*** Various**** 22 
 
Table 1.1 | Common Post-Translational Modifications. A table listing the seven most common14 PTMs 
in eukaryotes. *Nterm = N-terminus of protein. **Cterm = Carboxy-terminus of protein. *** N-Gly = N-
terminal glycine (after cleavage of initiator methionine. ****Lipidation in this case groups palmitoylation, 
farnesylation, geranylgeranylation, myristoylation, and acylation. Therefore, many enzymes are responsible 
for these PTMs.  
 
  Phosphorylation is the kinase-catalyzed transfer of a phosphate from ATP to a 
substrate Serine, Threonine or Tyrosine, and constitutes the most ubiquitous method of 
intracellular signal transduction, with one-third of the human proteome containing at least 
one phosphorylation site. Recent estimates of the human proteome suggest that there 
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are ~20,000 protein-coding genes,23,24 the protein products of which contain at least 
146,306 identified phosphorylation sites.25-27 When accounting for in silico predictions, 
the human phosphoproteome is expanded to over 500,000 phosphorylation sites, each 
of which is mediated by one of the 518 human kinases.27,28 However, only ~7,000 of these 
sites have been assessed experimentally,25 leaving a large gap in our knowledge of 




Figure 1.1 | Annotation of the Human Phosphoproteome 
 
The explosion in our knowledge of the phosphoproteome can be directly linked to 
advances in mass-spectrometry based phosphoproteomics. (Figure 1.2) While these 
experiments are capable of identifying tens of thousands of phosphorylation sites in a 
single run, they provide very little information about function and no value as far as kinase 
assignment. This in-depth examination of the human phosphoproteome has far outpaced 
the ability to annotate the kinases that mediate these PTMs, limiting the utility of this influx 
of data.29 However, the field of phosphoproteomics is uniquely positioned for identifying 
phosphorylation-site-biomarkers that correlate with phenotypes such as drug resistance30 
or an increased propensity for metastasis.31 This in-depth analysis of the 
phosphoproteome can aid in understanding viable combination treatments for cancer 
therapy,32 though only if the identified phospho-biomarkers can be confidently assigned 
to a known kinase. Because phosphorylation can elicit dramatic effects on a substrate, 
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and many substrates affect numerous cellular processes that are implicated in disease, 
understanding the kinases that regulate each site individually is critically important in 
piecing together signaling networks.  
 
 
Figure 1.2 | Phosphoproteomics Workflow. A typical phosphoproteomics workflow is shown. Proteins 
from different types samples (cells, tissue, etc) are collected, then digested into peptides using a protease 
such as trypsin. Those peptides harboring a phosphate group are isolated by affinity purification (often 
titanium dioxide colums) and analysed by LC-MS/MS. After assignment of MS2 spectra, phosphopeptides 
are quantified and differentially regulated sites are identified.33 
 
1.3  Kinases and Kinase Inhibitors in the Treatment of Cancer 
 Kinases regulate every process in cell biology, from growth and proliferation to 
apoptosis and metabolism. As such, numerous kinases have been implicated in 
facilitating uncontrolled proliferation in diseases such as cancer and pulmonary 
fibrosis.2,3,34 Indeed, a systematic evaluation of cancer-associated genetic mutations 
identified kinases as the most over-represented family in the dataset.35 Similar 
observations have been made upon consideration of gene overexpression and  
amplification.36 These findings, along with the unprecedented success of Imatinib, the 
second FDA approved, small-molecule kinase inhibitor,37 led to a burgeoning field of 
kinase-targeted therapeutics for treating cancers.34 Since Imatinib first gained FDA 
approval in 2001,38 46 small-molecule kinase inhibitors have been approved for use in 
oncology, 36 of which have been approved over the last 8 years (2011-2018). (Figure 
1.3) This number does not include monoclonal antibody inhibitors such as Cetuximab and 
Trastuzumab, which target EGFR and ERBB2 respectively.39  
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Figure 1.3 | FDA-Approved Small-Molecule Kinase Inhibitors Over the Years. Sirolimus, the first FDA-
approved kinase inhibitor, gained approval in 1999 as an immunosuppressant for preventing organ rejection 
following kidney transplant. Aside from Sirolimus, Baricitinib40 (rheumatoid arthritis), Netarsudil41 
(glaucoma), Fostamatinib42 (thrombocytopenia), Nintedanib43 (pulmonary fibrosis) and Tofacitinib44 
(rheumatoid arthritis) are the only FDA-approved kinase inhibitors used for a non-cancer indication.  
 
While these inhibitors have realized success in clinical oncology, the overall impact 
of small molecule kinase inhibitors is in question, in part due to emerging resistance.45,46 
Applying selective pressure to cells in the form of chronic kinase inhibition induces 
resistance in the form of acquired gatekeeper mutations,47 or via  hyperactivation of 
compensatory pathways.45 Strategies to overcome the former include development of 
type III, allosteric kinase inhibitors such as the MEK1/2 inhibitor Trametinib,48,49 or by 
pursuing molecules that are not reliant upon the gatekeeper residue.50 Identifying 
pathways that circumvent targeted kinase inhibitors is a question of uncovering and 
dissecting novel signaling paradigms, which requires a diverse array of biological and 
chemical tools. However, by achieving a better understanding of fundamental cancer 
biology in the context of kinase inhibitor resistance, new combination therapies can be 
pursued that lead to a more robust clinical outcome.51 
 
1.4  Current Methods for Uncovering Protein-Protein Interactions 
 Protein-protein interactions (PPIs) mediate the vast majority of biological 
processes including many that are involved in initiating and/or maintaining malignancy.52 
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As such, many techniques have been developed by which to elucidate binding partners 
for a protein of interest. One of the most well-established methods used to accomplish 
this is affinity purification coupled to mass spectrometry (AP-MS) (Figure 1.4). AP-MS 
experiments typically utilize an antibody raised against an epitope fused to the bait protein 
of interest, and cells expressing this fusion protein are lysed and passed over antibody-
conjugated resin. The bait protein is retained on the resin along with binding partners and 
non-specific interactors, while non-interacting partners are washed away. These proteins 
are then analyzed by LC-MS/MS to come up with a candidate list of bait-interacting protein 
partners. This technique has been successfully used to uncover a tremendous amount of 
biologically relevant PPIs, though identifying kinases that act on a substrate of interest 
using an AP-MS approach is difficult given the transient nature of kinase-substrate 
interactions. Indeed, one published analysis of ERK2 kinases using AP-MS failed to 
identify MAPK/ERK Kinase 1 or 2 (MEK1/2), the kinase known to phosphorylate ERK2.53 
Moreover, any kinase-substrate identification uncovered using affinity purification 
methods would provide no information regarding phosphorylation site specificity. As a 
result of this limitations, basic AP-MS techniques such as IP-MS (Figure 1.4) have largely 
failed to aid in the deconvolution of kinase mediated signaling events.  
 
 
Figure 1.4 | Affinity Purification and Mass Spectrometry. A scheme for Immunoprecipitation coupled to 
Mass Spectrometry (IP-MS) is shown. Resin conjugated with antibodies specific for an affinity tag is used 
to isolate proteins bound to a bait protein of interest while non-interacting proteins are removed by washing. 
These proteins are digested into peptides using a protease (typically trypsin), separated by liquid 
chromatography (LC) and analyzed by tandem mass spectrometry (MS/MS). These MS2 spectra are 
matched to known peptide sequences using database searching tools, which results in protein identification.  
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 However, given the importance of phosphorylation in many diseases, and the 
emergence of clinically successful kinase inhibitors, significant effort has been put into 
illuminating these signaling events via the development of novel methodologies. Proximity 
labeling (PL) has gained significant traction in recent years, with the advent of BioID and 
BioID2.11,54-57 (Figure 1.5A) These methods rely on the generation of a fusion protein 
between an promiscuous biotin ligase enzyme that generates biotinoyl-5’-Adenylate 
(B5A). (Figure 1.5B) This highly amine-reactive B5A diffuses away from the bait-ligase 
fusion protein, labeling surface-exposed lysines on proximal proteins with a biotin moiety. 
The biotinylated proteins are then isolated using streptavidin-conjugated affinity resin, and 
subsequently identified by LC-MS/MS. The proteins identified by this method should be 
largely comprised of proteins that interact with the bait, though proximal, non-interacting 
proteins are also isolated.  
The two biggest benefits of this technology are 1) The ability to probe for 
interactions within live cells without disrupting the cellular organization, which is a 
requirement of AP-MS assays 2) The ability to capture transient interactions such as 
those between a kinase and a substrate. However, the drawbacks of PL methods include 
1) Slow labeling rates with BioID (on the order of 18 hours), which limits the ability of this 
method to study discreet cellular signaling events. However, newer PL enzymes like 
Apex,58,59 which generates a biotinyl radical instead of B5A, and TurboID60 have been 
developed to work around this issue. 2) Isolation of thousands of proteins necessitates 
up-front fractionation of samples before LC-MS/MS analysis, which increases instrument 
time. 3) The need to engineer cell lines that stably express the required fusion protein 
increases the time required to set up this assay. 4) The size of the fusion protein, between 
30-45 kDa, may influence (positively or negatively) the PPIs engaged in by the bait 
protein. 5) No information regarding phosphorylation site specificity is garnered by these 
techniques. Despite these limitations, PL assays have successfully uncovered a handful 




Figure 1.5 | Proximity Labeling Techniques Using Promiscuous Biotin Ligases. A) Cells expressing 
a bait-proximity labeling (PL) enzyme, or a no bait control, are treated with excess biotin to induce 
generation of biotinoyl-5’-Adenylate (B5A). Diffusion of B5A results in labeling of lysine residues on proximal 
proteins, allowing for purification using streptavidin resin. Bound proteins are then identified by LC-MS/MS 
based proteomics. 
 
1.5 Chemical Probes for Kinase Discovery 
 AP-MS and PL approaches are useful for discovering new biology through 
uncovering novel PPIs. However, as each of these methods has significant drawbacks in 
the realm of uncovering novel kinase-substrate interactions, new technologies are 
required to fill this unmet need.62 One unique approach to mapping kinase signaling 
networks utilizes a bump-in-hole strategy, whereby a kinase of interest is modified to 
accommodate a modified ATP substrate, commonly N6-(benzyl)ATP-!-S, which is a poor 
substrate for endogenous kinases.63 (Table 1.2A) In this approach, the N6-(benzyl)ATP-
!-S probe is added to cell lysate along with recombinant analog-sensitive kinase (as-
kinase), which facilitates transfer of a thiophosphate group to all direct substrates. These 
thiophosphorylated peptides are then isolated using iodoacetamide conjugated resin,64 
or p-nitrobenzyl mesylate (PNBM) along with antibodies specific for the alkylated 
phosphorothioate epitope.65,66 Mass-spec based proteomics is then used to identify the 
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direct as-kinase substrate peptides. This is an attractive approach to large-scale 
deconvolution of the phosphoproteome, as most kinases have bulky gatekeeper residues 
that, upon mutation to an amino acid with a smaller side-chain, can utilize one of several 
N6 modified ATP substrates.67 While these probes have been used to uncover novel 
kinase-substrate interactions,7,64 they are not useful when the goal is uncovering a kinase 
that phosphorylates a particular site of interest.   
 



























































































































































ATP-based photocrosslinkers have also explored for the purpose of interrogating 
the kinase-substrate interactome.68-71 (Table 1.2B and 1.2C) These photocrosslinking 
probes rely on kinase catalyzed transfer of the gamma-phosphate, along with the PEG-
linked photoreactive benzophenone or aryl azide, to the substrate. The kinase is then 
trapped on the “phosphorylated” bait by UV induced crosslinking, and the complex is 
isolated by affinity purification and proteins are identified by MS/MS. Initial experiments 
utilizing these probes provided proof-of-concept using recombinant protein kinase A 
(PKA) and a seven amino acid, biotinylated peptide pseudosubstrate.68 However, a 
negative control peptide lacking the substreate serine residue still exhibited 50% labeling 
relative to the true substrate peptide. This finding calls into question the specificity of this 
approach, and the ability of the assay to find phosphosite specific kinases. When this 
assay (termed K-CLASP) was applied to cell lysate, PKA was positively identified by 
MS/MS.68 However, no new biology was uncovered in this analysis, as the only other 
kinases enriched over the negative control samples were not relavent to the peptide 
substrate. A similar approach was then used to identify novel kinases using full-length 
p53 as a bait substrate.69 As this method (termed K-CLIP) uses the full length substrate 
instead of a consensus substrate motif, it likely cannot identify kinases with 
phosphorylation site specificity. K-CLIP analysis of p53 kinases resulted in positive 
identification of a new p53 kinase, MRCKb, though with very low abundance (1-3 PSMs) 
even in samples treated with 10 mM ATP-based photocrosslinker probe. However, this 
interaction was validated in vitro and in cells, though the exact site at which MRCKb 
phosphorylates p53 was not identified. 
K-CLIP is the first published method by which an ATP-based chemical probe has 
uncovered a novel kinase-substrate interaction. However, there are severe limitations to 
these aryl-azide (Table 1.2B) and benzophenone (Table 1.2C) photocrosslinker probes, 
including: 1) Many kinases cannot accommodate a bulky substitution on the gamma-
phosphate of ATP.72 Differential activity or ability of a kinase to utilize gamma phosphate 
functionalized ATP probes creates a biased survey of kinases capable of phosphorylating 
the bait. 2) Poor labeling efficiency of arylazides and benzophenones.73 Increased 
labeling efficiency is only achieved under conditions that also cause protein damage. 3) 
The propensity of these groups to promote nonspecific crosslinking, typically to highly 
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abundant proteins instead of low abundance kinases. 4) Many proteins exhibit high affinity 
for these molecules even without UV activation, which can mask the reactive group for 
proteins of interest and increase nonspecific pulldown.74 5) The kinase-catalyzed 
photocrosslinker labeling is not bait specific, and the phospho-crosslinker can diffuse 
away from the kinase of interest before applying UV light. It is therefore possible that 
identified kinases are not acting on the bait substrate of interest. However, one benefit of 
this method is the possibility of performing the reverse experiment, where a kinase of 
interest is isolated along with potential substrates. Though this has not yet been done, 
this flexibility is attractive for achieving better annotation of the phosphoproteome.  
To enable the unbiased quantification of kinases across several conditions, 
promiscuous ATP-based biotinylation probe was developed.75-78 (Table 1.2D) This acyl-
phosphate containing probes rely on a conserved lysine residue present in the active site 
of 98% of eukaryotic kinases, that normally coordinates the negative charge on the g-
phosphate of ATP.79 Upon docking within the active site of a kinase, the carbonyl on the 
Biotinoyl-ATP probe is positioned near this conserved lysine. The amine of the lysine side 
chain attacks the carbonyl from the ATP analog, forming an amide linked biotin and 
releaseing free ATP. The biotinylated kinases are then purified using streptavidin resin 
and identified by MS/MS. This probe, which can engage and facilitate the purification of 
approximately 240 kinases,75 has been commercialized by ActivX Biosciences for 
studying kinase inhibitor selectivity as part of the KiNativ platform.  
These studies utilizing acyl-phosphate ATP probes opened up the possibility of 
leveraging similar techniques to uncover novel kinase-substrate interactions. The first 
approach that took advantage of this reactivity required a two-step mechanism between 
the conserved lysine, a cysteine residue on the bait peptide in place of the phosphorylated 
Ser/Thr/Tyr, and a dialdehyde group present on the probe.80 (Table 1.2E) Proof-of-
concept studies with this system left much to be desired, as the labeling was proven to 
be very inefficient.81 However, a second generation of this crosslinker demonstrated much 
more favorable characteristics, and will be discussed further in Chapter 3.81 (Table 1.2F) 
Though these methods proved valueable conceptually, each method utilized a peptide 
pseudosubstrate for in vitro characterization, thus limiting the biological relevance of the 
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approach. Likely as a result of this, neither probe successfully uncovered novel biology, 
though they set the groundwork for successful experiments to be discussed in Chapter 3. 
 
1.6 Conclusions 
The human proteome is highly dynamic, with ~20,000 protein coding genes giving 
rise to over 1,000,000 distict proteins after accounting for alternate splicing and post 
translational modifications (PTMs). Phosphorylation is one of the most relevant PTMs in 
the context of cancer, highlighted by the clinical success of many kinase inhibitors. 
However, as mass spectrometry technologies improve the ability of scientists to identify 
clinically relevant phosphorylation sites, new tools are required to provide actionable 
information for subsequent development and clinical implementation of kinase inhibitors. 
The standard toolkit for elucidating protein-protein interactions has proven incapable of 
rising to this challenge, and lead to the development of kinase-directed chemoproteomic 
probes. Previous attempts at designing activity-based, phosphosite-specific probes for 
kinase identification have used two approaches: (1) Assays that utilize peptide substrates 
that poorly recapitulate the activity of the bait protein62,80,81 (2) Photoaffinity probes, which 
are inherently promiscuous and favor the identification of high abundance proteins, 
preventing the identification of low-abundance kinases.68,71 These techniques have 
largely been unable to live up to their billing; however, each method has proven valuable 
in the context of establishing proof-of-concept for ways by which to more effectively 
uncover kinase-substrate interactions.  
 












































































































































































































































































































Chapter 2  
  
4E-BP1 Biology: An Overview 
 
 
2.1  Abstract 
Cap-dependent translation (CDT) is a critical cellular process that enables the 
expression of mRNA transcripts encoding for growth and survival proteins. Consequently, 
under normal growth conditions, CDT is under tight regulation, primarily through alteration 
of the phosphorylation status of the eukaryotic initiation factor 4E binding protein (4E-
BP1). 4E-BP1 serves as a gate-keeper of CDT by competing with translation initiation 
factors for binding to the m7G-cap-binding protein eIF4E. Under mitogenic stimulation and 
high nutrient availability, 4E-BP1 becomes hyperphosphorylated, dissociates from eIF4E, 
and translation is initiated. In many cancers, this process becomes dysregulated 
conferring constitutive CDT, and thus, cell proliferation, due to increased phosphorylation 
of 4E-BP1. This has provided rationale for the development of mechanistic Target Of 
Rapamycin (mTOR) inhibitors as cancer therapeutics since mTOR complex 1 (mTORC1) 
is responsible for phosphorylation of four of the seven bona fide phosphorylation sites on 
4E-BP1. Yet, there is speculation about the exclusivity of these sites due to reports of 4E-
BP1 hyperphosphorylation in cells treated with allosteric and active site mTOR inhibitors. 
Additionally, at least three other residues are also phosphorylated in vivo although there 
is no consensus as to which kinases are responsible for these post-translational 
modifications. Identification of these kinases will uncover new targets for therapeutic 
intervention in patients with hyperphosphorylated 4E-BP1 and be invaluable in further 
elucidating the signaling intermediates involved in regulating CDT in cancer. 
 
2.2  Cap-Dependent Translation and 4E-BP1 
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Synthesis of new proteins in eukaryotes is a highly regulated, key step in gene 
expression, necessary for both cellular maintenance and proliferation. Eukaryotic protein 
translation can be divided into two distinct processes: 1) Cap-Dependent Translation 
(CDT) (Figure 2.1) and 2) Cap-Independent Translation. CDT refers to eIF4E-driven 
translation of mRNA transcripts via assembly of initiation factors around the 7-
methylguanosine (m7G) cap at the 5’ end of the transcript. Transcripts translated strictly 
via CDT are those encoding proteins important for growth, proliferation and survival, such 
as the cyclins, VEGF, c-myc, and HIF-1a among other proteins implicated in 
oncogenesis.1-5 (Table 2.1) Conversely, cap-independent translation is largely 
responsible for translating housekeeping genes via an internal ribosomal entry site (IRES) 
mediated initiation mechanism.6 
Transcript Protein Function 
Cyclin D1/2/3 Cell cycle progression (G1àS)7 
c-Myc Proliferation, Promotes Malignant Transformation8 
Ornithine Decarboxylase Synthesis of Polyamines9 
VEGF Promotes Angiogenesis10 
Bcl-2 Inhibits Apoptosis11 
FGF-2 Proliferation and Angiogenesis12 
Pim-1 Proliferation, Stabilization of MYC13 
 
Table 2.1 | mRNA Transcripts Regulated by Cap-Dependent Translation 
 
CDT is an anabolic cellular process that is divided into four distinct steps: initiation, 
elongation, termination and recycling, with initiation acting as the rate limiting step.14,15 As 
protein translation is the most energy-expensive cellular process,14-16 it is highly regulated 
at several levels by many different signaling pathways following activation by extracellular 
signals such as high nutrient availability and mitogens. These stimuli activate the 
PI3K/AKT/MAPK signaling cascades, which converge on mTOR, (Figure 2.1) a highly-
conserved protein kinase present in two functionally distinct complexes, mTOR complex 
1 (mTORC1) and 2 (mTORC2).17 mTORC1, a master regulator of cellular anabolism, is 
essential for integrating input from several discrete pathways to promote a wide range of 
processes, from protein synthesis and autophagy, to mitochondrial biogenesis and lipid 
metabolism.18-20 mTORC1 positively regulates protein translation via phosphorylation of 
two main substrates: the ribosomal protein kinase p70S6K, which is activated by 
	 22	
phosphorylation, and the translational gatekeeper protein 4E-BP1, which becomes 
inactivated by phosphorylation.21-24 ( Figure 2.1) 
Hyperphosphorylated 4E-BP1 has a weakened affinity for eIF4E, the 7-
methylguanosine (m7G) cap binding protein, allowing it to be outcompeted by the 
scaffolding protein eIF4G for a common binding site on eIF4E.25-32 Upon eIF4G binding, 
assembly of the eIF4F translation initiation complex is promoted, thus stimulating initiation 
of CDT.33-37 Therefore, this interplay between eIF4E and its binding partners 4E-BP1 and 
eIF4G is the key event in the regulation of CDT, one that has been the subject of many 
drug discovery efforts. 
 
Figure 2.1 | Pathways Leading to mTORC1 and CDT 
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2.3 CDT and 4E-BP1 Phosphorylation in Cancer 
mTOR hyperactivation has been identified in most human tumors (>70% of 
patients),38,39 resulting in uncontrolled cell growth and proliferation. As mTOR promotes 
CDT, and this process facilitates the expression of proteins implicated in oncogenesis, 
the potential ramifications of dysregulated CDT in cancer are clear.22 It is therefore 
unsurprising that many cancers also show hallmarks of deregulated CDT.34,40 Through 
in-depth analysis of mTOR-driven cancer dependencies, CDT (via 4E-BP1 
hyperphosphorylation) has emerged as a principle mechanism by which oncogenic 
mTORC1 signaling promotes malignant transformation.5,41-44 As such, phosphorylated 
4E-BP1 has been implicated as a biomarker for interpreting the severity and 
aggressiveness of colorectal, prostate, gastric, ovarian, breast, lung, and pancreatic 
cancers. Relatedly, analysis of patient samples has uncovered a positive correlation 
between hyperphosphorylated 4E-BP1 and poor prognosis.45-54 In the laboratory, ectopic 
delivery of hypophosphorylated 4E-BP1 has been shown to reduce in vivo tumor 
progression,55 and non-phosphorylatable 4E-BP1 mutants inhibit cell migration and 
colony formation in cancer cell lines.56,57 Thus, these studies point to the 
hyperphosphorylation of 4E-BP1 as a key event in cancer progression, and emphasize 
the importance of fully deconvoluting the mechanisms of 4E-BP1 inactivation in cancer.58 
 
2.4  Current Efforts for Targeting Cap-Dependent Translation 
 Given the role that aberrant CDT plays in many cancers, and the identification of this 
process as a “druggable addiction”,5,59 significant effort has been put forth to develop 
mTORC1 inhibitors as therapeutics. First generation mTORC1 inhibitors were derivatives 
of rapamycin, the rapalogs (everolimus and temsirolimus), (Figure 2.2) that inhibit 
mTORC1 activity by dissociating mTOR from Raptor, preventing the recruitment of 
substrates to mTOR. Currently, two rapalogs are approved for the treatment of cancer; 
however, these drugs are only modestly effective for treating most malignancies outside 
of renal cell carcinoma.60-63 Many explanations for the limited efficacy of these drugs have 
been postulated, including rapalog-induced AKT activation and increased MAPK 
signaling due to the release of S6K1-mediated negative feedback signaling (Figure 
2.1).38,64-79 Of particular significance, nearly all reports of rapalog resistance refer to the 
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inability of these drugs to prevent the phosphorylation of 4E-BP1, although inhibition of 
S6K1 phosphorylation is maintained.80-82 
 
Figure 2.2 | Clinically Approved Allosteric mTORC1 Inhibitors 
 
 These observed mechanisms of resistance have fueled the development of ATP-
competitive mTOR inhibitors (mTORKis) (Figure 2.3) capable of inhibiting both mTOR 
complexes, thereby completely inhibiting 4E-BP1 phosphorylation, and abrogating the 
negative feedback loops that drive AKT activation downstream of mTORC2.65 While this 
is generally the case, a high incidence of resistance to these new mTOR inhibitors is still 
observed.81,83 The mechanisms driving this phenotype include incomplete inhibition of 
4E-BP1,81,84 and the mTORKi induced reduction of 4E-BP1 levels in a Snail-dependent 
downregulation of 4E-BP1 transcription.85 Despite these observed patterns of resistance, 
mTORKis have achieved great success in preclinical models, as well as some clinical 
efficacy, for treating certain malignancies, including NSCLC, hepatocellular carcinoma 
and ER+ breast cancers.86-90 However, an in-depth analysis of the factors leading to this 
efficacy over other cancers has not been performed. Because of this lack of information, 
as well as the broad toxicity profiles observed,91,92 most clinical trials using mTORKis 
have failed to achieve desired endpoints.93,94 
 



























































 Interestingly, mTOR inhibitor resistance is particularly evident in patients and cell 
lines with activating mutations of the GTPase KRAS.64,81,95-97 Indeed, several studies 
have identified 4E-BP1 inactivation as a key step in initiating and maintaining a metastatic 
phenotype in KRAS mutant cancers, due to an altered translational program that 
promotes epithelial-to-mesenchymal transition.57,98,99 RAS and PI3K pathways cooperate 
to promote eIF4E-driven CDT in situations with intact mTORC1 signaling, as well as in 
situations where mTORC1 activity has been compromised by allosteric inhibitors. This 
signaling dynamic has provided rationale for the use dual PI3K-mTOR inhibitors (Figure 
2.4) as a therapeutic strategy in cancer.100-102 These agents have shown great potential 
in cell lines and other preclinical models due to their ability to inhibit mTORC1/2 signaling, 
reduce AKT/MAPK activity, and induce apoptosis.100,103,104 These inhibitors have a similar 
story to mTORKis; strong activity in preclinical models followed by limited clinical 
efficacy.100 A phase I study comparing two such inhibitors, Gedatolisib and PF-04691502, 
demonstrated only a 5% response rate in advanced cancers.105 However, due to poor 
tolerability, the desired maximal dose was not achieved. This limitation highlights the 
difficulties with targeting two critical signaling nodes, as the propensity for inducing 
significant toxicities dramatically increases with this class of inhibtors.106,107 
 
Figure 2.4 | Select Dual mTOR-PI3K Inhibitors Used in Clinical Trials 
 
 Another therapeutic strategy for inhibiting CDT has come in the form of directly 
modulating the eIF4E-4E-BP1 and eIF4E-eIF4G protein-protein interactions.108 (Figure 
2.5) 4EGI-1, which was identified by a fluorescence-polarization-based high-throughput 


























































compound disrupts CDT by allegedly stabilizing the interaction between eIF4E-4E-BP1, 
while inhibiting the eIF4E-eIF4G interaction, thus preventing eIF4F complex assembly.110 
However, with a reported KD of 25µM,109 this molecule is only useful as a tool compound 
for in vitro assays. 4E1RCat and 4E2RCat, two other small molecule inhibitors of eIF4E, 
were identified by another highthroughput screening campaign using a TR-FRET 
platform.108,111 4E1RCat showed in vivo activity against a Eµ-Myc model of lymphoma, 
while 4E2RCat effectively inhibited coronavirus replication in cells, albeit at 
concentrations in excess of 50µM. Other groups have also successfully to modulated 
CDT using peptide mimetics of 4E-BP1 and eIF4G.112-115 While these peptides can 
effectively inhibit CDT in cell lines, the viability of this approach as a therapeutic is in 
question due to their poor drug-like properties of most peptides.116 While it is understood 
that all of these eIF4E-inhibiting molecules are best utilized as tool compounds, their 
success both in vitro and in cells provides evidence that it might be possible to inhibit 
eIF4E activity without directly modulating 4E-BP1 phosphorylation. However, until these 
molecules improve in selectivity, specificity and cell penetrability, this approach will not 
be a viable means by which to target CDT in a clinical setting. 
 
 
Figure 2.5 | Small Molecule Inhibitors of eIF4E  
 
2.5  Intricacies of 4E-BP1 Phosphorylation 
4E-BP1 is phosphorylated in a hierarchical fashion, with phosphorylation of 
Thr37/46 “priming” the subsequent phosphorylation of Ser65 and Thr70.117-119 Therefore, 
it is often difficult to assess the impact of each phosphorylation site individually. It is clear 
that 4E-BP1 inactivation is mediated by hyperphosphorylation at these four canonical 
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mTORC1-dependent sites, each of which immediately flanks the eIF4E binding region of 
the protein; though Ser65 and T70 are thought to make the largest contributions towards 
weakening the affinity between the two proteins.118-123 (Figure 2.6) However, up to 21 
phosphorylation sites have been identified by phosphoproteomic methods, many of which 
have been confirmed through experiments described in Chapter 3 and 4.124 Though each 
of these sites have been identified with high confidence, very few have been validated 




Figure 2.6 | 4E-BP1 Phosphorylation Sites Identified by Phosphoproteomics. All high-throughput 
phosphorylation sites identified in at least 5 experiments. The base of this figure was generated using 
phosphosite.org.124  
 
2.6 mTOR-Independent Phosphorylation of 4E-BP1 
 Inhibition of mTORC1 activity with allosteric rapalog inhibitors reactivates 4E-BP1 
via inducing hypophosphorylation. However, in cell lines and in vivo models, this 
phenotype is transient; within a few hours 4E-BP1 phosphorylation is restored, while S6K 
phosphorylation is fully abrogated throughout the duration of the treatment.125 The 
mechanism of phosphorylation for proteins is similar, with each substrate competing for 
binding to the mTORC1 subunit Raptor, which facilitates recruitment of substrates to 
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mTOR kinase.126-128 Therefore, the differential phosphorylation pattern between two of 
the best-validated mTORC1 substrates has led to speculation about the presence of 
additional kinases filling in for mTOR under conditions of mTORC1 inhibition.96,129 The 
poor clinical efficacy of second-generation mTORKis has also increased support for this 
hypothesis.96 
 Indeed, many kinases have been reported to phosphorylate 4E-BP1 in vitro and in 
cells including: ATM,130 casein kinase,131 ERK2,132 CDK1,133,134 GSK3b,135 p38 MAPK,136 
PIM2137 and PLK1.138 Though each of these have been reported, most have not been 
sufficiently validated outside of an in vitro kinase assay setting. As all four of the canonical 
phosphorylation sites are directly adjacent to the eIF4E binding site,139 4E-BP1 
phosphorylation is only relevant in the context of eIF4E binding; any kinase recognition 
motif surrounding these sites is blocked by eIF4E.140,141  In previous reports, many 
kinases exhibiting activity towards 4E-BP1 in vitro were not examined following pre-
incubation with eIF4E.135,136 Several that have been tested lost activity towards 4E-BP1 
as a substrate,142 shedding light on the importance of probing for kinase-substrate 
interactions in situ. However, the CDK1-4E-BP1 interaction was thoroughly validated 
across many cell types.133,134 Yet CDK1 is only capable of phosphorylating 4E-BP1 during 
the early stages of mitosis, a stage of the cell cycle which has long been known to exhibit 
mTOR-independent phosphorylation of 4E-BP1. 
 The identification of these kinases has, in some cases, contributed to our knowledge 
and understanding of mTORC1-independent regulation of 4E-BP1 phosphorylation. 
However, these relationships have not been established in vivo, and have not uncovered 
novel treatments for treating patients with cancer that is refractory to mTORC1 allosteric 
inhibitors. By elucidating definitive compensatory kinases capable of regulating CDT in 
the absence of mTORC1 signaling, combination therapies can be developed for creating 
a larger clinical impact. 
  
2.7  Conclusions 
 mTOR is one of the best-known oncoproteins in human cancer. Hyperactivation of 
this pathway induces controlled proliferation partly through increasing cap-dependent 
protein synthesis and lipid metabolism, while decreasing autophagy and apoptosis. 
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mTOR has long been considered a viable drug target for many diseases, however current 
therapies have fallen short of expectations due to poor tolerability, as well as drug 
resistance as a result of mTORC1 independent phosphorylation of 4E-BP1. Positive 
identification of a kinase that phosphorylates 4E-BP1 under conditions of mTORC1 
inhibition would be instrumental in understanding the observed resistance to each 
category of mTOR inhibitors, and would drive the design of rational combination therapies 






























































































































































































































































































































































































































































































































































Chapter 3  
  
Development of a Phosphosite Accurate Crosslinking Assay 
 
 
3.1  Abstract 
 Given the importance of kinase-catalyzed phosphorylation (discussed in Chaper 
2), and the dearth of available tools with which to reliably identify phosphorylation site 
specific kinases (discussed in Chapter 1), a new assay for allowing an unbiased query of 
the kinome was sorely needed. To address this need, a kinase crosslinking assay 
(PhAXA) was developed that, when coupled to LC-MS/MS analysis, provides a list of 
possible kinases for a phosphorylation site of interest. This chapter discusses the concept 
behind PhAXA, and the three kinase-substrate systems used as proof-of-concept for this 
activity-based, chemoproteomic pipeline.  
	
3.2  A Phosphosite Accurate Crosslinking Assay (PhAXA) 
 To improve upon a previous method of implementing biotinylated peptide 
pseudosubstrates for phosphosite specific kinase identification, a new assay was 
developed: the Phosphosite Accurate Crosslinking Assay, or PhAXA. (Figure 3.1) PhAXA 
was inspired by a previously reported1 ATP crosslinker probe in which the g-phosphate of 
ATP has been modified with a methacrylate moiety (Figure 3.1), allowing for the selective 
conversion of highly conserved active site lysines to an acrylamide. The position of this 
electrophilic handle within the active site of a kinase allows for a crosslinking reaction to 
occur via Michael addition with a cysteine thiol, which has been inserted in place of the 
serine, threonine, or tyrosine of a substrate protein of interest. The result is a hydrolytically 
stable bond formed between the acrylamide-kinase and cysteine mutant probe, allowing 
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this complex to be isolated by immunoprecipitation using anti-FLAG affinity resin and the 




Figure 3.1 | Workflow for identifying site-specific kinase-substrate interactions. A) PhAXA 
schematic and structure of ATP crosslinker probe 1. B) Generic workflow for the cell-based aspect of 
PhAXA. 
 
 The benefits of PhAXA are two-fold: (1) Kinases have been shown to achieve 
substrate specificity through complex docking interactions.2,3 As such, these interactions 
are impossible to achieve by using a peptide or partial substrate as bait for activity-based 
pulldown. In this method, the full-length protein is used, and thus, more biologically 
relevant. (2) By transiently expressing the substrate protein, as opposed to adding 
exogenous protein or peptide, the bait is present in situ and can engage in all 
physiologically relevant interactions prior to cell lysis, aiding in specificity. Moreover, 98% 
of all human protein kinases utilize an active site lysine to coordinate the negative charge 
of the gamma-phosphate on ATP.4 Because of this highly conserved residue, and the fact 
that all kinases utilize ATP as a phosphate donor, the ATP-methacrylate crosslinker is 
likely capable of converting the vast majority of the human kinome into a suitable 
electrophile for a Michael addition with a cysteine thiol. Therefore, this approach is likely 
amenable to the majority of kinase-substrate interactions, which is essential to achieve 
an unbiased scan of the kinome.  
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3.3  Assay Validation using c-Jun – MAPK8/9  
 Development of a phosphosite specific crosslinking assay required a model system 
for which the kinase, and the exact phosphorylation site, is known with absolute certainty. 
For initial proof-of-concept studies, the Jnk1/2-c-Jun kinase-substrate interaction was 
used, as phosphorylation-mediated activation of c-Jun has been of significant interest 
since the discovery of JUN as an oncogene in the 1980’s.5,6 c-Jun is a member of the AP-
1 transcription factor complex, which is present as both homodimers and heterodimers 
comprised of Fos (c-Fos, FosB, Fra1, and Fra2), Jun (c-Jun, JunB, and JunD), Jun 
dimerization partners (JDP1 and JDP2), and the activating transcription factors (B-ATF, 
ATF2 and ATF3).6,7 Each homo- and heterodimer activates transcription of a different 
subset of genes, though c-Jun can independently drive cell proliferation via 
downregulation of p53, p21 and p16, while upregulating Cyclin D1 and FasL.8 These 
findings implicated c-Jun in oncogenesis,9-12 and resulted in extensive investigation of the 
mechanism by which c-Jun is activated. Mechanistic evaluation of the cellular UV 
response found that the c-Jun N-terminal Kinases 1 and 2 (JNK1/2), also known as 
mitogen activated kinases 8 and 9 (MAPK8/9), phosphorylate the c-Jun transactivation 
domain at Ser63 and Ser73.13-16 This led to several drug discovery efforts for developing 
JNK inhibitors,17-22 the results of which further validated the JNK-c-Jun interaction. 
 JNK1/2-mediated c-Jun phosphorylation is induced by stress, UV light, loss of 
contact inhibition, and reactive oxygen species.13,15,23,24 In an in vitro setting, this is 
commonly induced via ionizing radiation,24 or by treatment with the protein synthesis 
inhibitor25 anisomycin.16 Due to ease of use, pharmacological induction of c-jun 
phosphorylation was preferable to using UV radiation, so anisomycin was used to 
stimulate JNK activity. JNK activation was verified by treating 293Ts with increasing 
doses of anisomycin for different times, leading to increased phosphorylation of both 
endogenous and transfected FLAG-c-Jun at each concentration and time that was 
examined. (Figure 3.2A) c-Jun is a transcription factor, which translocates to the nucleus 
upon activation. As kinases are known to exhibit differential activity in vitro in response to 
detergents, it was important to determine whether both Jnk1/2 and c-Jun could still be 
isolated with a mild, detergent-free kinase-assay buffer.26,27 Therefore, 293T cells were 
	 45	
stimulated with anisomycin and lysed with SDS-containing buffer (for whole-cell extract), 
or with buffer lacking detergent (cytoplasmic proteins only). (Figure 3.2B) Jnk was found 
in equal amounts in both cytoplasmic and whole cell fractions, while active, 
phosphorylated c-Jun was less abundant in the cytoplasmic fraction. However, there was 
still a relatively high proportion of c-Jun in lysate isolated from high density cells without 
using detergent. (Figure 3.2B) These initial optimization experiments provide the cellular 
conditions under which to observe the interaction of c-Jun and Jnk1/2 using PhAXA.  
 
Figure 3.2 | Evaluating the the Activation of c-Jun Using Anisomycin. A) Western Blot of 293T cells 
left untransfected or transfected with wild-type 3x-FLAG c-Jun after treatment with different concentrations 
and durations of anisomycin. Western Blot of 293T cells at high or low density treated with different 
concentrations of anisomycin. Cells were harvested in Tris-buffered saline (TBS) +/- 0.1% sodium dodecyl 
sulfate. 
 
 Finally, PhAXA was attempted using wild-type (WT) c-Jun as a bait protein. 
Unfortunately, Jnk was highly enriched from lysate expressing wild-type Flag-c-Jun 
protein when treated with crosslinker, with the observed mass shift indicating successful 
crosslinking between the kinase and substrate. (Figure 3.3A) However, no crosslinking 
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was observed without the addition of crosslinker, suggesting background labeling 
occurred through an endogenous cysteine. (Figure 3.3A) It was reasoned that pulldown 
with the WT probe was likely due to labeling at Cys99, which is located near three other 
JNK phosphorylation sites, Thr91, Thr93, and Thr95.28,29 This was confirmed by 
performing PhAXA using Flag-c-Jun (C99A) as bait, as very little crosslinking was 
observed upon removal of the endogenous cysteine. (Figure 3.3A) Robust pulldown was 
achieved with the C99A/S63C and C99A/S73A mutant probes relative to the C99A 
control. (Figure 3.3B) Jnk was also enriched over background with the cysteine mutant 
probes corresponding to the other Jnk substrate residues (C99A/T91A, C99A/T93C, and 
C99A/T95C), however the pulldown efficiency was lower. (Figure 3.3B) 
Kinase-substrate crosslinking was determined to be dependent on the catalytic 
lysine via utilizing an active site kinase inhibitor. Pre-treatment of lysate with the ATP 
competitive inhibitor SP60012519-21 prevented the pulldown of Jnk by Flag-c-Jun (S63C) 
probes from lysate treated with crosslinker, indicating that crosslinking occurs between 
the kinase active site and the incorporated cysteine. (Figure 3.3C,D) Moreover, 
enrichment of the Jnk was only abrogated at concentrations exceeding 40nM, the 
reported IC50 for this inhibitor.21 This experiment provides evidence that the level of 
enrichment from cell lysate is representative of the activity of that kinase towards the 




Figure 3.3 | Optimizing PhAXA Pulldown With c-Jun-Jnk1/2. A) Western blot comparing PhAXA 
pulldown efficiency between 3xFlag-c-Jun (WT) and (C99A) baits. B) 3xFlag-c-Jun phosphosite to cysteine 
mutant bait proteins selectively pull down Jnk when treated with crosslinker. C) SP600125 inhibition of Jnk 
pulldown from 5 μM − 10 nM D) Structure of the active-site Jnk inhibitor SP600125. 
 
To demonstrate that PHAT-ELKCA can be used for kinase identification by mass-
spectrometry (PhAXA-MS), and to profile selectivity of this method, the FLAG-c-Jun 
(C99A/S63C) and (C99A) probes were used to pulldown associated kinases from 
HEK293T lysate followed by LC-MS/MS analysis. Significant enrichment of high-scoring 
Jnk1/2 peptides from the sample prepared from C99A/S63C expressing cell lysate treated 
with the crosslinker 1, while very few Jnk1/2 peptides were identified in the ATP only and 
FLAG-c-Jun (C99A), crosslinker treated control samples (Table 3.1). Two biological 
replicates were performed, and kinases identified by at least 2 PSMs across both 
replicates were examined. These kinases were quantified in two ways: (1) By counting 
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the number of peptide spectrum matches (PSMs) in each sample30 (2) By quantifying the 
relative MS1 intensity of each identified peptide.31 In each case, the obtained value was 
used as a proxy for relative protein concentration, and fold changes were calculated for 
the phosphocysteine mutant, crosslinker treated sample versus each control. For each 
relative quantification method, MAPK8 (Jnk1) emerged as the top hit, with MAPK9 (Jnk2) 
as the second most enriched sample. These bona fide c-Jun kinases were the only two 
kinases across the dataset to exhibit two-fold enrichment over both negative control 
samples. These results demonstrate that PhAXA-MS is a viable method for the unbiased 
query of the kinome.  
 
Table 3.1 | c-Jun Interacting Kinases Identified by PhAXA-MS. Table of all kinases identified by at least 
two peptides in each biological replicate following filtering of common contaminants. (See Methods) 
Average peptide-spectrum matches (PSMs) are from two independent biological replicates. ‘+’ refers to 
samples treated with 1, while ‘-‘ refers to ATP only controls. Dashes were added for ratios that could not be 
calculated due to absence of any high scoring PSMs. Ratio of MS1 intensities was determined using 
Skyline. Fold change is represented as +/- standard deviation (n= 2 to 18). 
 
3.4  Assay Validation using ERK2 – MEK1/2 
 Using the JNK-c-Jun interaction as a proof of concept for PhAXA demonstrated 
that this approach is amenable to profiling serine serine/threonine kinases. However, tha 
majority FDA approved kinase inhibitors target tyrosine kinases,32-35 and many oncogenic 
activities directly or indirectly affect tyrosine phosphorylation.32,36,37 This highlights the fact 
that many kinases involved in cancer progression act to regulate tyrosine residues, which 
makes understanding the regulation of these events incredibly important in the context ot 
drug discovery. Moreover, kinase-kinase signaling cascades directly regulate and 
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indirectly affect nearly every known cellular process.38,39 Therefore, the application of 
PhAXA to a second model system involving tyrosine phosphorylation using a kinase 
substrate was explored.  
Extracellular regulated kinase 2 (ERK2), also known as mitogen activated protein 
kinase 1 (MAPK1), is one the oldest known kinases involved in signal transduction, as it 
was first described in the early 1980s.40-42 ERK2 is involved in phosphorylation of 
hundreds of substrates following activation of upstream cell receptors with mitogenic 
stimuli.40,42-45 ERK2 activation is implicated in cancer progression as it positively regulates 
many pro-growth processes such as cell cycle46 and protein translation,47,48 while 
negatively regulating apoptosis.49,50 Mechanistically, Erk2 is activated by phosphorylation 
at Thr185 and Tyr187, or the TEY motif, by the dual specific kinases MAPK2K1 and 
MAPK2K2 (MEK1/2).51-54 Phosphorylation of these residues within the activation loop 
induces structural changes in the catalytic domain that confer full enzymatic activity.55,56 
Though this phosphorylation event has been known since the early 1990s,51,57 the only 
validated kinases with activity towards Y185 are MEK1/2, making this an ideal system on 
which to build proof of concept for PhAXA.   
The MAP kinase pathway is swiftly and strongly activated by phorbol esters58-60; 
thus, PMA was used to stimulated MEK1/2 mediated phosphorylation, and thus 
crosslinking, of the FLAG-Erk2 cysteine mutant probes. Importantly, the rattus norvegicus 
Erk2 open reading frame (ORF) was used as a bait for these experiments. The amino 
acid sequences match with over 99% homology, however Y185 is homologous to Homo 
sapiens Y187. Applying the PhAXA workflow using 3xFLAG-Erk2 (Y185C) as a bait 
protein resulted in robust enrichment of MEK1/2 relative to the WT Erk2 probe as 
determined by Western blot. (Figure 3.4A) The expected mass shift of MEK1/2 was also 
observed in response to treatment with crosslinker, indicating successful covalent 
crosslinking between the two kinases. Inhibition of MEK1/2 pulldown with trametinib was 
achieved at concentrations of 10nM and above, which is in line with the reported IC50 of 
1nM for this compound.53,61 (Figure 3.4B) Interestingly, as trametinib functions as a type 
III, or allosteric, kinase inhibitor,62,63 pulldown inhibition is like achieved independently of 
crosslinker-mediated conversion of the active site lysine.  
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Figure 3.4 | Evaluating PhAXA Pulldown Using ERK2-MEK1/2 A) Y185C rnERK2 mutant pulls down 
MEK kinase. Rattus norvegicus ERK2 was used as a bait; Y185 is homologous to human Y187. B) 
Trametinib inhibition of MEK pulldown from 100 nM − 100 pM in 10-fold dilutions. Representative input 
samples are included in each figure to show the shift in mass upon crosslinking. 
 
 Using PhAXA-MS, the selectivity of the 3X-Flag-rnERK2 (Y185C) probe was 
determined. While the overall abundance was low based on spectral count, MEK2 was 
the only kinase exhibiting greater than 2-fold enrichment over both ATP treated control 
samples. (Table 3.2) The trend was maintained with both methods of fold change 
calculation, though S6KA5 was enriched by 1.99-fold between the Y185C and WT 
samples treated with crosslinker. These results still demonstrate that PhAXA-MS can be 
used for evaluating kinases that phosphorylate tyrosine residues with individual 
phosphosite resolution. Moreover, this assay is also amenable to the use of a kinase as 
a bait, and the possibility that using this type of protein would increase background was 
not realized.  
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Table 3.2 | ERK2 Interacting Kinases Identified by PhAXA-MS. Table of all kinases identified by at least 
two peptides in each biological replicate following filtering of common contaminants. (See Methods) 
Average peptide-spectrum matches (PSMs) are from two independent biological replicates. ‘+’ refers to 
samples treated with 1, while ‘-‘ refers to ATP only controls. Dashes were added for ratios that could not be 
calculated due to absence of any high scoring PSMs. Ratio of MS1 intensities was determined using 
Skyline. Fold change is represented as +/- standard deviation (n= 2 to 15). 
 
3.5  Assay Validation using 4E-BP1 – mTOR  
As discussed in Chapter 2, phosphorylation-mediated inactivation of 4E-BP1 by 
mTOR is a well-studied process. Mechanistically, 4E-BP1 is recruited to mTOR kinase by 
the mTORC1 subunit Raptor via interaction with the FEMDI motif at the C-terminus of 4E-
BP1; this motif is absolutely critical for 4E-BP1 phosphorylation by mTOR.64-67 Moreover, 
hypophosphorylated 4E-BP1 is thought to be exclusively phosphorylated while bound to 
eIF4E.68 Therefore, the peptide-based approach1 would likely not be effective for the 
activity-based crosslinking of mTOR-4E-BP1 using crosslinker 1.  
Initial proof-of-concept using 4E-BP1 as a bait for this activity-based kinase 
pulldown used the 4E-BP1 (T46C) cysteine mutant probe, as this site is well validated as 
an mTORC1 phosphorylation site, and is thought to be constitutively phosphorylated in 
proliferating cells.69 mTOR was enriched in a crosslinker-dependent manner from cell 
lysates expressing this probe. (Figure 3.5A) PhAXA pulldown was then performed at 
several other sites that are known to be phosphorylated by mTOR, as well as the poorly 
understood S101 site. HEK293T cells were transiently transfected with plasmids 
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encoding for 3xFLAG-4EBP1 wild-type (WT) or phosphosite to cysteine mutant constructs 
(e.g. T46C). As shown in Figure 3.5B, selective pulldown was achieved and mTOR was 
very clearly enriched from cells expressing the T37C and T46C 4E-BP1 mutants treated 
with crosslinker 1 relative to the WT and ATP controls. Unsurprisingly, mTOR pulldown 
was not observed with S65C, T70C or S101C probes, as these sites are considered poor 
substrates of mTOR.70  
 
 
Figure 3.5 | Initial Characterization of 4E-BP1-PhAXA. A) HEK293T cells transfected with 3xFlag-4E-
BP1 (T46C) were subjected to PhAXA using different concentrations of crosslinker then analyzed by 
Western blot. B) HEK293T cells transiently transfected with WT or 3XFLAG phosphosite-to-Cys mutant 4E-
BP1 constructs were treated with crosslinker or ATP as a control (250 µM) then analyzed by Western blot. 
 
 Further mechanistic experiments were then performed to verify the ability of this 
method to serve as a proxy for mTOR activity. First, the effect of mTORC1 inhibitors on 
mTOR pulldown was investigated. Pre-treatment of lysate with the ATP competitive, 
active-site mTOR inhibitor PP242 prevented the pulldown of mTOR by Flag-4E-BP1 
(T46C) probes from lysate treated with crosslinker. Inhibition was maintained at 
concentrations over 10nM, mirroring the reported IC50 of 8nM for this compound.71 
Specificity was further evaluated by disrupting pulldown of mTOR using rapamycin, an 
allosteric inhibitor. This provides evidence that inhibition of substrate docking, not just 
conversion of the active site lysine to an acrylamide, can inhibit kinase-substrate 
crosslinking.  
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Figure 3.6 | mTORC1 Inhibitors Prevent Pulldown of mTOR by PhAXA. A) PP242 (10,000-1 nM) and 
B, rapamycin (100 nM) inhibit the crosslinking of mTOR to the T46C 4E-BP1 probe in the presence of 
crosslinker (250 µM). 
 
As discussed previously, FEMDI motif on 4E-BP1 is required for substrate 
recruitment, and mutation of Phe114 to alanine decreases phosphorylation of 4E-BP1 at 
mTORC1-sensitive sites. (Figure 3.7A) Therefore, the effect of this mutation on mTOR 
pulldown was investigated. Flag-4E-BP1 (T37C) and (T46C) probes also containing a 
F114A mutation had almost no activity in this assay, mirroring the activity of mTORC1 
towards FEMDI null substrates. (Figure 3.7A,B) Finally, the assembly of mTORC1 
components is highly detergent sensitive, as mTORC1 is inactive when purified from cells 
lysed using most common detergents such as NP-40, Trition X100, and dodium dodecyl 
sulfate.26 Given this knowledge, PhAXA pulldown was applied to cells expressing the 4E-
BP1 (T46C) probe, lysed without detergent (normal conditions) or with 0.5% NP-40. 
mTOR was not enriched from cell lysate generated using NP-40. (Figure 3.7C) 
 
Figure 3.7 | Conditions that Inhibit mTORC1 Activity Prevent PhAXA Pulldown. A) HEK293T cells 
expressing WT of F114 Flag-4E-BP1 constructs were lysed and Flag-4E-BP1 phosphorylation was 
analyzed by Western Blot. B) F114 is critical for raptor-mediated recruitment of 4E-BP1 to mTOR. Mutation 
of this residue to alanine reduces pulldown of mTOR using the T37C and T46C probes. C) Non- ionic 
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detergents reduce mTORC1 in vitro activity. mTOR pulldown by the T46C mutant probe is inhibited when 
cells are lysed in buffer containing NP-40. 
 
  To investigate the ability of PhAXA-MS to identify novel 4E-BP1 kinases in 
HEK293T cells, the FLAG-4E-BP1 (T46C) and WT probes were used to query the kinome 
present in HEK293T lysate. Following LC-MS/MS analysis, significant enrichment of high-
scoring mTOR peptides from the sample prepared from T46C expressing cell lysate 
treated with the crosslinker 1 was observed, while no mTOR peptides were identified in 
the ATP only negative control sample and very few were identified in the FLAG-4E-BP1 
(WT), crosslinker 1 treated sample (Table 3.3). Specificity of the 3xFLAG 4E-BP1 (T46C) 
probe is demonstrated in Figure 3.8, which identifies mTOR as one of the most highly 
enriched proteins among all those identified.  
 Importantly, MS/MS analysis of proteins crosslinked to each cysteine probe resulted 
in very few kinases exhibiting significant enrichment over the WT protein. (Table 3.3) 
Significantly enriched kinases were considered to be those with an average of ³2-fold 
enrichment in the T46C, crosslinker treated sample relative to both WT + crosslinker, and 
T46C + ATP controls. By this metric, two significantly enriched kinases were identified: 
mTOR, as would be expected, as well as CDK4, which has never been described as a 
4E-BP1 kinase. This experiment provided a third example whereby PhAXA-MS identified 
a bona fide kinase as the top hit, and uncovered CDK4 as a potentially novel 4E-BP1 
kinase. 
 
Table 3.3 | 4E-BP1 Interacting Kinases Identified by PhAXA-MS. Table of kinases 
identified by at least two peptides in each biological replicate following filtering of common contaminants.72 
Average peptide-spectrum matches (PSMs) are from two independent biological replicates. ‘+’ refers to 
samples treated with 1; ‘-’ refers to ATP only controls. Dashes were added for ratios that could not be 
calculated due to absence of any high scoring PSMs. The ratio of MS1 intensities was determined using 




Figure 3.8 | mTOR is Highly Enriched by PhAXA-MS A scatterplot depicting all proteins identified by 
PhAXA-MS, Log2 fold change of spectral counts for non-filtered proteins plotted for the T46C probe relative 
to the appropriate controls. 1 PSM was added to each sample before averaging to enable calculation of the 
fold change for samples with no PSMs. 
 
3.6  Conclusions 
 The development of a phosphosite accurate crosslinking assay, PhAXA, as 
described in this chapter represents an important step forward in kinase-targeted 
activity-based protein profiling. This method has been demonstrated to be broadly 
applicable across several different classes of bait proteins, including transcription 
factors, kinases, and intrinsically disordered proteins. Moreover, the phosphocysteine 
probes used in this assay are suitable for mimicking phosphorylation of serines, 
threonines and tyrosines. For each of the three examples shown here, PhAXA-MS 
identified only bona fide kinases as significantly enriched relative to control samples, 
making this the first reported assay capable of reliable kinase assignment in a 
phosphosite-specific fashion. Though this assay has been successfully implemented, 
several possible improvements, as well as a few clear limitations, will be discussed in 
Chapter 6. 
 
3.7  Materials and Methods 
Small molecule reagents  
	 56	
Trametinib (Selleckchem), Rapamycin (Alfa Aesar), and SP600125 (ApexBio) were dissolved in 
DMSO. Human recombinant insulin was purchased from Sigma, PMA (Phorbol-12-Myristate-13-
Acetate) was purchased from Acros. Anisomycin was purchased from Cayman Chemical. 
3XFLAG peptide was purchased from ApexBio. All reagents were used as received. 
 
Cell Culture 
HEK293T cells were grown in DMEM (Corning) supplemented with 10% FBS, glutamine, 
penicillin, and streptomycin (Gibco). Cells were grown at 37 °C with 5% CO2 in a humidified 
incubator, passaged at least twice before use for experiments and no more than 10 times before 
returning to low passage stocks. All cell lines were authenticated by STR profiling, and regularly 
tested for mycoplasma contamination.  
 
Plasmids 
Annealed oligos corresponding to the N-terminal 3XFLAG tag were ligated into pcDNA3 at 
BamHI and EcoRI. 4E-BP1 cDNA was purchased from Promega in the pFN29K expression 
vector. HA-Erk2 (Rattus norvegicus) plasmid was generously shared by Dr. Diane Fingar. 4E-
BP1, Erk2 and c-Jun were cloned into the pcDNA3/3XFLAG vectors. All mutations were 
generated by PCR mutagenesis. The sequences for all primers used have been listed in Table 3.4. 
All constructs were fully sequenced by Sanger sequencing. 
 
ORF Purpose Sequence 5’ à 3’ 













T37C Forward GACTACAGCACGTGCCCCGGCGGCACG 
 Reverse CGTGCCGCCGGGGCACGTGCTGTAGTC 
T46C Forward GCTCTTCAGCACCTGCCCGGGAGGTACC 
 Reverse GGTACCTCCCGGGCAGGTGCTGAAGAGC 
S65C Forward CTGATGGAGTGTCGGAACTGTCCTGTGACCAAAACACCC 
 Reverse GGGTGTTTTGGTCACAGGACAGTTCCGACACTCCATCAG 
T70C Forward GAACTCACCTGTGACCAAATGTCCCCCAAGGGATCTGCCC 
 Reverse GGGCAGATCCCTTGGGGGACATTTGGTCACAGGTGAGTTC 
S101C Forward GCCACCTGCGCAATTGCCCAGAAGATAAGC 
 Reverse GCTTATCTTCTGGGCAATTGCGCAGGTGGC 
F114A Forward GCGGGCGGTGAAGAGTCACAGGCTGAGATGGACATT 
 Reverse AATGTCCATCTCAGCCTGTGACTCTTCACCGCCCGC 





C99A Forward CCACCCAGTTCCTGGCCCCCAAGAACGTGACAG 
 Reverse CTGTCACGTTCTTGGGGGCCAGGAACTGGGTGG 
S63C Forward CGGACCTCCTCACCTGCCCCGACGTGGGG 
 Reverse CCCCACGTCGGGGCAGGTGAGGAGGTCCG 
S73C Forward GCTCAAGCTGGCGTGCCCCGAGCTGGAGC 
 Reverse GCTCCAGCTCGGGGCACGCCAGCTTGAGC 
T91C Forward GGGCACATCACCACCTGTCCGACCCCCACCC 
 Reverse GGGTGGGGGTCGGACAGGTGGTGATGTGCCC 
T93C Forward CATCACCACCACGCCGTGCCCCACCCAGTTCC 
 Reverse GGAACTGGGTGGGGCACGGCGTGGTGGTGATG 
T95C Forward CCACCACGCCGACCCCCTGCCAGTTCCTGG 
 Reverse CCAGGAACTGGCAGGGGGTCGGCGTGGTGG 
D11WT Forward GGAAACGACCTTCTATGACGATGCCCTCAACGCC 
 Reverse GGCGTTGAGGGCATCGTCATAGAAGGTCGTTTCC 
rnErk2 
Cloning to 3xFLAG pcDNA3 
Forward AATAGCGGCCGCAATACGCTAGCATGGCGGCG 
Reverse GCTATCTAGATCAGGCCGCTTGTTAAGATCTGTA 
Mutagenesis Y185C Forward CAGGGTTCTTGACAGAGTGTGTAGCCACGCGTTGG  Reverse CCAACGCGTGGCTACACACTCTGTCAAGAACCCTG 
 




Immunoprecipitates from PhAXA pulldowns, or cell lysates from HEK293T cells were 
resolved on 4-20% Tris-glycine gels (Invitrogen), transferred to 0.45-µm PVDF (Thermo) using 
Towbin’s buffer (low amperage for ~4 h at 4 °C), blocked with 5% non-fat milk in TBST, then 
probed with primary antibodies overnight at 4 °C. Antibodies used in this study were the following: 
Actin-HRP (sc-47778) from Santa Cruz Biotechnology; DYKDDDK tag (14793), MEK1/2 
(9122), mTOR (2972), p4E-BP1 (T37/46) (2855), p4E-BP1 (S65/101) (9451), SAPK/Jnk (9252), 
4E-BP1 (9644), from Cell Signaling Technology; and FLAG-M2 (F1804) from Sigma. 
 
PhAXA  
For Western blot analysis, HEK293T cells were grown in 10-cm plates to 50% confluence 
and transfected with DNA (6 µg) by calcium phosphate precipitation. 18 h later, the media was 
changed to serum-free DMEM (4E-BP1 and rnErk2 pulldowns), or growth media (c-Jun 
pulldown). After 24 h, cells were stimulated as follows: 10 min with growth media containing 
insulin (150 nM) for 4E-BP1 pulldown, 15 min with growth media containing PMA (100 nM) for 
rnERK2 pulldown, or 30 min with growth media containing anisomycin (10 µg/µL) for c-Jun 
pulldown. Cells were then harvested in NLB buffer (1 mL; 50 mM Tris pH 8.0, 150 mM NaCl, 10 
mM MgCl2, 10 µg/mL aprotinin, 5 µg/mL leupeptin, 7 µg/mL pepstatin) per plate by scraping. 
Cells were lysed by forcefully passing through a 28.5G insulin syringe 5´ consecutively on ice. 
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Debris was pelleted at 18,000´g for 10 min at 4 °C. Cleared lysate was split into 500 µL aliquots 
(´2) in 1.5-mL tubes, and 1 or ATP was added to a final concentration of 250 µM. Lysate was 
incubated at 30 °C for 60 min under constant agitation. FLAG-BAIT complexes were then isolated 
by immunoprecipitation for 12-15 h at 4 °C with end-over-end rotation. The resin was 
subsequently washed 3´ for 15 min under constant agitation with 1´ TBS containing Triton X-
100 (2% v/v), then thrice with TBS for 30 s each; 1 mL was used for each wash. Proteins were 
eluted with 2´ Laemmli buffer and resolved by SDS-PAGE. 
For analysis by LC-MS/MS, the protocol is similar to that above with the following 
modifications: HEK293T cells were grown in 15-cm plates (´4) to 50% confluence and transfected 
with WT or Cys-mutant plasmid DNA (12 µg per plate) by calcium phosphate precipitation. Each 
plate was harvested in lysis buffer (2.5 mL), and samples were processed as above through the 
immunoprecipitation step. We found it critical to keep volumes at 500 µL per tube with 5 tubes 
per reaction condition. After overnight immunoprecipitation and following the final wash with 
TBS, complexes were eluted with elution buffer (250 µL; TBS, 0.1% sodium deoxycholate, 1 
mg/mL 3XFLAG peptide) per tube. Elutions were carried out for 90 min at 25 °C with constant 
agitation on a plate shaker (120 rpm). Common eluents were pooled, tricholoracetic acid was 
added to a final concentration of 10% (w/v), and samples were incubated on ice for 60 min. Tubes 
were then centrifuged at 21,000´g for 15 min at 4 °C before discarding supernatants. Protein 
pellets were re-suspended in ice-cold acetone (1.5´ eluate volume) for each wash using a water 
bath sonicator. After another 30 min on ice, the protein was again precipitated and the supernatant 
discarded. The acetone wash was repeated once more, and the protein pellets were re-suspended 
in 10 mM HEPES buffer (pH 8.0) containing 8 M urea (50 µL) and immediately frozen at -80 °C 
until processing by in-solution digestion. 
 
In-solution digestion 
Protein samples were treated with ammonium bicarbonate buffer (pH ~8), which was 
added to a final concentration of 100 mM. Cysteine residues were reduced by adding 10 mM DTT 
(50 µl) and incubation at 45 °C for 30 min. Samples were cooled to room temperature, and 
alkylation of cysteines was achieved by incubating with 2-chloroacetamide (65 mM) under 
darkness for 30 min at room temperature. Upon diluting the urea to a final concentration of <1 M, 
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overnight digestion with sequencing grade, modified trypsin (1 ug) was carried out at 37 °C. 
Digestion was stopped by acidification and peptides were desalted using SepPak C18 cartridges 
using manufacturer’s protocol (Waters). Samples were completely dried using a Vacufuge 
concentrator (Eppendorf).     
 
Mass spectrometry 
Peptides resulting from trypsin digestion were dissolved in 0.1% formic acid/2% 
acetonitrile solution (9 mL). 2 mL of the resulting peptide solution were resolved on a nano-
capillary reverse phase column (Acclaim PepMap C18, 2 micron, 50 cm, ThermoScientific) using 
a 0.1% formic acid/acetonitrile gradient at 300 nl/min over a period of 90 min (in-gel digests) or 
180 min (in-solution digests). Eluent was directly introduced into a Q Exactive HF mass 
spectrometer (Thermo Scientific, San Jose CA) using an EasySpray source. MS1 scans were 
acquired at 60K resolution (AGC target = 3 ´ 106; max IT = 50 ms). Data-dependent collision-
induced dissociation MS/MS spectra were acquired on the 20 most abundant ions following each 
MS1 scan (NCE ~28%; AGC target = 1 ´ 105; max IT = 45 ms). 
 
Data analysis 
The resulting raw files were converted into mzXML files and centroided using MSConvert.73 
Spectra were searched against the Swiss-Prot Human protein database (2.15.17 Download) 
appended with all isoforms and cRAP contaminants using the COMET74 search engine as part of 
the Trans-Proteomic Pipeline (TPP) (version 5.0).75 Peptide mass tolerance was set to 10 ppm, 
fragment bin tolerance to 0.02 Da, and two missed cleavages were allowed. Met oxidation 
(+15.9949), Ser/Thr/Tyr phosphorylation (+79.966331) and Gln/Asn deamidation (+0.98402) 
were included as variable modifications; carbamidomethylated Cys (+57.021464) was set as a 
fixed modification. The resulting pep.xml files were analyzed for peptide probability using 
PeptideProphet,76 where a minimum peptide probability of 0.95 was required, with only the expect 
score used as a discriminant. Protein level validation was performed using ProteinProphet;77 only 
proteins with a probability of >0.97 were considered. 
Protein-level quantification was performed in two ways to account for the relatively low 
peptide-spectrum match (PSM) count of observed peptides. First, spectral counts were compiled 
using Abacus,30 and the “adjusted spectral count” was used to compare relative protein 
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concentrations between samples. Each experiment was performed in biological duplicate, and 
PSMs from each duplicate sample were averaged. Second, relative quantification of proteins using 
MS1 intensity was accomplished using Skyline.31 Briefly, spectral libraries were built from amino 
acid sequences for all kinases meeting initial refinement criteria (see below). MS1 intensities were 
extracted for proteotypic peptides within a mass error of 10 ppm that eluted within a 10 min 
window between runs. MS1 intensities were compared between samples where the corresponding 
peptide was positively identified by PeptideProphet with a probability >0.95. Comparisons were 
only made between samples that were simultaneously prepared, i.e. only within the first or second 
replicate, not between replicates. Between 1-15 peptides were compared for each protein 
depending on the number of positive identifications.  
 
Data refinement 
Initial data refinement for kinase identification was performed as follows. Only kinases 
found with at least 2 PSMs in both biological replicates (where applicable) were considered. These 
identified proteins were compared to a list of common contaminating proteins using CRAPome.72 
Briefly, a repository was built from the top 20 experiments (in terms of number of positive 
identified proteins) using FLAG magnetic resin and total cell lysate from HEK293 cells. Any 
kinase found in more than 75% of these experiments was not considered for further 
characterization; this removed STK38, STK38L and PRKDC. 
 
Synthesis of Crosslinker 1 
 
 
The synthesis of 1 was adapted from that reported.1 ATP-triethylammonium salt (0.1 g, 0.11 
mmol) was dissolved in anhydrous DMSO (3 mL) under nitrogen. A solution of methacrylic 
anyhydride (0.44 mmol), anhydrous DMSO (1 mL), dioxane (1 mL), anhydrous DMF (1 mL) was 
added, and the mixture was stirred at room temperature under nitrogen. After 4 d, the reaction was 
quenched with water (5 mL) and extracted with ethyl acetate (3 ´ 5 mL). The aqueous layer was 















































preparative reverse-phase HPLC using an Agilent 1260 Infinity HPLC equipped with a PrepHT 
XDB-C18 column (21.2 ´ 150 mm; 5 µm) at a flow rate of 20 mL/min using 100 % water as a 
mobile phase and detection at 254 nm. Fractions were analyzed off-line using an Agilent Q-TOF 
HPLC-MS. 1-containing fractions were pooled and lyophilized to dryness. Purified compound 1 
(0.028 g) was subsequently dissolved in D2O, and the stock concentration was determined by 
quantitative NMR using a 4,4-dimethyl-4-silapentane-1-sulfonic acid capillary normalized using 
calcium formate. Single-use aliquots (13.3 mM) were stored at -80 °C.  
 











31P NMR Spectrum of 1 
 
 


































































































































































































































































































Chapter 4  
  
Validation of CDK4 as a 4E-BP1 Kinase 
 
 
4.1  Abstract 
 PhAXA-MS analysis of 4E-BP1 kinases uncovered an interesting interaction 
between CDK4 and 4E-BP1 that had previously never been identified. This chapter will 
discuss the background of CDK4 biology, the application of CDK4 inhibitors as a cancer 
therapy, and the validation of CDK4 as a 4E-BP1 kinase. Through mechanistic evaluation 
of CDK4-4E-BP1 signaling, a new insight into the regulation of the oncogene c-Myc is 
uncovered, and preliminary evidence of a phosphorylation site-based biomarker for 
CDK4/6 inhibitors is provided. The discovery of this novel signaling axis sheds new light 
on the mechanisms by which CDK4/6 inhibitors control cell proliferation and constitutes 
the first example of successful kinase discovery using an activity-based, kinase-directed 
probe. 
 
4.2   Cell Cycle Regulation and the Role of CDK4 
 Coordinated regulation of cell cycle progression is essential for the cell growth and 
proliferation. Three well-defined checkpoints exist within the several phases of the cell 
cycle: 1) between G1 and S phases, also known as the “restriction point;” 2) between G2 
phase and mitosis; 3) the intra-mitotic checkpoint. (Figure 4.1A) Each of these transitions 
is regulated by signaling events that provide quality control over cellular contents, thereby 
preventing malignant transformation. However, dysregulation of this process is a hallmark 
of cancer progression, and occurs through a variety of mechanisms. One common 
mechanism by which cells maintain unchecked cell cycle progression is via over activity 
of the CDK4/6-RB1/E2F signaling axis.  
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 CDK4 and CDK6 are homoglogous serine/threonine kinases that, in concert with 
the D-type cyclins, phosphorylate several substrates to drive cell cycle progression 
through the restriction point at the end of G1 phase.1 The most notable CDK4/6 substrate 
is the retinoblastoma-associated protein (pRb), a tumor suppressor that negatively 
regulates of E2F, a family of master regulators that drive the cell-cycle dependent 
transcriptional program.2 When hypophosphorylated, pRb sequesters E2F, preventing 
cell-cycle progression.3-5 However, when pRb is hyperphosphorylated by CDK4/6-Cyclin 
D complexes, the interaction is disrupted, and E2F proteins facilitate the transcription of 
many genes that contribute to cell proliferation, including cyclin A, CDK2, thymidine 
kinase, cdc2, and cdc25a.6,7 (Figure 4.1B) 
 
Figure 4.1 | Cell Cycle Checkpoints and the Role of CDK4 A) The three main cell cycle checkpoints 
are shown (red STOP signs) in relation to the main cell cycle phases: G1 – Gap 1 phase; S – Synthesis 
phase; G2 – Gap 2 phase; M – Mitosis B) A simplified scheme of the CDK-Cyclin complexes that regulate 
phosphorylation of pRb at during each phase of the cell cycle.  
 
4.3  CDK4/6 Inhibitors in the Treatment of Cancers 
 A built-in regulatory mechanism exists with the naturally occurring CDK4/6 inhibitor 
p16, which normally inhibits CDK4/6-Cyclin D complexes, thus enforcing the G1àS 
restriction point.8,9 However, p16 is commonly lost in cancer, giving rise to dysregulated 
pRb phosphorylation.10 Restoration of p16 expression induces a G1 arrest in a number 
of cancer cell lines via reactivation of pRb, and sequestration of the E2F transcription 
factors.11-13 These findings, in tandem with the role of CDK4/6 in driving cell proliferation 
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in many cancers, led to the development of several selective CDK4/6 inhibitors, including 
palbociclib,14 ribociclib,15 and abemaciclib.16  
 While CDK4/6 inhibitors have had only marginal efficacy as single-agent 
therapies,17 they have achieved great success as part of combination treatments. Each 
of the three inhibitors has been approved for treating HR+/HER2- breast cancer in 
combination with endocrine therapies, which were the previous standard of care for this 
patient cohort.18,19 As success with these combinations was realized, preclinical studies 
identified more viable combinations with CDK4/6 targeted therapies in a variety of cancer 
types and backgrounds. These include combinations with chemotherapy regimens,20 
radiation,21 and with MEK inhibitors for Ras-driven cancers.22-25 however, the most 
striking finding comes from several groups that have uncovered synergy between CDK4/6 
and mTOR pathway inhibitors, often from unbiased inhibitor screens.26-35 This 
combination has shown promising enough to move into phase I and II clinical trials. 
Biomarkers that predict the efficacy of CDK4/6 inhibitors have not come easily, 
limiting the ultimate benefit of these drugs.36,37 Presence of pRb seems to be necessary, 
but not this marker alone is not sufficient for patient stratification.38 This may be due to a 
disconnect between pRb inactivation and deletion (and likewise homozygous vs 
heterozygous deletions), as this distinction has been shown to make a difference in 
progression and it might make a difference in biomarker as well.39 Other biomarkers, such 
as p16, CCND1, CCND3 and CDK4 have not translated to clinical success. Therefore, 
given the potential of these inhibitors, more efforts need to be put into identification of 
suitable biomarkers by which to select the appropriate patients receiving these drugs.  
 
4.4   4E-BP1 is a CDK4 Substrate 
 To validate relationship between CDK4 and 4E-BP1, the activity of CDK4 towards 
4EBP1 at each well-documented 4E-BP1 phosphorylation site was investigated using 
PhAXA. (Figure 4.2) Indeed, CDK4 was enriched from lysate expressing the T37C, T46C, 
T70C, and S101C cysteine-mutant probes, though showed no increase in activity towards 
S65C. Of note, due to the small size of CDK4, successful crosslinking to 4E-BP1 initiates 
a large mass-shift on a denaturing, reducing, SDS-PAGE gel, further suggesting an on-
target mode of action of these probes. 
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Figure 4.2 | CDK4 is Enriched by 4E-BP1 Using PhAXA CDK4 is pulled down from lysate expressing 
3x-FLAG-4E-BP1 phosphosite-to-Cys mutants when treated with crosslinker. A representative input is 
shown to demonstrate the mass-shift of CDK4 upon crosslinking to 4E-BP1. 
 
 Each CDK associates with a specific subset of binding proteins, the cyclins, that are 
required for kinase activity by providing substrate specificity via recognition of a required 
RXL motif.1,40 4E-BP1 contains one RXL motif (R73DL) in a region of the protein that is 
free in solution while bound to eIF4E.41 CDK4 also demonstrates substrate specificity via 
recognition of the consensus sequence Ser/Thr-Pro with optimal substrates containing 
one or more basic amino acids downstream of this motif. 4E-BP1 has several 
phosphosites that fit the optimal CDK4 motif, including Thr10, Ser65, Thr70 and S101; 
while Thr37, Thr46 and S83 contain the minimal S/T-P motif. Moreover, 4E-BP1 can be 
found in the nucleus as well as the cytoplasm (Figure 4.3),42 providing evidence that a 
difference in subcellular localization would not prevent CDK4 from phosphorylating 4E-
BP1.43 
 
Figure 4.3 | 4E-BP1 and Cyclin D3 are Present in Common Cellular Compartments. 
Immunofluorescence imaging shows 4E-BP1 is present in the nucleus and cytoplasm, while cyclin D3 is 
mostly localized to the nucleus   
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CDK4 associates with cyclins D1, D2 and D3; thus, in vitro kinase assays were 
performed with each of these complexes. The presence of a D-cyclin proved necessary 
for CDK4 activity, and large differences in the in vitro activities of each CDK4-cyclin D 
complex were observed, with CDK4-cyclin D3 demonstrating the greatest kinase activity 
(Figure 4.4A). However, CDK4 appears to associate with D3 more readily than D1 or D2 
so this may account for the perceived increase in activity. Nevertheless, these complexes 
efficiently phosphorylated 4E-BP1 at each of the canonical mTOR phosphorylation sites. 
No in vitro activity was observed with any of the three CDK6-cyclin D complexes (not 
shown). To verify that the activity observed was due to CDK4 and not a co-purifying 
kinase, the highly selective active site CDK4/6 inhibitor palbociclib14 was used in this 
assay. Phosphorylation of 4E-BP1 was inhibited at concentrations between 5-50 nM, 
mirroring the reported in vitro IC50 value (Figure 4.4B),14 providing additional confidence 
in our finding that 4E-BP1 is a CDK4 substrate. 
 
Figure 4.4 | CDK4-Cyclin D Complexes Phosphorylate 4E-BP1 in vitro. A) Immunopurified Flag-
CDK4/myc-Cyclin D complexes phosphorylate recombinant 4E-BP1 in vitro. B) Palbociclib (50 µM – 500 
pM) inhibits in vitro phosphorylation of 4E-BP1 by CDK4-cyclin D3. C) In vitro kinase assay using WT, 
S65A and S101A 4E-BP1 substrates phosphorylated by immunoprecipitated CDK4-cyclin D3 complexes. 
D) MS analysis of in vitro phosphorylated 4E-BP1 by cyclin D3/CDK4. Phospho-sites identified following 
manual curation of MS/MS assignments (See Methods) from ATP-treated sample are shown in red. No 
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suitable phospho-peptides were identified in the no ATP control sample. Gold asterisk = canonical 
mTORC1 sites, Blue asterisk = non-canonical phosphorylation sites. 
 
 S101 is a poorly studied 4E-BP1 phosphosite;44 however, a large 
phosphoproteomics study observed hyperphosphorylation of this site in response to 
rapamycin treatment, suggesting a potential mechanism of resistance to mTORC1 
inhibition.45 Given the enrichment of CDK4 with the S101C mutant and its lack of activity 
with S65C (Figure 4.2), the activity of CDK4 towards S101 was explored by in vitro kinase 
assay. Due to high sequence similarity between these sites, phospho-specific antibodies 
recognize both phosphosites; thus, the relative contribution of each phosphorylation event 
was determined using Ser®Ala mutants (Figure 4.4C). Interestingly, the signal observed 
for phosphorylation at S65/101 was unaffected by mutation of S65; however, it was 
diminished with the S101A mutant. CDK4 was further validated as a S101 kinase using 
PhAXA, which, when analyzed by MS, identified only CDK4 and ERK2 as enriched in the 
S101C mutant over the controls (Table 4.1). While ERK2 is known to phosphorylate free 
4E-BP1 in vitro, this relationship has never been validated in vivo or in cells.46 
CDK4-cyclin D3-mediated 4E-BP1 phosphorylation was also analyzed via 
phosphoproteomics, which confirmed S101 as a CDK4 substrate in addition to uncovering 
several potential non-canonical phosphorylation sites (Figure 4.4D). Some of the sites do 
not fit the CDK4 recognition motif, which may be due to STK38, a common contaminating 
kinase in FLAG pulldowns.47 
 
Table 4.1 | 4E-BP1 (S101) Kinases Identified by PhAXA-MS. Table of all kinases identified by at least 
two peptides in at least one sample after filtering of common contaminants. This is a single biological 
replicate. Ratio of MS1 intensities were determined using Skyline. 
 
4E-BP1 is known to be phosphorylated in an ordered fashion;48 however, the role 
of S101 in the hierarchy has not been established. To probe this, non-phosphorylatable 
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Ala mutants were expressed in HEK293T cells. A near-complete loss of signal at S65/101 
in S101A transfected cells was observed, whereas S65A-transfected cells showed only 
a modest decrease compared to the control (Figure 4.5A). Intriguingly, S101, which is 
highly conserved across mammals (Figure 4.5B), has a robust effect on global 4E-BP1 
function, with S101A showing marked decrease in phosphorylation at each site that was 
investigated. This indicates a previously unknown reliance upon S101 and its role in 
initiating or maintaining the inactivation of 4E-BP1. 
 
 
Figure 4.5 | S101 is Highly Conserved and Affects Global 4E-BP1 Phosphorylation. A)  
 
4.5 CDK4 Promotes Rapamycin-Resistant 4E-BP1 Phosphorylation 
To further characterize CDK4-cyclin D-mediated inactivation of 4E-BP1, 
overexpression studies were performed. HEK293T cells were transfected with FLAG-
CDK4 and/or myc-Cyclin D2/D3 before stimulating with serum and insulin. Cells 
expressing cyclin D2 or D3 showed increased phosphorylation of 4E-BP1, an effect that 
became more evident in cells also treated with rapamycin (Figure 4.5A). Based on the in 
vitro kinase assay and PhAXA data shown above, this phenotype likely extends primarily 
to the non-canonical phosphosites such as S101, as other sites were largely unaffected.  
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Figure 4.6 | CDK4 Promotes Rapamycin-Resistant 4E-BP1 Phosphorylation. A) Western blots of 
3xFLAG-CDK4 and/or myc-D-cyclin transfected 293Ts stimulated with serum and insulin (150 nM) for 2 h 
with rapamycin (100 nM) or DMSO following 24-hour serum deprivation. B) 293Ts were deprived of serum 
for 24 h, followed by stimulation with media containing serum and insulin (150 nM), with or without 
rapamycin (100 nM) and/or palbociclib (5 µM) for the indicated duration. C) In vitro activity of immunopurified 
mTORC1 from serum starved, mitotic, or asynchronously 293Ts using recombinant, full length 4E-BP1 
(pre-incubated with HaloTag-eIF4E) as a substrate. Palbociclib (5 µM) was included in all buffers where 
appropriate after treating cells for 2-hours. 
 
Next, the role CDK4 in the previously observed, time-sensitive, rapamycin-resistant 
phosphorylation of 4E-BP1 was assessed.49 HEK293T cells were treated with rapamycin 
and palbociclib following serum starvation, and 4E-BP1 phosphorylation was monitored 
over time. At 2 h post stimulation, reduced phosphorylation at S65/101 was observed, 
indicated by a decrease in the highly phosphorylated, slow migrating phosphoform 
(Figure 4.6B). 6 h post-treatment, S65/101 phosphorylation was nearly restored in cells 
treated with rapamycin alone; those treated with the combination, however, showed a 
marked decrease in phosphorylation. Interestingly, most other sites for which 
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phosphorylation-specific antibodies exist were only slightly affected by this co-treatment, 
strengthening the link between CDK4 and S101 phosphorylation (Figure 4.6B). This 
decrease in 4E-BP1 phosphorylation was accompanied by a decrease in cyclin D2, the 
translation of which has been demonstrated to be cap-dependent.50 No changes in the 
phosphorylation of ribosomal protein S6 (a common readout of mTORC1 activity) were 
observed, verifying that palbociclib does not affect mTORC1 activity (Figure 4.6B). 
Additionally, the no changes were observed in the in vitro activity of mTORC1 isolated 
from palbociclib-treated cells (Figure 4.6C). These experiments clearly demonstrate that 
CDK4 phosphorylates 4E-BP1 in HEK293T cells under the same conditions in which 
PhAXA identified CDK4. Thus, these cumulative results serve as validation and 
strengthen the applicability of this assay to identify novel, physiologically relevant kinases.  
 
 
Figure 4.7 | Verification of Palbociclib and Rapamycin Sensitivity in Cell Lines. A) Colony formation 
of MCF-7, MDA-MB-468 and MDA-MB-231 cell lines treated with rapamycin (100 nM) and/or palbociclib (1 µM) 
for 10 days. B) Quantification of cell density from (A). Signal intensity is normalized relative to the no treatment 
control for each cell line. Error bars indicate standard deviation (n=3) for three biological replicates. Results are 
representative of three independent experiments. 
 
Palbociclib has recently been approved for the treatment of HR+, HER2- breast 
cancers;51 therefore, the correlation between CDK4 inhibitor sensitivity and CDK4-
mediated phosphorylation of 4E-BP1 was investigated. In line with literature, the ER+ 
MCF-7 and triple negative MDA-MB-231 cell lines were found to be palbociclib-sensitive, 
and the triple-negative MDA-MB-468 cell line to be resistant (Figure 4.7A and 4.7B).52 
Inhibition of CDK4/6 resulted a decrease in 4E-BP1 phosphorylation in the MCF-7 and 
MDA-MB-231 cell lines; this effect is magnified in cells co-treated with rapamycin (Figure 
4.9A) However, in the MDA-MB-468 cell line, palbociclib had no effect on 4E-BP1 
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phosphorylation. Though this cell line expresses CDK4 at levels commensurate with other 
cell lines, D cyclin expression is nearly undetectable at the protein level (Figure 4.8), likely 
contributing to palbociclib insensitivity.  
 
 
Figure 4.8 | CDK4 and D cyclin Expression Across Several Cell Lines. Western blot of CDK4 and D-
cyclins in a variety of cell lines in asynchronous culture or arrested in prometaphase with nocodazole. 
 
Next, the effect of combined inhibition of CDK4 and mTORC1 on cap-dependent 
translation (CDT) was investigated using cells stably expressing a bicistronic reporter 
construct containing Renilla and Firefly luciferase separated by the poliovirus internal 
ribosomal entry site (IRES).53 With this dual-luciferase reporter assay, the combination of 
palbociclib and rapamycin was found to cause a functional impact by decreasing CDT in 
MCF-7 cells, whereas palbociclib provided no added benefit over rapamycin treatment 
alone in MDA-MB-468 cells. (Figure 4.9B) The current understanding of rapamycin 
resistance suggests mTORC1 can carry-out rapamycin-insensitive activities, thus active-
site mTOR inhibitors (mTORKIs) such as INK128 are used to promote robust 4E-BP1 
reactivation.54 However, the combination of palbociclib and rapamycin was as effective 
as INK128 at reducing relative rates of CDT in this assay (Figure 4.9B), likely due to the 
significant reduction in total 4E-BP1 levels following chronic treatment with mTORKIs 








Figure 4.9 | mTORC1 and CDK4/6 cooperate to regulate cap-dependent translation. A) Western blot 
of MCF-7, MDA-MB-468 and MDA-MB-231 cell lines treated with rapamycin (100 nM) and/or palbociclib (1 
µM) for 72 hours. Vertical bars separate samples run on separate blots or different exposures B) Cap-
dependent dual luciferase assay of cells treated with rapamycin (100 nM) and/or palbociclib (1 µM) and/or 
INK128 (100 nM) for 72 hours. Normalized renilla luciferase is shown relative to the no-treatment control 
for each cell line. Data represented as mean +/- standard deviation (n=4), and are representative of three 
independent replicates. *P<0.05, **P<0.01 ***P<0.001, Statistical significance for all graphs was 
determined using an unpaired, two-tailed student’s t-test. C) Wastern blot of cells treated as in (A), but 
including INK128 (100 nM). 
 
4.6  Inhibition of CDK4 Downregulates c-Myc via 4E-BP1 
 After verifying the effect of CDK4/6 and mTOR inhibition on global rates of CDT, the 
effect of this combination on the expression of the oncogenic transcription factor c-Myc 
was investigated. MYC mRNA is known to be translated via CDT, and is commonly used 
to benchmark efficacy of CDT-targeting therapies.56 Intriguingly, c-Myc protein expression 
decreased in palbociclib-sensitive cells treated with the combination, while no change 
was observed in the resistant MDA-MB-468 cells. (Figure 4.10A) Downregulation of c-
Myc expression was determined to be due to decreased rates of translation, rather than 
a E2F-dependent decrease in MYC transcription,57 as rapamycin treatment resulted in an 
increase in MYC transcript levels in both cell lines (Figure 4.10D). mRNA expression of 
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several c-Myc target genes,58 including NPM1, EIF4E, ODC1, and CDK4 were then 
profiled to investigate the functional consequences of diminished c-Myc protein 
expression. In MCF-7 cells, inhibition of mTORC1 and CDK4 decreased c-Myc 
transcriptional activity, with the most robust decrease in activity observed in the 
combination treatment (Figure 4.10E). MDA-MB-468 cells showed very little change in c-
Myc transcriptional activity, which is in-line with the observed response at the protein level 
(Figure 4.10A and 4.10E). 
 
 
Figure 4.10 | c-Myc Expression is Dependent Upon Phosphorylation of S101. A) Western blot of c-
Myc expression in MCF-7, MDA-MB-468, and MDA-MB-231 cell lines treated with rapamycin (100 nM) 
and/or palbociclib (1 µM) for 72 hours. B) Expression of c-Myc in MDA-MB-468 and MCF-7 cell lines stably 
expressing doxycycline inducible FLAG-4E-BP1 mutants. Sub-confluent cells were harvested 8 days after 
addition of 1µg/mL and 0.1µg/mL dox for MDA-MB-468 and MCF-7, respectively. 6A mutant refers to 
concurrent mutation of T37A, T46A, S65A, T70A, S83A, and S101A. C) Western blot of c-Myc expression 
in 4E-BP1 knockout or control cells treated as in (A) Vertical bars separate images obtained from separate 
exposures. D-E) Relative RNA expression of D) MYC and E) c-Myc target genes from cells treated as in 
(A). Expression is normalized to the no treatment control sample for each cell line. UBB was used as an 
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For further verificaiton that this phenotype is a direct result of inhibition of 4E-BP1 
phosphorylation, doxycycline-inducible cell lines were generated. Importantly, these cell 
lines were engineered to express non-phosphorylatable forms of 4E-BP1 at near-
physiological levels. c-Myc downregulation was equivalent in MCF-7 cell lines expressing 
the S101A mutant and the fully nonphosphorylatable, 6A (T37A, T46A, S65A, T70A, 
S83A, and S101A) mutant, which is a strong negative regulator of global CDT. Other 
mutations had minimal effect on c-Myc protein levels, whereas only the 4E-BP1 (T37/46A) 
expressing MDA-MB-468 cell lines showed any change. These findings correlate with the 
effect these 4E-BP1 mutations have on the in vitro proliferation of these two cell lines 
(Figure 4.11). Finally, to further explore the involvement of 4E-BP1 in the palbociclib-
induced downregulation of c-Myc, 4E-BP1 knockout (KO) cell were generated using 
CRISPR Cas9. In MCF-7 cells lacking 4E-BP1, palbociclib treatment had no effect on c-
Myc expression (Figure 4.10C). Alternatively, treating cells with rapamycin resulted in 
increased c-Myc expression, which correlated with MYC transcript levels. As expected, 
palbociclib had no effect on c-Myc expression in MDA-MB-468 cells following 4E-BP1 
knockout. (Data not shown) 
 
 
Figure 4.11 | S101 Affects Proliferation in Palbociclib-Sensitive Cells. In vitro proliferation of MDA-MB-
468 and MCF-7 cell lines from main text Figure 5C. Cells were maintained in subconfluent culture for 12 
days after plating 200,000 cells per dish. Experiment was performed in biological triplicate; data is 
presented as mean +/- standard deviation. 4E-BP1 expression was induced with 1µg/mL and 0.1µg/mL dox 




 We next investigated the effects of CDK4 inhibition on cyclin D3, the translation of 
which is also cap-dependent.59,60 Treatment of MCF-7 control KO cells with palbociclib 
resulted in a slight reduction in the expression of cyclin D3, an effect which was reversed 
by 4E-BP1 KO (Figure 4.12A). To further probe the effect of CDK4 mediated 
phosphorylation of 4E-BP1 on global regulation of CDT, 4E-BP1 KO and control cells 
stably expressing the dual luciferase CDT reporter construct were created. 4E-BP1 KO 
had very little effect on the rate of CDT in response to palbociclib treatment alone; 
however, treatment of 4E-BP1 KO cells with both rapamycin and palbociclib resulted in a 
2.2-fold increase in CDT relative to control cells subjected to the same conditions (Figure 
4.12B). These experiments provide further evidence that CDK4 and mTOR converge on 




Figure 4.12 | 4E-BP1 Knockout Attenuates CDK4-driven Cap-Dependent Translation. A) Western blot 
of cyclin D3 expression in 4E-BP1 knockout or control cells treated +/- palbociclib (1 µM) for 72 hours B) Cap-
dependent dual luciferase assay of cells treated with rapamycin (100 nM) and/or palbociclib (1 µM) for 72 hours. Data 
represented as mean +/- SEM (n=3) after normalization to no treatment control for the appropriate cell line. *P<0.05, 
**P<0.01 Statistical significance for all graphs was determined using an unpaired, two-tailed student’s t-test. 
 
4.7  4E-BP1 as a Biomarker for Palbociclib 
CDK4/6 inhibitors are thought to function primarily by reducing phosphorylation-
mediated inactivation of the RB1 tumor suppressor, thereby inducing a cell cycle arrest 
at the G1-S transition. While RB1 is a useful biomarker for predicting response to this 
class of inhibitors in cell lines and preclinical models,14,52 the utility of RB1 as a biomarker 
in the clinic is controversial. 36,38,61 As it is clear that more biomarkers are needed to allow 
for better predictors of drug sensitivity, 37 the antiproliferative effects of palbociclib on 4E-
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BP1 KO cells was investigated. These experiments were performed with the goal of 
gaining an understanding of the value of 4E-BP1 in regulating the response to CDK4/6 
inhibition. Intriguingly, MCF-7 cells lacking 4E-BP1 were less sensitive than control cells 
to both palbociclib and rapamycin (Figure 4.13AA), indicating that inactivation of 4E-BP1 
contributes to the global role of CDK4 as an oncogene. 4E-BP1 knockout had no effect 
on the sensitivity of MDA-MB-468 cells to rapamycin and palbociclib (Not Shown). 
 
 
Figure 4.13 | CDK4-Mediated Phosphorylation of 4E-BP1 as a Biomarker. A) Proliferation of MCF-7 
cells +/- 4E-BP1 knockout was assessed by CellTiter Glow assay. Cell proliferation was assessed after 6 
days of treatment with rapamycin (100 nM) and/or palbociclib (1 µM). Treated samples are shown relative 
to no treatment control for that cell line. Bars represent mean +/- standard deviation (n=3) ***P<0.001, 
****P<0.0001 Statistical significance for all graphs was determined using an unpaired, two-tailed student’s 
t-test. B) A list of proteins/antibodies with the highest correlation to survival in the BRCA dataset from TCPA. 
Shown are all antibodies with a Log-Rank P value of <0.01. P-values were used as reported by TCPA. C) 
Kaplain-Meyer curves showing the total survival time for BRCA patients from the TCPA dataset with high 
(red) and low (blue) p4E-BP1(S65/101) 
 
To further evaluate the impact of CDK4-medated phosphorylation of 4E-BP1 in breast 
cancer patients, clinical data from the Reverse-Phase Protein Array (RPPA) Breast 
Invasive Carcinoma (BRCA) datasets available through The Cancer Proteome Atlas 
(TCPA) was mined.62 In-depth analysis of these datasets found that phosphorylation of 
4E-BP1 at S65/101 was the third most significant marker associated with overall survival 
across all 224 antibodies used in the array, while phosphorylation of T37/46 had no 
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predictive value in this dataset (Figures 4.13B and 4.13C). Analysis of protein biomarkers 
co-regulated with S101 phosphorylation found a strong positive correlation between 
phosphorylation of 4E-BP1 at S65/101 and Rb at S807/811 (Figure 4.14), indicating that 
these phosphorylation events are upregulated in similar patient populations. This 
correlation strengthens the link between, and the importance of, CDK4-mediated 
phosphorylation of S101 in BRCA. 
 
 
Figure 4.14 | 4E-BP1 (S65/101) Phosphorylation Mirrors pRb Phosphorylation. Histogram showing 
the Pearson Coefficient for pairwise regression between p4E-BP1 (S65/101) and every other antibody in 




Using PhAXA-MS, a new interaction between CDK4 as a 4E-BP1 was identified. In-
depth validation of this signaling axis demonstrated that CDK4 phosphorylates 4E-BP1 
to maintain rapamycin-resistant cap-dependent translation. Expansion of PhAXA to other 
4E-BP1 phosphorylation sites identified S101, a previously poorly understood 
phosphorylation site, as a bona fide CDK4 substrate. Mechanistic evaluation of CDK4-
mediated phospohorylation of this residue uncovered the mechanism by which CDK4 
promotes expression of c-Myc. However, it is currently unclear if this is strictly due to 
translational control, or through a combination of other mechanisms such as nuclear 
export, as the entirety of its function have yet to be elucidated. Finally, preliminary 
evidence that 4E-BP1, namely 4E-BP1 hyperphosphorylated at S101, is provided. These 
studies demonstrate that this phosphosite should be investigated as a biomarker for 
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predicting sensitivity to palbociclib and other CDK4/6 inhibitors. Unfortunately, it is 
impossible to differentiate between the phosphorylation of S65 and S101 by Western blot, 
RPPA or IHC given the promiscuity of the antibody, so targeted mass-spec based 
methods, such as Selected Reaction Monitoring (SRM), will need to be developed for 
accurate analysis of S101 as biomarker. 
Given this newly discovered role of CDK4, it is likely that inhibition of this process is a 
previously unknown function of CDK4/6 inhibitors such as palbociclib, ribociclib and 
abemaciclib. Recently, several studies have reported potent in vivo antitumor effects by 
combined inhibition of mTOR and CDK4/6,18,31-33 while a large phenotypic screen found 
the strongest cooperation between PI3K/mTORC1 and CDK4/6 inhibitors.35 In addition, 
many ongoing clinical trials are investigating the efficacy of this combination in treating a 
range of cancers (Table 4.2); however, the rationale for this combination is lacking, as an 
in-depth understanding of the molecular mechanisms for this observed cooperativity is 
not understood. The data presented in this chapter promote the idea that these drugs 
provide an additive benefit over standalone therapies, in part, by inhibiting CDT, thereby 
decreasing the expression of anabolic proteins, and by altering the c-Myc transcriptional 
program that drives a wide range of cancers.63 These findings support the investigation 
of this combination for treating cancers displaying clear hallmarks of an addiction to 
CDT.64 
 
Table 4.2 | US Clinical Trials Using Combination of CDK4/6 Inhibitors and Rapalogs 
 
4.9  Materials and Methods 
 
Small molecule reagents  
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Palbociclib Isethionate (Selleckchem) was dissolved in water to 10 mM. Rapamycin (Alfa 
Aesar), was dissolved in DMSO. Human recombinant insulin was purchased from Sigma. 
All reagents were used as received. 
 
Cell Culture 
HEK293T and HeLa cells were grown in DMEM (Corning) supplemented with 10% FBS, 
glutamine, penicillin, and streptomycin (Gibco). U2 OS cells were kindly provided by Dr. 
Beth Lawlor and cultured according to ATCC guidelines. MDA-MB-231 cells were a kind 
gift from Dr. Nouri Neamati and grown in RPMI-1640 media supplemented with 10% FBS 
and glutamine. MDA-MB-468 and MCF-7 cells were a kind gift from Dr. Max Wicha. MDA-
MB-468 cells were grown in DMEM (Corning) supplemented with 10% FBS and 
glutamine. MCF-7 cells were cultured according to ATCC guidelines. Cells were grown at 
37 °C with 5% CO2 in a humidified incubator, passaged at least twice before use for 
experiments and no more than 10 times before returning to low passage stocks. All cell 




Annealed oligos corresponding to the C-terminal myc-tag were cloned into pcDNA3 at 
XbaI and ApaI. pcDNA3/Au1-mTOR and pRK5/HA-Raptor plasmids were generously 
shared by Dr. Diane Fingar. CDK4, CDK6, CCND1, CCND2 and CCND3 cDNA were 
cloned directly from A549 cDNA prepared using the Superscript III first-strand synthesis 
kit (Invitrogen). CDK4, CDK6, 4E-BP1, and Raptor were cloned into the pcDNA3/3XFLAG 
vectors. CCND1, CCND2, CCND3 were cloned into the pcDNA3/myc tag vectors. MBP-
4E-BP1 (wild type and alanine mutants) was prepared by cloning into pMCSG9 (Univ. of 
Michigan Center for Structural Biology) using LIC cloning. HaloTag-eIF4E has been 
described elsewhere.65 All mutations were generated by PCR mutagenesis. The 
sequences for all primers used are listed in Table 4.3. All constructs were fully sequenced 
by Sanger sequencing. 
ORF Purpose Sequence 5’ à 3’ 
   
Tags c-Term Myc  Forward CTAGAGAACAAAAACTCATCTCAGAAGAGGATCTGTGAGGGCC Reverse CTCACAGATCCTCTTCTGAGATGAGTTTTTGTTCT 
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T37A Forward GACTACAGCACGGCCCCCGGCGGCACG  
 Reverse CGTGCCGCCGGGGGCCGTGCTGTAGTC  
T46A Forward GCTCTTCAGCACCGCCCCGGGAGGTACC  
 Reverse GGTACCTCCCGGGGCGGTGCTGAAGAGC  
S65A Forward CTGATGGAGTGTCGGAACGCACCTGTGACCAAAACAC 
 Reverse GTGTTTTGGTCACAGGTGCGTTCCGACACTCCATCAG 
S65A/T70A Forward GCACCTGTGACCAAAGCACCCCCAAGGGATCTGC 
 Reverse GCAGATCCCTTGGGGGTGCTTTGGTCACAGGTGC 
T70A Forward CTCACCTGTGACCAAAGCACCCCCAAGGGATCTGC 
 Reverse GCAGATCCCTTGGGGGTGCTTTGGTCACAGGTGAG 
S83A Forward CCGGGGGTCACCGCCCCTTCCAGTGATG 
 Reverse CATCACTGGAAGGGGCGGTGACCCCCGG 
S101A Forward GAGCCACCTGCGCAATGCCCCAGAAGATAAGCGG 




UTR Forward CAGCTGCCCAGGAAGAG Reverse AAATGCTCCGGAGAGGAG 
Coding Forward AATTGAATTCATGGAACACCAGCTCCTG Reverse GCTATCTAGAGATGTCCACGTCCCGCAC 
CCND2 
UTR Forward TTCTGCTCCACCTTCTCT Reverse GGATTCCCTTATGCTGTACTT 
Coding Forward AATTGAATTCATGGAGCTGCTGTGCCAC Reverse GCTATCTAGACAGGTCGATATCCCGCAC 
CCND3 
UTR Forward TTCCACGGTTGCTACATCG Reverse TCCCTTGGGCTTTGTGAAGG 
Coding Forward AATTGAATTCATGGAGCTGCTGTGTTGC Reverse GCTATCTAGACAGGTGTATGGCTGTGACAT 
CDK4 
UTR Forward TCCCTTGATCTGAGAATGGCT Reverse TCCATTGCTCACTCCGGATT 
Coding Forward AATTGAATTCATGGCTACCTCTCGATATGAG Reverse GCTATCTAGATCACTCCGGATTACCTTCATC 
CDK6 
UTR Forward GGAGCAAGTAAAGCTAGACC Reverse ACAGTAAACTAGGCGGTTTC 
Coding Forward AATTGAATTCATGGAGAAGGACGGCCTGT Reverse GCTATCTAGATCAGGCTGTATTCAGCTCCG 
 
Table 4.3 | List of Primers Used for Cloning and Mutagenesis 
 
Lentivirus and stable cell lines 
rLuc-PolIRES-fLuc was digested out of pcDNA3 (a kind gift from Dr. Peter Bitterman) 
using NheI and XhoI then ligated into pLentiLoxEV (UM vector core). The multiple cloning 
site of PLVX-Tre3G-mCherry (Clontech) was modified to include a XbaI restriction site by 
ligating annealed oligos into MluI and EcoRI. 3X-FLAG-4E-BP1 constructs were cloned 
from pcDNA3 into MluI and XbaI. PLVX-Tet3G (Clontech) was used for making rtTA-
packaging lentivirus. Lentiviruses were packaged in HEK293T cells by cotransfection of 
the transfer plasmid, pMD2.G (a gift from D. Trono, Addgene plasmid 12259) and psPAX2 
(a gift from D. Trono, Addgene plasmid 12260) using linear PEI (3:1 ratio of PEI to DNA). 
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Media was changed 16 h after transfection, and viral supernatant was collected after an 
additional 24 and 48 h, before filtering through 0.45-µm filters and storing in aliquots at -
80 oC. Titer was determined by colony formation assay where possible. Cells were 
infected at a MOI of <0.5 in the presence of polybrene (Santa Cruz Biotechnology) (8 
µg/mL), then after 48 h, selected with geneticin (1 mg/mL) (Gibco) for 3 weeks or 
puromycin (2 µg/mL) (Sigma) for 6 d; no selection was used for the dual luciferase cell 
lines. Polyclonal cell lines were maintained in geneticin (300 µg/mL) and puromycin, 1 
µg/mL for MDA-MB-231 and MDA-MB-468, and 0.25 µg/mL for MCF-7. Expression of 3X-
FLAG-4E-BP1 was induced with doxycycline (Alfa Aesar), 1 µg/mL for MDA-MB-231 and 
MDA-MB-468 and 0.1 µg/mL for MCF-7.  
 
CRISPR Knockouts 
pSpCAS9(BB)-2A-GFP (a gift from Feng Zheng, Addgene plasmid #48138) was digested 
with BbsI and oligos targeting nothing (for non-target control) or exon 1 of EIF4EBP1 
(designed using http://tools.genome-engineering.org) were added. 1e6 MCF-7 or MDA-
MB-468 cells were transfected using Lipofectamine LTX with PLUS reagent according to 
the manufacturer’s instructions, and media was changed after 18 hours. After a 48-hour 
recovery, GFP-positive cells were sorted and saved using a MoFlo Astrios flow cytometer. 
Single cell clones were then isolated in 96-well plates by limiting dilution, and knockout 
was confirmed by western blot and sanger sequencing. For the final cell lines used in the 
experiments, five clones were pooled together (knockout or non-targeting control) and all 
experiments were then performed within 3 passages.  
Target Orientation Sequence 5’ à 3’ 
Non-Target Forward CACCGGTAGCGAACGTGTCCGGCGT Reverse AAACACGCCGGACACGTTCGCTACC 
EIF4EBP1 Forward CACCGCGCACAGGAGACCATGTCCG Reverse AAACCGGACATGGTCTCCTGTGCGC 
 
Table 4.4 | List of Primers Used for CRISPR Knockout Constructs 
 
Kinase Assays 
For CDK4/CDK6 kinase assays, HEK293T cells were grown in 10-cm plates to 60-70% 
confluence. Cells were subsequently transfected with 3XFLAG-CDK4/6 (3 µg) and myc-
CCND1/2/3 or empty pcDNA3 (3 µg) using linear PEI (3:1 ratio of PEI to DNA). After 18 
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h, the media was changed to plain growth media. ~20 h later, cells were stimulated with 
insulin (150 nM) for 60 min, and then harvested by scraping into TBST (50 mM Tris pH 
7.4, 150 mM NaCl, 0.1% Tween-20) with aprotinin (10 µg/mL), leupeptin (5 µg/mL), 
pepstatin (7 µg/mL), NaF (10 mM), sodium orthovanadate (2 mM), b-glycerophosphate 
(10 mM), and sodium pyrophosphate (2 mM). The cells were disrupted by pipetting up-
and-down (20´) and rotated end-over-end for 15 min at 4 °C. The resulting lysate was 
cleared by centrifugation at 18,000´g for 10 min at 4 °C. CDK4/6 complexes were isolated 
from 1 mg of lysate (1 mL) by immunoprecipation with packed, prewashed FLAG-M2 
magnetic resin (15 µL) for 90 min at 4 °C. The resin was then washed with lysis buffer (1 
mL, 3´), TBS with b-glycerophosphate (10 mM) (1 mL, 1´), and TBS containing MgCl2 
(10 mM) and b-glycerophosphate (1 mM) with or without ATP (1 mM) (1 mL, 1´). After 
washing, the resin was suspended in 1x TBS (30 µL) with 4E-BP1 (1 µM), HaloTag-eIF4E 
(2 µM), MgCl2 (10 mM), DTT (1 mM) and b-glycerophosphate (10 mM), with or without 
ATP (1 mM) and palbociclib as described. The kinase reaction was incubated at 30 °C 
for 30 min, and subsequently quenched with 5´ Laemmli buffer (7 µL).  
 
mTOR kinase assays were performed similar to those with CDK4/6 complexes with a few 
notable exceptions. HEK293T cells were transfected with 3XFLAG-Raptor (4 µg) and 
Au1-mTOR (3 µg). Lysis was performed in HEPES buffer (pH 7.4, 20 mM) containing 
NaCl (100 mM), CHAPS (0.3% v/v) and protease/phosphatase inhibitors as described 
above. For assessing the effect of CDK4/6 inhibition on mTORC1 activity in vitro, 
palbociclib (5 µM) was included in all lysis buffers, wash buffers and assay buffers, in 
addition to using cells treated with palbociclib (5 µM) for 2 h before lysis.  
 
Immunoblotting 
MCF-7, MDA-MB-231, MDA-MB-468 cells were lysed directly in-well using RIPA buffer 
(10 mM Tris-HCl, 150 mM NaCl, 1% Triton, 1% sodium deoxycholate, 0.1% SDS, pH 7.2) 
supplemented with 10 µg/mL aprotinin, 5 µg/mL leupeptin, 7 µg/mL pepstatin, 10 mM 
NaF, 2 mM sodium orthovanadate, 10 mM b-glycerophosphate, and 2 mM sodium 
pyrophosphate). Lysates were then sonicated thoroughly on ice. Protein concentrations 
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were normalized by the BCA assay (Pierce), resolved on 4-20% Tris-glycine gels 
(Invitrogen), transferred to 0.45-µm PVDF (Thermo) using Towbin’s buffer (low amperage 
for ~4 h at 4 °C), blocked with 5% non-fat milk in TBST, then probed with primary 
antibodies overnight at 4 °C. Antibodies used in this study were the following: Actin-HRP 
(sc-47778) and Myc-9E10 (sc-40) from Santa Cruz Biotechnology; CDK4 (12790), CDK6 
(13331), Cyclin D2, (3741), DYKDDDK tag (14793), MEK1/2 (9122), mTOR (2972), S6 
(2217), pS6 (240/244) (2215), p4E-BP1 (T37/46) (2855), p4E-BP1 (S65/101) (9451), 
p4E-BP1 (T70) (9455), 4E-BP1 (9644), c-Myc (13987), Rb (9313) and pRb (S780) (3590) 
from Cell Signaling Technology; and FLAG-M2 (F1804) from Sigma. 
 
Protein expression and purification 
MBP-tagged 4E-BP1 proteins were expressed and purified from BL21 Rosetta 2 (DE3) 
E. coli. LB media supplemented with ampicillin and chloramphenicol (500 mL) was 
inoculated with an overnight culture (5 mL) and grown to an OD600 of 0.8 before 
expression was induced with IPTG (1 mM) for 2 h at 37 °C. After centrifugation (15 min 
at 7,500´g), cell pellets were re-suspended in NiA buffer (30 mL; 50 mM sodium 
phosphate, 100 mM NaCl, 20 mM imidazole, 2 mM DTT) containing guanidine-HCl (6M), 
and then sonicated on ice for 4 min (pulse: 1sec on/1sec off at 35% amplitude). Cleared 
lysate (18,000´g for 20 min at 4 °C) was added to packed Ni-NTA resin (4 mL; Qiagen) 
by gravity filtration. The resin was washed with NiA buffer with guanidine-HCl (6M) (25 
mL, 1´), NiA buffer (25 mL, 1´), and then eluted with NiB buffer (NiA buffer with 500 mM 
imidazole). Eluted protein was cleaved with TEV protease overnight at 4 °C and dialyzed 
into Tris-buffered saline (TBS) with 2mM DTT (6 L). Dialyzed protein was passed through 
Ni-NTA resin and pure, cleaved 4E-BP1 was collected as flow through. Purity was verified 
as >95% by Coomassie stain. Protein concentration was determined by absorbance at 





Total RNA was isolated using TRIzol reagent (Invitrogen), and cDNA was subsequently 
prepared using the Superscript III first-strand synthesis kit (Invitrogen) according to 
manufacturer’s instructions. For gene expression analysis, qPCR was performed using 
the PowerUP sybr green master mix (Applied Biosystems) on a Viia 7 thermocycler using 
the fast-qPCR protocol. The relative fold change was calculated using the comparative 
threshold cycle (CT) method.66 PCR amplification efficiency controls were performed for 
each primer set and dissociation curves verified single product amplification.  
Target Efficiency Orientation Sequence 5’ à 3’ 
UBB 1.988 Forward GCGCATAGAGGAGAAGGGAAA Reverse CCTCCCGAGAGGCAGTTTAG 
MYC 2.185 Forward TGCCTTGGTTCATCTGGGTC Reverse GCTTAGGAGTGCTTGGGACA 
EIF4E 2.072 Forward GACTGTCGAACCGGAAACCA Reverse GCCCATCTGTTCTGTAGGGG 
NPM1 2.124 Forward TCGCGAGATCTTCAGGGTCTA Reverse AGAGAAGGCGGACGGAGATA 
ODC1 2.07 Forward GCTTTCACGCTTGCAGTTAATA Reverse CACTCGACTCATCTTCGTCATC 
CDK4 2.11 Forward GCTCTGCAGCACTCTTATCTAC Reverse CTCAGTGTCCAGAAGGGAAATG 
 
Table 4.5 | List of Primers Used for qRT-PCR 
 
Dual Luciferase reporter assay 
The cap-dependent translation luciferase reporter assay was performed using the dual 
glo luciferase assay system according to manufacturer’s instructions (Promega). Briefly, 
polyclonal rLuc-polIRES-fLuc expressing cell lines were plated at 20,000 cells per well in 
96-well, white, tissue culture-treated plates, and treated as described in the figure 
legends. After 72 h, media was aspirated and OptiMEM (75 µL) (Gibco) was added to 
each well. Cells were lysed in firefly luciferase buffer, and total (firefly luciferase) 
luminescence was measured after 15 min. Total luminescence (renilla luciferase) was 
measured within one hour after addition of Stop & Glo reagent. 
 
In-gel digestion 
TEV-cleaved 4E-BP1 (30 pmol) was used as a substrate for in vitro phosphorylation by 
cyclin D3-CDK4 complex with or without ATP (1 mM). The samples were separated by 
SDS-PAGE and stained with Coomassie R-250 (Bio-Rad). The protein samples were 
processed and analyzed at the Proteomics Resource Facility at the University of 
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Michigan. The gel slice corresponding to TEV-cleaved 4E-BP1 was destained with 30% 
methanol for 4 h. Following reduction and cysteine alkylation as described in Chapter 3, 
proteins were digested overnight with sequencing grade, modified trypsin (Promega) (500 
ng) at 37 °C. Peptides were extracted by incubating the gel with of 50% acetonitrile/0.1% 
TFA (150 mL) for 30 min at room temperature. A second extraction with 100% 
acetonitrile/0.1% TFA (150 mL) was also performed. Both extracts were combined and 
dried in a Vacufuge concentrator (Eppendorf). 
 
Mass spectrometry  
Performed as described in Chapter 3 
 
Phosphosite identification by MS/MS 
To identify phosphorylation sites on 4E-BP1 following in vitro phosphorylation by 
CDK4/cyclin D3, MS/MS spectra were manually inspected after COMET search (as 
described above); however, a database of only cleaved 4E-BP1 was used. Only those 
phosphopeptides for which the phosphate could be clearly localized to one residue were 
considered putative CDK4 substrates. No other peptide or protein level validation was 
performed. 
 
Cell Proliferation Assay 
Cells were plated at a density of 2,000 cells per well in white-bottom, tissue culture 
treated, 96-well plates. The following day, cells were treated as stated in the figure 
legends; media (+/- drug) was changed every 48-hours. After 6-days, proliferation was 
assessed using Cell-Titer Glo (Promega). All samples were normalized to the no-
treatment control.  
 
Immunofluorescence  
MCF-7 cells were grown in 24-well plates on poly-L-lysine-coated coverslips (Fisher) until 
~50% confluent. Cells were washed twice with ice-cold 1´ PBS, and then fixed with 4% 
paraformaldehyde for 15 min at room temperature. Fixed cells were washed twice with 
1´ PBS, permeabilized with 0.2% Triton X-100 in PBS for 30 min, blocked with 1% BSA 
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in PBS and 0.1% Triton X-100 for 1 h at room temperature, and then probed with primary 
antibody (1:500 for 4E-BP1 and CCND3) in blocking buffer overnight at 4 °C. Coverslips 
were washed 3´ with PBS for 10 min each before probing with AlexaFluor488-conjugated 
donkey anti-rabbit (Invitrogen) or AlexaFluor647-conjugated goat anti-mouse secondary 
antibodies (1:1000 dilution for each). Cover slips were subsequently washed 3´ with 1´ 
PBS for 10 min before mounting onto glass slides with Prolong diamond antifade 
mountant with DAPI. Images were taken using a Nikon A1 Spectral confocal microscope 
with a 60x objective. All images were compared to no-primary or cross-primary controls 
to ensure a specific signal. Images were compiled using Adobe Photoshop (CS6). 
 
Colony formation assay 
Cells were seeded in 6-well plates at a density of 20,000 cells per well for MCF-7 and 
MDA-MB-468 cells, and 1,000 cells per well for MDA-MB-231 cells. The next day, cells 
were treated with rapamycin (100 nM), palbociclib (5 µM) or DMSO (0.001% v/v). Fresh 
media containing the appropriate inhibitors was added after 5 days. On day 10, cells were 
fixed with glutaraldehyde (6% v/v) and stained with crystal violet (0.25% w/v) for 3 hours 
at room temperature. After removing excess stain, plates were dried overnight before 
imaging and quantifying cell density using an Odyssey CLx (Licor).  
 
TCPA dataset mining 
The TCGA-L4 breast invasive carcinoma (BRCA) Reverse-Phase Protein Array (RPPA) 
dataset (901 samples) was downloaded from The Cancer Proteome Atlas (TCPA) on 
04/08/2018. Pairwise linear regressions were run for each antibody against p4EBP1_S65, 
and Pearson coefficients were extracted and plotted as a histogram using R version 3.4.4.  
 
Statistics 
Two-sided t-tests were performed using Prism (v7); equal variance between samples 
being compared was established. Graphs show mean +/- S.E.M or +/- standard deviation 




































































































































































































































































Chapter 5  
  
CDK4 Regulates 4E-BP1 During Mitosis 
 
5.1  Abstract 
 Chapter 4 outlined the contribution of CDK4 in the maintenance of 4E-BP1 
phosphorylation under conditions of mTORC1-inhibitor resistance. In this same vein, 
mTORC1 inhibitors have been proven to be unable to inhibit the hyperphosphorylation of 
4E-BP1, a phenotype that is a hallmark of cells undergoing mitosis. In this chapter, 
PhAXA-MS analysis of mitotic 4E-BP1 kinases again reveals an unexpected role of 
CDK4. Mechanistic evaluation of this signaling event uncovers a controversial finding 
linking CDK4 to the progression of cells from metaphase, through cytokinesis, and into 
the G1 phase of the cell cycle. Finally, a speculative model is suggested that incorporates 
these findings into those linking CDK1 activity to both mitotic progression and 4E-BP1 
phosphorylation. 
 
5.2   Mitosis and the MàG1 Transition 
 Mitosis and cytokinesis ultimately result in the formation of two daughter cells and 
represent the culmination of the eukaryotic cell cycle. This process, consisting of 
prophase, metaphase, anaphase and telophase, is responsible for the orderly 
dissemination of genetic material to a new generation. Dysregulation of mitosis can lead 
to improper chromosomal distribution, or aneuploidy, which can lead to birth defects and 
cancers.1,2 Therefore, progression through mitosis is highly regulated by a number of 
important pathways, including by many kinases.3 However, the kinase that is generally 
recognized as being responsible for progression into cytokinesis is CDK1. CDK1 
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positively regulates most aspects of mitosis, including mitotic entry, chromosome 
condensation, spindle assembly and breakdown of the nuclear envelope.4 Upon bipolar 
spindle assembly, the E3 ligase anaphase-promoting complex or cyclosome (APC/C) 
promotes inactivation of CDK1 via degradation of Cyclin B1, pushing cells into anaphase.5 
 
Figure 5.1 | Phases of Mitosis with Arresting Agents. The phases of mitosis are shown in the context of 
the beginning of G1-phase (interphase). Nocodazole and RO-3306 are shown with respect to the specific 
point at which these agents induce cell cycle arrest.  
 
 One difficulty with studying discrete, mitosis-specific signaling events is the relative 
complexity of each step and the dearth of tools available with which to isolate cells in 
each phase. Some of these tools include the non-specific CDK1 inhibitor RO-3306, which 
arrests cells at the G2/M border, and nocodazole, which arrests cells in prometaphase. 
(Figure 5.1) Few other tools, aside from microscopy, exist to study signaling events within 
each discrete phase of mitosis. This, coupled with the promiscuity of CDK16 and the lack 
of CDK1 activity after metaphase,5 leaves open the possibility of undiscovered biology 
within the context of the MàG1 transition. 
 
5.3  Phosphorylation of 4E-BP1 in Mitosis 
One hallmark of mitosis is the hyperphosphorylation of 4E-BP1 (Figure 5.2), 




Figure 5.2 | Cells Arrested in Mitosis Exhibit Hyperphosphorylation of 4E-BP1. Western blot of 
phosphorylated 4E-BP1 from cell lines growing asynchronously, or treated +/- 500 nM nocodazole for 20 
hours to induce a prometaphase arrest. 
 
The ramifications of 4E-BP1 phosphorylation during this phase of the cell cycle are 
not well understood, as most reports agree that cap-dependent translation (CDT) is 
reduced during mitosis.10-14 However, these findings are controversial, as other groups 
have found that most mitotic protein synthesis is cap-dependent, and driven by 
CDK1/Cyclin B1-mediated phosphorylation of 4E-BP1.8 Further evaluation of mitosis-
specific 4E-BP1 phosphorylation sites in the context of the optimal CDK1 recognition motif 
yielded the identification of S83 as a novel CDK1 phosphorylation site.9 While this 
phosphorylation event has no effect on CDT, S83-phosphorylated 4E-BP1 reportedly 
associates with centrosomes upon chromatin condensation, hinting at a function of mitotic 
4E-BP1 that is independent of translational control. However, the studies implicating 
CDK1 in the phosphorylation of 4E-BP1 relied heavily on the highly non-specific CDK1 
inhibitor RO-3308. As this molecule is typically used as a tool compound for inducing a 
mitotic arrest at the precipice of prophase, these studies provide only a snapshot of the 
regulation of 4E-BP1 during a very narrow window of mitosis. Moreover, the promiscuity 
of this inhibitor at the high concentration that was used (9 µM) makes assessment of 
these findings quite difficult.  
 
5.4   CDK4 Regulation of Mitotic 4E-BP1 
 Given the relative lack of information regarding 4E-BP1 phosphorylation in mitosis, 
and the knowledge that this process is mTOR independent, PhAXA-MS was used to 
identify candidate 4E-BP1 kinases. Using the microtubule inhibitor nocodazole, HEK293T 
cells were arrested in prometaphase, and released into medium containing insulin for 1 
hour before harvesting and proceeding with PhAXA-MS analysis. Four kinases were 
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enriched in the T46C sample treated with crosslinker relative to the controls. (Table 5.1) 
CDK4 was again identified as a top hit, though this was unexpected given the relative 
lack of information linking CDK4 to regulation of mitosis and/or cytokinesis.  
 
Table 5.1 | Mitosis-Specific 4E-BP1 Kinases Identified by PhAXA-MS. 4E-BP1 (T46) kinases from 
nocodazole-arrested HEK293T cells. Table consists of all kinases identified by at least two peptides in at 
least one sample after filtering of common contaminants. This is a single biological replicate. Relative 
quantification of protein levels using MS1 intensity is not shown due to a lack of shared peptides between 
samples. ‘+’ refers to samples treated with 1, while ‘-‘ refers to ATP only controls 
 
However, given the role of CDK4 in regulating rapamycin resistant 4E-BP1 
phosphorylation, as discussed in Chapter 4, this same signaling event was again 
investigated, but in the context of mitosis. To assess mitosis-specific CDK4-mediated 
phosphorylation of 4E-BP1, a variety of cell lines were arrested in prometaphase, and 
released into medium containing insulin with or without rapamycin and/or palbociclib. 
(Figure 5.3) As expected, rapamycin has no effect on the mitotic phosphorylation of 4E-
BP1. However, cells released from nocodazole arrest in medium containing palbociclib 
show a marked decrease in phosphorylation, as demonstrated by the disappearance of 
the b, and g bands. This effect is markedly increased in cells treated with both rapamycin 
and palbociclib, indicating that mTOR and CDK4 act in concert to regulate 4E-BP1 
phosphorylation following release from prometaphase arrest.  
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Figure 5.3 | Mitotic Phosphorylation of 4E-BP1 is Palbociclib-Sensitive. Nocodazole-arrested cells 
were treated with rapamycin (100 nM) and/or palbociclib (5 µM) in fresh media containing insulin (150 nM) 
for 2 h. Blots for pRb in HEK293T and MDA-MB-468 cells are not shown as they are Rb inactive and null, 
respectively. 
 
Palbociclib has recently been approved for treatment of HR+, HER2- breast 
cancers; therefore, a correlation between CDK4 inhibitor sensitivity and CDK4-mediated 
mitotic phosphorylation of 4E-BP1 was investigated. Three commonly used breast cancer 
cell lines, for which palbociclib sensitivity has been previously established using an in vitro 
cell proliferation assay, were further evaluated.15 Using MCF-7, MDA-MB-231 and MDA-
MB-468 cell lines, which show high, intermediate, and low sensitivity to palbociclib, 
respectively, a striking correlation was uncovered in relation to the mitotic 4E-BP1 
phosphorylation in response to palbociclib treatment. CDK4 inhibition almost completely 
abrogated mitotic phosphorylation of 4E-BP1 in the ER+ MCF-7 cell line, whereas no 
effect was observed in the triple-negative MDA-MB-468 cell line even when treated in 
combination with rapamycin. A slight response was also observed in the MDA-MB-231 
cell line, which correlates to the previously reported, intermediate sensitivity to 
palbociclib.15  
To verify that the palbociclib treatment was on-target, the phosphorylation state of 
4E-BP1 phosphorylation was compared to that of Rb at S780, the canonical CDK4 
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across cell lines was observed, ranging from <330nM in U2 OS, to ~1.25uM in HeLa cells. 
However, the effective concentration of palbociclib required to inhibit both 4E-BP1 and 
Rb phosphorylation at S780 correlated with the relative expression of CDK4 in each cell 
line. (Figure 5.4B) A similar effect is seen with 293Ts, which require a concentration of 
~2.5uM to fully inhibit 4E-BP1 phosphorylation and have the highest relative expression 
of CDK4 at the protein level. (Not shown) While there are clearly other factors that affect 
CDK4 inhibitor sensitivity, including Rb status and D-cyclin expression levels, among 
others, this correlation was noteworthy. 
 
Figure 5.4 | 4E-BP1 phosphorylation mirrors pRb dose-dependently. A) Nocodazole arrested cells 
were treated with rapamycin (100 nM) and/or palbociclib (5 µM – 313 nM) in fresh media containing insulin 
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(150 nM) for 2 h. B) Western blot of relative CDK4 expression in cell lines used in (A). Samples were run 
on the same gel and are from the same exposure. 
 
5.5  Palbociclib and Mitotic Cap-Dependent Translation 
CDK4 inhibition results in reduced mitotic phosphorylation of 4E-BP1; however, it 
was unclear whether this directly affects rates of cap-dependent translation. To measure 
assembly of the eIF4F translation initiation complex, the 7-methyl guanosine (m7G) cap 
binding assay was used. Mitotic MCF-7 cells treated with rapamycin showed a marginal 
increase in 4E-BP1, and a corresponding slight decrease in eIF4G, associated with cap-
bound eIF4E (Figure 5.5A). Similar results were observed in palbociclib treated cells; 
however, mitotic MCF-7s treated with the combination showed a robust increase in m7G 
associated 4E-BP1, and a large decrease in eIF4G. This benefit was only observed in 
MCF-7 cells recently release from nocodazole arrest, as palbociclib had very little effect 
eIF4F complex association in asynchronous cells. As expected, MDA-MB-468 cells did 
not respond to CDK4 inhibition, but displayed a predictable response to rapamycin.  
The m7G cap affinity assay is a robust way of analyzing the ratio of 4E-BP1- and 
eIF4G-bound eIF4E, however it is performed in lysate, thus rendering any intricacies in 
sub-cellular localization of these proteins indeterminable. Therefore, a split-
nanoluciferase-based assay was developed to quantify the eIF4E-4E-BP1 interaction in 
live cells. (Figure 5.6) Using this assay, CDK4 inhibition was found to cause a large 
increase in this interaction in live cells; the effect is compounded by tandem inhibition of 
mTORC1 with rapamycin. Attempts to use this assay for measuring the eIF4E-eIF4G 
interaction were unsuccessful, as no signal was observed under any conditions. This is 
likely due to the large size of eIF4G (220kDa) and the relative orientation of the two 
protein’s N- and C-termini.  
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Figure 5.5 | mTOR and CDK4 Co-regulate Mitotic Cap-Dependent Translation. a, m7G cap affinity 
assay. Palbociclib and rapamycin synergize to increase eIF4E-4E-BP1 association and decrease 
eIF4E-eIF4G association in Palbociclib-sensitive cells. B) Schematic for the cap-affinity assay. C) 
Palbociclib results in the reduction of cap-dependent translation of Cyclin D2 in nocodazole-arrested U2 
OS cells. All experiments were performed in biological triplicate; representative images are shown. 
 
Though it was clearly established that CDK4 inhibition during mitosis increased 
eIF4E association with 4E-BP1, and decreased eIF4E association with eIF4G, it was still 
unclear of the effects this had on the expression of cap-dependent transcripts at the 
protein level. Therefore, the expression of cyclin D2, a bona fide cap-dependent 
transcript, was analyzed in both mitotic and asynchronous cells treated with palbociclib 
and/or rapamycin. In asynchronous U2 OS cells, palbociclib had no effect on cyclin D2 
levels, whereas rapamycin markedly reduced the levels of this protein. Conversely, in 
cells recently released from a prometaphase block, rapamycin had very little effect, while 
inhibition of CDK4 resulted in a drastic reduction of cyclin D2 at the protein level. (Figure 
5.5C) Moreover, Cyclin D2 expression was found to be higher in nocodazole arrested 




Figure 5.6 | mTOR and CDK4 Regulate eIF4E-4E-BP1 Association in Mitotic Cells. A) Schematic for 
the nanoluciferase assay monitoring the eIF4E-4E-BP1 interaction in live cells. S=SmBit, LG=LargeBit. 
Data shown in panel B) Error is plotted as +/- SEM, n = 5. 
 
5.6  CDK4 Controls the MàG1 Transition 
 To characterize the effect of CDK4 inhibition on progression through mitosis into G1, 
the cell cycle distribution was analyzed at several time points following release from a 
prometaphase arrest. MCF-7 cells treated with palbociclib showed a profound G2 block, 
relative to control cells, as they were unable to transition into G1. (Figure 5.7A and 5.7B) 
However, in the CDK4 inhibitor resistant MDA-MB-468 cell line, palbociclib had very little 
effect after an initial G2 delay. As expected, the MDA-MB-231 cell line showed an 
intermediate G2 block compared to these other two cell lines. These results were not 




Figure 5.7 | CDK4 Inhibition Results in a G2-Block in Palbociclib-Sensitive cells. A) Full cell-cycle 
profiles of cells arrested with nocodazole, and then released into media with or without palbociclib (5 μM) 
for the indicated time points. B) Quantification of the percentage of cells from a with 2N DNA content from 
(A). C) Quantification of the percentage of cells from a with >4N DNA content from (A) Data are represented 
as the mean +/- standard deviation of three biological replicates. 
 
 These results are quite interesting in the context of the canonical role of CDK4, as it 
is primarily responsible for controlling the checkpoint at the G1àS transition. However, it 
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has previously been demonstrated that Cyclin D3/CDK4 activity is essential for 
progression through G2, and that ionizing radiation activates p16 causing CDK4 inhibition 
leading to a G2 phase delay.16 Additionally, analysis of pRb phosphorylation at S780, 
showed an increase in CDK4 activity in cells released from a prometaphase arrest across 
a panel of cell lines. (Figure 5.8) These data support the essential role of CDK4/Cyclin 
D3 in progression into G1 from G2/M, and provides evidence that pharmacological 
inhibition can result in a G2 block even in p16 null cancer cell lines, such as MCF 7.17  
However, the exact mechanism of this G2 delay is not fully understood. It is possible that 
inhibition of Rb phosphorylation is the primary factor, though an inability to translate 
critical anabolic proteins, due to inhibited cap-dependent translation, may also play a role. 
However, the fact that palbociclib treatment slows G1 entry in Rb-null MDA-MB-468 cells 
at early time points following release, suggests that other CDK4/6 activity is important for 
regulation of this transition. This could be due to an altered transcriptional program 
induced by inhibition of phosphorylation of FOXM1, a master transcription factor that 
regulates expression of genes essential for mitosis.18 Moreover, it is unclear at what stage 
of the cell cycle these cells are being blocked, whether in later stages of mitosis or simply 
a failure to undergo cytokinesis. However, it is clear that a post-mitotic checkpoint is in 
part regulated by CDK4, and gaining a better understanding of the mechanism behind 
this warrants further consideration. 
 
Figure 5.8 | Cells Arrested in Mitosis Exhibit Increased CDK4 Activity. Western blot of phosphorylated 







 In this chapter, evidence was presented suggesting that CDK4 phosphorylates 4E-
BP1 during mitosis, maintaining cap-dependent translation. Given this newly discovered 
role, it is likely that inhibition of this process is a previously unknown function of CDK4 
inhibitors such as palbociclib. However, it is important to point out a discrepancy between 
our findings and previous studies that have investigated the mechanism of action of 
CDK4/6 inhibitors. It is well established that long-term inhibition of CDK4/6 activity results 
in a robust G1 arrest. However, these findings have demonstrated that inhibition of CDK4 
during mitosis results in an arrest at the MàG1 transition. It is likely that cells that escape 
mitosis and transit into G1 do so with lower levels of important proteins that would 
otherwise contribute to the G1àS transition, such as the D-type cyclins, thereby 
increasing the propensity for a G1 arrest. Moreover, those cells that do not escape CDK4 
inhibitor induced G2 arrest may, after an extended period, undergo apoptosis or necrosis. 
Though this has not been observed at time points up to 8 hours, (data not shown) longer 
time points may yield a better understanding of these discrepancies. 
 It is important to try to reconcile these observations with those previously observed 
that report CDK1 as the kinase that phosphorylates 4E-BP1 during mitosis.8,9 It is possible 
that, given the differences in experimental design between this report and those of Shuda 
et. al, CDK1 phosphorylates 4E-BP1 in prometaphase, but in later stages of mitosis 
and/or cytokinesis (following degradation of cyclin B1), CDK4 assumes that role. (Figure 
5.9) It is also possible that S101 phosphorylation is strictly CDK4 dependent (See Chapter 
4), but the effect it has on global phosphorylation of 4E-BP1, renders CDK1 effectively 
null towards the reported CDK1 sites. Therefore, it is possible that mTOR, CDK1 and 
CDK4 all act in concert to regulate cap-dependent translation during mitosis and the 
transition into G1. 
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Figure 5.9 | Proposed Scheme for Regulation of Mitotic 4E-BP1 Phosphorylation. In this scheme, 4E-
BP1 phosphorylation is maintained at medium levels during interphase (G1, S, G2), but induction of CDK1 
activity in prophase induces hyperphosphorylation. This phenotype is maintained by Cyclin D-CDK4 
complexes through cytokinesis after degradation of Cyclin B1 to start Anaphase.  
 
 
5.8  Materials and Methods 
Small molecule reagents  
Palbociclib Isethionate (Selleckchem) was dissolved in water to 10 mM. Rapamycin (Alfa 
Aesar), and SP600125 (ApexBio) were dissolved in DMSO. Human recombinant insulin 
was purchased from Sigma. Nocodazole and 3XFLAG peptide were purchased from 
ApexBio. All reagents were used as received. 
 
Cell Culture 
HEK293T and HeLa cells were grown in DMEM (Corning) supplemented with 10% FBS, 
glutamine, penicillin, and streptomycin (Gibco). U2 OS cells were kindly provided by Dr. 
Beth Lawlor and cultured according to ATCC guidelines. MDA-MB-231 cells were a kind 
gift from Dr. Nouri Neamati and grown in RPMI-1640 media supplemented with 10% FBS 
and glutamine. MDA-MB-468 and MCF-7 cells were a kind gift from Dr. Max Wicha. MDA-
MB-468 cells were grown in DMEM (Corning) supplemented with 10% FBS and 
glutamine. MCF-7 cells were cultured according to ATCC guidelines. Cells were grown at 
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37 °C with 5% CO2 in a humidified incubator, passaged at least twice before use for 
experiments and no more than 10 times before returning to low passage stocks. All cell 
lines were authenticated by STR profiling, and regularly tested for mycoplasma 
contamination. 
 
Preparation of m7GDP resin 
 m7GDP resin synthesis was adapted from that reported.19 m7GDP sodium salt (2.3 mg; 
Sigma) was dissolved in water (500 µL), and a solution of sodium periodate (1.1 mg) in 
sodium acetate buffer (100 µL; 0.1M, pH 6) was added. The resulting mixture was 
agitated at room temperature for 30 min protected from light. Adipic acid dihydrazide 
agarose (1 mL packed; Sigma) was washed with water (1´ 20 mL) followed by sodium 
acetate buffer (1´ 20mL), and then re-suspended in sodium acetate buffer (2 mL). To this 
slurry was added with aniline (10 µL) and the oxidized m7GDP solution. The resin mixture 
was then shaken at room temperature for 45 min before adding sodium cyanoborohydride 
(5 mg) and agitated overnight at 4 °C. The resin was washed with NaCl (1M; 5´ 5 mL), 
equilibrated in buffer A (5 mL; 50 mM HEPES, pH 7, 200 mM KCl), and stored at 4 °C.  
 
m7G cap affinity assay 
Cap pull-down assay was carried out as previously described20. Briefly, cells were lysed 
in cap pull-down buffer (50 mM HEPES-KOH pH 7.5, 150 mM KCl, 1 mM EDTA, 2 mM 
DTT and 0.1% Tween 20) containing protease and phosphatase inhibitors and freeze-
thawed thrice. Cell lysate was centrifuged at 20,000´g for 25 min. Supernatant was then 
incubated for 2 h at 4 °C with m7GDP-agarose resin. Resin was washed with cap pull-
down buffer (3´) followed by TBS and water. Proteins were then eluted by boiling in 2´ 
LDS sample buffer (10 min at 70 °C) and analyzed by Western blotting.  
 
Nanobit/split luciferase assay 
pFN33K LgBiT-eIF4E and pFN35K SmBiT-4EBP1 (50 ng each) were reverse-transfected 
into MCF-7 and MDA-MB-468 cells in a 96-well white opaque plate using Lipfectamine 
LTX with PLUS reagent.  After 16 h, cells were arrested with nocodazole (500 nM). 20 h 
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later, cells were treated with rapamycin (100 nM) and/or palbociclib (5 µM). After 2 h 
incubation, Nano-Glo Live cell reagent (Promega #N2011; 25 µL) was added and total 
luminescence was read within 40 min on a BioTek Cytation 3 reader. 
 
DNA constructs 
eIF4E was digested out of HaloTag-eIF4E using SgfI and PmeI, and then ligated into 
pFN33K (Promega) to obtain the LargeBit-eIF4E construct. 4E-BP1 was cloned into 
pFN35K (Promega) using the same method to obtain the SmallBit-4E-BP1 construct. 
HaloTag-4E-BP1 and -eIF4E have been described elsewhere.21 
 
Flow cytometry 
Cells were harvested with trypsin, washed once with ice-cold 1´ PBS, re-suspended in 
ice cold 1´ PBS, and then 100% ice-cold ethanol was added dropwise to a final 
concentration of 70%. Cells were fixed at -20 °C for 4 h, and then stored at 4 °C for 18-96 
h. Fixed cells were washed twice with ice-cold 1´ PBS, re-suspended in 1´ PBS 
containing propidium iodide (50 µg/mL; Sigma) and RNase A (100 µg/mL, Fisher), and 
incubated at 37 °C for 30 min. Cells were then filtered and analyzed using a Cytoflex flow 
cytometer (Beckman). Cell cycle distributions were analyzed using FlowJo (v10).  
 
Statistics 
Two-sided t-tests were performed using Prism (v7); equal variance between samples 
being compared was established. Graphs show mean +/- S.E.M or +/- standard deviation 
as described in the figure legends. 
 
Immunoblotting and PhAXA-MS 



























































































Conclusions and Future Directions 
 
6.1  PhAXA: Limitations and Further Optimization  
 The development of activity-based probes for kinase discovery has been an active 
area of interest for over 15 years. Yet, the tools that have so far been developed have not 
reached the desired goal of reliably identifying novel kinase-substrate interactions. This 
work has demonstrated the ability of PhAXA to fill this unmet need, constituting the first 
reported successful kinase discovery using an activity-based probe. PhAXA was proven 
to be broadly applicable relative to the desired bait protein, as it performed well using 
three distinct classes of substrate proteins (4E-BP1, c-Jun and Erk2). Moreover, this 
method has been deemed amenable to using serine, threonine, and tyrosine to cysteine 
mutants as phosphosite mimetics. However, it is important to emphasize that the work-
flow for this assay will need to be optimized for each bait protein of interest. Each bait 
system described here utilized the exact same assay conditions with respect to buffers, 
additives, detergents, lysis methods and cell lines. It is possible that, with further 
optimization of these assay parameters, PhAXA can provide more robust enrichment of 
the appropriate kinase or kinases. However, the conditions outlined in this report provide 
a starting point for pursuing other kinase-substrate systems of interest, and serve as a 
testament to the robust nature of this chemoproteomic approach.  
 The largest limitation of this assay is the need to perform the pulldown in lysate, 
rather than with intact cells, as subcellular localization is known to significantly contribute 
to kinase activity.1,2 Moreover, a positive identification may arise from a kinase that is 
normally localized to a compartment that would preclude an interaction with the bait of 
interest. This hypothetical scenario highlights the importance of thoroughly validating any 
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identified relationships in a more physiological setting. Some groups have attempted to 
make cell permeable, kinase-directed probes to circumvent the issue of cell 
permeability.3,4 While the goal of cell permeability can be achieved, these probes lose 
affinity to kinases, resulting in under-sampling the available kinome relative to the non-
cell permeable probes used in lysate. Thus, it is clear that this is a balancing act between 
achieving increased target engagement vs increased physiological relevance. It seems 
the most prudent course would be to couple PhAXA for an unbiased query of the available 
kinome, with a proximity labeling technique that maintains cellular integrity. 
Implementation of this type of orthogonal approach would yield very high-confidence 
interactions, but would also substantially increase the amount of work required for 
answering a biological question.  
 Another potentially useful adaptation to PhAXA would be to incorporate ADP-based 
methacrylate crosslinkers into the workflow, as the conserved active-site lysine targeted 
by these probes can be shifted towards the beta-phosphate in some kinases. This 
modified crosslinker would likely improve kinome coverage, as a similar finding was 
observed with the nucleotide acyl phosphate probes discussed in Chapter 1.5 Finally, to 
achieve a more accurate and sensitive quantification between samples, an approach 
utilizing isobaric tags6 should be used. When coupled with Real-Time Searching (RTS) 
and MS3 analysis of reporter ions,7 this method can provide more accurate 
peptide/protein quantitation and significantly reduced acquisition time relative to label free 
methods.8 
 
6.2 4E-BP1 as a Biomarker for CDK4/6 Inhibitors 
The lack of biomarkers that predict the efficacy of CDK4/6 inhibitors has 
significantly limited the clinical success of these drugs.9,10. Biomarker such as RB1, p16, 
CCND1, CCND3 and CDK4 have not translated to clinical success, likely due to an 
incomplete understanding of the mechanism by which these drugs ultimately work.11,12 
However, implementation of PhAXA for identifying kinases capable of mTOR-
independent phosphorylation of 4E-BP1 identified a novel function of CDK4, and CDK4/6 
inhibitors by extension. The finding that CDK4 phosphorylates 4E-BP1, thereby 
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maintaining cap-dependent translation under conditions of mTOR inhibition is a critical 
insight into how CDK4/6 inhibitors regulate cell proliferation in cancers.  
The identification of S101, a previously poorly understood phosphorylation site, as 
a bona fide CDK4 substrate has far-reaching applications. Data presented in Chapter 4 
shows S65/101 phosphorylation can predict overall survival of patients with breast 
cancer, while T37/46 provide no prognostic value. As Ser65, Thr37, and Thr46 are all 
canonical mTORC1 substrates, while Ser101 is not, it is possible that S101 
phosphorylation could provide the majority of predictive value in this patient cohort. 
Unfortunately, it is impossible to differentiate between the phosphorylation of S65 and 
S101 by Western blot, RPPA or IHC given the promiscuity of the antibody, so targeted 
mass-spec based methods, such as Selected Reaction Monitoring (SRM), will need to be 
developed for accurate analysis of S101 as biomarker. However, given that 
phosphorylation of this residue promotes expression of c-Myc, an oncogene that strongly 
promotes malignant transformation, successful adaptation of S101 as a clinical biomarker 
could open up a new patient population that may benefit from CDK4/6 inhibitors. 
 
6.3 Palbociclib and Rapalog Therapy in the Clinic 
  CDK4/6 inhibitors are largely ineffective as standalone therapies for cancer, likely 
due their properties as cytostatic, rather than cytotoxic, drugs.13 However, as field of 
leveraging kinase inhibitors as cancer therapeutics moves in the direction of double or 
triple agent therapies,14,15 the future of CDK4/6 inhibitors lies in two realms. First, in the 
field of immunotherapeutics, CDK4/6 inhibitors have been shown to cooperate with anti-
PD-L1 antibodies to modulate the immune response, thereby increasing infiltration of 
tumors by cytotoxic T-cells.16 This has been shown to occur via upregulation of the PD-
L1 protein in response to CDK4/6 inhibition.17 Second, several studies have reported 
potent in vivo antitumor effects by combined inhibition of mTOR and CDK4/6, 18-21 while 
a large phenotypic screen found the strongest synergy between PI3K/mTORC1 and 
CDK4/6 inhibitors.22 In addition, many ongoing clinical trials are investigating the efficacy 
of this combination in treating a range of cancers (Table 4.2). However, the rationale for 
this combination is lacking, as an in-depth understanding of the molecular mechanisms 
for this observed cooperativity is not understood.  
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 Findings presented in Chapter 4 clearly demonstrate that these drugs provide an 
additive benefit over standalone therapies, in part, by inhibiting CDT, thereby decreasing 
the expression of anabolic proteins, and by altering the c-Myc transcriptional program that 
drives a wide range of cancers.23 These findings support the investigation of this 
combination for treating cancers displaying clear hallmarks of an addiction to CDT.24 
Finally, investigations should be made into this using this combination as a therapy for 
KRAS driven cancers. Tumors harboring activated KRAS are the most resistant to mTOR 
inhibitors, and CDK4/6 inhibition can partially downregulate the KRAS-associated gene 
signature.25-28  
 
6.4  Concluding Remarks 
 As our knowledge of the human phosphoproteome expands, development of tools 
for confidently assigning kinases to these tens of thousands of orphan phosphorylation 
sites is paramount. By filling in these gaps of knowledge, scientists can uncover signaling 
intermediates and biomarkers important for more effective treatment of cancers and other 
diseases. Despite the potential for improvements, wide-spread application of the existing 
PhAXA platform will help achieve this result. Leveraging these new findings will uncover 
novel drug targets, while maximizing the clinical benefit of existing inhibitors through a 

































































































Appendix A  
 

































































































































P05412 541 634 481 499 1546 1537 1260 1235 1043.5 1085.5 870.5 867
P30153 96 41 104 49 275 106 324 132 185.5 73.5 214 90.5
P06748 135 156 133 137 248 337 271 335 191.5 246.5 202 236
O14744 167 177 151 176 210 207 252 246 188.5 192 201.5 211
P63151 92 29 88 36 194 62 253 74 143 45.5 170.5 55
Q9BQA1 190 201 158 193 159 145 161 172 174.5 173 159.5 182.5
TRYP_PIG 126 129 108 100 211 210 206 240 168.5 169.5 157 170
A0A087X2H 115 14 105 18 119 31 137 30 117 22.5 121 24
P78347 122 123 106 111 120 152 124 142 121 137.5 115 126.5
O95373 93 99 78 88 128 68 152 118 110.5 83.5 115 103
H0YIV4 55 126 58 98 198 259 151 248 126.5 192.5 104.5 173
P67775 42 25 44 26 109 37 153 36 75.5 31 98.5 31
O15397 61 46 74 38 95 13 105 21 78 29.5 89.5 29.5
P07437 80 66 85 60 42 38 68 54 61 52 76.5 57
P23588 0 87 138 93 5 4 6 5 2.5 45.5 72 49
Q99733-2 33 64 45 63 103 138 77 152 68 101 61 107.5
A0A0A0MR 105 87 113 91 6 5 7 11 55.5 46 60 51
P55072 105 122 117 125 2 1 1 1 53.5 61.5 59 63
P50990 65 74 72 74 35 31 44 34 50 52.5 58 54
P68363 36 9 72 47 44 42 38 41 40 25.5 55 44
Q16531 57 42 41 39 79 55 68 31 68 48.5 54.5 35
O75643 88 76 68 65 24 7 30 12 56 41.5 49 38.5
P78371 53 76 60 69 29 29 37 35 41 52.5 48.5 52
P26641 41 45 47 43 51 34 50 15 46 39.5 48.5 29
P17987 53 62 58 60 25 34 36 29 39 48 47 44.5
P11142 47 45 59 46 39 29 33 24 43 37 46 35
P48643 51 67 55 61 29 31 34 37 40 49 44.5 49
Q9Y5B9 79 78 84 90 0 2 2 1 39.5 40 43 45.5
Q66LE6 21 5 28 5 42 7 51 12 31.5 6 39.5 8.5
P78527 92 93 73 83 3 1 6 2 47.5 47 39.5 42.5
Q6P2Q9 56 58 54 51 12 9 25 7 34 33.5 39.5 29
Q01105-2 19 32 17 28 87 98 60 70 53 65 38.5 49
Q15393 33 33 40 36 34 35 37 26 33.5 34 38.5 31
O43719 55 42 57 39 24 12 15 16 39.5 27 36 27.5
P54105 51 61 51 46 13 11 20 11 32 36 35.5 28.5
P17544-6 38 34 28 37 46 57 42 65 42 45.5 35 51
P21333 73 61 66 58 3 3 4 3 38 32 35 30.5
B8ZZU6 25 48 35 40 29 37 34 46 27 42.5 34.5 43
O15355 41 20 28 23 66 27 41 31 53.5 23.5 34.5 27
Q14204 77 71 61 73 5 5 7 11 41 38 34 42
A0A0G2JIW 52 50 44 37 24 18 24 17 38 34 34 27
Q99832 41 63 41 52 20 27 26 27 30.5 45 33.5 39.5
P04264 89 61 47 80 45 39 19 17 67 50 33 48.5
G5E9A6 0 7 21 21 2 9 45 38 1 8 33 29.5
P68104 53 54 39 46 26 18 24 18 39.5 36 31.5 32
Q8NHY2 28 24 28 23 36 40 35 21 32 32 31.5 22
P04075 50 65 62 74 0 0 0 0 25 32.5 31 37
Q9C0C9 37 41 26 36 46 66 35 55 41.5 53.5 30.5 45.5
O75533 37 38 36 32 24 22 25 30 30.5 30 30.5 31
P45984 15 1 11 9 30 1 50 20 22.5 1 30.5 14.5
P62714 22 3 19 5 48 14 41 21 35 8.5 30 13
P40227 31 56 37 41 16 19 23 24 23.5 37.5 30 32.5
Replicate 1 PSMs Replicate 2 PSMs Average PSMs
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P11021 40 36 35 27 26 23 25 15 33 29.5 30 21
Q92688 36 42 35 32 38 41 23 43 37 41.5 29 37.5
P50991 45 55 43 43 8 14 14 16 26.5 34.5 28.5 29.5
P45983-3 4 0 21 0 6 0 35 3 5 0 28 1.5
P13645 64 50 46 49 46 42 9 25 55 46 27.5 37
Q01105 56 68 50 56 23 18 4 24 39.5 43 27 40
Q15208 31 40 28 32 20 20 26 23 25.5 30 27 27.5
P09651-2 47 36 45 40 4 6 9 7 25.5 21 27 23.5
Q9BT78 31 2 18 2 40 3 36 2 35.5 2.5 27 2
Q13200 34 37 32 41 22 10 19 16 28 23.5 25.5 28.5
Q02930 21 38 28 28 15 24 22 34 18 31 25 31
P49368 40 47 39 52 6 10 11 7 23 28.5 25 29.5
P13489 17 7 16 10 44 31 33 26 30.5 19 24.5 18
P05455 23 30 23 19 16 26 25 31 19.5 28 24 25
Q15029 32 34 31 28 14 7 17 11 23 20.5 24 19.5
Q9BRS2 42 32 41 29 5 4 5 3 23.5 18 23 16
Q15750 45 43 43 50 0 0 1 1 22.5 21.5 22 25.5
Q7KZF4 45 50 44 57 0 0 0 0 22.5 25 22 28.5
E9PRY8 31 28 27 19 17 13 17 4 24 20.5 22 11.5
Q12899 19 18 17 22 39 34 26 37 29 26 21.5 29.5
Q9BUA3 36 44 41 35 0 1 1 1 18 22.5 21 18
P24534 20 18 23 16 12 13 19 4 16 15.5 21 10
Q9BQE3 50 40 13 15 18 0 28 0 34 20 20.5 7.5
P35908 41 44 34 44 0 0 7 8 20.5 22 20.5 26
Q99613 40 40 35 36 6 7 6 10 23 23.5 20.5 23
Q08945 39 37 41 41 0 0 0 0 19.5 18.5 20.5 20.5
P07900 34 41 40 41 1 0 0 2 17.5 20.5 20 21.5
Q99460 37 40 34 41 9 5 6 4 23 22.5 20 22.5
P35527 55 36 24 54 26 11 15 20 40.5 23.5 19.5 37
Q9Y4B6 16 16 16 11 29 36 23 26 22.5 26 19.5 18.5
B0QY89 31 26 24 24 13 14 15 15 22 20 19.5 19.5
P61201 22 6 16 4 32 2 23 0 27 4 19.5 2
A0A0J9YXJ8 0 19 19 17 0 0 19 0 0 9.5 19 8.5
P17980 27 31 30 28 8 4 8 7 17.5 17.5 19 17.5
P09874 40 29 38 36 0 0 0 1 20 14.5 19 18.5
P26640 33 32 37 24 2 1 1 0 17.5 16.5 19 12
P36578 18 18 19 17 21 31 18 22 19.5 24.5 18.5 19.5
P04406 37 42 36 40 0 0 0 0 18.5 21 18 20
Q14152 31 33 36 33 1 0 0 0 16 16.5 18 16.5
Q96EB6 10 11 13 13 23 43 22 38 16.5 27 17.5 25.5
Q8WWY3 38 32 30 28 7 8 5 5 22.5 20 17.5 16.5
E7EU96 14 17 11 15 28 32 24 25 21 24.5 17.5 20
P60228 25 21 24 23 12 11 11 17 18.5 16 17.5 20
J3QLE5 15 16 17 17 15 15 18 15 15 15.5 17.5 16
P18847 10 9 8 7 21 19 26 21 15.5 14 17 14
P62191 19 23 26 14 9 10 8 9 14 16.5 17 11.5
Q9Y4X5 20 5 13 5 38 5 21 2 29 5 17 3.5
Q02878 20 20 16 14 13 24 17 23 16.5 22 16.5 18.5
P35998 22 22 24 21 10 6 8 7 16 14 16 14
C9JEH3 19 0 8 0 49 0 24 0 34 0 16 0
P39687 30 22 26 18 6 8 5 5 18 15 15.5 11.5
P61978 30 23 21 25 8 5 10 7 19 14 15.5 16
P11940 8 8 9 9 20 33 22 31 14 20.5 15.5 20
Q08211 22 18 23 20 8 16 8 12 15 17 15.5 16
P53621 29 32 31 23 0 0 0 0 14.5 16 15.5 11.5
A0A087WU 17 13 22 13 14 5 9 2 15.5 9 15.5 7.5
P49902 31 3 25 2 2 0 6 2 16.5 1.5 15.5 2
P19338 18 19 16 22 21 30 14 31 19.5 24.5 15 26.5
P35580 30 29 30 35 0 0 0 0 15 14.5 15 17.5
P52272 19 21 26 14 2 11 4 11 10.5 16 15 12.5
P46060 11 17 23 21 3 1 7 4 7 9 15 12.5
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A0A087X2I 22 25 24 23 5 6 5 3 13.5 15.5 14.5 13
Q09028 13 16 18 15 6 7 11 8 9.5 11.5 14.5 11.5
A0A0U1RQ 20 21 28 20 0 0 1 0 10 10.5 14.5 10
Q12906 9 9 10 9 17 17 18 25 13 13 14 17
B3KS98 22 22 21 17 5 5 7 8 13.5 13.5 14 12.5
Q92598 17 5 12 8 17 5 16 7 17 5 14 7.5
Q9UNF1 10 13 20 12 6 5 8 6 8 9 14 9
C9JFE4 17 1 10 3 27 1 18 0 22 1 14 1.5
Q14974 13 6 16 6 14 3 12 5 13.5 4.5 14 5.5
P22626 29 30 25 26 0 1 2 0 14.5 15.5 13.5 13
O00231 26 24 23 24 6 4 4 5 16 14 13.5 14.5
Q14011 12 21 20 13 6 6 7 7 9 13.5 13.5 10
P53618 28 29 26 26 0 1 1 1 14 15 13.5 13.5
Q9Y657 15 20 22 18 6 6 5 6 10.5 13 13.5 12
Q9Y230 20 20 21 15 2 3 6 2 11 11.5 13.5 8.5
P23396 8 7 13 7 11 9 14 4 9.5 8 13.5 5.5
Q92973 8 1 13 2 8 0 14 0 8 0.5 13.5 1
P17535 8 14 10 6 20 17 16 16 14 15.5 13 11
P08238 19 19 22 23 0 0 4 2 9.5 9.5 13 12.5
ALBU_BOV 25 22 16 23 16 11 10 13 20.5 16.5 13 18
P55884 26 23 25 21 1 0 1 0 13.5 11.5 13 10.5
Q9UMS4 11 17 20 17 6 4 6 10 8.5 10.5 13 13.5
P51991 16 16 24 19 0 0 2 0 8 8 13 9.5
P62316 13 10 18 11 6 7 8 7 9.5 8.5 13 9
G8JLB6 23 14 17 16 15 11 8 9 19 12.5 12.5 12.5
P62195 20 19 19 19 7 6 6 12 13.5 12.5 12.5 15.5
Q9Y678 26 30 24 21 1 2 1 1 13.5 16 12.5 11
P60709 16 14 20 15 10 5 5 12 13 9.5 12.5 13.5
O75688 20 11 17 15 7 4 8 6 13.5 7.5 12.5 10.5
Q9Y6Y0 27 35 20 30 2 0 4 1 14.5 17.5 12 15.5
Q9P2R3 24 24 24 30 0 0 0 0 12 12 12 15
O43242 19 24 19 24 4 5 5 2 11.5 14.5 12 13
Q9Y4E8 15 19 21 21 1 3 3 0 8 11 12 10.5
O95905 15 6 9 3 21 0 15 0 18 3 12 1.5
P30154 7 0 4 0 10 0 19 1 8.5 0 11.5 0.5
P39023 24 24 18 24 9 15 5 11 16.5 19.5 11.5 17.5
O00303 19 16 16 20 8 9 7 12 13.5 12.5 11.5 16
P43686 20 22 20 20 4 4 3 5 12 13 11.5 12.5
P53396 15 25 23 20 0 0 0 0 7.5 12.5 11.5 10
A0A087WV 9 12 14 16 9 8 9 9 9 10 11.5 12.5
PRDX1_HU 5 5 12 8 10 6 11 10 7.5 5.5 11.5 9
Q2TAY7 19 16 23 12 0 0 0 0 9.5 8 11.5 6
Q92905 13 1 7 2 21 2 16 1 17 1.5 11.5 1.5
Q14103 15 18 23 9 0 0 0 0 7.5 9 11.5 4.5
P13010 27 26 22 25 2 11 0 15 14.5 18.5 11 20
P12956 19 25 19 23 1 12 3 22 10 18.5 11 22.5
Q00839 26 20 18 15 7 10 4 5 16.5 15 11 10
Q15057 26 34 22 27 0 0 0 0 13 17 11 13.5
O75607 7 9 7 6 16 23 15 25 11.5 16 11 15.5
Q13347 21 16 20 16 3 6 2 3 12 11 11 9.5
Q9NYJ8 23 19 22 19 0 0 0 0 11.5 9.5 11 9.5
B4DY09 7 7 10 7 15 17 12 16 11 12 11 11.5
Q14008 28 20 22 15 0 0 0 0 14 10 11 7.5
H3BLZ8 16 15 22 17 1 0 0 2 8.5 7.5 11 9.5
Q8N5C8 21 16 22 15 0 0 0 0 10.5 8 11 7.5
H0Y8C6 15 13 12 8 8 0 10 3 11.5 6.5 11 5.5
B1AKJ5 14 34 13 26 9 32 8 29 11.5 33 10.5 27.5
P61247 15 9 11 10 17 26 10 20 16 17.5 10.5 15
P62424 15 16 15 15 16 14 6 10 15.5 15 10.5 12.5
Q7L2H7 14 15 13 14 3 4 8 5 8.5 9.5 10.5 9.5
P61163 12 17 16 16 3 2 5 3 7.5 9.5 10.5 9.5
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Q14566 17 16 21 17 0 0 0 0 8.5 8 10.5 8.5
O75694 11 0 13 0 3 0 8 0 7 0 10.5 0
E9PDP5 22 4 15 1 32 4 5 8 27 4 10 4.5
P35606 30 30 20 25 0 0 0 0 15 15 10 12.5
O43318-2 24 23 20 20 0 0 0 1 12 11.5 10 10.5
P25205 22 22 20 20 0 0 0 0 11 11 10 10
Q13263 24 19 19 14 1 0 1 0 12.5 9.5 10 7
O60506-3 13 13 17 17 7 1 3 4 10 7 10 10.5
Q15233 13 12 17 16 0 1 3 1 6.5 6.5 10 8.5
P55036 9 11 16 13 4 3 4 7 6.5 7 10 10
E7EM64 13 2 6 0 27 0 14 0 20 1 10 0
Q9BTY7 5 0 5 1 6 0 15 0 5.5 0 10 0.5
Q71U36 5 27 0 4 19 21 19 21 12 24 9.5 12.5
A0A0J9YVP 25 0 0 17 21 15 19 20 23 7.5 9.5 18.5
Q15365 16 11 8 12 9 7 11 16 12.5 9 9.5 14
Q13561 22 14 15 10 4 2 4 2 13 8 9.5 6
P33993 20 22 19 18 0 0 0 0 10 11 9.5 9
P23246 18 18 18 10 1 0 1 0 9.5 9 9.5 5
P49736 15 20 19 21 0 0 0 0 7.5 10 9.5 10.5
P31689 16 11 18 13 1 0 1 1 8.5 5.5 9.5 7
Q4G0J3 7 8 6 10 17 16 12 20 12 12 9 15
P61353 8 7 7 6 15 14 11 14 11.5 10.5 9 10
Q13435 10 18 13 13 7 8 5 6 8.5 13 9 9.5
Q07021 1 4 0 4 12 19 18 25 6.5 11.5 9 14.5
Q9BTT0 9 18 17 13 6 9 1 9 7.5 13.5 9 11
P62979 10 4 7 6 9 13 11 7 9.5 8.5 9 6.5
P62701 12 10 10 7 8 11 8 10 10 10.5 9 8.5
O00203 11 16 17 11 1 1 1 0 6 8.5 9 5.5
Q9UNS2 11 0 7 1 16 0 11 0 13.5 0 9 0.5
Q8TEB1 6 1 6 0 13 0 12 0 9.5 0.5 9 0
P06753-2 13 0 12 1 0 0 6 0 6.5 0 9 0.5
Q13185 2 5 9 4 1 0 9 1 1.5 2.5 9 2.5
O00232 20 25 15 17 0 4 2 2 10 14.5 8.5 9.5
A0A0C4DG 24 22 17 16 0 0 0 0 12 11 8.5 8
B0YIW6 17 16 16 22 0 0 1 1 8.5 8 8.5 11.5
P15880 5 4 7 5 14 14 10 13 9.5 9 8.5 9
Q9Y265 13 15 15 15 0 3 2 3 6.5 9 8.5 9
Q16875 20 11 14 9 1 1 3 0 10.5 6 8.5 4.5
O43143 13 6 15 7 2 2 2 1 7.5 4 8.5 4
Q93008 12 7 15 8 1 0 2 0 6.5 3.5 8.5 4
P68371 7 3 6 4 30 25 10 12 18.5 14 8 8
P61978-3 0 23 6 0 8 5 10 7 4 14 8 3.5
P62241 6 11 6 6 10 12 10 12 8 11.5 8 9
P62906 6 9 6 9 15 20 10 17 10.5 14.5 8 13
Q9Y2H1 16 15 13 18 3 2 3 1 9.5 8.5 8 9.5
O95347 24 25 16 20 1 0 0 0 12.5 12.5 8 10
P09661 12 10 12 12 8 4 4 7 10 7 8 9.5
O15371 11 13 15 7 0 0 1 0 5.5 6.5 8 3.5
Q9UPN9-2 10 5 16 4 2 1 0 0 6 3 8 2
Q9BUF5 14 9 15 3 0 1 0 2 7 5 7.5 2.5
Q9NTJ3 22 19 15 21 0 2 0 2 11 10.5 7.5 11.5
J3QQ67 10 11 7 6 9 12 8 15 9.5 11.5 7.5 10.5
Q9NP73 19 17 15 9 0 0 0 0 9.5 8.5 7.5 4.5
P35637 11 17 13 14 1 1 2 0 6 9 7.5 7
Q15020 13 10 14 10 2 1 1 0 7.5 5.5 7.5 5
O60825 15 5 15 5 0 0 0 0 7.5 2.5 7.5 2.5
Q9Y383 10 7 13 6 3 2 2 1 6.5 4.5 7.5 3.5
G3V5T9 7 0 5 0 16 0 10 0 11.5 0 7.5 0
Q8TEX9 4 1 6 1 11 1 9 1 7.5 1 7.5 1
H0Y4R1 5 3 9 2 0 0 6 0 2.5 1.5 7.5 1
H0YM23 4 0 5 5 25 12 9 8 14.5 6 7 6.5
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E9PB61 6 5 5 6 13 12 9 12 9.5 8.5 7 9
Q14683 23 21 14 14 0 0 0 0 11.5 10.5 7 7
P46777 14 17 14 16 3 5 0 0 8.5 11 7 8
Q14498 8 7 8 7 8 8 6 8 8 7.5 7 7.5
Q15021 17 16 14 12 0 0 0 0 8.5 8 7 6
Q9NSD9 13 15 14 15 0 0 0 0 6.5 7.5 7 7.5
P49321 17 12 13 12 1 0 1 0 9 6 7 6
Q0VDG4 4 6 8 10 2 4 6 13 3 5 7 11.5
Q92499 7 11 14 12 0 0 0 0 3.5 5.5 7 6
O76071 5 1 4 1 12 1 10 0 8.5 1 7 0.5
P02533 9 8 11 10 2 8 2 0 5.5 8 6.5 5
Q7Z6Z7 23 12 9 13 8 5 4 6 15.5 8.5 6.5 9.5
P33991 15 19 13 14 0 0 0 0 7.5 9.5 6.5 7
O43390 6 3 6 5 3 5 7 8 4.5 4 6.5 6.5
P26368 12 10 9 8 5 1 4 0 8.5 5.5 6.5 4
B2R5W2 2 4 3 3 11 12 10 12 6.5 8 6.5 7.5
P25398 5 7 5 5 8 7 8 9 6.5 7 6.5 7
Q9UQ80 14 12 13 15 0 0 0 0 7 6 6.5 7.5
P52907 8 5 8 5 8 3 5 4 8 4 6.5 4.5
G3V5Z7 12 13 13 14 0 0 0 0 6 6.5 6.5 7
O60256 9 14 13 11 0 0 0 1 4.5 7 6.5 6
Q6PD62 7 8 9 3 4 7 4 5 5.5 7.5 6.5 4
Q93009 13 7 10 4 4 1 3 2 8.5 4 6.5 3
O95376 7 0 6 0 14 0 7 0 10.5 0 6.5 0
P35579 16 21 12 17 0 0 0 0 8 10.5 6 8.5
E7EV71 5 17 7 12 2 6 5 8 3.5 11.5 6 10
P26599 21 16 10 13 1 2 2 1 11 9 6 7
Q15008 16 17 11 13 4 2 1 1 10 9.5 6 7
P23284 18 19 11 16 0 1 1 1 9 10 6 8.5
P62318 10 9 9 8 6 4 3 4 8 6.5 6 6
C9J2Y9 17 22 12 11 0 0 0 0 8.5 11 6 5.5
P62917 10 9 6 6 6 12 6 8 8 10.5 6 7
P52597 5 6 6 8 3 0 6 1 4 3 6 4.5
P67870 5 5 5 6 6 12 7 12 5.5 8.5 6 9
P84090 6 5 3 4 7 8 9 9 6.5 6.5 6 6.5
O95218 9 10 10 8 5 6 2 4 7 8 6 6
P24928 14 14 12 12 0 0 0 0 7 7 6 6
O94776 12 14 12 10 0 0 0 0 6 7 6 5
P18077 3 7 4 5 6 10 8 7 4.5 8.5 6 6
F8VPD4 10 13 12 10 0 0 0 1 5 6.5 6 5.5
C9JNW5 6 5 6 5 5 9 6 6 5.5 7 6 5.5
M0QXS5 9 10 11 9 0 0 1 0 4.5 5 6 4.5
G8JLA2 6 11 12 8 1 0 0 1 3.5 5.5 6 4.5
E9PGT6 3 0 4 0 12 1 8 0 7.5 0.5 6 0
P17544 0 0 0 0 0 0 11 0 0 0 5.5 0
P19784 11 7 6 6 11 8 5 6 11 7.5 5.5 6
P55795 2 3 6 1 0 0 5 0 1 1.5 5.5 0.5
O00487 9 13 9 11 3 2 2 4 6 7.5 5.5 7.5
P62753 6 3 4 4 7 11 7 9 6.5 7 5.5 6.5
A0A024R4M 7 3 3 3 12 8 8 6 9.5 5.5 5.5 4.5
P67809 3 10 8 9 5 7 3 4 4 8.5 5.5 6.5
P62314 7 4 5 5 8 6 6 5 7.5 5 5.5 5
A0A087WX 4 6 5 4 6 6 6 6 5 6 5.5 5
Q13162 9 6 5 6 0 0 6 4 4.5 3 5.5 5
P62888 8 7 7 7 4 5 4 3 6 6 5.5 5
Q9BPX3 10 13 10 9 0 0 1 1 5 6.5 5.5 5
A0A075B6S 4 4 5 5 5 5 6 7 4.5 4.5 5.5 6
O76094 6 7 9 6 1 1 2 1 3.5 4 5.5 3.5
Q8TD19 7 3 6 3 4 2 5 1 5.5 2.5 5.5 2
Q9Y6A5 5 6 11 9 0 0 0 0 2.5 3 5.5 4.5
P62937 2 5 6 2 1 2 5 5 1.5 3.5 5.5 3.5
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Q15170-2 0 0 5 4 1 2 6 7 0.5 1 5.5 5.5
P20248 2 0 3 0 9 0 8 0 5.5 0 5.5 0
P60891 11 26 10 14 0 0 0 1 5.5 13 5 7.5
O75487 9 9 6 11 6 10 4 7 7.5 9.5 5 9
P11908 0 7 10 7 0 0 0 1 0 3.5 5 4
Q9UQE7 20 13 10 15 0 0 0 0 10 6.5 5 7.5
P05387 4 4 4 3 7 11 6 14 5.5 7.5 5 8.5
P26373 6 7 7 7 4 8 3 2 5 7.5 5 4.5
Q9UNM6 7 14 9 14 1 0 1 0 4 7 5 7
P33992 15 11 10 15 0 0 0 0 7.5 5.5 5 7.5
P51665 11 9 8 12 0 2 2 2 5.5 5.5 5 7
P07814 11 14 10 10 0 0 0 0 5.5 7 5 5
P62829 6 3 4 5 5 8 6 7 5.5 5.5 5 6
P98179 8 8 8 8 3 3 2 3 5.5 5.5 5 5.5
O43823 11 9 10 8 0 0 0 0 5.5 4.5 5 4
P18754 11 12 10 6 0 0 0 0 5.5 6 5 3
E9PLL6 3 8 7 5 1 6 3 5 2 7 5 5
E7EX90 8 10 10 8 0 0 0 0 4 5 5 4
Q7RTV0 3 1 3 6 6 4 7 5 4.5 2.5 5 5.5
O14617 8 8 10 8 0 0 0 0 4 4 5 4
P08579 6 5 6 0 3 2 4 3 4.5 3.5 5 1.5
Q8WUA2 6 7 10 6 0 0 0 0 3 3.5 5 3
P15408 2 4 6 4 2 1 4 1 2 2.5 5 2.5
Q15459 6 3 10 3 0 0 0 0 3 1.5 5 1.5
Q13885 9 4 3 11 5 1 6 0 7 2.5 4.5 5.5
Q9BVA1 0 4 3 0 5 1 6 0 2.5 2.5 4.5 0
P41091 17 14 9 18 0 0 0 0 8.5 7 4.5 9
F6VRR5 4 4 2 1 8 10 7 5 6 7 4.5 3
Q9UPN9 0 5 0 4 2 1 9 0 1 3 4.5 2
P10155 3 5 4 6 8 9 5 5 5.5 7 4.5 5.5
E5RJR5 8 7 3 6 5 3 6 5 6.5 5 4.5 5.5
O75821 8 9 9 5 1 1 0 1 4.5 5 4.5 3
A0A024RA5 5 8 9 12 0 0 0 1 2.5 4 4.5 6.5
Q6GMV2 5 3 2 2 11 4 7 3 8 3.5 4.5 2.5
Q7L2J0 4 4 4 3 5 5 5 3 4.5 4.5 4.5 3
Q9Y3I0 12 8 9 8 0 0 0 0 6 4 4.5 4
A0A087WU 3 1 3 1 6 7 6 9 4.5 4 4.5 5
P62750 6 3 3 4 4 4 6 5 5 3.5 4.5 4.5
Q01804 6 10 9 7 0 0 0 0 3 5 4.5 3.5
Q8N7H5 4 5 6 1 4 3 3 2 4 4 4.5 1.5
Q9Y3B4 7 3 7 5 2 2 2 1 4.5 2.5 4.5 3
B0YJC4 9 2 8 8 0 0 1 0 4.5 1 4.5 4
E7EVA0 7 6 9 5 0 0 0 0 3.5 3 4.5 2.5
Q6PEV8 3 3 5 3 2 0 4 4 2.5 1.5 4.5 3.5
P27694 0 2 1 2 2 5 8 6 1 3.5 4.5 4
Q712K3 4 1 2 0 11 1 7 0 7.5 1 4.5 0
P40222 6 4 9 3 0 0 0 0 3 2 4.5 1.5
Q9UBW8 4 0 2 0 11 0 7 1 7.5 0 4.5 0.5
O60763 7 5 9 3 0 0 0 0 3.5 2.5 4.5 1.5
Q9UHB9 5 5 9 3 0 0 0 0 2.5 2.5 4.5 1.5
Q9UJX3 1 1 5 1 0 0 4 0 0.5 0.5 4.5 0.5
Q9HAV4 1 0 2 0 0 0 7 0 0.5 0 4.5 0
P04350 4 9 5 10 0 0 3 0 2 4.5 4 5
Q16576 5 7 4 6 8 1 4 3 6.5 4 4 4.5
P19474 9 13 7 4 2 2 1 1 5.5 7.5 4 2.5
A0A0A0MR 3 5 1 2 6 9 7 10 4.5 7 4 6
P53539 2 3 8 7 0 7 0 0 1 5 4 3.5
P05388 0 3 1 3 8 13 7 10 4 8 4 6.5
P42356 11 13 8 13 0 0 0 0 5.5 6.5 4 6.5
M0QYS1 6 7 6 3 5 7 2 8 5.5 7 4 5.5
Q99729-3 9 13 8 10 0 0 0 0 4.5 6.5 4 5
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P46778 6 9 5 5 4 6 3 4 5 7.5 4 4.5
Q12874 11 7 6 10 1 1 2 1 6 4 4 5.5
M0QXB4 7 8 8 12 0 0 0 0 3.5 4 4 6
Q96JK2 6 6 5 3 4 6 3 4 5 6 4 3.5
P20618 6 13 8 10 0 0 0 0 3 6.5 4 5
P62280 4 3 4 3 5 8 4 5 4.5 5.5 4 4
B1AK87 5 5 5 4 5 2 3 4 5 3.5 4 4
Q9Y237 5 7 7 9 1 0 1 1 3 3.5 4 5
P14618 9 9 7 6 1 0 1 2 5 4.5 4 4
A0A087WZ 5 4 5 5 1 2 3 1 3 3 4 3
P35244 1 2 0 1 5 4 8 6 3 3 4 3.5
Q92616 6 6 8 10 0 0 0 0 3 3 4 5
P13639 5 6 6 5 0 1 2 0 2.5 3.5 4 2.5
H3BLV9 9 2 5 1 4 0 3 0 6.5 1 4 0.5
O14818 5 10 8 6 0 0 0 0 2.5 5 4 3
P63173 3 2 3 2 5 2 5 5 4 2 4 3.5
O00505 5 0 3 1 11 2 5 0 8 1 4 0.5
I3L397 3 0 2 1 5 2 6 3 4 1 4 2
P14625 5 2 8 2 0 0 0 0 2.5 1 4 1
P62258 2 3 3 1 3 1 5 0 2.5 2 4 0.5
P30041 4 4 5 3 0 1 3 4 2 2.5 4 3.5
A0A087WW 6 6 7 3 0 0 1 0 3 3 4 1.5
Q92922 6 3 8 6 0 0 0 0 3 1.5 4 3
Q9BQ67 3 5 3 1 4 0 5 0 3.5 2.5 4 0.5
A0A087WS 6 1 6 0 4 0 2 0 5 0.5 4 0
A0A087X0M 7 1 8 3 0 0 0 0 3.5 0.5 4 1.5
Q9Y2X3 3 2 4 0 4 0 4 1 3.5 1 4 0.5
Q9UHW5 2 0 3 1 4 0 5 0 3 0 4 0.5
Q5THR1 1 1 1 0 2 2 7 0 1.5 1.5 4 0
J3QRG6 1 0 2 0 1 0 6 2 1 0 4 1
K22E_HUM 8 0 0 0 34 33 7 8 21 16.5 3.5 4
P09972 13 6 7 9 0 0 0 0 6.5 3 3.5 4.5
O43164 5 4 4 8 3 13 3 14 4 8.5 3.5 11
Q14558 9 26 7 20 0 0 0 1 4.5 13 3.5 10.5
P18124 8 7 4 11 8 11 3 9 8 9 3.5 10
P68133 2 2 2 2 0 0 5 1 1 1 3.5 1.5
J3KTA4 7 5 7 4 1 0 0 2 4 2.5 3.5 3
P27635 6 8 6 8 4 9 1 8 5 8.5 3.5 8
P61313 8 7 3 8 4 7 4 7 6 7 3.5 7.5
Q9UBF2 6 10 6 9 0 0 1 1 3 5 3.5 5
P09132 5 2 1 2 5 9 6 6 5 5.5 3.5 4
Q13045 14 10 7 9 0 0 0 0 7 5 3.5 4.5
Q9Y3U8 5 4 4 3 4 7 3 7 4.5 5.5 3.5 5
Q13547 7 10 7 9 0 1 0 1 3.5 5.5 3.5 5
A0A0D9SF5 2 6 7 4 0 0 0 0 1 3 3.5 2
Q9BVP2 7 5 6 4 2 3 1 2 4.5 4 3.5 3
Q9NR30 6 3 6 3 4 8 1 2 5 5.5 3.5 2.5
Q9UMZ2 8 9 7 9 0 0 0 0 4 4.5 3.5 4.5
P26358 8 7 7 9 0 0 0 0 4 3.5 3.5 4.5
P49207 3 4 3 3 3 5 4 5 3 4.5 3.5 4
A0A0C4DG 7 6 7 6 0 0 0 0 3.5 3 3.5 3
Q9H2U1 5 8 7 8 0 0 0 0 2.5 4 3.5 4
A0A0R4J2E 2 5 3 4 1 5 4 5 1.5 5 3.5 4.5
P28074 5 8 7 9 0 0 0 0 2.5 4 3.5 4.5
Q86YM7 7 6 7 7 0 0 0 1 3.5 3 3.5 4
J3KTE4 5 2 5 3 2 5 2 4 3.5 3.5 3.5 3.5
Q9NPA8 1 2 0 3 4 5 7 5 2.5 3.5 3.5 4
Q9Y2T2 5 5 7 6 0 0 0 0 2.5 2.5 3.5 3
Q8WXF1 4 9 6 5 1 0 1 0 2.5 4.5 3.5 2.5
Q13409-2 7 6 6 5 0 0 1 0 3.5 3 3.5 2.5
Q9NU22 8 4 7 6 0 0 0 0 4 2 3.5 3
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P47813 5 5 5 2 3 1 2 1 4 3 3.5 1.5
Q14257 5 6 6 6 0 0 1 0 2.5 3 3.5 3
P0DN76 7 3 6 2 2 1 1 0 4.5 2 3.5 1
Q9Y224 5 6 7 2 0 0 0 1 2.5 3 3.5 1.5
P62249 3 1 4 1 2 4 3 2 2.5 2.5 3.5 1.5
Q99459 4 3 4 2 1 1 3 1 2.5 2 3.5 1.5
J3KQ34 3 0 1 0 9 0 6 0 6 0 3.5 0
Q9NSB8 2 3 7 1 0 0 0 0 1 1.5 3.5 0.5
E7EX17 134 87 0 93 5 4 6 5 69.5 45.5 3 49
M0R117 7 4 4 5 5 11 2 5 6 7.5 3 5
P52756 4 7 6 7 0 0 0 0 2 3.5 3 3.5
O95163 13 14 6 9 0 0 0 0 6.5 7 3 4.5
P50914 5 7 4 7 5 6 2 5 5 6.5 3 6
A0A087WU 13 5 6 7 0 0 0 0 6.5 2.5 3 3.5
K7ERF1 8 7 3 6 2 4 3 5 5 5.5 3 5.5
E9PHA2 7 12 6 10 0 0 0 0 3.5 6 3 5
P62244 4 1 3 3 4 3 3 6 4 2 3 4.5
A0A0A0MS 3 0 1 3 5 7 5 4 4 3.5 3 3.5
P30050 4 3 3 3 2 7 3 7 3 5 3 5
P46940 9 12 6 3 0 0 0 0 4.5 6 3 1.5
Q5W0B1 6 9 6 7 0 0 0 0 3 4.5 3 3.5
P62266 4 1 2 2 5 4 4 5 4.5 2.5 3 3.5
C9JFV4 3 3 0 3 3 6 6 3 3 4.5 3 3
P28072 4 9 6 5 0 0 0 0 2 4.5 3 2.5
P27348 2 0 5 1 7 1 1 0 4.5 0.5 3 0.5
E7ESY4 2 2 6 5 0 0 0 0 1 1 3 2.5
TRY1_BOVI 1 3 3 5 3 3 3 3 2 3 3 4
O95400 7 5 5 5 1 0 1 0 4 2.5 3 2.5
Q05519 7 5 5 4 2 0 1 0 4.5 2.5 3 2
G3V3M6 5 7 6 3 0 0 0 0 2.5 3.5 3 1.5
Q969G3 4 6 6 5 0 0 0 0 2 3 3 2.5
O60271 7 4 6 5 0 0 0 0 3.5 2 3 2.5
O60884 8 3 5 3 1 0 1 0 4.5 1.5 3 1.5
J3QT28 3 6 6 6 0 0 0 0 1.5 3 3 3
O94906 10 3 6 2 0 0 0 0 5 1.5 3 1
P25788 3 5 6 6 0 0 0 1 1.5 2.5 3 3.5
A8MWD9 1 2 3 2 4 1 3 5 2.5 1.5 3 3.5
P62913 1 2 2 2 2 4 4 3 1.5 3 3 2.5
Q9UER7 6 2 5 2 0 1 1 0 3 1.5 3 1
Q9Y2L1 3 6 6 5 0 0 0 0 1.5 3 3 2.5
J3KR24 4 5 6 5 0 0 0 0 2 2.5 3 2.5
Q9P258 3 4 5 6 1 0 1 0 2 2 3 3
Q9NZI8 6 2 5 3 0 1 1 1 3 1.5 3 2
H0YGW7 7 2 6 3 0 0 0 0 3.5 1 3 1.5
J3QRS3 5 2 3 1 1 2 3 0 3 2 3 0.5
O14776 5 2 6 4 0 0 0 0 2.5 1 3 2
P08621 4 2 6 5 0 0 0 0 2 1 3 2.5
Q8IWV8-4 0 0 0 0 5 4 6 1 2.5 2 3 0.5
P08708 1 0 3 1 2 3 3 2 1.5 1.5 3 1.5
P46736 1 3 2 1 1 0 4 0 1 1.5 3 0.5
Q6ULP2 2 1 6 2 0 0 0 0 1 0.5 3 1
O14929 1 1 2 0 0 0 4 0 0.5 0.5 3 0
P13647 20 9 5 8 1 3 0 0 10.5 6 2.5 4
D6RHC4 1 4 0 1 4 0 5 0 2.5 2 2.5 0.5
P60510 1 3 5 2 0 0 0 0 0.5 1.5 2.5 1
P48556 8 6 4 9 3 1 1 1 5.5 3.5 2.5 5
P62140 2 6 5 6 0 8 0 3 1 7 2.5 4.5
B2WTI3 4 5 3 2 4 7 2 3 4 6 2.5 2.5
Q92769 4 6 4 4 1 1 1 1 2.5 3.5 2.5 2.5
A0A024QZP 4 3 5 7 0 0 0 0 2 1.5 2.5 3.5
P05198 10 10 5 7 0 0 0 0 5 5 2.5 3.5
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O14646 8 3 4 2 1 6 1 2 4.5 4.5 2.5 2
P25786 5 9 5 10 0 0 0 0 2.5 4.5 2.5 5
P78332 6 0 5 3 0 0 0 0 3 0 2.5 1.5
P62304 6 5 3 5 2 1 2 3 4 3 2.5 4
Q9UG63 6 4 5 7 1 1 0 2 3.5 2.5 2.5 4.5
Q9BWJ5 6 1 2 3 4 2 3 5 5 1.5 2.5 4
O60814 3 0 3 0 2 5 2 7 2.5 2.5 2.5 3.5
P42285 8 6 5 5 0 0 0 0 4 3 2.5 2.5
B1AJY7 5 3 3 4 2 2 2 2 3.5 2.5 2.5 3
Q32MZ4 6 6 5 6 0 0 0 0 3 3 2.5 3
Q4J6C6 4 0 1 0 13 0 4 0 8.5 0 2.5 0
P05386 3 2 4 1 3 4 1 3 3 3 2.5 2
F5H2F4 4 6 5 6 0 0 0 0 2 3 2.5 3
B8ZZU8 5 2 4 4 3 0 1 2 4 1 2.5 3
P62854 1 2 3 1 0 6 2 5 0.5 4 2.5 3
C9JR56 3 5 5 5 0 0 0 0 1.5 2.5 2.5 2.5
Q96DI7 6 2 5 4 0 0 0 0 3 1 2.5 2
Q13464 1 5 5 7 0 0 0 0 0.5 2.5 2.5 3.5
O43865 2 0 1 1 2 4 4 3 2 2 2.5 2
Q8N8S7 4 4 5 4 0 0 0 0 2 2 2.5 2
P35268 3 4 4 2 0 0 1 2 1.5 2 2.5 2
H0Y6I0 0 0 1 0 0 0 4 3 0 0 2.5 1.5
O75934 1 0 3 1 1 2 2 1 1 1 2.5 1
O43776 3 4 5 3 0 0 0 0 1.5 2 2.5 1.5
Q9NWU2 1 4 4 3 0 0 1 2 0.5 2 2.5 2.5
A0A087WT 4 3 5 3 0 0 0 0 2 1.5 2.5 1.5
O95273 0 0 1 0 4 0 4 0 2 0 2.5 0
P11802 0 0 1 0 0 0 4 0 0 0 2.5 0
Q9UHV9 2 3 4 3 0 0 1 1 1 1.5 2.5 2
Q06481 4 1 3 1 1 0 2 1 2.5 0.5 2.5 1
E7ESD2 4 2 5 2 0 0 0 0 2 1 2.5 1
B4DKA4 4 2 5 2 0 0 0 0 2 1 2.5 1
Q15717 2 4 5 1 0 0 0 0 1 2 2.5 0.5
Q7Z7L7 0 0 0 0 6 1 5 0 3 0.5 2.5 0
Q96PK6 3 3 5 1 0 0 0 0 1.5 1.5 2.5 0.5
Q9BUQ8 3 0 4 2 0 0 1 0 1.5 0 2.5 1
P32119 1 1 1 2 3 2 3 6 2 1.5 2 4
D3YTB1 6 6 3 4 3 7 1 1 4.5 6.5 2 2.5
P11387 5 1 2 4 2 5 2 6 3.5 3 2 5
P11047 8 4 4 3 1 3 0 0 4.5 3.5 2 1.5
Q9GZS3 5 4 3 3 3 3 1 4 4 3.5 2 3.5
P49721 4 9 4 7 0 0 0 0 2 4.5 2 3.5
O14654 11 4 4 3 0 0 0 0 5.5 2 2 1.5
A0A087WU 3 5 4 2 0 0 0 0 1.5 2.5 2 1
P28070 5 6 4 3 0 0 0 0 2.5 3 2 1.5
P23458 8 7 4 4 0 0 0 0 4 3.5 2 2
P62269 2 0 2 2 2 5 2 7 2 2.5 2 4.5
P46779 7 5 4 4 0 1 0 1 3.5 3 2 2.5
Q09161 3 4 3 5 1 1 1 4 2 2.5 2 4.5
P49458 2 3 1 2 3 4 3 4 2.5 3.5 2 3
O75909 0 1 0 0 4 7 4 5 2 4 2 2.5
P25789 3 8 4 6 0 0 0 0 1.5 4 2 3
Q9BPZ2 4 3 4 4 0 0 0 0 2 1.5 2 2
Q9H7D7 5 5 3 4 0 1 1 1 2.5 3 2 2.5
Q07666 5 4 3 3 3 0 1 0 4 2 2 1.5
Q9HD40 3 8 4 1 0 0 0 0 1.5 4 2 0.5
P37108 4 4 3 2 1 1 1 3 2.5 2.5 2 2.5
O75937 5 5 4 4 0 0 0 0 2.5 2.5 2 2
P52294 1 1 4 6 0 0 0 0 0.5 0.5 2 3
Q15007 5 4 4 5 0 0 0 0 2.5 2 2 2.5
Q96HR8 0 1 1 3 3 3 3 3 1.5 2 2 3
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O60684 4 6 4 2 0 0 0 0 2 3 2 1
F8VVA7 4 5 4 2 0 0 0 0 2 2.5 2 1
Q13033 5 3 4 1 0 0 0 0 2.5 1.5 2 0.5
Q86YP4 2 6 4 3 0 0 0 0 1 3 2 1.5
B5MCP9 1 2 2 1 3 1 2 4 2 1.5 2 2.5
J3KN16 4 4 4 4 0 0 0 0 2 2 2 2
P40937 2 3 4 2 0 2 0 1 1 2.5 2 1.5
Q99575 6 5 4 1 0 0 0 0 3 2.5 2 0.5
Q96AV8 6 4 4 2 0 0 0 0 3 2 2 1
E7EQU1 2 1 3 2 1 1 1 0 1.5 1 2 1
Q00688 4 3 4 4 0 0 0 0 2 1.5 2 2
O43290 5 4 4 2 0 0 0 0 2.5 2 2 1
P10644 2 2 3 3 0 0 1 0 1 1 2 1.5
P36954 2 4 3 2 1 0 1 1 1.5 2 2 1.5
O43251-6 5 2 4 3 0 0 0 0 2.5 1 2 1.5
K7EK33 4 5 4 1 0 0 0 0 2 2.5 2 0.5
A2A2Q9 3 5 4 2 0 0 0 0 1.5 2.5 2 1
Q16659 4 3 4 3 0 0 0 0 2 1.5 2 1.5
P05204 3 3 4 2 0 1 0 0 1.5 2 2 1
O94888 3 0 1 0 5 0 3 0 4 0 2 0
P39019 4 2 4 2 0 0 0 1 2 1 2 1.5
Q16186 3 3 4 3 0 0 0 0 1.5 1.5 2 1.5
Q9NY27 2 5 4 2 0 0 0 0 1 2.5 2 1
Q15427 1 0 2 2 1 2 2 1 1 1 2 1.5
Q12788 2 4 4 3 0 0 0 0 1 2 2 1.5
Q8N3U4 3 3 4 2 0 0 0 0 1.5 1.5 2 1
O14519 2 2 3 2 0 0 1 0 1 1 2 1
E5RHG8 3 2 1 3 0 0 3 0 1.5 1 2 1.5
Q8ND56 3 2 4 1 0 0 0 0 1.5 1 2 0.5
Q96PU8 4 0 2 0 2 0 2 0 3 0 2 0
Q9NR55 0 3 3 1 1 1 1 1 0.5 2 2 1
Q8N163 4 1 4 2 0 0 0 0 2 0.5 2 1
H0YCK3 2 2 4 3 0 0 0 0 1 1 2 1.5
Q6IN85 4 2 4 1 0 0 0 0 2 1 2 0.5
P10599 1 0 1 1 1 1 3 3 1 0.5 2 2
Q9H5V9 2 1 4 4 0 0 0 0 1 0.5 2 2
P25685 3 2 4 1 0 0 0 0 1.5 1 2 0.5
Q9NUQ3 1 3 4 1 0 0 0 0 0.5 1.5 2 0.5
P46783 2 0 3 0 0 1 1 1 1 0.5 2 0.5
Q96N67 3 1 4 0 0 0 0 0 1.5 0.5 2 0
P49792 2 1 4 1 0 0 0 0 1 0.5 2 0.5
E9PJM3 1 1 3 1 0 0 1 1 0.5 0.5 2 1
Q13112 0 1 3 1 0 0 1 0 0 0.5 2 0.5
K7ER96 1 0 2 0 1 0 2 0 1 0 2 0
Q8WVC0 1 0 3 1 0 0 1 0 0.5 0 2 0.5
P08779 9 0 1 1 2 0 2 5 5.5 0 1.5 3
B1ANR0 1 1 0 0 3 2 3 2 2 1.5 1.5 1
F8VZX2 0 1 3 3 0 0 0 0 0 0.5 1.5 1.5
O00468-6 2 8 1 4 5 8 2 4 3.5 8 1.5 4
P10412 1 2 3 1 5 9 0 12 3 5.5 1.5 6.5
P28066 7 4 3 6 0 0 0 0 3.5 2 1.5 3
A0A024R4E 8 5 3 5 0 0 0 0 4 2.5 1.5 2.5
Q08499-12 2 1 1 3 3 5 2 4 2.5 3 1.5 3.5
P0C0S8 1 1 2 0 4 5 1 6 2.5 3 1.5 3
P61254 3 5 3 3 1 2 0 1 2 3.5 1.5 2
H0YK48 0 0 1 0 0 0 2 0 0 0 1.5 0
E9PKP7 0 0 0 0 5 3 3 7 2.5 1.5 1.5 3.5
Q9Y608 3 4 3 6 0 0 0 0 1.5 2 1.5 3
A0A0D9SET 1 1 2 0 0 0 1 0 0.5 0.5 1.5 0
E7EWR4 4 4 3 5 0 0 0 0 2 2 1.5 2.5
A0A0D9SEI 3 5 2 2 0 2 1 0 1.5 3.5 1.5 1
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Q92734 5 4 3 3 0 0 0 0 2.5 2 1.5 1.5
Q9UKF6 4 4 3 3 0 0 0 0 2 2 1.5 1.5
Q8WV44 5 0 3 1 5 0 0 0 5 0 1.5 0.5
A0A087WV 2 3 2 3 0 1 1 2 1 2 1.5 2.5
H0Y6E7 2 4 3 1 2 0 0 2 2 2 1.5 1.5
G3V3G9 3 3 3 5 0 0 0 0 1.5 1.5 1.5 2.5
P46063 4 4 3 1 0 0 0 0 2 2 1.5 0.5
Q92878 3 4 3 3 0 0 0 0 1.5 2 1.5 1.5
O15160 4 4 3 2 0 0 0 0 2 2 1.5 1
B4E0T2 4 3 3 3 0 0 0 0 2 1.5 1.5 1.5
Q5BIX2 0 0 0 0 4 2 3 3 2 1 1.5 1.5
Q52LJ0 4 3 3 3 0 0 0 0 2 1.5 1.5 1.5
P06576 2 4 3 3 0 0 0 0 1 2 1.5 1.5
O75935 3 3 2 2 0 0 1 1 1.5 1.5 1.5 1.5
Q9UJW0 1 3 3 2 0 0 0 0 0.5 1.5 1.5 1
P09429 3 2 3 3 0 0 0 1 1.5 1 1.5 2
E7EMB3 2 4 2 3 0 0 1 0 1 2 1.5 1.5
Q15046 3 4 3 2 0 0 0 0 1.5 2 1.5 1
Q8WUM0 4 2 3 3 0 0 0 0 2 1 1.5 1.5
Q8NC51 4 2 3 1 1 1 0 0 2.5 1.5 1.5 0.5
Q2NL82 3 3 3 3 0 0 0 0 1.5 1.5 1.5 1.5
O14530 2 3 3 4 0 0 0 0 1 1.5 1.5 2
P14868 3 4 3 1 0 0 0 0 1.5 2 1.5 0.5
Q5VTR2 2 4 3 1 0 0 0 0 1 2 1.5 0.5
E9PCY5 4 2 3 2 0 0 0 0 2 1 1.5 1
F8WJN3 3 3 3 2 0 0 0 0 1.5 1.5 1.5 1
Q6P1J9 0 4 3 2 0 0 0 2 0 2 1.5 2
Q9Y5B6 0 1 2 2 0 0 1 1 0 0.5 1.5 1.5
Q99436 1 3 3 4 0 0 0 0 0.5 1.5 1.5 2
P62306 2 2 1 1 1 1 2 1 1.5 1.5 1.5 1
O95777 2 2 2 2 0 1 1 1 1 1.5 1.5 1.5
O95782 2 4 3 0 0 0 0 0 1 2 1.5 0
P17858 2 4 3 1 0 0 0 0 1 2 1.5 0.5
Q8IX12 3 3 3 1 0 0 0 0 1.5 1.5 1.5 0.5
P63167 2 1 2 2 1 1 1 0 1.5 1 1.5 1
M0R2B7 1 2 3 4 0 0 0 0 0.5 1 1.5 2
B7Z4C8 1 2 2 1 1 1 1 1 1 1.5 1.5 1
Q96J01 2 3 2 2 0 0 1 0 1 1.5 1.5 1
Q9UPQ9 3 3 3 1 0 0 0 0 1.5 1.5 1.5 0.5
P54136 3 2 3 1 0 0 0 0 1.5 1 1.5 0.5
Q9Y5Q8 5 0 3 1 0 0 0 0 2.5 0 1.5 0.5
A0A024RCR 1 1 3 4 0 0 0 0 0.5 0.5 1.5 2
C9JLU1 3 2 3 1 0 0 0 0 1.5 1 1.5 0.5
D3DQV9 2 2 3 2 0 0 0 0 1 1 1.5 1
A0A087WX 2 1 1 0 1 1 2 1 1.5 1 1.5 0.5
E9PEB5 1 2 3 3 0 0 0 0 0.5 1 1.5 1.5
A0A075B6F 0 0 0 1 0 0 3 5 0 0 1.5 3
A6NCC9 2 2 3 2 0 0 0 0 1 1 1.5 1
Q9UHI6 2 1 3 3 0 0 0 0 1 0.5 1.5 1.5
O60518 1 0 1 0 2 0 2 0 1.5 0 1.5 0
Q8N2I9 4 0 3 2 0 0 0 0 2 0 1.5 1
O00743 3 2 2 0 1 0 1 0 2 1 1.5 0
D6R9A6 1 2 3 0 0 0 0 1 0.5 1 1.5 0.5
F8W7U8 2 2 3 1 0 0 0 0 1 1 1.5 0.5
A8MQB8 4 0 3 1 0 0 0 0 2 0 1.5 0.5
Q96ST3 2 2 3 1 0 0 0 0 1 1 1.5 0.5
Q3YEC7 1 3 3 1 0 0 0 0 0.5 1.5 1.5 0.5
P35249 4 1 3 0 0 0 0 0 2 0.5 1.5 0
E7EQI7 2 1 3 1 0 0 0 0 1 0.5 1.5 0.5
D6RER5 1 2 3 1 0 0 0 0 0.5 1 1.5 0.5
P22102 0 2 2 0 1 0 1 1 0.5 1 1.5 0.5
135
P08243 1 1 1 1 0 0 2 0 0.5 0.5 1.5 0.5
Q5T4S7 1 1 2 0 0 0 1 1 0.5 0.5 1.5 0.5
P30419 1 1 3 1 0 0 0 0 0.5 0.5 1.5 0.5
P00492 0 0 0 1 1 1 3 0 0.5 0.5 1.5 0.5
A0A0A0MT 2 0 3 1 0 0 0 0 1 0 1.5 0.5
E9PH82 3 0 3 0 0 0 0 0 1.5 0 1.5 0
Q96C92-4 2 0 2 0 1 0 1 0 1.5 0 1.5 0
A0A087WY 2 0 3 1 0 0 0 0 1 0 1.5 0.5
F5H1Y4 3 0 3 0 0 0 0 0 1.5 0 1.5 0
Q8NFH3 0 1 3 2 0 0 0 0 0 0.5 1.5 1
O15294 1 1 3 1 0 0 0 0 0.5 0.5 1.5 0.5
P40938 0 1 3 1 0 0 0 0 0 0.5 1.5 0.5
Q9Y5K6 0 1 3 0 0 0 0 0 0 0.5 1.5 0
P52292 1 0 2 0 0 0 1 0 0.5 0 1.5 0
O43663 1 0 3 0 0 0 0 0 0.5 0 1.5 0
P31153 1 0 2 0 0 0 1 0 0.5 0 1.5 0
P22314 1 0 2 0 0 0 1 0 0.5 0 1.5 0
C9J4Z3 0 0 3 0 0 0 0 0 0 0 1.5 0
H0YHQ5 0 0 1 0 0 0 2 0 0 0 1.5 0
B7Z9C2 3 6 1 7 2 23 1 26 2.5 14.5 1 16.5
Q13509 0 0 2 0 1 0 0 0 0.5 0 1 0
P29692-3 11 3 2 10 0 0 0 4 5.5 1.5 1 7
Q05639 7 5 2 3 0 0 0 0 3.5 2.5 1 1.5
A0A075B73 8 9 2 9 0 0 0 0 4 4.5 1 4.5
Q5JUX0 0 1 2 1 0 0 0 0 0 0.5 1 0.5
E9PKG1 7 9 2 7 0 0 0 0 3.5 4.5 1 3.5
P06899 0 2 0 2 2 0 2 0 1 1 1 1
B0QYK0 9 5 2 5 0 0 0 0 4.5 2.5 1 2.5
G3V529 2 5 1 4 0 5 1 2 1 5 1 3
O43818 4 4 1 3 2 3 1 2 3 3.5 1 2.5
Q9Y625 1 0 0 1 1 1 2 1 1 0.5 1 1
Q96PY6 0 4 2 3 1 6 0 2 0.5 5 1 2.5
J3KMX5 2 2 1 2 2 3 1 4 2 2.5 1 3
Q14978-3 2 2 2 2 0 6 0 3 1 4 1 2.5
ALBU_HUM 0 0 2 1 0 0 0 0 0 0 1 0.5
P62851 3 2 2 2 2 2 0 3 2.5 2 1 2.5
A6NEM2 4 4 2 6 0 0 0 0 2 2 1 3
Q13107 1 0 0 0 0 0 2 0 0.5 0 1 0
Q12996 3 7 2 3 0 0 0 0 1.5 3.5 1 1.5
P12081 3 4 2 6 0 0 0 0 1.5 2 1 3
P49354 1 4 1 4 2 1 1 1 1.5 2.5 1 2.5
K7ER00 3 2 2 5 0 0 0 0 1.5 1 1 2.5
Q05048 3 4 2 4 0 0 0 0 1.5 2 1 2
E7EQ64 0 0 0 2 0 0 2 3 0 0 1 2.5
A0A087X2D 1 2 1 1 1 2 1 1 1 2 1 1
A0A0A0MQ 1 1 1 1 2 2 1 2 1.5 1.5 1 1.5
Q92900 3 6 2 2 0 0 0 0 1.5 3 1 1
Q96F63 4 2 2 4 0 0 0 0 2 1 1 2
P81605 3 2 1 1 2 1 1 1 2.5 1.5 1 1
Q13868 2 3 2 5 0 0 0 0 1 1.5 1 2.5
B9ZVN9 3 4 2 2 0 0 0 0 1.5 2 1 1
P35250 3 3 2 3 0 0 0 0 1.5 1.5 1 1.5
Q9UBB9 4 3 2 1 0 0 0 1 2 1.5 1 1
O43172 4 2 2 1 1 0 0 1 2.5 1 1 1
P47914 2 2 2 2 0 1 0 1 1 1.5 1 1.5
Q92572 1 3 2 3 0 0 0 1 0.5 1.5 1 2
Q9H9Y6 1 4 2 3 0 0 0 0 0.5 2 1 1.5
P19387 1 3 2 4 0 0 0 0 0.5 1.5 1 2
D6RAN4 3 2 2 3 0 0 0 0 1.5 1 1 1.5
P26196 4 2 2 2 0 0 0 0 2 1 1 1
P31151 2 2 2 4 0 0 0 0 1 1 1 2
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Q96S59 3 3 2 2 0 0 0 0 1.5 1.5 1 1
O43815 1 1 2 0 0 0 0 0 0.5 0.5 1 0
P62310 2 2 2 2 1 0 0 1 1.5 1 1 1.5
Q96DG6 1 3 2 3 0 0 0 0 0.5 1.5 1 1.5
Q9Y5Q9 2 3 2 2 0 0 0 0 1 1.5 1 1
M0QXL5 4 2 1 0 1 0 1 0 2.5 1 1 0
E5RHU3 2 1 2 2 0 1 0 1 1 1 1 1.5
J3KQN4 2 1 1 0 2 2 1 0 2 1.5 1 0
B1AKR6 2 2 2 0 1 1 0 1 1.5 1.5 1 0.5
Q96T76 4 0 0 0 3 0 2 0 3.5 0 1 0
P15927 1 1 1 1 0 1 1 3 0.5 1 1 2
CASB_BOV 0 3 2 2 0 0 0 0 0 1.5 1 1
Q9Y4C2 1 3 2 3 0 0 0 0 0.5 1.5 1 1.5
P23381 2 2 2 1 0 0 0 0 1 1 1 0.5
O96019 2 2 2 2 0 0 0 0 1 1 1 1
Q8TEQ6 3 1 2 2 0 0 0 0 1.5 0.5 1 1
H0YEB6 0 2 2 4 0 0 0 0 0 1 1 2
J3QT87 1 3 2 2 0 0 0 0 0.5 1.5 1 1
P06702 3 1 2 2 0 0 0 0 1.5 0.5 1 1
Q00577 0 0 1 0 0 3 1 3 0 1.5 1 1.5
P49427 3 0 2 0 3 0 0 0 3 0 1 0
A0A0B4J2E 3 1 2 2 0 0 0 0 1.5 0.5 1 1
P52701 2 1 2 2 0 0 0 0 1 0.5 1 1
Q6IA86 1 1 2 3 0 0 0 0 0.5 0.5 1 1.5
Q9NV70 1 1 2 1 0 0 0 0 0.5 0.5 1 0.5
Q12789 3 2 2 0 0 0 0 0 1.5 1 1 0
Q7Z4Q2 1 1 1 0 3 0 1 0 2 0.5 1 0
A0A0C4DFR 1 1 2 0 0 0 0 0 0.5 0.5 1 0
B3KQ25 1 3 2 1 0 0 0 0 0.5 1.5 1 0.5
E9PLA9 2 1 2 2 0 0 0 0 1 0.5 1 1
A0A0X1KG7 1 3 2 0 0 0 0 1 0.5 1.5 1 0.5
A0A087WS 2 2 2 1 0 0 0 0 1 1 1 0.5
F8W733 2 1 2 2 0 0 0 0 1 0.5 1 1
F5GX77 2 1 1 1 0 0 1 1 1 0.5 1 1
A0A087X2I 0 1 1 0 0 1 1 1 0 1 1 0.5
O75449 2 1 2 2 0 0 0 0 1 0.5 1 1
Q9BVG4 2 2 2 1 0 0 0 0 1 1 1 0.5
P60866 0 2 2 2 0 0 0 0 0 1 1 1
P42677 3 0 2 1 0 0 0 0 1.5 0 1 0.5
P62857 2 1 1 0 0 0 1 1 1 0.5 1 0.5
Q9H2P0 1 2 2 1 0 0 0 0 0.5 1 1 0.5
Q9Y6D5 1 1 2 2 0 0 0 0 0.5 0.5 1 1
Q15018 0 3 2 1 0 0 0 0 0 1.5 1 0.5
Q8WXC6 1 0 1 0 2 0 1 1 1.5 0 1 0.5
Q9Y295 1 2 2 1 0 0 0 0 0.5 1 1 0.5
Q9UKN8 2 1 2 1 0 0 0 0 1 0.5 1 0.5
F2Z2W6 1 2 2 1 0 0 0 0 0.5 1 1 0.5
H3BR35 0 1 1 1 0 1 1 1 0 1 1 1
E7EQR4 0 3 2 1 0 0 0 0 0 1.5 1 0.5
M0R0F0 0 0 1 2 0 1 1 1 0 0.5 1 1.5
A0A087X25 1 1 2 1 1 0 0 0 1 0.5 1 0.5
P20774 1 2 2 1 0 0 0 0 0.5 1 1 0.5
P52298 1 1 1 1 0 0 1 1 0.5 0.5 1 1
Q15637 1 1 2 2 0 0 0 0 0.5 0.5 1 1
P83369 1 2 2 1 0 0 0 0 0.5 1 1 0.5
Q9NT62 1 1 1 1 1 0 1 0 1 0.5 1 0.5
Q6NZY4 1 2 2 1 0 0 0 0 0.5 1 1 0.5
Q9H0D6 2 0 2 1 0 0 0 0 1 0 1 0.5
O95816 2 0 1 1 0 0 1 0 1 0 1 0.5
Q9Y3Y2 0 0 1 0 1 1 1 1 0.5 0.5 1 0.5
P49916 1 1 2 1 0 0 0 0 0.5 0.5 1 0.5
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Q8WXX5 0 0 0 0 1 2 2 0 0.5 1 1 0
Q9NS91 1 0 1 0 1 0 1 1 1 0 1 0.5
Q9UKB1 2 0 2 0 1 0 0 0 1.5 0 1 0
Q13151 1 0 2 2 0 0 0 0 0.5 0 1 1
B4DXZ6 2 0 2 0 0 0 0 0 1 0 1 0
B1AHD1 0 0 0 0 0 0 2 3 0 0 1 1.5
A0A087WY 2 0 0 0 1 0 2 0 1.5 0 1 0
E7ER68 0 2 2 1 0 0 0 0 0 1 1 0.5
C9JHW1 2 0 2 1 0 0 0 0 1 0 1 0.5
A0A0A0MS 1 0 1 0 2 0 1 0 1.5 0 1 0
Q8N108 1 1 2 1 0 0 0 0 0.5 0.5 1 0.5
Q15785 0 2 2 1 0 0 0 0 0 1 1 0.5
P26038 1 0 2 1 0 0 0 0 0.5 0 1 0.5
P57740 1 1 2 1 0 0 0 0 0.5 0.5 1 0.5
O00567 1 0 1 0 0 1 1 1 0.5 0.5 1 0.5
Q8NB46 1 1 1 0 1 0 1 0 1 0.5 1 0
CAS1_BOVI 0 2 1 0 0 1 1 0 0 1.5 1 0
Q7KZ85 2 0 2 1 0 0 0 0 1 0 1 0.5
Q9Y333 1 1 2 0 1 0 0 0 1 0.5 1 0
A2RU37 0 0 1 1 0 0 1 0 0 0 1 0.5
P54727 0 1 2 2 0 0 0 0 0 0.5 1 1
Q96RL7 1 0 1 0 2 0 1 0 1.5 0 1 0
P61964 2 0 2 1 0 0 0 0 1 0 1 0.5
Q96CT7 1 0 2 1 0 0 0 0 0.5 0 1 0.5
P38432 1 0 2 1 0 0 0 0 0.5 0 1 0.5
P50570 0 1 2 1 0 0 0 0 0 0.5 1 0.5
Q9Y450 2 0 2 0 0 0 0 0 1 0 1 0
A0A0A0MR 0 1 2 1 0 0 0 0 0 0.5 1 0.5
B4DEH8 1 0 2 1 0 0 0 0 0.5 0 1 0.5
Q9HCD5 1 0 2 1 0 0 0 0 0.5 0 1 0.5
Q9Y3F4 1 0 2 1 0 0 0 0 0.5 0 1 0.5
HBA_HUMA 1 1 2 0 0 0 0 0 0.5 0.5 1 0
Q7L5Y6 1 0 2 0 0 0 0 0 0.5 0 1 0
Q99871 0 1 2 0 0 0 0 0 0 0.5 1 0
J3QRS9 1 0 2 0 0 0 0 0 0.5 0 1 0
E9PK25 0 1 2 0 0 0 0 0 0 0.5 1 0
F8W726 1 0 2 0 0 0 0 0 0.5 0 1 0
C4B7M2 0 0 2 1 0 0 0 0 0 0 1 0.5
C9J494 0 0 0 0 1 0 2 0 0.5 0 1 0
Q66K74 1 0 2 0 0 0 0 0 0.5 0 1 0
O43805 0 0 2 0 0 0 0 0 0 0 1 0
Q709C8 0 0 2 0 1 0 0 0 0.5 0 1 0
Q9P1U0 0 0 2 0 0 0 0 0 0 0 1 0
O00479 0 0 0 0 0 0 2 0 0 0 1 0
H0YEL5 0 0 2 0 0 0 0 0 0 0 1 0
A0A140T8Y 0 0 1 0 0 0 1 0 0 0 1 0
K7EQA9 0 0 2 0 0 0 0 0 0 0 1 0
Q9NYK1 0 0 1 0 0 0 1 0 0 0 1 0
H0Y711 0 0 0 0 0 0 1 1 0 0 0.5 0.5
C9JZI7 0 0 0 0 1 1 1 1 0.5 0.5 0.5 0.5
M0QZM1 0 0 1 1 0 0 0 0 0 0 0.5 0.5
O60825-2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q7Z3Y7 0 0 0 0 0 0 1 1 0 0 0.5 0.5
P42025 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P09012 2 1 1 4 3 0 0 3 2.5 0.5 0.5 3.5
P35052 2 3 1 3 1 5 0 3 1.5 4 0.5 3
P62805 2 0 1 0 2 8 0 9 2 4 0.5 4.5
Q96RG2 0 3 1 4 0 6 0 8 0 4.5 0.5 6
Q58FF6 2 0 0 0 0 0 1 1 1 0 0.5 0.5
K7ER90 0 0 1 0 1 0 0 0 0.5 0 0.5 0
P15924 8 1 1 2 0 1 0 1 4 1 0.5 1.5
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Q99767 0 1 1 3 1 3 0 5 0.5 2 0.5 4
Q9Y6G9 5 7 1 3 0 0 0 0 2.5 3.5 0.5 1.5
E7EX29 2 0 1 1 0 1 0 0 1 0.5 0.5 0.5
A0A0U1RR 6 2 1 5 0 0 0 0 3 1 0.5 2.5
Q9NQ29 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q96B23-2 2 0 1 1 4 2 0 3 3 1 0.5 2
J3KPP4 4 5 1 4 0 0 0 0 2 2.5 0.5 2
P23258 5 3 1 1 0 0 0 0 2.5 1.5 0.5 0.5
Q9P1Y5 2 5 1 5 0 0 0 0 1 2.5 0.5 2.5
Q14315 0 0 1 0 0 0 0 0 0 0 0.5 0
O95983 4 6 1 2 0 0 0 0 2 3 0.5 1
Q9H814 2 2 0 2 2 2 1 2 2 2 0.5 2
Q86YZ3 6 0 1 5 0 0 0 0 3 0 0.5 2.5
P42166 2 4 1 5 0 0 0 0 1 2 0.5 2.5
Q92804 4 1 1 0 0 0 0 0 2 0.5 0.5 0
O60216 4 4 1 2 0 0 0 0 2 2 0.5 1
P31942 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A0B4J2B 1 1 1 1 0 1 0 1 0.5 1 0.5 1
A0A0D9SG 2 5 1 2 0 1 0 0 1 3 0.5 1
Q9BW61 1 1 0 2 2 2 1 1 1.5 1.5 0.5 1.5
P12273 4 3 1 2 0 0 0 0 2 1.5 0.5 1
Q9H0A0 2 2 1 3 0 2 0 0 1 2 0.5 1.5
Q9P2P6 2 2 1 1 2 1 0 1 2 1.5 0.5 1
O94973 2 1 1 2 0 0 0 0 1 0.5 0.5 1
Q96I24 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
P15407 2 3 1 0 1 0 0 0 1.5 1.5 0.5 0
F8VZN8 0 1 1 1 0 3 0 3 0 2 0.5 2
A0A087WU 0 6 1 2 0 0 0 0 0 3 0.5 1
P49591 1 3 1 4 0 0 0 0 0.5 1.5 0.5 2
Q86TV6 2 3 1 3 0 0 0 0 1 1.5 0.5 1.5
P08237 3 1 1 2 0 0 0 0 1.5 0.5 0.5 1
P53567 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
B4DL54 2 0 1 3 1 0 0 1 1.5 0 0.5 2
P60842 1 0 1 1 3 1 0 1 2 0.5 0.5 1
K7EM18 2 2 1 3 0 0 0 0 1 1 0.5 1.5
F5H039 1 4 1 2 0 0 0 0 0.5 2 0.5 1
P78346 1 3 1 3 0 0 0 0 0.5 1.5 0.5 1.5
P49756 4 2 1 1 0 0 0 0 2 1 0.5 0.5
P31431 1 1 0 0 2 2 1 1 1.5 1.5 0.5 0.5
Q9Y5A9 3 2 1 2 0 0 0 0 1.5 1 0.5 1
P11388 0 2 1 2 0 0 0 0 0 1 0.5 1
P63172 2 1 1 2 0 0 0 1 1 0.5 0.5 1.5
P01859 1 1 0 1 1 1 1 1 1 1 0.5 1
O00629 0 0 1 0 0 0 0 0 0 0 0.5 0
O15131 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YIE9 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
D6RJ96 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YKE4 2 1 0 2 0 0 1 1 1 0.5 0.5 1.5
O60341 2 2 1 2 0 0 0 0 1 1 0.5 1
Q13242 1 3 1 2 0 0 0 0 0.5 1.5 0.5 1
TRY2_BOVI 1 1 1 0 1 0 0 0 1 0.5 0.5 0
Q9P013 3 2 0 0 1 0 1 0 2 1 0.5 0
Q14232 1 3 1 2 0 0 0 0 0.5 1.5 0.5 1
Q9NR50 1 2 1 3 0 0 0 0 0.5 1 0.5 1.5
Q9Y4Z0 4 1 1 1 0 0 0 0 2 0.5 0.5 0.5
Q70CQ2 0 0 0 0 1 3 1 2 0.5 1.5 0.5 1
A5YKK6 1 2 1 2 0 0 0 0 0.5 1 0.5 1
Q9NQ92 2 1 1 2 0 0 0 0 1 0.5 0.5 1
P49643 2 2 1 1 0 0 0 0 1 1 0.5 0.5
Q6P2E9 2 2 1 1 0 0 0 0 1 1 0.5 0.5
O60306 2 2 1 1 0 0 0 0 1 1 0.5 0.5
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I3L3U9 0 1 1 0 0 2 0 2 0 1.5 0.5 1
D6RBW1 3 1 1 1 0 0 0 0 1.5 0.5 0.5 0.5
E9PKF6 0 2 1 1 0 0 0 1 0 1 0.5 1
G3V1S7 1 1 0 1 0 1 1 1 0.5 1 0.5 1
A0A087WW 1 4 1 0 0 0 0 0 0.5 2 0.5 0
B5MBZ0 2 2 1 1 0 0 0 0 1 1 0.5 0.5
J3KNS1 2 1 1 2 0 0 0 0 1 0.5 0.5 1
Q5T749 3 0 1 2 0 0 0 0 1.5 0 0.5 1
O76041 0 2 0 0 3 0 1 0 1.5 1 0.5 0
P53350 2 1 1 2 0 0 0 0 1 0.5 0.5 1
O95721 2 2 1 1 0 0 0 0 1 1 0.5 0.5
Q9UPU7 0 1 0 0 0 1 1 0 0 1 0.5 0
Q9NXF1 1 1 1 0 1 1 0 1 1 1 0.5 0.5
Q08J23 0 1 1 2 0 0 0 0 0 0.5 0.5 1
Q01813 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q9NR09 1 0 1 2 0 1 0 0 0.5 0.5 0.5 1
O95239 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
P00742 0 0 0 0 1 2 1 1 0.5 1 0.5 0.5
Q9Y3Z3 3 1 1 0 0 0 0 0 1.5 0.5 0.5 0
P53803 1 1 1 1 1 0 0 0 1 0.5 0.5 0.5
Q14258 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
Q9NQT4 1 1 1 2 0 0 0 0 0.5 0.5 0.5 1
P51654 0 1 0 0 0 1 1 2 0 1 0.5 1
Q9NY12 1 1 1 2 0 0 0 0 0.5 0.5 0.5 1
Q9P2D3 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
O60337-5 1 0 0 1 1 1 1 0 1 0.5 0.5 0.5
A0A0U1RQ 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
A0A087WV 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
K7EMK7 0 1 1 1 1 0 0 0 0.5 0.5 0.5 0.5
A0A0D9SES 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
D6RIY6 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
A0A087WU 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
J3KNN5 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
Q15773 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
Q9BZE4 1 1 1 1 1 0 0 0 1 0.5 0.5 0.5
Q13610 0 0 1 0 1 1 0 2 0.5 0.5 0.5 1
P35659 0 3 1 1 0 0 0 0 0 1.5 0.5 0.5
O15084 3 0 1 1 0 0 0 0 1.5 0 0.5 0.5
O00268 1 1 1 2 0 0 0 0 0.5 0.5 0.5 1
P49770 1 3 1 0 0 0 0 0 0.5 1.5 0.5 0
Q7Z2T5 0 1 1 3 0 0 0 0 0 0.5 0.5 1.5
Q2TAM9 1 1 1 1 0 1 0 0 0.5 1 0.5 0.5
P42766 1 0 1 0 0 1 0 1 0.5 0.5 0.5 0.5
P02765 2 0 1 0 0 0 0 1 1 0 0.5 0.5
Q9UJX2 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
Q9P2I0 2 1 1 0 0 0 0 0 1 0.5 0.5 0
O43175 1 1 1 0 0 0 0 1 0.5 0.5 0.5 0.5
Q8IYD1 0 1 0 0 0 1 1 1 0 1 0.5 0.5
Q9NPD3 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
P82970 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
Q7Z353 3 0 1 0 0 0 0 0 1.5 0 0.5 0
O95861-2 0 1 1 0 0 0 0 0 0 0.5 0.5 0
A0A087WT 1 0 1 0 0 0 0 0 0.5 0 0.5 0
H7C3P6 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
B1AQK6 0 1 1 0 0 0 0 0 0 0.5 0.5 0
F8WA39 0 0 1 3 0 0 0 0 0 0 0.5 1.5
A0A0A0MT 1 2 1 0 0 0 0 0 0.5 1 0.5 0
B1ALD9 0 1 1 0 0 0 0 0 0 0.5 0.5 0
A0A0G2JRX 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
A0A087X1B 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
A0A087WT 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
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A0A0B4J21 1 0 0 0 0 0 1 2 0.5 0 0.5 1
H3BM60 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
Q8WXA9-2 1 1 0 0 0 0 1 1 0.5 0.5 0.5 0.5
E5RFF9 1 1 0 0 1 0 1 0 1 0.5 0.5 0
B4DDH2 0 1 1 0 0 0 0 0 0 0.5 0.5 0
A6NIZ0 1 1 1 0 0 1 0 0 0.5 1 0.5 0
J3QQJ0 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
B1AMU3 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
J3KQR7 1 1 1 0 0 0 0 1 0.5 0.5 0.5 0.5
O75037 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
Q9P2J5 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
O75400 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
Q6PI26 0 0 0 0 2 0 1 1 1 0 0.5 0.5
Q15428 2 0 1 1 0 0 0 0 1 0 0.5 0.5
P17028 2 1 1 0 0 0 0 0 1 0.5 0.5 0
Q06203 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
Q8NHZ8 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
P32121 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q9NWV8 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q8WTR2 1 1 0 0 0 0 1 0 0.5 0.5 0.5 0
Q92538 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
Q9HCN4 1 0 1 0 1 0 0 0 1 0 0.5 0
P17096 0 2 1 0 0 0 0 0 0 1 0.5 0
Q09472 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
P20719 2 0 1 0 0 0 0 0 1 0 0.5 0
E9PM92 1 0 1 0 1 0 0 0 1 0 0.5 0
B3KXD6 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
F5H2E5 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
J3KNV1 1 0 1 0 0 0 0 1 0.5 0 0.5 0.5
E2QRF9 0 0 0 0 1 1 1 0 0.5 0.5 0.5 0
A8MX94 0 0 1 0 0 0 0 2 0 0 0.5 1
D6REM4 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
A8MU27 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
A0A0A0MQ 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
A0A024R7W 1 0 1 0 0 0 0 0 0.5 0 0.5 0
F2Z2W7 2 0 1 0 0 0 0 0 1 0 0.5 0
H7C466 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
D6RFW3 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
D6RJ98 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
Q5TDF0 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
F2Z2B9 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
E9PHH9 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
H7C5M7 0 0 0 0 1 0 1 1 0.5 0 0.5 0.5
A0A0R4J2F 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
P33176 2 0 1 0 0 0 0 0 1 0 0.5 0
Q12756 1 0 1 0 0 0 0 0 0.5 0 0.5 0
O00139 2 0 1 0 0 0 0 0 1 0 0.5 0
Q14114 1 1 0 0 0 0 1 0 0.5 0.5 0.5 0
Q8WW12 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q13371 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q9UNQ2 0 0 1 2 0 0 0 0 0 0 0.5 1
Q5VTE6 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
A8MVW0 0 1 1 0 0 0 0 1 0 0.5 0.5 0.5
A0A0A6YYF 1 0 1 0 1 0 0 0 1 0 0.5 0
Q9NRJ7 0 1 1 0 1 0 0 0 0.5 0.5 0.5 0
Q5T280 0 0 1 1 0 1 0 0 0 0.5 0.5 0.5
A6NDX5 0 0 1 1 0 1 0 0 0 0.5 0.5 0.5
Q13283 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
Q8N5L8 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q9H6T3 0 2 1 0 0 0 0 0 0 1 0.5 0
O43347 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
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CASK_BOVI 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q13838 2 0 1 0 0 0 0 0 1 0 0.5 0
Q5VSL9 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
Q86W42 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
A0A0A0MR 0 1 0 0 0 0 1 1 0 0.5 0.5 0.5
P17275 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q8WUH2 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
Q969L4 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
A0A0B4J20 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
Q9H269 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
Q8TAF3 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
Q6UXN9 0 0 1 1 0 0 0 1 0 0 0.5 1
Q8N3C0 0 1 1 0 0 0 0 0 0 0.5 0.5 0
P49588 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q96S55 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q4LE39 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q6PJG6 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q15417 0 0 0 0 1 0 1 0 0.5 0 0.5 0
O43852 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P45973 0 0 0 0 0 0 1 0 0 0 0.5 0
Q6P1N0 0 1 1 0 0 0 0 0 0 0.5 0.5 0
C9J1V9 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q9NQT5 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q75N90 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q5JY77 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q9NX24 0 0 1 0 0 0 0 1 0 0 0.5 0.5
Q9NX55 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0A096LNV 0 0 0 1 0 0 1 0 0 0 0.5 0.5
K7EKT4 0 0 1 1 0 0 0 0 0 0 0.5 0.5
A0A087X0X 0 0 1 0 0 1 0 0 0 0.5 0.5 0
H0Y9A0 1 0 1 0 0 0 0 0 0.5 0 0.5 0
E7EMW7 0 1 1 0 0 0 0 0 0 0.5 0.5 0
E7EWD9 0 0 1 1 0 0 0 0 0 0 0.5 0.5
K7EM90 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A8MW50 0 0 0 0 0 0 1 1 0 0 0.5 0.5
E9PR30 0 1 0 0 0 0 1 0 0 0.5 0.5 0
H0YIQ2 0 0 1 0 0 1 0 0 0 0.5 0.5 0
A8K878 1 0 1 0 0 0 0 0 0.5 0 0.5 0
B4DWR3 1 0 1 0 0 0 0 0 0.5 0 0.5 0
D6RG19 0 1 1 0 0 0 0 0 0 0.5 0.5 0
E9PQ57 0 0 0 1 0 0 1 0 0 0 0.5 0.5
A0A0A0MT 1 0 1 0 0 0 0 0 0.5 0 0.5 0
H7C072 0 1 1 0 0 0 0 0 0 0.5 0.5 0
B1AL79 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q5VU13-2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
B7ZLT2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
H3BRX1 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A0A0MS 1 0 1 0 0 0 0 0 0.5 0 0.5 0
H3BSW0 0 0 0 0 0 1 1 0 0 0.5 0.5 0
E9PQ73 1 0 0 0 0 0 1 0 0.5 0 0.5 0
A0A087WY 0 0 0 0 0 0 1 1 0 0 0.5 0.5
E9PMG1 0 1 1 0 0 0 0 0 0 0.5 0.5 0
B8ZZ47 1 0 1 0 0 0 0 0 0.5 0 0.5 0
K7ELS0 1 0 1 0 0 0 0 0 0.5 0 0.5 0
C9IZE1 1 0 1 0 0 0 0 0 0.5 0 0.5 0
F8WA32 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A0C4DFZ 0 1 0 0 0 0 1 0 0 0.5 0.5 0
Q5JR04 0 0 0 0 1 0 1 0 0.5 0 0.5 0
H0YIH0 0 1 1 0 0 0 0 0 0 0.5 0.5 0
A0A087WT 1 0 1 0 0 0 0 0 0.5 0 0.5 0
C9J7E8 1 0 1 0 0 0 0 0 0.5 0 0.5 0
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B1ANM7 0 0 0 0 1 0 1 0 0.5 0 0.5 0
B4DM50 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q9BRS8 0 1 1 0 0 0 0 0 0 0.5 0.5 0
P55081 1 0 1 0 0 0 0 0 0.5 0 0.5 0
O60830 0 0 1 0 0 0 0 1 0 0 0.5 0.5
Q99558 0 0 1 0 0 0 0 1 0 0 0.5 0.5
Q9NXX6 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9H4L5 0 0 0 0 0 1 1 0 0 0.5 0.5 0
Q5VUB5 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q8TF72 1 0 1 0 0 0 0 0 0.5 0 0.5 0
P0C860 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P34896 1 0 1 0 0 0 0 0 0.5 0 0.5 0
CAS2_BOVI 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q96GM8 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q7L0X0 0 1 1 0 0 0 0 0 0 0.5 0.5 0
O75896 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q9Y4Y9 0 1 1 0 0 0 0 0 0 0.5 0.5 0
H7C155 0 0 1 0 0 0 0 0 0 0 0.5 0
G3V461 0 0 1 0 0 0 0 0 0 0 0.5 0
A6NIT2 0 0 1 0 0 0 0 0 0 0 0.5 0
C9J1X3 0 0 0 0 0 0 1 0 0 0 0.5 0
B7ZA25 0 0 1 0 0 0 0 0 0 0 0.5 0
E9PIX7 0 0 0 0 0 0 1 0 0 0 0.5 0
M0QYT7 0 0 1 0 0 0 0 0 0 0 0.5 0
P28482 0 0 1 0 0 0 0 0 0 0 0.5 0
P42345 0 0 1 0 0 0 0 0 0 0 0.5 0
P06748-3 7 0 0 2 0 0 0 0 3.5 0 0 1
F8VVB5 0 3 0 3 0 4 0 4 0 3.5 0 3.5
Q3ZCM7 2 2 0 0 0 0 0 0 1 1 0 0
H0YJP0 1 0 0 0 0 0 0 0 0.5 0 0 0
P02538 0 1 0 2 0 0 0 0 0 0.5 0 1
F6SS63 2 0 0 0 0 0 0 0 1 0 0 0
Q58FF7 0 0 0 0 0 0 0 1 0 0 0 0.5
Q8TDI0 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q58FG1 1 0 0 0 0 0 0 0 0.5 0 0 0
J3KN67 1 0 0 1 7 0 0 0 4 0 0 0.5
P62136 2 6 0 1 0 0 0 0 1 3 0 0.5
F8VYE8 1 0 0 0 0 0 0 0 0.5 0 0 0
P16989 0 1 0 0 0 0 0 0 0 0.5 0 0
P15408-2 2 1 0 0 2 1 0 0 2 1 0 0
Q562R1 0 1 0 0 0 0 0 0 0 0.5 0 0
Q58FG0 0 0 0 0 0 0 0 1 0 0 0 0.5
P62263 4 1 0 3 0 2 0 2 2 1.5 0 2.5
O75531 0 1 0 5 0 4 0 7 0 2.5 0 6
Q8NB90 0 0 0 2 0 0 0 0 0 0 0 1
P61981 1 1 0 0 0 1 0 0 0.5 1 0 0
F8VZY9 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9UKA9 1 0 0 0 0 0 0 0 0.5 0 0 0
Q5JZB7 1 0 0 0 0 0 0 1 0.5 0 0 0.5
E7EQY4 1 0 0 2 0 0 0 0 0.5 0 0 1
O14556 0 1 0 0 0 0 0 0 0 0.5 0 0
Q96SI9 1 1 0 0 0 0 0 0 0.5 0.5 0 0
B5MD17 0 1 0 0 1 0 0 0 0.5 0.5 0 0
F5GYK2 4 0 0 0 0 0 0 0 2 0 0 0
Q14004 0 0 0 0 0 0 0 2 0 0 0 1
F5H6Z0 0 0 0 0 0 2 0 0 0 1 0 0
E7ETY2 0 1 0 2 1 2 0 3 0.5 1.5 0 2.5
E7ERS3 0 0 0 0 2 3 0 4 1 1.5 0 2
F8VXC8 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q13615 1 5 0 1 0 0 0 2 0.5 2.5 0 1.5
P20794 0 0 0 1 0 0 0 0 0 0 0 0.5
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Q5TAH2 1 0 0 0 1 0 0 1 1 0 0 0.5
Q15024 1 5 0 2 0 0 0 0 0.5 2.5 0 1
P31948 0 7 0 1 0 0 0 0 0 3.5 0 0.5
Q01826 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A087X1A 1 1 0 0 0 2 0 3 0.5 1.5 0 1.5
J3QR65 0 0 0 1 1 3 0 0 0.5 1.5 0 0.5
P61221 2 3 0 1 0 0 0 0 1 1.5 0 0.5
P17812 1 2 0 1 1 0 0 1 1 1 0 1
Q8IWV7 0 4 0 2 0 0 0 0 0 2 0 1
H3BP71 2 0 0 3 0 0 0 0 1 0 0 1.5
I3L2C7 2 3 0 1 0 0 0 0 1 1.5 0 0.5
A0A087WV 0 1 0 0 0 0 0 0 0 0.5 0 0
H0YGK9 0 0 0 0 1 0 0 0 0.5 0 0 0
P46821 2 2 0 2 0 0 0 0 1 1 0 1
P46087 1 2 0 1 0 1 0 1 0.5 1.5 0 1
Q9UKV8 3 2 0 1 0 0 0 0 1.5 1 0 0.5
Q6ZU15 1 2 0 1 0 0 0 0 0.5 1 0 0.5
P11172 1 0 0 0 2 3 0 0 1.5 1.5 0 0
Q15147 0 0 0 2 0 0 0 1 0 0 0 1.5
Q5RKV6 2 2 0 1 0 0 0 0 1 1 0 0.5
O00425 0 0 0 0 0 1 0 1 0 0.5 0 0.5
P19525 1 2 0 0 0 1 0 1 0.5 1.5 0 0.5
Q96PK6-5 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q8N1N4 2 0 0 0 0 0 0 0 1 0 0 0
Q92620 0 3 0 2 0 0 0 0 0 1.5 0 1
Q8IX18 1 3 0 1 0 0 0 0 0.5 1.5 0 0.5
Q9NTI5 1 2 0 2 0 0 0 0 0.5 1 0 1
P07996 0 2 0 3 0 0 0 0 0 1 0 1.5
Q96QR8 0 0 0 0 0 1 0 2 0 0.5 0 1
Q69YN2 0 3 0 1 0 0 0 0 0 1.5 0 0.5
P51116 2 0 0 0 0 0 0 0 1 0 0 0
E7EUU4 1 2 0 1 0 0 0 0 0.5 1 0 0.5
A0A0A0MS 0 0 0 0 1 1 0 0 0.5 0.5 0 0
Q5JVF3-4 0 1 0 0 1 0 0 0 0.5 0.5 0 0
F5GY73 1 0 0 1 0 0 0 0 0.5 0 0 0.5
A0A075B74 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q8N9N2-2 1 3 0 0 0 0 0 0 0.5 1.5 0 0
F5H0F9 1 1 0 2 0 0 0 0 0.5 0.5 0 1
Q04721 0 1 0 2 0 1 0 0 0 1 0 1
Q5SY16 3 0 0 0 0 1 0 0 1.5 0.5 0 0
Q9H6S0 0 0 0 0 1 1 0 2 0.5 0.5 0 1
Q06323 1 2 0 1 0 0 0 0 0.5 1 0 0.5
Q9C005 0 1 0 1 1 0 0 1 0.5 0.5 0 1
Q13123 2 1 0 0 0 1 0 0 1 1 0 0
P05109 1 0 0 0 0 1 0 0 0.5 0.5 0 0
Q6ZS86 0 0 0 0 0 1 0 1 0 0.5 0 0.5
Q99986 0 1 0 3 0 0 0 0 0 0.5 0 1.5
Q9H0U9 0 3 0 1 0 0 0 0 0 1.5 0 0.5
Q49AR2 0 0 0 0 3 0 0 1 1.5 0 0 0.5
Q9BZH6 0 2 0 2 0 0 0 0 0 1 0 1
O15060 0 2 0 2 0 0 0 0 0 1 0 1
Q9HB71 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q9NX58 1 0 0 0 0 0 0 2 0.5 0 0 1
Q08554 2 0 0 1 0 0 0 0 1 0 0 0.5
P62875 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q99543 2 0 0 1 0 0 0 0 1 0 0 0.5
Q96B26 2 0 0 1 0 0 0 0 1 0 0 0.5
P0C2W1 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q5D862 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q8WUA4 2 1 0 0 0 0 0 0 1 0.5 0 0
Q9H3P7 2 0 0 0 1 0 0 0 1.5 0 0 0
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A0A0G2JM 2 1 0 0 0 0 0 0 1 0.5 0 0
A0A087WW 1 1 0 0 0 0 0 0 0.5 0.5 0 0
A0A0A0MR 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
F8WE71 0 0 0 0 0 0 0 1 0 0 0 0.5
B5MDF5 2 1 0 0 0 0 0 0 1 0.5 0 0
A0A0A0MR 3 0 0 0 0 0 0 0 1.5 0 0 0
J3KSD8 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
F5H658 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0D9SEU 0 0 0 1 0 0 0 0 0 0 0 0.5
C9J6P4 0 2 0 1 0 0 0 0 0 1 0 0.5
A0A087WY 2 0 0 0 0 0 0 1 1 0 0 0.5
M0R2U7 0 0 0 0 0 1 0 0 0 0.5 0 0
B4E3S0 2 1 0 0 0 0 0 0 1 0.5 0 0
P14923 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q9GZU2 2 0 0 1 0 0 0 0 1 0 0 0.5
Q9H0S4 2 1 0 0 0 0 0 0 1 0.5 0 0
Q9H871 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q15291 1 0 0 0 2 0 0 0 1.5 0 0 0
P57772 1 0 0 2 0 0 0 0 0.5 0 0 1
Q9UPN7 2 1 0 0 0 0 0 0 1 0.5 0 0
A6NHR9 1 0 0 2 0 0 0 0 0.5 0 0 1
O95620 0 0 0 0 0 1 0 2 0 0.5 0 1
O94763 1 2 0 0 0 0 0 0 0.5 1 0 0
Q9NZ32 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q9BR61 0 0 0 0 0 1 0 1 0 0.5 0 0.5
Q9UKA4 0 2 0 0 0 0 0 0 0 1 0 0
Q02952 0 2 0 0 0 0 0 0 0 1 0 0
Q13155 2 0 0 0 0 0 0 0 1 0 0 0
P25705 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q8N4T0 0 2 0 0 0 0 0 0 0 1 0 0
P39060 0 1 0 0 0 1 0 0 0 1 0 0
P42695 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q13618 2 0 0 0 0 0 0 0 1 0 0 0
Q14999 0 2 0 0 0 0 0 0 0 1 0 0
Q02413 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q969P6 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8TD57 0 1 0 0 0 0 0 1 0 0.5 0 0.5
O60869 0 1 0 1 0 0 0 0 0 0.5 0 0.5
P20042 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q9BYI3 0 0 0 2 0 0 0 0 0 0 0 1
Q4G0P3 0 1 0 0 0 0 0 1 0 0.5 0 0.5
Q8IV63 0 0 0 2 0 0 0 0 0 0 0 1
H0YHK5 1 0 0 1 0 0 0 0 0.5 0 0 0.5
H0YAN8 1 0 0 1 0 0 0 0 0.5 0 0 0.5
H7C2Q2 0 0 0 0 1 1 0 0 0.5 0.5 0 0
E9PQG0 0 0 0 0 1 0 0 1 0.5 0 0 0.5
A0A087WZ 1 0 0 1 0 0 0 0 0.5 0 0 0.5
H0YKL9 0 1 0 1 0 0 0 0 0 0.5 0 0.5
H3BP07 1 0 0 1 0 0 0 0 0.5 0 0 0.5
E9PHH3 0 0 0 0 1 1 0 0 0.5 0.5 0 0
A2IDA3 2 0 0 0 0 0 0 0 1 0 0 0
A0A096LNL 1 0 0 0 1 0 0 0 1 0 0 0
A0A0C4DG 2 0 0 0 0 0 0 0 1 0 0 0
E9PP40 1 0 0 0 0 1 0 0 0.5 0.5 0 0
G8JLG2 1 0 0 1 0 0 0 0 0.5 0 0 0.5
A0A0B4J1Z 1 0 0 0 0 1 0 0 0.5 0.5 0 0
A0A087WW 0 2 0 0 0 0 0 0 0 1 0 0
E7EPB1 0 1 0 0 1 0 0 0 0.5 0.5 0 0
E9PG32 0 1 0 0 0 1 0 0 0 1 0 0
H0Y9L8 1 0 0 1 0 0 0 0 0.5 0 0 0.5
E7ESC9 1 0 0 1 0 0 0 0 0.5 0 0 0.5
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A0A1B0GV 2 0 0 0 0 0 0 0 1 0 0 0
A0A0C4DG 0 2 0 0 0 0 0 0 0 1 0 0
F5H0C4 0 2 0 0 0 0 0 0 0 1 0 0
F5H0W7 0 1 0 1 0 0 0 0 0 0.5 0 0.5
J9JIC5 1 0 0 1 0 0 0 0 0.5 0 0 0.5
E7ESG2 0 0 0 0 0 1 0 1 0 0.5 0 0.5
D6RAP6 1 1 0 0 0 0 0 0 0.5 0.5 0 0
A0A0A0MR 0 0 0 1 1 0 0 0 0.5 0 0 0.5
M0QY97 0 2 0 0 0 0 0 0 0 1 0 0
F8W0Q0 0 1 0 0 0 1 0 0 0 1 0 0
J3KSL8 0 1 0 1 0 0 0 0 0 0.5 0 0.5
E5RHR6 1 0 0 1 0 0 0 0 0.5 0 0 0.5
E7EW58 0 0 0 0 1 0 0 1 0.5 0 0 0.5
Q8IW41 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q96PG2 1 1 0 0 0 0 0 0 0.5 0.5 0 0
A6NFA1 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q15014 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q8WVJ2 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q9UBD5 2 0 0 0 0 0 0 0 1 0 0 0
Q9Y3Q4 1 0 0 0 1 0 0 0 1 0 0 0
Q5VTL8 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q9ULR0 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q9NUL7 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q15751 1 0 0 0 0 0 0 1 0.5 0 0 0.5
Q8NBJ5 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q9BRP1 1 0 0 0 1 0 0 0 1 0 0 0
Q8IVF2 0 0 0 1 1 0 0 0 0.5 0 0 0.5
Q08174 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q6ZN68 0 0 0 0 0 1 0 1 0 0.5 0 0.5
Q8IXW5 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q15042 2 0 0 0 0 0 0 0 1 0 0 0
Q9NZL6 0 0 0 1 0 1 0 0 0 0.5 0 0.5
Q9P227 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9NRR4 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q9Y4W2 1 1 0 0 0 0 0 0 0.5 0.5 0 0
P21817 1 1 0 0 0 0 0 0 0.5 0.5 0 0
A0A087X0R 0 0 0 0 1 1 0 0 0.5 0.5 0 0
O75170 2 0 0 0 0 0 0 0 1 0 0 0
Q562F6 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q16650 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q99614 0 0 0 1 0 1 0 0 0 0.5 0 0.5
O60779 0 0 0 0 1 0 0 1 0.5 0 0 0.5
Q13144 0 2 0 0 0 0 0 0 0 1 0 0
Q9Y2S6 0 1 0 1 0 0 0 0 0 0.5 0 0.5
P60174 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q9UPU5 1 0 0 0 1 0 0 0 1 0 0 0
H3BMM5 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q9UNX4 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q9Y2I7 0 0 0 0 1 0 0 0 0.5 0 0 0
J3KR82 0 0 0 0 1 0 0 0 0.5 0 0 0
D6RCP9 0 1 0 0 0 0 0 0 0 0.5 0 0
H0YJF2 0 0 0 1 0 0 0 0 0 0 0 0.5
I3L112 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A087WZ 0 0 0 0 1 0 0 0 0.5 0 0 0
H0YDJ3 0 0 0 0 0 1 0 0 0 0.5 0 0
H0Y9K2 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0C4DG 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A087WV 1 0 0 0 0 0 0 0 0.5 0 0 0
J3KT82 0 1 0 0 0 0 0 0 0 0.5 0 0
A8MYT4 0 1 0 0 0 0 0 0 0 0.5 0 0
A0A0C4DG 0 1 0 0 0 0 0 0 0 0.5 0 0
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K7ELH3 0 0 0 0 0 0 0 1 0 0 0 0.5
O94806 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9UL54 0 0 0 0 0 1 0 0 0 0.5 0 0
Q15772 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9ULD0 0 0 0 0 0 0 1 0
P49189 0 0 1 0 0 0 0 0
Q8WXS8 0 0 0 0 1 0 0 0
Q8IZT6 0 0 0 1 0 0 0 0
Q9NUB1 0 0 0 0 0 0 0 1
Q8WYK0 0 0 1 0 0 0 0 0
Q01518 0 0 1 0 0 0 0 0
Q86V24 0 0 0 0 0 0 0 1
Q66PJ3 0 0 0 0 0 0 0 1
P03973 0 0 0 0 0 0 0 1
P02647 0 1 0 0 0 0 0 0
Q9HCS5 0 1 0 0 0 0 0 0
Q68DE3 0 0 0 0 1 0 0 0
P22914 1 0 0 0 0 0 0 0
Q9NRL2 1 0 0 0 0 0 0 0
Q96CX2 0 1 0 0 0 0 0 0
Q9NXV2 0 0 0 1 0 0 0 0
O75844 1 0 0 0 0 0 0 0
Q8WUQ7 0 1 0 0 0 0 0 0
P17655 0 0 0 0 1 0 0 0
Q9NRB3 0 0 0 0 1 0 0 0
P16152 0 1 0 0 0 0 0 0
P50416 0 1 0 0 0 0 0 0
Q9H8G2 0 1 0 0 0 0 0 0
Q9H7T0 0 0 1 0 0 0 0 0
Q00587 1 0 0 0 0 0 0 0
Q92674 0 0 1 0 0 0 0 0
Q9C0F1 0 0 0 0 0 0 1 0
P35523 1 0 0 0 0 0 0 0
Q8NCU4 0 0 0 0 0 1 0 0
P25940 0 0 0 0 0 0 0 1
A6NMZ7 0 0 0 1 0 0 0 0
Q9UP83 0 1 0 0 0 0 0 0
P83436 0 0 0 0 0 0 1 0
Q9P232 0 0 0 0 0 1 0 0
Q9HCH3 1 0 0 0 0 0 0 0
P18846 0 0 0 1 0 0 0 0
O60583 0 0 1 0 0 0 0 0
Q8N1N5 0 0 1 0 0 0 0 0
Q9P021 0 0 1 0 0 0 0 0
P35462 0 0 1 0 0 0 0 0
P0C7V8 0 1 0 0 0 0 0 0
Q96BY6 0 1 0 0 0 0 0 0
Q6PJP8 0 0 0 0 1 0 0 0
Q9NRF9 1 0 0 0 0 0 0 0
O15446 1 0 0 0 0 0 0 0
Q8IXB1 0 0 1 0 0 0 0 0
A8MYV0 0 0 0 0 1 0 0 0
Q9P225 0 0 0 1 0 0 0 0
Q9Y508 0 0 0 1 0 0 0 0
Q9Y252 0 0 1 0 0 0 0 0
Q96EB1 0 0 0 1 0 0 0 0
P60507 1 0 0 0 0 0 0 0
Q14511 0 1 0 0 0 0 0 0
A8K979 1 0 0 0 0 0 0 0
O14980 0 0 1 0 0 0 0 0
O15360 0 0 0 0 1 0 0 0
147
Q8N4B4 0 0 0 0 0 0 1 0
A9Z1Z3 1 0 0 0 0 0 0 0
Q9C0D6 0 0 0 0 0 0 0 1
Q86WI1 0 0 1 0 0 0 0 0
Q5SZK8 1 0 0 0 0 0 0 0
P48169 0 0 0 1 0 0 0 0
O76003 0 0 0 1 0 0 0 0
O75311 0 0 0 0 0 1 0 0
P54840 0 0 1 0 0 0 0 0
Q96MS3 0 0 0 0 0 0 1 0
P51810 0 0 0 0 0 0 1 0
Q8WXG9 0 0 0 0 0 0 0 1
P54826 0 0 1 0 0 0 0 0
O00178 0 0 1 0 0 0 0 0
Q9BT25 0 0 0 0 1 0 0 0
Q0VDF9 1 0 0 0 0 0 0 0
Q92522 0 0 0 0 0 1 0 0
P01860 0 0 0 0 0 0 1 0
A0A0C4DH 0 0 0 1 0 0 0 0
A0A075B6S 0 0 0 0 0 0 1 0
A6NCW7 0 0 0 0 0 1 0 0
Q01968 0 0 1 0 0 0 0 0
P20592 0 0 0 0 0 0 1 0
Q13325 0 0 0 1 0 0 0 0
A0A096LNU 1 0 0 0 0 0 0 0
A0A1B0GTP 0 0 1 0 0 0 0 0
A0A024QYW 0 0 0 0 0 0 1 0
A0A087X0T 0 0 1 0 0 0 0 0
H0Y6I8 0 1 0 0 0 0 0 0
A0A087WT 1 0 0 0 0 0 0 0
M0R2X1 0 0 0 1 0 0 0 0
F8W785 0 0 0 0 0 0 0 1
B4DHN5 0 0 1 0 0 0 0 0
A0A1B0GU 0 1 0 0 0 0 0 0
G3V331 0 0 0 1 0 0 0 0
A0A075B7B 0 0 0 0 1 0 0 0
C9JZD1 0 0 0 1 0 0 0 0
H3BRW4 0 0 0 0 0 0 1 0
H3BUM4 0 1 0 0 0 0 0 0
A0A087WW 1 0 0 0 0 0 0 0
H3BND3 1 0 0 0 0 0 0 0
H7BXZ5 0 0 1 0 0 0 0 0
G3V4D9 0 0 0 1 0 0 0 0
B8ZZL3 0 0 0 1 0 0 0 0
E5RGS4 0 0 1 0 0 0 0 0
O75061-2 0 0 1 0 0 0 0 0
A0A096LPD 0 1 0 0 0 0 0 0
A0A088AW 0 1 0 0 0 0 0 0
E9PLT0 1 0 0 0 0 0 0 0
A0A1B0GV 0 1 0 0 0 0 0 0
A0A0G2JP7 1 0 0 0 0 0 0 0
A0A075B6R 0 0 0 0 0 0 1 0
E9PC87 0 0 0 0 0 1 0 0
A0A0C4DG 0 0 0 0 1 0 0 0
A0A0J9YX6 0 1 0 0 0 0 0 0
A0A0A0MQ 0 0 0 1 0 0 0 0
B3KWA8 0 1 0 0 0 0 0 0
O95803-2 0 0 0 1 0 0 0 0
A0A087WX 0 0 0 0 0 0 1 0
A8MUF7 0 0 0 0 0 0 0 1
F8W943 0 0 1 0 0 0 0 0
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C9J3N8 1 0 0 0 0 0 0 0
F2Z3K5 0 1 0 0 0 0 0 0
B8ZZA1 0 0 1 0 0 0 0 0
A0A087WT 0 0 1 0 0 0 0 0
A0A087WT 1 0 0 0 0 0 0 0
F5GZD9 1 0 0 0 0 0 0 0
A0A0A0MS 0 0 1 0 0 0 0 0
A8MUH2 1 0 0 0 0 0 0 0
K7EL89 0 0 1 0 0 0 0 0
E7EV59 0 0 1 0 0 0 0 0
J3KPD9 0 0 0 0 1 0 0 0
D3YTI2 0 0 0 0 0 0 0 1
B7Z2B6 0 0 1 0 0 0 0 0
E9PAQ1 0 0 0 0 1 0 0 0
J3KRV2 0 0 0 1 0 0 0 0
H0YGD4 0 0 0 0 0 1 0 0
C9J0J7 1 0 0 0 0 0 0 0
H0Y8U4 0 0 0 0 0 0 0 1
E7ES19 0 0 0 0 0 0 1 0
M0QXN5 0 0 0 0 0 0 1 0
I3L3E9 1 0 0 0 0 0 0 0
K7EIF9 0 1 0 0 0 0 0 0
A0A0A0MS 0 0 0 0 0 0 0 1
A0A0D9SFU 0 0 0 1 0 0 0 0
A0A0U1RQ 1 0 0 0 0 0 0 0
A0A1B0GTM 0 0 0 1 0 0 0 0
H3BMQ0 1 0 0 0 0 0 0 0
B1AKY9 0 0 0 0 0 0 1 0
H3BQ95 0 0 0 1 0 0 0 0
H0YE37 0 0 0 0 0 0 0 1
P51800-3 0 0 0 1 0 0 0 0
A8MZF9 0 0 0 0 0 1 0 0
A8MQ02 0 0 1 0 0 0 0 0
H7C3V3 0 0 0 0 0 0 1 0
A0A1B0GU 0 0 0 0 1 0 0 0
I3L1E7 0 0 0 0 0 0 0 1
E7ER26 0 0 0 1 0 0 0 0
H0YDB7 0 0 0 0 1 0 0 0
M0R2W9 0 0 0 0 0 0 1 0
A0A024R7E 0 1 0 0 0 0 0 0
H0YDL5 0 0 0 0 1 0 0 0
A0A0D9SG7 1 0 0 0 0 0 0 0
F5GYI5 0 0 0 0 0 1 0 0
F8WF45 1 0 0 0 0 0 0 0
F5GZB0 0 0 0 0 0 1 0 0
A0A087X0P 0 0 0 0 1 0 0 0
A0A0A0MR 1 0 0 0 0 0 0 0
D6RAT2 0 1 0 0 0 0 0 0
H0Y8R3 1 0 0 0 0 0 0 0
Q07444-2 0 0 0 0 0 1 0 0
F5H1D6 0 1 0 0 0 0 0 0
J3KSR8 1 0 0 0 0 0 0 0
Q0GE19-5 0 0 1 0 0 0 0 0
F8VS81 0 0 0 0 0 0 1 0
F8VWL0 0 1 0 0 0 0 0 0
A0A0A0MR 0 0 0 1 0 0 0 0
H7C101 0 0 0 0 0 0 0 1
F8VVF8 1 0 0 0 0 0 0 0
K7EN45 0 0 0 0 0 0 1 0
F5GXJ9 1 0 0 0 0 0 0 0
B1ALK7 1 0 0 0 0 0 0 0
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B7Z5R6 0 1 0 0 0 0 0 0
A0A087WY 0 0 0 0 1 0 0 0
F8WBH5 0 0 0 1 0 0 0 0
B5MCX3 0 0 1 0 0 0 0 0
C9JXD7 0 1 0 0 0 0 0 0
A0A0A0MT 1 0 0 0 0 0 0 0
A0A0D9SFS 0 0 0 1 0 0 0 0
G3V4Q5 0 0 1 0 0 0 0 0
B7Z5N5 1 0 0 0 0 0 0 0
F8W7U0 0 0 0 0 0 0 1 0
A0A0A0MQ 0 0 0 0 0 0 0 1
F5H7S1 0 0 0 0 0 1 0 0
F8WCH7 0 0 0 0 1 0 0 0
K7N7D6 0 0 0 1 0 0 0 0
G3V3G0 0 0 0 0 0 1 0 0
A0A1B0GU 0 0 0 0 0 0 0 1
K7ELG9 1 0 0 0 0 0 0 0
F5H435 0 0 1 0 0 0 0 0
C9JPQ4 1 0 0 0 0 0 0 0
A8MUM1 0 0 0 1 0 0 0 0
A0A0J9YXM 0 0 0 0 1 0 0 0
G3V2W9 0 1 0 0 0 0 0 0
H7BY83 1 0 0 0 0 0 0 0
B1AQM6 0 0 0 0 1 0 0 0
A0A0A0MT 0 0 1 0 0 0 0 0
H0Y904 1 0 0 0 0 0 0 0
E7ES50 0 0 1 0 0 0 0 0
F6VX93 0 0 0 1 0 0 0 0
Q5VUA4-2 0 0 0 0 0 0 0 1
Q68CQ7-2 1 0 0 0 0 0 0 0
A0A087WW 0 0 0 0 1 0 0 0
A0A1B0GU 1 0 0 0 0 0 0 0
A0A087WZ 0 0 0 0 0 1 0 0
A0A087WU 0 0 0 0 0 0 1 0
C9JYQ9 0 0 0 0 0 0 1 0
Q6SZW1-2 0 0 0 0 1 0 0 0
C9JMQ9 0 0 0 0 0 0 1 0
D6REK3 1 0 0 0 0 0 0 0
E9PB18 0 0 0 0 0 0 1 0
B4DX60 0 0 0 0 0 0 0 1
H0Y2S9 0 0 0 1 0 0 0 0
G3V218 0 0 0 0 0 0 1 0
Q6ZMY3-4 0 0 1 0 0 0 0 0
B4DQT1 1 0 0 0 0 0 0 0
X6R717 1 0 0 0 0 0 0 0
F8W6G5 1 0 0 0 0 0 0 0
E5RHG5 0 0 1 0 0 0 0 0
E9PRC5 0 0 0 0 0 0 1 0
E9PGH5 0 0 1 0 0 0 0 0
F8WA11 0 1 0 0 0 0 0 0
K7ERA4 0 0 0 0 1 0 0 0
A0A087X1S 0 0 1 0 0 0 0 0
A0A0A0MS 0 0 0 1 0 0 0 0
K7EM46 0 0 0 0 0 1 0 0
A0A087X1P 1 0 0 0 0 0 0 0
C9JEH4 0 0 0 0 0 0 0 1
F2Z2E2 0 1 0 0 0 0 0 0
C9J7J4 0 1 0 0 0 0 0 0
A0A0C4DG 0 0 0 0 1 0 0 0
J3KRD0 0 0 1 0 0 0 0 0
Q86W56-4 0 0 0 0 1 0 0 0
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H0YFE4 0 0 0 0 1 0 0 0
F8WE06 1 0 0 0 0 0 0 0
Q86Y39-2 0 0 1 0 0 0 0 0
K7EQF1 0 1 0 0 0 0 0 0
J3KR22 1 0 0 0 0 0 0 0
A0A088AW 0 1 0 0 0 0 0 0
H3BU53 1 0 0 0 0 0 0 0
H0UI80 0 0 0 0 0 0 0 1
J3KRG7 0 0 0 0 0 1 0 0
A0A087X0G 0 0 0 0 0 0 1 0
C9IZ46 0 0 0 0 0 0 0 1
J3KNJ7 0 0 0 0 1 0 0 0
A0A087WX 0 1 0 0 0 0 0 0
E9PCJ7 1 0 0 0 0 0 0 0
Q5TA05 0 0 0 0 0 0 0 1
H0YMU7 0 0 0 0 0 0 0 1
F8W925 0 0 0 0 0 0 0 1
B7Z2D2 0 0 0 1 0 0 0 0
H0Y3Y7 0 0 0 0 0 0 1 0
A0A087WT 0 0 0 0 1 0 0 0
H0YEB0 0 0 0 0 0 0 0 1
J3KRU1 1 0 0 0 0 0 0 0
A0A087WV 1 0 0 0 0 0 0 0
A0A087WZ 1 0 0 0 0 0 0 0
B8ZZ98 0 0 1 0 0 0 0 0
C9JDE6 0 0 1 0 0 0 0 0
U3KQE6 0 0 0 0 0 0 0 1
C9JSD5 0 1 0 0 0 0 0 0
C9JE27 1 0 0 0 0 0 0 0
H0Y448 0 0 0 0 1 0 0 0
A0A087WW 0 0 1 0 0 0 0 0
A0A0J9YWM 0 1 0 0 0 0 0 0
H7C0W4 0 0 0 0 0 0 0 1
K7EQS2 1 0 0 0 0 0 0 0
K7EJA9 0 1 0 0 0 0 0 0
B4DHE8 1 0 0 0 0 0 0 0
M0QYI9 0 0 1 0 0 0 0 0
H0Y9X1 1 0 0 0 0 0 0 0
K7ELQ6 0 0 0 0 0 0 0 1
H3BM29 0 0 0 0 0 1 0 0
H0YIS8 1 0 0 0 0 0 0 0
K7ESB7 0 0 0 1 0 0 0 0
E9PD99 1 0 0 0 0 0 0 0
G3V4L6 0 0 1 0 0 0 0 0
A0A087WU 0 0 1 0 0 0 0 0
H0Y7Q2 0 0 0 0 0 0 0 1
H0Y8W1 0 1 0 0 0 0 0 0
Q96KV7-3 0 0 1 0 0 0 0 0
A0A1B0GTU 0 0 0 0 1 0 0 0
E5RGX6 0 0 0 1 0 0 0 0
A0A087WT 1 0 0 0 0 0 0 0
H0Y853 0 0 0 0 0 0 0 1
E7ESL9 0 0 0 0 1 0 0 0
H0YLN8 0 0 0 1 0 0 0 0
A0A0A0MQ 0 0 0 0 1 0 0 0
A0A087WW 1 0 0 0 0 0 0 0
A0A1B0GW 1 0 0 0 0 0 0 0
H3BPF6 0 0 0 0 0 0 1 0
F8W6K1 0 0 0 1 0 0 0 0
K7EIH8 0 0 1 0 0 0 0 0
F5GXW5 0 0 1 0 0 0 0 0
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F5H492 0 0 1 0 0 0 0 0
A0A0A0MS 0 0 1 0 0 0 0 0
K7EIN2 0 0 1 0 0 0 0 0
A0A087WT 1 0 0 0 0 0 0 0
I3NI31 0 0 0 0 0 0 1 0
H0YCH4 0 0 1 0 0 0 0 0
A0A087WT 1 0 0 0 0 0 0 0
A0A087WV 0 0 1 0 0 0 0 0
A2A2L6 0 0 1 0 0 0 0 0
B1AQT4 1 0 0 0 0 0 0 0
A0A0D9SF2 0 1 0 0 0 0 0 0
A0A087WT 0 0 1 0 0 0 0 0
H0YL62 0 0 1 0 0 0 0 0
A0A024QZ3 1 0 0 0 0 0 0 0
A0A0B4J2F 0 0 1 0 0 0 0 0
I6L9I8 0 0 0 0 0 0 1 0
A0A087WX 0 1 0 0 0 0 0 0
B3KVZ3 1 0 0 0 0 0 0 0
A0A024R57 1 0 0 0 0 0 0 0
H3BS42 1 0 0 0 0 0 0 0
B4DHR0 1 0 0 0 0 0 0 0
A6NGY7 0 0 0 1 0 0 0 0
G3V541 0 1 0 0 0 0 0 0
A0A075B6H 0 0 0 0 1 0 0 0
A0A0A0MS 1 0 0 0 0 0 0 0
F5H3T4 0 0 0 1 0 0 0 0
A0A1B0GU 0 1 0 0 0 0 0 0
F8VUA2 0 0 0 1 0 0 0 0
Q9NPA1-5 0 0 0 0 0 1 0 0
K7ENT1 0 0 0 0 0 1 0 0
Q5T911 0 0 0 1 0 0 0 0
A0A087X2D 0 0 0 0 0 1 0 0
F8WBJ6 0 1 0 0 0 0 0 0
Q9NS73-5 1 0 0 0 0 0 0 0
A0A0B4J22 1 0 0 0 0 0 0 0
F8W7R3 0 0 1 0 0 0 0 0
H3BNW0 1 0 0 0 0 0 0 0
E9PJA7 0 1 0 0 0 0 0 0
H7BXP1 1 0 0 0 0 0 0 0
A0A087WV 0 0 1 0 0 0 0 0
A0A0G2JLW 0 0 0 1 0 0 0 0
B5ME80 0 0 0 0 0 0 0 1
H7C254 0 0 0 0 0 0 0 1
K7EK91 0 0 1 0 0 0 0 0
F5GZ56 0 1 0 0 0 0 0 0
E7EMB1 0 0 0 0 0 1 0 0
E9PGN6 0 0 0 0 0 0 0 1
Q6B8I1-3 0 0 0 0 1 0 0 0
Q5QPL9 0 0 0 0 1 0 0 0
Q9UKZ4-2 0 0 0 0 0 1 0 0
A0A087X1Z 0 1 0 0 0 0 0 0
A0A0C4DG 1 0 0 0 0 0 0 0
A0A087WY 0 0 0 0 0 0 0 1
A0A0J9YWA 0 1 0 0 0 0 0 0
A0A0A0MR 0 0 0 1 0 0 0 0
A0A0A0MS 0 0 0 1 0 0 0 0
E7EMX0 1 0 0 0 0 0 0 0
E9PCD7 1 0 0 0 0 0 0 0
A0A0J9YYL5 0 0 1 0 0 0 0 0
A0A087X12 0 1 0 0 0 0 0 0
F5H5G4 0 1 0 0 0 0 0 0
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D6R8Y9 0 0 0 0 0 1 0 0
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G3XAE9 0 0 0 0 1 0 0 0
C9J014 0 0 1 0 0 0 0 0
J3KPG9 0 0 0 0 0 0 1 0
E5RJA8 0 0 0 0 0 0 0 1
H3BRH0 1 0 0 0 0 0 0 0
F8VVR0 0 0 0 0 0 0 0 1
Q9HDC5 0 0 1 0 0 0 0 0
Q86V97 0 0 0 0 1 0 0 0
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Q5VUJ6 0 0 1 0 0 0 0 0
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Q9Y4C4 0 0 0 0 0 0 0 1
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Q8TE76 1 0 0 0 0 0 0 0
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P46531 0 1 0 0 0 0 0 0
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O15050 0 0 0 0 0 1 0 0
Q96RI8 0 0 0 0 0 1 0 0
P23193 1 0 0 0 0 0 0 0
O15525 0 0 1 0 0 0 0 0
O60675 0 0 1 0 0 0 0 0
P08047 1 0 0 0 0 0 0 0
P62995 0 1 0 0 0 0 0 0
Q9BX84 0 0 0 0 1 0 0 0
P17152 0 0 0 0 0 0 0 1
A2RUT3 0 0 1 0 0 0 0 0
P54577 0 0 0 1 0 0 0 0
Q96K76 0 0 0 1 0 0 0 0
Q92890 0 0 0 1 0 0 0 0
Q9UGI0 0 1 0 0 0 0 0 0
154
Q14CS0 0 0 0 0 1 0 0 0
P22310 0 0 1 0 0 0 0 0
A0A0U1RQ 0 1 0 0 0 0 0 0
Q6NUN7 0 0 0 0 0 0 1 0
Q8NEP4 0 1 0 0 0 0 0 0
Q8NBC4 0 0 1 0 0 0 0 0
H3BNL8 0 0 0 0 0 0 1 0
K7ENM7 0 0 0 1 0 0 0 0
B0I1T2 0 0 1 0 0 0 0 0
Q9BUW7 0 0 0 0 1 0 0 0
A8MWY0 0 0 0 0 0 0 1 0
Q9P253 1 0 0 0 0 0 0 0
Q9UID3 0 0 1 0 0 0 0 0
Q8N1B4 0 0 1 0 0 0 0 0
O75396 0 0 0 0 1 0 0 0
Q96A05 0 0 1 0 0 0 0 0
A4D1P6 0 1 0 0 0 0 0 0
Q6P2C0 0 0 0 0 0 1 0 0
O95389 0 1 0 0 0 0 0 0
Q2TBF2 0 0 0 0 0 0 1 0
Q05516 0 0 0 0 0 1 0 0
Q5SVQ8 0 0 0 0 0 1 0 0
Q68DK2 0 0 0 0 0 0 0 1
O95405 0 1 0 0 0 0 0 0
Q9UL59 0 0 0 0 0 0 1 0
P59817 0 1 0 0 0 0 0 0
Q8IYI8 0 0 0 0 1 0 0 0
Q76KX8 0 0 0 0 0 1 0 0
Q5T7W0 0 1 0 0 0 0 0 0
P17098 1 0 0 0 0 0 0 0
Q86V15 0 0 0 0 1 0 0 0
O95409 0 0 0 1 0 0 0 0
Q9UPR6 0 1 0 0 0 0 0 0
A7E2V4 1 0 0 0 0 0 0 0
Q8TAD4 0 1 0 0 0 0 0 0


















































































































P28482 633 624 536 529 1951 2145 1499 1507 1292 1384.5 1017.5 1018
O14744 63 58 64 63 258 295 243 264 160.5 176.5 153.5 163.5
Q9BQA1 51 58 56 66 161 189 178 211 106 123.5 117 138.5
P78347 67 55 62 51 129 141 150 143 98 98 106 97
TRYP_PIG 46 48 43 45 153 179 158 167 99.5 113.5 100.5 106
P51812 38 36 33 8 141 190 144 40 89.5 113 88.5 24
P68363 30 17 43 19 103 85 131 61 66.5 51 87 40
P07437 25 18 20 20 92 84 130 85 58.5 51 75 52.5
P68104 11 6 18 8 80 70 111 68 45.5 38 64.5 38
Q99956 16 3 25 2 82 23 94 27 49 13 59.5 14.5
P49327 9 1 21 3 31 11 74 17 20 6 47.5 10
P12268 21 0 17 0 88 0 67 0 54.5 0 42 0
G8JLB6 10 0 17 7 33 23 66 16 21.5 11.5 41.5 11.5
E9PGT3 16 19 18 0 82 70 60 10 49 44.5 39 5
Q15208 4 6 12 8 60 68 65 60 32 37 38.5 34
P61978 4 5 10 1 39 22 67 22 21.5 13.5 38.5 11.5
P50990 23 19 18 18 57 63 58 57 40 41 38 37.5
P48643 18 12 15 10 48 56 61 62 33 34 38 36
P78371 15 9 14 7 61 62 61 50 38 35.5 37.5 28.5
P17987 18 13 20 16 53 51 54 45 35.5 32 37 30.5
P52597 6 2 13 2 29 14 49 6 17.5 8 31 4
P04264 30 20 22 30 51 28 38 45 40.5 24 30 37.5
Q99832 15 10 15 5 46 41 45 52 30.5 25.5 30 28.5
Q9UK32 3 2 5 6 30 12 53 6 16.5 7 29 6
O75582 7 0 17 0 26 1 40 1 16.5 0.5 28.5 0.5
P11142 5 2 8 6 39 18 44 18 22 10 26 12
H3BLZ8 0 1 1 1 34 2 48 2 17 1.5 24.5 1.5
Q15393 13 12 12 9 33 33 36 40 23 22.5 24 24.5
P78527 16 4 12 0 60 23 35 20 38 13.5 23.5 10
Q13162 8 8 10 12 41 57 36 63 24.5 32.5 23 37.5
A0A0J9YVP 12 5 9 5 21 23 35 19 16.5 14 22 12
P13645 23 13 21 28 44 10 19 19 33.5 11.5 20 23.5
P68371 0 0 0 0 70 45 39 8 35 22.5 19.5 4
P40227 7 3 4 6 36 36 35 28 21.5 19.5 19.5 17
P49368 9 7 8 6 27 23 31 24 18 15 19.5 15
Q16531 11 5 9 6 19 11 29 12 15 8 19 9
P13639 8 6 9 5 22 10 29 7 15 8 19 6
Q7Z3B4 1 0 1 0 13 0 37 0 7 0 19 0
P54886 0 0 11 0 0 0 27 0 0 0 19 0
Q9BVA1 1 0 5 3 18 14 32 10 9.5 7 18.5 6.5
Q13435 5 2 4 2 20 15 33 20 12.5 8.5 18.5 11
P60709 11 3 10 1 23 15 26 9 17 9 18 5
ALBU_BOV 21 21 17 20 13 15 18 9 17 18 17.5 14.5
Q15365 4 2 9 4 20 27 26 17 12 14.5 17.5 10.5
Q14204 14 13 13 15 21 36 21 32 17.5 24.5 17 23.5
Q9BYB4 9 0 10 0 27 0 24 0 18 0 17 0
Q9BQE3 7 5 2 5 37 16 31 25 22 10.5 16.5 15
P50991 2 2 3 2 22 17 30 24 12 9.5 16.5 13
Q9UJ70 8 0 7 0 42 0 26 0 25 0 16.5 0
Q15029 8 1 11 5 16 7 22 9 12 4 16.5 7
A0A0G2JIW 6 0 6 2 21 3 26 8 13.5 1.5 16 5
Q07666 0 0 3 0 8 0 29 0 4 0 16 0
A0A087WT 1 1 5 0 14 3 26 2 7.5 2 15.5 1
Replicate 1 PSMs Replicate 2 PSMs Average PSMs
157
O75676 2 0 4 0 14 1 27 1 8 0.5 15.5 0.5
A0A0A0MR 11 9 4 5 23 27 26 50 17 18 15 27.5
P21333 0 1 0 0 23 22 30 33 11.5 11.5 15 16.5
P52564 6 0 5 0 35 0 25 0 20.5 0 15 0
Q15637-6 0 0 3 0 17 13 27 10 8.5 6.5 15 5
A0A087WT 2 1 4 2 17 8 26 6 9.5 4.5 15 4
PRDX1_HU 7 8 8 11 13 20 21 36 10 14 14.5 23.5
O75643 1 0 3 0 27 17 26 9 14 8.5 14.5 4.5
Q6P2Q9 8 6 10 5 18 7 19 7 13 6.5 14.5 6
P55072 12 10 10 6 29 24 18 27 20.5 17 14 16.5
Q0VDG4 4 4 3 4 21 26 25 23 12.5 15 14 13.5
P50548 1 0 6 0 12 7 22 3 6.5 3.5 14 1.5
P08238 9 3 9 3 11 3 18 5 10 3 13.5 4
Q9P258 2 0 5 0 4 0 22 0 3 0 13.5 0
E9PB61 2 3 3 3 29 27 23 23 15.5 15 13 13
P35527 9 15 14 7 13 11 12 17 11 13 13 12
H3BSW6 7 0 4 0 23 0 22 0 15 0 13 0
F6VRR5 0 0 2 1 22 30 23 35 11 15 12.5 18
O60701 2 0 3 0 10 0 22 0 6 0 12.5 0
P49137 1 1 4 0 7 0 21 0 4 0.5 12.5 0
Q15121 0 0 4 0 6 0 20 0 3 0 12 0
P55795 0 5 8 0 4 3 15 0 2 4 11.5 0
B0QY89 5 7 6 6 17 20 17 19 11 13.5 11.5 12.5
Q9UMS4 8 3 3 2 18 16 20 15 13 9.5 11.5 8.5
O75533 2 1 1 0 18 13 22 22 10 7 11.5 11
H7BYF2 0 0 1 0 9 0 22 0 4.5 0 11.5 0
P04350 3 7 15 0 0 0 7 8 1.5 3.5 11 4
F5H2F4 5 1 8 1 12 1 14 1 8.5 1 11 1
P09874 0 0 1 0 21 0 21 0 10.5 0 11 0
Q8WUA2 0 0 5 0 2 0 17 0 1 0 11 0
Q15366-2 0 0 4 0 11 2 17 3 5.5 1 10.5 1.5
Q15233 3 0 1 0 28 8 19 4 15.5 4 10 2
F8VPD4 2 1 5 1 11 9 15 2 6.5 5 10 1.5
Q13263 2 3 8 0 4 0 12 1 3 1.5 10 0.5
P35908 12 10 13 31 24 2 6 8 18 6 9.5 19.5
P60228 7 5 5 5 16 14 14 15 11.5 9.5 9.5 10
A0A087WV 3 8 7 6 15 16 12 15 9 12 9.5 10.5
Q16829 0 0 4 0 6 1 15 1 3 0.5 9.5 0.5
E7EX17 7 2 5 1 14 11 14 11 10.5 6.5 9.5 6
Q15750 3 4 6 2 13 10 12 7 8 7 9 4.5
F8W6I7 4 1 1 1 17 11 17 9 10.5 6 9 5
Q8WWY3 1 0 3 0 10 9 15 12 5.5 4.5 9 6
P04406 4 1 4 0 13 5 14 4 8.5 3 9 2
Q96K76 2 0 6 0 8 0 12 0 5 0 9 0
Q8NC51 2 0 4 0 6 0 14 1 4 0 9 0.5
O00303 4 3 5 5 12 10 12 11 8 6.5 8.5 8
A0A087WW 6 7 9 5 6 8 8 10 6 7.5 8.5 7.5
P30041 6 4 5 6 12 10 11 25 9 7 8 15.5
P84090 3 1 5 1 13 13 11 9 8 7 8 5
Q13200 3 1 5 2 12 9 11 10 7.5 5 8 6
O43143 1 0 1 0 12 8 15 6 6.5 4 8 3
P67775 2 0 5 1 5 0 11 0 3.5 0 8 0.5
A0A0U1RR 1 0 4 0 4 0 12 0 2.5 0 8 0
O43823 0 1 4 1 4 1 12 0 2 1 8 0.5
A0A0R4J2E 2 0 5 0 2 0 11 0 2 0 8 0
P07900 7 0 3 3 7 4 12 5 7 2 7.5 4
B5ME19 8 1 5 3 11 8 10 14 9.5 4.5 7.5 8.5
P61163 4 2 4 1 10 7 11 12 7 4.5 7.5 6.5
H0Y8C6 8 1 4 0 21 2 11 2 14.5 1.5 7.5 1
E9PM69 2 2 3 2 13 5 12 8 7.5 3.5 7.5 5
P11021 1 2 0 1 12 10 15 7 6.5 6 7.5 4
158
J3KTA4 2 1 4 1 4 0 11 0 3 0.5 7.5 0.5
P22102 0 0 2 1 7 2 13 2 3.5 1 7.5 1.5
O15371 2 0 5 0 0 2 10 3 1 1 7.5 1.5
Q9BUB5 0 0 2 0 8 0 13 0 4 0 7.5 0
E9PMI6 6 1 4 4 12 10 10 12 9 5.5 7 8
A0A075B6S 4 3 2 2 12 10 12 11 8 6.5 7 6.5
Q13347 5 5 6 1 7 7 8 8 6 6 7 4.5
Q14011 2 2 6 5 7 9 8 11 4.5 5.5 7 8
Q9NQW7-3 5 0 2 0 31 0 12 0 18 0 7 0
P35998 3 1 4 1 6 7 10 7 4.5 4 7 4
M0QXS5 4 0 5 0 9 1 9 1 6.5 0.5 7 0.5
C9JIR6 3 0 3 1 3 4 11 1 3 2 7 1
P37198 0 0 1 0 6 0 13 0 3 0 7 0
P52272 0 0 3 0 6 0 11 0 3 0 7 0
Q09028 0 2 0 3 13 13 13 16 6.5 7.5 6.5 9.5
P43686 1 2 2 2 10 9 11 10 5.5 5.5 6.5 6
Q9Y657 3 2 3 2 8 8 10 9 5.5 5 6.5 5.5
A0A087X2I 2 1 2 0 11 7 11 10 6.5 4 6.5 5
Q12874 2 3 5 3 6 9 8 5 4 6 6.5 4
H0YEN5 5 0 4 0 4 1 9 3 4.5 0.5 6.5 1.5
P22626 3 0 3 1 12 3 9 0 7.5 1.5 6 0.5
P30153 4 1 2 0 8 0 10 0 6 0.5 6 0
P15170-2 4 0 5 1 4 0 7 0 4 0 6 0.5
P25205 4 0 4 0 6 0 8 1 5 0 6 0.5
Q8WUM4 1 0 1 0 5 0 11 0 3 0 6 0
Q8IWX8 0 0 0 0 4 0 12 0 2 0 6 0
Q5T7U1 1 0 5 0 2 0 7 0 1.5 0 6 0
Q5QPM7 0 0 4 0 2 0 8 0 1 0 6 0
P62937 6 2 3 5 8 8 8 9 7 5 5.5 7
E9PBS1 6 1 3 0 3 1 8 1 4.5 1 5.5 0.5
A0A0A0MS 3 0 4 0 6 1 7 0 4.5 0.5 5.5 0
K9J957 1 0 2 0 2 0 9 0 1.5 0 5.5 0
A0A0D9SF5 2 0 2 0 0 0 9 0 1 0 5.5 0
Q96I24 0 0 1 0 6 0 10 0 3 0 5.5 0
O15042 0 0 0 0 1 0 11 0 0.5 0 5.5 0
E9PC52 4 2 3 3 4 4 7 2 4 3 5 2.5
A0A087WZ 1 2 3 2 13 8 7 5 7 5 5 3.5
P23284 0 0 0 0 10 11 10 9 5 5.5 5 4.5
P62316 2 3 2 2 6 4 8 8 4 3.5 5 5
O60506 2 1 2 1 16 2 8 0 9 1.5 5 0.5
D6RG13 4 1 2 2 4 4 8 5 4 2.5 5 3.5
P98179 2 2 4 2 4 3 6 3 3 2.5 5 2.5
Q9HBH9 0 0 2 0 4 0 8 5 2 0 5 2.5
P49643 2 0 3 0 3 0 7 0 2.5 0 5 0
P63151 0 0 1 0 5 0 9 0 2.5 0 5 0
Q9BRS2 2 0 4 0 2 0 6 0 2 0 5 0
Q12906 0 0 0 0 4 0 10 0 2 0 5 0
Q15417 1 0 3 0 2 0 7 1 1.5 0 5 0.5
F8W726 0 0 0 0 3 0 10 0 1.5 0 5 0
Q9Y5X1 0 0 4 0 0 0 6 0 0 0 5 0
Q9BUF5 0 0 1 0 2 0 8 5 1 0 4.5 2.5
A0A0J9YXJ8 0 5 9 5 21 23 0 19 10.5 14 4.5 12
P62195 3 1 2 2 14 12 7 11 8.5 6.5 4.5 6.5
Q9Y2H1 1 0 0 0 7 2 9 7 4 1 4.5 3.5
Q7L2H7 3 5 2 3 7 8 7 7 5 6.5 4.5 5
Q01804 1 0 0 0 4 9 9 18 2.5 4.5 4.5 9
J3QLE5 3 1 1 0 8 11 8 6 5.5 6 4.5 3
P55884 0 1 1 0 7 9 8 12 3.5 5 4.5 6
Q7RTV0 3 3 3 2 8 5 6 5 5.5 4 4.5 3.5
Q9Y230 3 2 5 2 6 4 4 4 4.5 3 4.5 3
P62318 1 2 3 3 5 5 6 4 3 3.5 4.5 3.5
159
P23246 1 0 0 0 13 2 9 1 7 1 4.5 0.5
P53618 1 1 1 1 6 3 8 5 3.5 2 4.5 3
Q00839 4 0 2 0 5 3 7 5 4.5 1.5 4.5 2.5
P10599 3 2 2 1 7 1 7 2 5 1.5 4.5 1.5
A0A087WT 1 0 2 0 6 5 7 4 3.5 2.5 4.5 2
Q96GM8 0 0 1 0 16 0 8 0 8 0 4.5 0
Q5THR1 7 1 8 1 3 2 1 2 5 1.5 4.5 1.5
O00487 1 2 5 1 4 1 4 2 2.5 1.5 4.5 1.5
F5H4R6 1 0 0 1 5 2 9 3 3 1 4.5 2
P19338 1 0 2 0 5 2 7 2 3 1 4.5 1
P53396 2 0 2 0 6 0 7 0 4 0 4.5 0
P61962 0 0 1 1 4 1 8 2 2 0.5 4.5 1.5
P41162 0 0 2 0 3 0 7 0 1.5 0 4.5 0
P36507 1 0 3 0 2 0 6 0 1.5 0 4.5 0
Q14247 0 0 0 0 0 0 9 0 0 0 4.5 0
O14613 0 0 1 0 0 0 8 0 0 0 4.5 0
F2Z2J1 1 5 6 2 8 12 2 2 4.5 8.5 4 2
Q13561 2 2 1 1 9 10 7 11 5.5 6 4 6
P62191 2 3 2 2 7 9 6 5 4.5 6 4 3.5
Q9BUA3 3 2 3 3 6 7 5 5 4.5 4.5 4 4
B1ALA9 0 0 2 0 1 6 6 11 0.5 3 4 5.5
P25398 3 1 1 1 3 3 7 3 3 2 4 2
A0A087WZ 1 1 4 2 4 3 4 3 2.5 2 4 2.5
E9PL09 2 1 2 0 6 3 6 1 4 2 4 0.5
Q86X55 4 0 5 0 4 0 3 0 4 0 4 0
J3QRG6 1 0 2 1 4 0 6 1 2.5 0 4 1
B8ZZU8 1 1 4 0 3 2 4 0 2 1.5 4 0
P31689 1 0 2 0 4 1 6 0 2.5 0.5 4 0
Q14974 0 0 2 1 4 0 6 1 2 0 4 1
Q92598 3 0 4 0 1 0 4 0 2 0 4 0
Q9NP73 1 0 4 2 2 0 4 0 1.5 0 4 1
A2RQR6 1 0 2 0 3 0 6 0 2 0 4 0
I3L2N2 0 0 2 0 3 0 6 0 1.5 0 4 0
Q96HA7 0 0 2 1 0 0 6 2 0 0 4 1.5
P55265 0 0 2 0 2 0 6 0 1 0 4 0
C9J0I9 0 0 3 0 0 0 5 0 0 0 4 0
P49366 13 4 2 7 36 43 5 32 24.5 23.5 3.5 19.5
P11802 5 0 4 2 4 0 3 0 4.5 0 3.5 1
Q13547 2 5 5 4 3 3 2 2 2.5 4 3.5 3
P09661 1 1 1 3 5 3 6 6 3 2 3.5 4.5
O00231 5 2 4 0 4 3 3 4 4.5 2.5 3.5 2
E5RJR5 4 2 3 1 4 3 4 3 4 2.5 3.5 2
H3BNT7 1 1 2 1 6 3 5 4 3.5 2 3.5 2.5
Q9BWJ5 0 1 3 1 4 4 4 3 2 2.5 3.5 2
E9PK25 2 1 3 3 3 2 4 1 2.5 1.5 3.5 2
P62979 2 0 2 0 3 3 5 3 2.5 1.5 3.5 1.5
Q16644 1 1 0 0 8 0 7 0 4.5 0.5 3.5 0
Q96J01 2 1 3 2 2 1 4 1 2 1 3.5 1.5
P13010 1 0 2 0 5 1 5 1 3 0.5 3.5 0.5
O14654 0 0 0 0 3 2 7 0 1.5 1 3.5 0
P05412 0 0 1 0 4 0 6 0 2 0 3.5 0
O00743 0 0 2 0 3 0 5 0 1.5 0 3.5 0
E7EPP6 0 0 0 0 2 0 7 0 1 0 3.5 0
Q9ULX6 0 0 1 0 0 0 6 0 0 0 3.5 0
P27694 2 0 0 0 7 8 6 7 4.5 4 3 3.5
Q9NPA8 2 1 1 2 9 5 5 4 5.5 3 3 3
P35244 2 2 1 1 6 5 5 6 4 3.5 3 3.5
K7ERF1 3 2 3 1 6 3 3 4 4.5 2.5 3 2.5
J3QLI9 1 0 0 0 7 4 6 6 4 2 3 3
Q9Y265 1 1 1 0 6 5 5 3 3.5 3 3 1.5
P55036 1 0 2 0 4 4 4 6 2.5 2 3 3
160
B7Z6Z4 1 1 3 1 5 3 3 3 3 2 3 2
P63167 0 0 0 1 6 3 6 2 3 1.5 3 1.5
E9PD53 0 0 0 0 2 3 6 6 1 1.5 3 3
P06748 3 0 1 0 5 1 5 1 4 0.5 3 0.5
P17858 2 0 3 0 3 1 3 0 2.5 0.5 3 0
Q9C0B7 3 0 3 0 6 0 3 0 4.5 0 3 0
E9PKG1 2 1 1 0 3 1 5 2 2.5 1 3 1
P62701 0 0 1 1 3 2 5 2 1.5 1 3 1.5
Q86XN8 1 0 1 0 5 2 5 0 3 1 3 0
P14618 4 1 2 1 1 0 4 0 2.5 0.5 3 0.5
Q5JVS0 1 0 1 0 5 0 5 0 3 0 3 0
Q7Z7A3 0 0 0 0 5 0 6 0 2.5 0 3 0
E5RHG8 0 0 0 0 4 0 6 0 2 0 3 0
B1AHB1 1 0 3 1 0 0 3 1 0.5 0 3 1
Q96D09 0 0 0 0 2 0 6 0 1 0 3 0
Q9ULW0 0 0 0 0 1 0 6 0 0.5 0 3 0
P11413 0 0 4 0 1 0 2 0 0.5 0 3 0
H3BR83 0 0 1 0 1 0 5 0 0.5 0 3 0
Q9P215 0 0 1 0 1 0 5 0 0.5 0 3 0
O60678 0 0 1 0 0 0 5 0 0 0 3 0
A0A087WW 0 0 2 0 0 0 4 0 0 0 3 0
Q14008 0 0 0 0 0 0 6 0 0 0 3 0
E9PKF6 0 0 0 0 0 0 6 0 0 0 3 0
Q14152 1 0 0 1 3 5 5 9 2 2.5 2.5 5
P49458 2 2 2 1 4 3 3 4 3 2.5 2.5 2.5
Q9Y6Y0 2 2 4 3 1 4 1 3 1.5 3 2.5 3
P48556 1 2 2 0 3 4 3 2 2 3 2.5 1
J3KT73 0 1 0 0 2 5 5 4 1 3 2.5 2
Q15008 1 0 1 1 3 4 4 2 2 2 2.5 1.5
P06733 2 1 0 1 2 1 5 3 2 1 2.5 2
P45985 3 0 1 0 7 0 4 0 5 0 2.5 0
P63241 1 2 0 0 3 2 5 2 2 2 2.5 1
F2Z2I2 5 0 3 0 4 0 2 1 4.5 0 2.5 0.5
O95163 0 0 0 0 8 0 5 0 4 0 2.5 0
O43318 0 0 0 0 2 2 5 1 1 1 2.5 0.5
A0A0U1RQ 0 0 1 0 2 1 4 4 1 0.5 2.5 2
P12277 2 1 1 1 1 0 4 1 1.5 0.5 2.5 1
P00492 2 1 3 0 1 1 2 0 1.5 1 2.5 0
B1AHC9 1 0 2 0 2 1 3 1 1.5 0.5 2.5 0.5
P46109 1 0 3 0 4 0 2 0 2.5 0 2.5 0
Q93008 1 0 2 0 4 0 3 0 2.5 0 2.5 0
Q96DI7 0 0 0 0 2 3 5 0 1 1.5 2.5 0
P43246 0 0 0 0 3 0 5 0 1.5 0 2.5 0
Q9Y4E8 0 0 4 0 1 0 1 0 0.5 0 2.5 0
B4DY09 0 0 2 0 2 0 3 1 1 0 2.5 0.5
A0A0X1KG7 1 0 1 0 1 0 4 0 1 0 2.5 0
P60174 0 0 1 0 0 0 4 1 0 0 2.5 0.5
E7EU96 0 0 0 0 1 0 5 0 0.5 0 2.5 0
Q08J23 1 0 1 0 0 0 4 0 0.5 0 2.5 0
E9PM92 0 0 1 0 0 0 4 0 0 0 2.5 0
F8W7U8 0 0 0 0 0 0 5 0 0 0 2.5 0
Q96F86 0 0 1 0 0 0 4 0 0 0 2.5 0
Q96I25 0 0 0 0 0 0 5 0 0 0 2.5 0
Q9BWF3 0 0 2 0 0 0 3 0 0 0 2.5 0
Q9H2U1 0 0 0 1 11 26 4 23 5.5 13 2 12
Q92576 1 0 0 0 8 16 4 9 4.5 8 2 4.5
P32119 3 2 2 3 4 5 2 17 3.5 3.5 2 10
O43242 3 3 1 4 3 4 3 8 3 3.5 2 6
P46734 2 0 1 0 8 0 3 0 5 0 2 0
Q92616 9 0 1 0 14 0 3 0 11.5 0 2 0
O60307 0 0 1 0 0 4 3 0 0 2 2 0
161
O95347 1 0 0 1 5 7 4 4 3 3.5 2 2.5
Q9Y3B4 1 1 0 2 3 6 4 4 2 3.5 2 3
P47813 0 0 0 1 6 6 4 4 3 3 2 2.5
J3QRS3 3 3 2 1 4 2 2 3 3.5 2.5 2 2
Q92769 1 0 0 1 0 0 4 2 0.5 0 2 1.5
P24666 4 6 3 4 0 1 1 0 2 3.5 2 2
P62304 0 0 1 0 4 4 3 3 2 2 2 1.5
P15927 0 0 1 1 4 4 3 3 2 2 2 2
A8MWD9 0 1 1 1 2 3 3 1 1 2 2 1
O43809 0 0 0 0 8 0 4 0 4 0 2 0
P62913 1 1 0 0 2 2 4 2 1.5 1.5 2 1
O00232 1 0 0 1 1 1 4 3 1 0.5 2 2
Q14562 0 0 1 0 1 0 3 0 0.5 0 2 0
Q9UBB9 2 1 3 0 0 0 1 3 1 0.5 2 1.5
P62310 1 0 1 1 2 1 3 1 1.5 0.5 2 1
Q92900 0 0 1 0 1 0 3 0 0.5 0 2 0
Q9BQ67 3 0 3 0 1 0 1 0 2 0 2 0
G5E9A6 0 0 1 0 3 0 3 0 1.5 0 2 0
O14929 1 0 0 0 2 0 4 0 1.5 0 2 0
O15294 0 0 1 1 0 0 3 2 0 0 2 1.5
P22314 1 0 2 1 1 0 2 0 1 0 2 0.5
Q6PJG6 1 0 1 0 2 0 3 0 1.5 0 2 0
A0A1C7CYX 0 0 0 0 1 1 4 1 0.5 0.5 2 0.5
P26368 1 0 3 0 1 0 1 0 1 0 2 0
P0DN76 0 0 1 0 2 0 3 0 1 0 2 0
P26641 2 0 2 0 0 0 2 0 1 0 2 0
H0Y8G5 0 0 0 0 2 0 4 0 1 0 2 0
I1E4Y6 0 0 0 0 2 0 4 0 1 0 2 0
Q9NPD3 0 0 2 0 2 0 2 0 1 0 2 0
Q04864 0 1 1 0 1 0 3 0 0.5 0.5 2 0
P19623 1 0 1 0 0 0 3 0 0.5 0 2 0
A0A087WW 0 0 2 0 1 0 2 0 0.5 0 2 0
P17482 0 0 0 0 1 0 4 0 0.5 0 2 0
P28562 0 0 1 0 1 0 3 0 0.5 0 2 0
Q13868 1 0 1 0 0 0 3 0 0.5 0 2 0
A0A087X28 0 0 1 0 1 0 3 0 0.5 0 2 0
K7EP90 0 0 1 0 1 0 3 0 0.5 0 2 0
Q9Y3F4 1 0 2 0 0 0 2 0 0.5 0 2 0
O15355 0 0 2 0 1 0 2 0 0.5 0 2 0
Q96HR8 0 0 2 0 1 0 2 0 0.5 0 2 0
P49757 0 0 0 0 0 0 4 0 0 0 2 0
Q93009 0 0 1 0 0 0 3 0 0 0 2 0
P08779 9 3 0 3 2 0 3 1 5.5 1.5 1.5 2
P02533 3 3 0 3 2 0 3 1 2.5 1.5 1.5 2
TRY1_BOVI 1 1 1 2 4 4 2 3 2.5 2.5 1.5 2.5
B0YIW6 0 0 0 0 4 4 3 4 2 2 1.5 2
P05204 0 0 0 0 3 4 3 2 1.5 2 1.5 1
B1AKR6 0 0 0 0 4 4 3 1 2 2 1.5 0.5
H0Y720 0 0 0 0 1 5 3 3 0.5 2.5 1.5 1.5
P01859 1 0 1 1 2 2 2 2 1.5 1 1.5 1.5
P20839 2 0 1 0 6 0 2 0 4 0 1.5 0
E7EW58 1 0 0 0 0 3 3 3 0.5 1.5 1.5 1.5
Q13409 0 0 1 1 2 2 2 2 1 1 1.5 1.5
A0A0A0MS 0 0 1 1 1 3 2 2 0.5 1.5 1.5 1.5
G5E9W3 2 0 1 0 2 1 2 1 2 0.5 1.5 0.5
B0YJC4 1 0 1 1 2 1 2 1 1.5 0.5 1.5 1
P35606 1 2 0 1 0 0 3 2 0.5 1 1.5 1.5
P63104 2 0 0 0 0 0 3 1 1 0 1.5 0.5
F5GX77 0 1 1 0 1 2 2 2 0.5 1.5 1.5 1
H7C0N4 0 0 0 0 2 3 3 1 1 1.5 1.5 0.5
P81605 0 1 1 1 2 1 2 1 1 1 1.5 1
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GSTP1_HUM 0 1 2 0 0 2 1 2 0 1.5 1.5 1
P05387 2 1 1 0 1 1 2 0 1.5 1 1.5 0
E7ERL0 3 0 3 0 1 1 0 0 2 0.5 1.5 0
A0A024QZP 0 0 1 0 0 0 2 0 0 0 1.5 0
P49642 0 0 1 1 4 0 2 0 2 0 1.5 0.5
A1L020 1 0 1 0 2 0 2 0 1.5 0 1.5 0
O43175 1 0 2 0 2 1 1 0 1.5 0.5 1.5 0
O43719 0 0 1 0 2 1 2 1 1 0.5 1.5 0.5
J3KNN5 2 0 2 0 0 1 1 0 1 0.5 1.5 0
Q9Y3I0 0 0 0 0 2 1 3 0 1 0.5 1.5 0
O60884 0 0 1 0 1 0 2 0 0.5 0 1.5 0
D6RBW1 1 1 2 0 0 1 1 0 0.5 1 1.5 0
P08237 0 0 0 0 1 0 3 0 0.5 0 1.5 0
J3KT12 1 0 1 0 2 0 2 0 1.5 0 1.5 0
Q9H7S9 1 0 0 0 1 1 3 0 1 0.5 1.5 0
J3KQ32 1 1 2 1 0 0 1 0 0.5 0.5 1.5 0.5
A0A087X2D 0 0 1 0 1 1 2 1 0.5 0.5 1.5 0.5
P42285 0 0 0 0 1 1 3 0 0.5 0.5 1.5 0
P85037 1 0 0 0 1 0 3 0 1 0 1.5 0
Q5T6F2 0 0 0 0 1 1 3 0 0.5 0.5 1.5 0
Q8ND56 0 0 1 0 2 0 2 0 1 0 1.5 0
J3KR97 0 0 0 0 2 0 3 0 1 0 1.5 0
P62241 0 0 0 0 0 1 3 1 0 0.5 1.5 0.5
Q9HAV4 0 0 1 0 1 0 2 0 0.5 0 1.5 0
P08243 0 0 0 0 1 0 3 0 0.5 0 1.5 0
Q01813 0 0 3 0 0 0 0 0 0 0 1.5 0
A0A0A0MR 0 0 0 0 1 0 3 0 0.5 0 1.5 0
P26196 0 0 0 0 1 0 3 0 0.5 0 1.5 0
Q6P2H3 0 0 1 0 1 0 2 0 0.5 0 1.5 0
Q96PK6 0 0 0 0 1 0 3 0 0.5 0 1.5 0
D6R9Z6 0 1 0 0 0 0 3 0 0 0.5 1.5 0
O75792 0 0 0 0 0 0 3 0 0 0 1.5 0
A0A0A0MT 0 0 0 0 0 0 3 0 0 0 1.5 0
P23921 0 0 0 0 0 0 3 0 0 0 1.5 0
E7EVA0 0 0 0 0 0 0 3 0 0 0 1.5 0
A0A087WU 0 0 0 0 0 0 3 0 0 0 1.5 0
P42166 0 0 0 0 0 0 3 0 0 0 1.5 0
D3YTB5 0 0 0 0 0 0 3 0 0 0 1.5 0
Q6P158 0 0 1 0 0 0 2 0 0 0 1.5 0
E9PQA6 0 0 0 0 0 0 3 0 0 0 1.5 0
F5H442 0 0 1 0 0 0 2 0 0 0 1.5 0
Q9BRP1 0 0 1 0 0 0 2 0 0 0 1.5 0
E9PN81 0 0 0 0 0 0 3 0 0 0 1.5 0
H0YDQ8 0 0 0 0 0 0 3 0 0 0 1.5 0
Q96RG2 0 0 0 0 0 0 3 0 0 0 1.5 0
P68032 1 3 1 1 1 1 1 1 1 2 1 1
P13647 3 1 2 2 2 0 0 1 2.5 0.5 1 1.5
O43390 2 0 0 1 0 2 2 2 1 1 1 1.5
Q96GX5 0 0 0 0 2 1 2 1 1 0.5 1 0.5
P01033 0 0 0 0 3 5 2 3 1.5 2.5 1 1.5
P19474 4 1 2 1 1 2 0 1 2.5 1.5 1 1
Q15427 0 0 0 0 3 4 2 3 1.5 2 1 1.5
A0A087WU 1 0 1 1 3 3 1 2 2 1.5 1 1.5
O60814 2 0 0 0 0 1 2 1 1 0.5 1 0.5
Q08499-12 1 0 0 0 1 3 2 4 1 1.5 1 2
O94952 1 1 2 3 0 0 0 0 0.5 0.5 1 1.5
Q5H9B5 0 0 0 0 0 0 2 3 0 0 1 1.5
Q9H6R7 0 1 0 0 1 4 2 1 0.5 2.5 1 0.5
Q9Y383 2 0 0 1 1 2 2 1 1.5 1 1 1
P52907 1 0 0 2 3 0 2 0 2 0 1 1
Q15428 0 0 0 0 2 2 2 2 1 1 1 1
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P14174 0 1 0 0 2 2 2 1 1 1.5 1 0.5
Q9P2P6 0 0 0 0 2 2 2 2 1 1 1 1
Q8NBS9 0 0 0 0 1 1 2 4 0.5 0.5 1 2
A0A024RA5 0 0 0 0 2 3 2 0 1 1.5 1 0
Q99459 0 0 0 0 2 1 2 2 1 0.5 1 1
P35813 0 0 2 1 0 0 0 0 0 0 1 0.5
A0A0U1RR 0 1 0 0 1 1 2 1 0.5 1 1 0.5
P31153 0 0 0 1 3 0 2 0 1.5 0 1 0.5
C9JD84 0 0 0 0 1 1 2 2 0.5 0.5 1 1
O60573 1 0 0 0 2 0 2 0 1.5 0 1 0
B8ZZA1 2 1 1 0 0 0 1 0 1 0.5 1 0
P49902 0 0 1 0 3 0 1 0 1.5 0 1 0
P67809 1 1 1 0 0 1 1 0 0.5 1 1 0
F5H6X6 1 0 0 0 1 0 2 1 1 0 1 0.5
Q15021 0 0 0 0 1 0 2 2 0.5 0 1 1
Q8N684 0 0 1 0 3 0 1 0 1.5 0 1 0
P56545 1 0 1 0 2 0 1 0 1.5 0 1 0
H0YN81 0 0 2 0 1 1 0 1 0.5 0.5 1 0.5
Q8WTR2 0 0 0 0 1 0 2 1 0.5 0 1 0.5
Q9UHV9 0 0 0 0 0 1 2 1 0 0.5 1 0.5
F2Z2W6 0 0 0 0 1 1 2 0 0.5 0.5 1 0
H7BYH4 1 0 0 0 0 1 2 0 0.5 0.5 1 0
P0DN79 0 0 0 0 1 1 2 0 0.5 0.5 1 0
E9PMD7 0 0 2 0 2 0 0 0 1 0 1 0
P12004 1 0 0 0 1 0 2 0 1 0 1 0
Q02878 2 0 0 0 0 0 2 0 1 0 1 0
A0A024QZX 1 0 0 0 1 0 2 0 1 0 1 0
Q15717 1 1 1 0 0 0 1 0 0.5 0.5 1 0
P04080 1 0 0 0 1 0 2 0 1 0 1 0
C9JLI6 0 0 0 0 1 1 2 0 0.5 0.5 1 0
K7ELS0 0 0 1 0 1 1 1 0 0.5 0.5 1 0
Q96CX2 0 0 0 0 2 0 2 0 1 0 1 0
P39900 0 0 0 0 0 2 2 0 0 1 1 0
H7C3G1 0 0 1 0 1 0 1 0 0.5 0 1 0
O75934 0 0 1 0 0 1 1 0 0 0.5 1 0
A0A087WZ 0 0 0 0 1 0 2 0 0.5 0 1 0
P05386 0 0 0 0 1 0 2 0 0.5 0 1 0
P17028 1 0 2 0 0 0 0 0 0.5 0 1 0
P30307 0 0 0 0 0 1 2 0 0 0.5 1 0
P48634 0 0 0 0 0 1 2 0 0 0.5 1 0
P67870 0 0 1 0 1 0 1 0 0.5 0 1 0
G3V198 0 0 0 0 0 1 2 0 0 0.5 1 0
Q14331 0 0 0 0 1 0 2 0 0.5 0 1 0
A0A087WY 0 0 2 0 0 1 0 0 0 0.5 1 0
E9PM04 0 0 1 0 1 0 1 0 0.5 0 1 0
D6RC52 0 0 1 0 1 0 1 0 0.5 0 1 0
Q9Y3Z3 0 0 0 0 1 0 2 0 0.5 0 1 0
A6NDF3 0 1 2 0 0 0 0 0 0 0.5 1 0
P62906 0 0 0 0 0 1 2 0 0 0.5 1 0
P78318 0 0 0 0 1 0 2 0 0.5 0 1 0
Q06587 0 0 1 0 1 0 1 0 0.5 0 1 0
C9J470 1 0 0 0 0 0 2 0 0.5 0 1 0
F2Z2R5 0 0 0 0 0 1 2 0 0 0.5 1 0
H3BN98 1 0 1 0 0 0 1 0 0.5 0 1 0
K7EP06 0 0 0 0 0 0 2 0 0 0 1 0
Q9BPU6 0 0 0 0 0 0 2 0 0 0 1 0
A0A087WY 0 0 0 0 0 0 2 0 0 0 1 0
A1A564 0 0 0 0 0 0 2 0 0 0 1 0
P24534 0 0 1 0 0 0 1 0 0 0 1 0
Q9H3P7 0 0 0 0 0 0 2 0 0 0 1 0
Q9HB71 0 0 1 0 0 0 1 0 0 0 1 0
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H0YKU1 0 0 0 0 0 0 2 0 0 0 1 0
O43290 0 0 0 0 0 0 2 0 0 0 1 0
F5GXS2 0 0 0 0 0 0 2 0 0 0 1 0
H7C3X0 0 0 0 0 0 0 2 0 0 0 1 0
C9IYT0 0 0 0 0 0 0 2 0 0 0 1 0
O75534 0 0 0 0 0 0 2 0 0 0 1 0
P31260 0 0 0 0 0 0 2 0 0 0 1 0
P36578 0 0 1 0 0 0 1 0 0 0 1 0
H7C422 0 0 0 0 0 0 2 0 0 0 1 0
P56192 0 0 0 0 0 0 2 0 0 0 1 0
Q12948 0 0 0 0 0 0 2 0 0 0 1 0
A0A0G2JNZ 0 0 0 0 0 0 2 0 0 0 1 0
Q16342 0 0 0 0 0 0 2 0 0 0 1 0
A0A087WV 0 0 1 0 0 0 1 0 0 0 1 0
Q6UUV7 0 0 0 0 0 0 2 0 0 0 1 0
Q8N163 0 0 1 0 0 0 1 0 0 0 1 0
Q8TD19 0 0 0 0 0 0 2 0 0 0 1 0
F5GXS8 0 0 0 0 0 0 2 0 0 0 1 0
Q9P2E3 0 0 1 0 0 0 1 0 0 0 1 0
Q9Y3I1 0 0 0 0 0 0 2 0 0 0 1 0
Q9Y3R0 0 0 0 0 0 0 2 0 0 0 1 0
O15084 0 0 0 0 0 0 2 0 0 0 1 0
Q8WU90 0 0 0 0 0 0 2 0 0 0 1 0
Q96S90 0 0 0 0 0 0 2 0 0 0 1 0
Q70JA7 0 0 1 0 0 0 1 0 0 0 1 0
J3QT28 0 0 0 0 0 0 2 0 0 0 1 0
J3KS31 0 0 0 0 0 0 2 0 0 0 1 0
E7EQZ7 0 0 0 0 0 0 2 0 0 0 1 0
Q8N1G4 0 0 0 0 0 0 2 0 0 0 1 0
E9PFL1 0 0 0 0 0 0 2 0 0 0 1 0
D6RA57 0 0 0 0 0 0 2 0 0 0 1 0
H3BUR4 0 0 1 0 0 0 1 0 0 0 1 0
H0Y873 0 0 0 0 0 0 2 0 0 0 1 0
Q96RS6 0 0 1 0 0 0 1 0 0 0 1 0
Q13509 3 0 0 3 0 0 1 0 1.5 0 0.5 1.5
E9PI65 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0C4DG 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
CAS1_BOVI 7 3 0 0 1 0 1 1 4 1.5 0.5 0.5
Q15459 0 0 0 0 3 3 1 6 1.5 1.5 0.5 3
Q8IYD1 0 0 0 0 0 0 1 0 0 0 0.5 0
K7EQL0 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8N5C6 1 0 0 0 4 3 1 2 2.5 1.5 0.5 1
P62258 2 2 1 0 0 2 0 1 1 2 0.5 0.5
Q08174 0 1 0 0 2 2 1 4 1 1.5 0.5 2
B1ANR0 1 0 0 0 2 0 1 0 1.5 0 0.5 0
P08579 1 0 0 1 2 2 1 1 1.5 1 0.5 1
A0A0A0MS 0 0 0 0 1 2 1 1 0.5 1 0.5 0.5
Q9H496 0 0 0 0 6 0 1 0 3 0 0.5 0
P61221 0 0 0 0 4 1 1 1 2 0.5 0.5 0.5
Q1L5Z9 2 0 1 0 4 0 0 0 3 0 0.5 0
G8JLD5 0 0 0 0 5 0 1 0 2.5 0 0.5 0
Q8IZL9 0 0 0 0 0 0 1 0 0 0 0.5 0
Q02750 1 0 0 0 0 0 1 0 0.5 0 0.5 0
P53621 0 0 0 1 2 2 1 0 1 1 0.5 0.5
A0A087WV 0 1 0 0 0 2 1 2 0 1.5 0.5 1
Q96DG6 0 0 0 0 2 2 1 1 1 1 0.5 0.5
O15160 0 0 0 0 2 2 1 0 1 1 0.5 0
O43660 0 0 0 0 1 1 1 0 0.5 0.5 0.5 0
O75449 0 0 0 0 3 1 1 0 1.5 0.5 0.5 0
P23258 1 0 1 0 1 1 0 1 1 0.5 0.5 0.5
E9PGM9 0 0 0 0 0 0 1 0 0 0 0.5 0
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B4DP31 0 0 1 0 1 2 0 1 0.5 1 0.5 0.5
P62306 1 1 0 0 2 0 1 0 1.5 0.5 0.5 0
Q9Y6G9 0 0 0 0 0 2 1 2 0 1 0.5 1
Q13395 1 0 1 0 3 0 0 0 2 0 0.5 0
Q7Z2Z2 1 0 1 0 1 0 0 0 1 0 0.5 0
Q9UJ68 1 1 1 0 1 0 0 1 1 0.5 0.5 0.5
REF_HEVBR 0 3 0 0 0 0 1 0 0 1.5 0.5 0
O00429-7 0 0 0 0 0 0 1 0 0 0 0.5 0
O75909 0 0 0 1 1 1 1 0 0.5 0.5 0.5 0.5
P05455 0 0 0 0 2 1 1 0 1 0.5 0.5 0
A0A0A0MR 1 0 0 0 1 0 1 1 1 0 0.5 0.5
CAS2_BOVI 3 0 1 0 0 0 0 0 1.5 0 0.5 0
Q08211 0 0 0 0 3 0 1 0 1.5 0 0.5 0
A0A087WX 0 0 0 0 2 1 1 0 1 0.5 0.5 0
P35372-13 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q86U70 0 0 0 0 1 0 1 2 0.5 0 0.5 1
A0A087WT 0 0 1 0 0 0 0 0 0 0 0.5 0
B5MCP9 0 0 0 0 1 1 1 1 0.5 0.5 0.5 0.5
Q9NYJ8 0 0 0 0 2 1 1 0 1 0.5 0.5 0
H7C4I3 0 0 1 0 0 0 0 0 0 0 0.5 0
P62269 0 0 0 0 1 1 1 1 0.5 0.5 0.5 0.5
O00401 0 0 0 0 1 1 1 1 0.5 0.5 0.5 0.5
P25705 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
P54296 0 0 0 0 1 2 1 0 0.5 1 0.5 0
F8VVA7 0 0 0 0 1 1 1 1 0.5 0.5 0.5 0.5
A0A087WX 0 0 0 0 3 0 1 0 1.5 0 0.5 0
K7EIH8 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
Q16650 0 0 0 0 1 1 1 0 0.5 0.5 0.5 0
O43172 0 0 0 0 2 0 1 0 1 0 0.5 0
A0A0G2JJZ9 0 0 0 0 1 0 1 1 0.5 0 0.5 0.5
O95400 1 1 0 0 0 0 1 0 0.5 0.5 0.5 0
P10644 0 0 0 0 0 1 1 1 0 0.5 0.5 0.5
P17812 1 0 0 0 1 0 1 0 1 0 0.5 0
A0A087WV 1 1 0 0 0 0 1 0 0.5 0.5 0.5 0
P37108 0 0 0 0 2 0 1 0 1 0 0.5 0
A0A024R4M 1 0 0 0 0 0 1 1 0.5 0 0.5 0.5
P54136 1 0 0 0 1 0 1 0 1 0 0.5 0
A8MXH2 0 0 0 0 0 0 1 0 0 0 0.5 0
Q15020 0 0 0 0 0 0 1 2 0 0 0.5 1
Q29RF7 0 0 0 0 1 1 1 0 0.5 0.5 0.5 0
Q2TAY7 0 0 0 1 1 0 1 0 0.5 0 0.5 0.5
Q7Z2T5 1 0 1 0 1 0 0 0 1 0 0.5 0
Q96N67 0 0 0 0 2 0 1 0 1 0 0.5 0
Q9BPX3 0 0 0 0 1 0 1 1 0.5 0 0.5 0.5
Q9UMX1 0 0 1 0 2 0 0 0 1 0 0.5 0
Q13185 1 0 1 0 0 1 0 0 0.5 0.5 0.5 0
P62805 2 0 1 0 0 0 0 0 1 0 0.5 0
A0A0B4J2B 0 0 0 0 2 0 1 0 1 0 0.5 0
F5GWN5 1 0 0 0 0 1 1 0 0.5 0.5 0.5 0
E7EMB3 0 0 1 1 0 1 0 0 0 0.5 0.5 0.5
A0A087X1R 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
A0A087X2I 1 0 0 0 0 1 1 0 0.5 0.5 0.5 0
Q96F63 1 0 1 0 1 0 0 0 1 0 0.5 0
P28072 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
A0A0A0MR 1 0 0 0 0 0 1 0 0.5 0 0.5 0
P38432 0 0 0 0 1 0 1 0 0.5 0 0.5 0
H7C0F4 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q9H0D6 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0A087WU 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P30050 0 0 0 0 0 0 1 1 0 0 0.5 0.5
Q9UNS1 1 0 1 0 0 0 0 0 0.5 0 0.5 0
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O75925 0 0 1 0 1 0 0 0 0.5 0 0.5 0
O95239 0 0 0 0 1 0 1 0 0.5 0 0.5 0
O95487 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P19784 0 0 0 0 0 0 1 0 0 0 0.5 0
F5GWX5 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q5T280 0 0 0 0 0 1 1 0 0 0.5 0.5 0
Q9UER7 0 0 1 0 1 0 0 0 0.5 0 0.5 0
Q9Y295 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q7Z3Z4 1 0 1 0 0 0 0 0 0.5 0 0.5 0
P07737 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P33993 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q9UJX5 0 1 1 0 0 0 0 0 0 0.5 0.5 0
F5H0Y3 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q8NCM8 0 0 1 0 0 1 0 0 0 0.5 0.5 0
F5H303 0 0 1 0 1 0 0 0 0.5 0 0.5 0
P98088 0 1 0 0 0 0 1 0 0 0.5 0.5 0
O60346 0 0 0 0 1 0 1 0 0.5 0 0.5 0
C9JIZ0 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P02765 1 0 1 0 0 0 0 0 0.5 0 0.5 0
C9J896 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P23458 0 0 0 0 0 0 1 1 0 0 0.5 0.5
P23526 1 0 0 0 0 0 1 0 0.5 0 0.5 0
P25788 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P30520 0 0 1 0 1 0 0 0 0.5 0 0.5 0
P33981 0 0 0 0 1 0 1 0 0.5 0 0.5 0
M0QZN2 0 0 0 0 0 0 1 1 0 0 0.5 0.5
C9JL85 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A087WU 0 0 0 0 1 0 1 0 0.5 0 0.5 0
G5E953 1 0 0 0 0 0 1 0 0.5 0 0.5 0
A0A0A0MQ 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q8IXB1 0 0 0 0 1 0 1 0 0.5 0 0.5 0
B5MDQ0 0 0 1 0 1 0 0 0 0.5 0 0.5 0
K7EK33 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q9GZN8 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9UBV8 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0A075B6F 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0A0A0MS 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0A0D9SES 0 0 0 0 1 0 1 0 0.5 0 0.5 0
Q92922 0 0 0 0 1 0 1 0 0.5 0 0.5 0
P0C2W1 0 0 0 0 0 1 1 0 0 0.5 0.5 0
P62857 1 0 0 0 0 0 1 0 0.5 0 0.5 0
Q9UPN7 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YEH2 0 0 0 0 0 0 1 0 0 0 0.5 0
F2Z356 0 0 1 0 0 0 0 0 0 0 0.5 0
P28715 0 0 0 0 0 0 1 0 0 0 0.5 0
J3KRL6 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0C4DG 0 0 1 0 0 0 0 0 0 0 0.5 0
B4DTN4 0 0 0 0 0 0 1 0 0 0 0.5 0
Q96SY0-3 0 0 1 0 0 0 0 0 0 0 0.5 0
A6NFU8 0 0 0 0 0 0 1 0 0 0 0.5 0
Q5SZ59 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8IZF0 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9UPM8 0 0 0 0 0 0 1 0 0 0 0.5 0
H3BM45 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A0U1RQ 0 0 0 0 0 0 1 0 0 0 0.5 0
Q96S55 0 0 0 0 0 0 1 0 0 0 0.5 0
D6RAX7 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9H9A6 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A024QZ3 0 0 0 0 0 0 1 0 0 0 0.5 0
F8WB94 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9HD33 0 0 0 0 0 0 1 0 0 0 0.5 0
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H7BXY3 0 0 0 0 0 0 1 0 0 0 0.5 0
J3KNE8 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9UNN8 0 0 0 0 0 0 1 0 0 0 0.5 0
Q6STE5 0 0 1 0 0 0 0 0 0 0 0.5 0
H0YJ14 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8N967 0 0 0 0 0 0 1 0 0 0 0.5 0
Q92731 0 0 0 0 0 0 1 0 0 0 0.5 0
Q15772 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A087WV 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NZM1-2 0 0 0 0 0 0 1 0 0 0 0.5 0
Q02930 0 0 1 0 0 0 0 0 0 0 0.5 0
J3KS22 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8TC57 0 0 0 0 0 0 1 0 0 0 0.5 0
C9JLW8 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087X0W 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YKE6 0 0 1 0 0 0 0 0 0 0 0.5 0
A7MCY6 0 0 1 0 0 0 0 0 0 0 0.5 0
H3BTW3 0 0 0 0 0 0 1 0 0 0 0.5 0
P62312 0 0 1 0 0 0 0 0 0 0 0.5 0
A8MYT4 0 0 1 0 0 0 0 0 0 0 0.5 0
Q96K49 0 0 1 0 0 0 0 0 0 0 0.5 0
Q16384 0 0 1 0 0 0 0 0 0 0 0.5 0
E7EPG1 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087WZ 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9UNS2 0 0 0 0 0 0 1 0 0 0 0.5 0
D6RG18 0 0 1 0 0 0 0 0 0 0 0.5 0
Q5TDE7 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NRC6 0 0 0 0 0 0 1 0 0 0 0.5 0
A6H8Y7 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8NDH2 0 0 1 0 0 0 0 0 0 0 0.5 0
A2RRE5 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087WT 0 0 0 0 0 0 1 0 0 0 0.5 0
D6RGI5 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A0A0MT 0 0 0 0 0 0 1 0 0 0 0.5 0
Q96PE2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NP31 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9Y2Z4 0 0 0 0 0 0 1 0 0 0 0.5 0
Q711Q0 0 0 0 0 0 0 1 0 0 0 0.5 0
D6R9Q9 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8N3C0 0 0 0 0 0 0 1 0 0 0 0.5 0
P42575 0 0 0 0 0 0 1 0 0 0 0.5 0
F8WBW2 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A075B7F 0 0 1 0 0 0 0 0 0 0 0.5 0
C9IYV2 0 0 1 0 0 0 0 0 0 0 0.5 0
A6NGJ6 0 0 0 0 0 0 1 0 0 0 0.5 0
A8MUF7 0 0 1 0 0 0 0 0 0 0 0.5 0
O14733 0 0 0 0 0 0 1 0 0 0 0.5 0
O43353 0 0 1 0 0 0 0 0 0 0 0.5 0
O60422 0 0 1 0 0 0 0 0 0 0 0.5 0
O60566 0 0 0 0 0 0 1 0 0 0 0.5 0
O75607 0 0 1 0 0 0 0 0 0 0 0.5 0
O75815 0 0 0 0 0 0 1 0 0 0 0.5 0
P05060 0 0 1 0 0 0 0 0 0 0 0.5 0
P12955 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PIK5 0 0 1 0 0 0 0 0 0 0 0.5 0
E9PKL5 0 0 0 0 0 0 1 0 0 0 0.5 0
G3V4L3 0 0 1 0 0 0 0 0 0 0 0.5 0
C9J8M3 0 0 0 0 0 0 1 0 0 0 0.5 0
P35268 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0A0MS 0 0 0 0 0 0 1 0 0 0 0.5 0
C9JH72 0 0 0 0 0 0 1 0 0 0 0.5 0
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P52952 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087X1E 0 0 1 0 0 0 0 0 0 0 0.5 0
F6RFD5 0 0 1 0 0 0 0 0 0 0 0.5 0
M0QZC5 0 0 0 0 0 0 1 0 0 0 0.5 0
J3KTJ3 0 0 0 0 0 0 1 0 0 0 0.5 0
P82094 0 0 1 0 0 0 0 0 0 0 0.5 0
E9PJF6 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0D9SFL 0 0 0 0 0 0 1 0 0 0 0.5 0
Q02809 0 0 0 0 0 0 1 0 0 0 0.5 0
Q04760 0 0 0 0 0 0 1 0 0 0 0.5 0
Q06124 0 0 0 0 0 0 1 0 0 0 0.5 0
Q08AD1 0 0 0 0 0 0 1 0 0 0 0.5 0
Q15437 0 0 0 0 0 0 1 0 0 0 0.5 0
Q2VY69 0 0 0 0 0 0 1 0 0 0 0.5 0
Q5T4S7 0 0 1 0 0 0 0 0 0 0 0.5 0
Q5VYS8 0 0 0 0 0 0 1 0 0 0 0.5 0
Q5VZK9 0 0 0 0 0 0 1 0 0 0 0.5 0
M0QX46 0 0 0 0 0 0 1 0 0 0 0.5 0
Q6UY01 0 0 0 0 0 0 1 0 0 0 0.5 0
H3BMJ2 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087WU 0 0 0 0 0 0 1 0 0 0 0.5 0
Q70CQ2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q86W56 0 0 0 0 0 0 1 0 0 0 0.5 0
E5RHH7 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087X21 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YMR4 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8WYQ5 0 0 0 0 0 0 1 0 0 0 0.5 0
E7EN38 0 0 1 0 0 0 0 0 0 0 0.5 0
Q96A99 0 0 0 0 0 0 1 0 0 0 0.5 0
Q96E09 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PPJ9 0 0 0 0 0 0 1 0 0 0 0.5 0
A8MVZ6 0 0 1 0 0 0 0 0 0 0 0.5 0
Q96MD7-1 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9BUH6 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9BXT5 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9C0B0 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PE10 0 0 0 0 0 0 1 0 0 0 0.5 0
H0YM60 0 0 0 0 0 0 1 0 0 0 0.5 0
F5H039 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NXB9 0 0 0 0 0 0 1 0 0 0 0.5 0
H0Y8C3 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9UBB4 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9UBN7 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9UEG4 0 0 1 0 0 0 0 0 0 0 0.5 0
E9PIZ4 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PBL0 0 0 1 0 0 0 0 0 0 0 0.5 0
Q5H909 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A0A0MT 0 0 0 0 0 0 1 0 0 0 0.5 0
G3V4C6 0 0 0 0 0 0 1 0 0 0 0.5 0
C9JQG7 0 0 1 0 0 0 0 0 0 0 0.5 0
B1AMU3 0 0 0 0 0 0 1 0 0 0 0.5 0
H3BRS3 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A087WV 0 0 1 0 0 0 0 0 0 0 0.5 0
C9JDM3 0 0 0 0 0 0 1 0 0 0 0.5 0
F8W8Y7 0 0 1 0 0 0 0 0 0 0 0.5 0
V9GYZ8 0 0 1 0 0 0 0 0 0 0 0.5 0
P62633 0 0 1 0 0 0 0 0 0 0 0.5 0
D6RAN6 0 0 0 0 0 0 1 0 0 0 0.5 0
O15111 0 0 1 0 0 0 0 0 0 0 0.5 0
O75663 0 0 1 0 0 0 0 0 0 0 0.5 0
B4DKY1 0 0 0 0 0 0 1 0 0 0 0.5 0
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Q6IQ49 0 0 0 0 0 0 1 0 0 0 0.5 0
C9JYQ9 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A087WV 0 0 0 0 0 0 1 0 0 0 0.5 0
B7Z493 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9NW64 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9Y5G6 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PQP8 0 0 0 0 0 0 1 0 0 0 0.5 0
D6RIZ8 0 0 1 0 0 0 0 0 0 0 0.5 0
J3KRD8 0 0 0 0 0 0 1 0 0 0 0.5 0
A1A5B4 0 0 0 0 0 0 1 0 0 0 0.5 0
P09429 0 0 0 0 0 0 1 0 0 0 0.5 0
D6R9L5 0 0 1 0 0 0 0 0 0 0 0.5 0
A6NNN6 0 0 0 0 0 0 1 0 0 0 0.5 0
H3BND0 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A087WZ 0 0 0 0 0 0 1 0 0 0 0.5 0
Q99543 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9BV73 0 0 1 0 0 0 0 0 0 0 0.5 0
B8ZZZ9 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0D9SF2 0 0 0 0 0 0 1 0 0 0 0.5 0
P55073 0 0 1 0 0 0 0 0 0 0 0.5 0
Q07973 0 0 1 0 0 0 0 0 0 0 0.5 0
F5H478 0 0 0 0 0 0 1 0 0 0 0.5 0
K7EPZ9 0 0 1 0 0 0 0 0 0 0 0.5 0
Q12756 0 0 1 0 0 0 0 0 0 0 0.5 0
H0YDR7 0 0 0 0 0 0 1 0 0 0 0.5 0
A6NIV2 0 0 0 0 0 0 1 0 0 0 0.5 0
Q04656 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9Y2X9 0 0 0 0 0 0 1 0 0 0 0.5 0
E5RHG6 0 0 0 0 0 0 1 0 0 0 0.5 0
F8VU51 0 0 0 0 0 0 1 0 0 0 0.5 0
Q86VD1 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8N4E4 0 0 0 0 0 0 1 0 0 0 0.5 0
M0QXB0 0 0 0 0 0 0 1 0 0 0 0.5 0
C9J9J4 0 0 0 0 0 0 1 0 0 0 0.5 0
Q6ZW49 0 0 0 0 0 0 1 0 0 0 0.5 0
F8WEF8 0 0 1 0 0 0 0 0 0 0 0.5 0
J3KTQ5 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8IWI9 0 0 1 0 0 0 0 0 0 0 0.5 0
H3BTH6 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8N475 0 0 0 0 0 0 1 0 0 0 0.5 0
Q96PB1 0 0 0 0 0 0 1 0 0 0 0.5 0
D6R9W6 0 0 0 0 0 0 1 0 0 0 0.5 0
Q5JZB8 0 0 0 0 1 0 1 0 0.5 0 0.5 0
A0AVF1 0 0 1 0 0 0 0 0 0 0 0.5 0
I3L1Y9 0 0 0 0 0 0 1 0 0 0 0.5 0
A2A2Y4 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A087WX 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9NYZ3 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9Y2H2 0 0 0 0 0 0 1 0 0 0 0.5 0
O60341 0 0 0 0 0 0 1 0 0 0 0.5 0
Q6PIU1 0 0 0 0 0 0 1 0 0 0 0.5 0
H0Y760 0 0 0 0 0 0 1 0 0 0 0.5 0
C9J798 0 0 1 0 0 0 0 0 0 0 0.5 0
P28482-2 0 0 0 0 0 2 0 2 0 1 0 1
E9PJF0 0 0 0 0 2 0 0 1 1 0 0 0.5
H0YD75 0 0 0 0 0 1 0 0 0 0.5 0 0
Q16659 0 0 0 0 1 0 0 0 0.5 0 0 0
P04259 0 1 0 0 0 0 0 0 0 0.5 0 0
P02538 12 0 0 0 2 0 0 0 7 0 0 0
K1M1_SHE 23 0 0 0 0 0 0 0 11.5 0 0 0
O94822 0 6 0 0 1 26 0 0 0.5 16 0 0
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P08727 1 0 0 0 0 0 0 0 0.5 0 0 0
Q562R1 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9Y573 0 4 0 7 0 7 0 7 0 5.5 0 7
O95678 1 0 0 0 0 0 0 0 0.5 0 0 0
P42025 0 0 0 1 0 0 0 1 0 0 0 1
K2M3_SHE 20 0 0 0 0 0 0 0 10 0 0 0
KRHB6_HU 8 0 0 0 0 0 0 0 4 0 0 0
K1H6_HUM 5 0 0 0 0 0 0 0 2.5 0 0 0
Q58FF8 1 0 0 0 0 0 0 0 0.5 0 0 0
C4AM86 1 0 0 0 0 0 0 0 0.5 0 0 0
E7ERL6 0 0 0 0 0 1 0 0 0 0.5 0 0
K2M2_SHE 3 0 0 0 0 0 0 0 1.5 0 0 0
Q99504 2 0 0 0 11 0 0 0 6.5 0 0 0
E7EQ64 1 1 0 0 0 2 0 2 0.5 1.5 0 1
E9PM09 1 0 0 0 0 0 0 0 0.5 0 0 0
K2M1_SHE 5 0 0 0 0 0 0 0 2.5 0 0 0
P31942 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9Y5B6 1 3 0 1 0 1 0 2 0.5 2 0 1.5
O76041 0 0 0 0 0 0 0 3 0 0 0 1.5
P21281 1 0 0 0 4 1 0 0 2.5 0.5 0 0
G3V1S7 1 0 0 2 0 1 0 2 0.5 0.5 0 2
Q9P2R3 0 0 0 0 2 2 0 1 1 1 0 0.5
O75821 0 0 0 0 3 0 0 2 1.5 0 0 1
Q58FF6 0 0 0 0 1 1 0 0 0.5 0.5 0 0
B1AK85 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
A0A087WV 1 0 0 1 0 0 0 3 0.5 0 0 2
Q86YZ3 0 5 0 0 0 0 0 0 0 2.5 0 0
Q9UGR2 0 0 0 0 4 0 0 0 2 0 0 0
Q9Y3Y2 0 0 0 0 1 2 0 1 0.5 1 0 0.5
O14818 0 1 0 1 0 1 0 1 0 1 0 1
A8MQ02 0 0 0 0 4 0 0 0 2 0 0 0
Q5JX49 1 0 0 1 0 0 0 0 0.5 0 0 0.5
Q9BX84 0 0 0 0 1 0 0 1 0.5 0 0 0.5
Q06495 0 0 0 0 1 1 0 0 0.5 0.5 0 0
A0A087WW 0 0 0 0 1 0 0 1 0.5 0 0 0.5
H3BSW0 2 1 0 1 0 0 0 0 1 0.5 0 0.5
A0A087WX 0 0 0 0 0 2 0 0 0 1 0 0
F5H435 1 0 0 0 1 2 0 0 1 1 0 0
Q9UJX3 1 0 0 0 2 0 0 0 1.5 0 0 0
E9PF10 1 0 0 0 2 0 0 0 1.5 0 0 0
P15924 2 0 0 0 0 0 0 1 1 0 0 0.5
P20742 0 0 0 0 1 0 0 1 0.5 0 0 0.5
P30044 0 0 0 0 0 0 0 3 0 0 0 1.5
P31025 3 0 0 0 0 0 0 0 1.5 0 0 0
P31151 1 0 0 0 0 2 0 0 0.5 1 0 0
P15104 1 0 0 0 2 0 0 0 1.5 0 0 0
CASB_BOV 3 0 0 0 0 0 0 0 1.5 0 0 0
P35573 0 0 0 0 3 0 0 0 1.5 0 0 0
Q4KMP7 0 0 0 0 3 0 0 0 1.5 0 0 0
P51991 0 0 0 0 3 0 0 0 1.5 0 0 0
Q9Y678 0 0 0 0 2 0 0 1 1 0 0 0.5
Q5S007 0 0 0 1 0 2 0 0 0 1 0 0.5
E9PK41 0 0 0 0 1 1 0 1 0.5 0.5 0 0.5
C9J0J7 0 1 0 1 1 0 0 0 0.5 0.5 0 0.5
F6SS63 1 0 0 0 0 2 0 0 0.5 1 0 0
Q9P244 1 0 0 1 0 0 0 0 0.5 0 0 0.5
F8W079 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q9NWU2 0 0 0 1 0 0 0 1 0 0 0 1
Q9UKX3 0 1 0 0 1 0 0 0 0.5 0.5 0 0
F5H4R1 1 0 0 0 1 0 0 0 1 0 0 0
ALDOA_RA 1 0 0 0 0 0 0 1 0.5 0 0 0.5
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A0A087X1Q 0 1 0 0 1 0 0 0 0.5 0.5 0 0
F8VWS0 1 1 0 0 0 0 0 0 0.5 0.5 0 0
P07195 1 0 0 1 0 0 0 0 0.5 0 0 0.5
A0A087WU 2 0 0 0 0 0 0 0 1 0 0 0
A0A0C4DG 0 1 0 1 0 0 0 0 0 0.5 0 0.5
C9J2Y9 0 0 0 0 2 0 0 0 1 0 0 0
CASK_BOVI 2 0 0 0 0 0 0 0 1 0 0 0
P59665 2 0 0 0 0 0 0 0 1 0 0 0
M0R1L2 0 0 0 0 1 0 0 1 0.5 0 0 0.5
P20930 1 0 0 0 0 1 0 0 0.5 0.5 0 0
F5H459 0 0 0 0 1 0 0 1 0.5 0 0 0.5
Q96AG4 0 0 0 0 2 0 0 0 1 0 0 0
B7WPG3 0 0 0 0 2 0 0 0 1 0 0 0
A0A0A0MR 0 0 0 0 0 2 0 0 0 1 0 0
C9J3R0 1 0 0 0 1 0 0 0 1 0 0 0
B7ZKJ8 1 1 0 0 0 0 0 0 0.5 0.5 0 0
A0A0A0MR 0 0 0 0 0 0 0 2 0 0 0 1
Q5VU13-2 1 0 0 0 1 0 0 0 1 0 0 0
Q9NP98 0 0 0 0 1 1 0 0 0.5 0.5 0 0
K7EQQ8 0 0 0 0 2 0 0 0 1 0 0 0
Q9UPU7 1 0 0 0 0 1 0 0 0.5 0.5 0 0
Q96EF0 0 0 0 0 0 0 0 2 0 0 0 1
A0A087X2G 0 0 0 0 1 1 0 0 0.5 0.5 0 0
F5GX23 1 0 0 0 1 0 0 0 1 0 0 0
P53803 1 0 0 0 0 1 0 0 0.5 0.5 0 0
Q5T750 0 1 0 1 0 0 0 0 0 0.5 0 0.5
H0YL69 0 0 0 0 1 0 0 1 0.5 0 0 0.5
A0A0U1RQ 0 0 0 0 1 1 0 0 0.5 0.5 0 0
Q6P2C0 0 0 0 0 1 0 0 0 0.5 0 0 0
O75937 0 0 0 0 0 0 0 1 0 0 0 0.5
Q5QGS0 0 0 0 0 0 1 0 0 0 0.5 0 0
Q6IMI6 0 0 0 0 0 0 0 1 0 0 0 0.5
Q8N7X1 0 0 0 0 0 1 0 0 0 0.5 0 0
B1AH58 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8NEZ3 0 0 0 0 0 0 0 1 0 0 0 0.5
Q9P2G4 0 0 0 0 0 1 0 0 0 0.5 0 0
Q4G0P3 0 0 0 0 1 0 0 0 0.5 0 0 0
A8MTJ6 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A0J9YXJ0 0 0 0 0 0 0 0 1 0 0 0 0.5
F5H6B2 0 0 0 0 0 1 0 0 0 0.5 0 0
P31629 1 0 0 0 0 0 0 0 0.5 0 0 0
E7ESA6 1 0 0 0 0 0 0 0 0.5 0 0 0
Q13231-4 0 0 0 0 0 0 0 1 0 0 0 0.5
G3V3G9 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9ULM3 0 0 0 0 0 1 0 0 0 0.5 0 0
C0MHM2 0 0 0 0 0 1 0 0 0 0.5 0 0
F8WBW9 1 0 0 0 0 0 0 0 0.5 0 0 0
K7EIR6 0 0 0 1 0 0 0 0 0 0 0 0.5
J3KNS5 1 0 0 0 0 0 0 0 0.5 0 0 0
H0YLZ8 0 0 0 1 0 0 0 0 0 0 0 0.5
Q6XUX3 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0C4DG 0 0 0 1 0 0 0 0 0 0 0 0.5
B4DGJ5 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9Y6X0 1 0 0 0 0 0 0 0 0.5 0 0 0
Q68DA7-3 0 0 0 0 0 0 0 1 0 0 0 0.5
H3BR40 0 0 0 1 0 0 0 0 0 0 0 0.5
Q6ZVD7 0 1 0 0 0 0 0 0 0 0.5 0 0
A0A1B0GTC 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9NQS3-3 0 1 0 0 0 0 0 0 0 0.5 0 0
J3QTJ6 0 1 0 0 0 0 0 0 0 0.5 0 0
Q7Z7H8 0 0 0 0 1 0 0 0 0.5 0 0 0
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Q92539 0 0 0 1 0 0 0 0 0 0 0 0.5
J3KNK1 0 0 0 0 1 0 0 0 0.5 0 0 0
E5RGL8 0 0 0 0 1 0 0 0 0.5 0 0 0
O60271-9 0 0 0 0 1 0 0 0 0.5 0 0 0
P61244-5 0 0 0 0 0 1 0 0 0 0.5 0 0
Q6ZUT6 0 0 0 1 0 0 0 0 0 0 0 0.5
H7C2Y3 0 0 0 0 0 1 0 0 0 0.5 0 0
O43745 1 0 0 0 0 0 0 0 0.5 0 0 0
Q2M1P5 0 0 0 0 1 0 0 0 0.5 0 0 0
Q7Z7B7 0 0 0 0 1 0 0 0 0.5 0 0 0
E7ERS3 1 0 0 0 0 0 0 0 0.5 0 0 0
KRA61_SHE 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A087WW 0 0 0 0 0 0 0 1 0 0 0 0.5
Q5VUA4 0 0 0 0 0 1 0 0 0 0.5 0 0
E7ER45 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9NYQ8 0 1 0 0 0 0 0 0 0 0.5 0 0
O95711 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9BRH9 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9BRX2 0 0 0 0 1 0 0 0 0.5 0 0 0
B4E0T2 0 1 0 0 0 0 0 0 0 0.5 0 0
Q2L4Q9 0 1 0 0 0 0 0 0 0 0.5 0 0
Q99683 0 0 0 0 0 1 0 0 0 0.5 0 0
G3V3G3 0 0 0 0 0 1 0 0 0 0.5 0 0
H3BPR3 0 0 0 0 0 1 0 0 0 0.5 0 0
O96019 1 0 0 0 0 0 0 0 0.5 0 0 0
P12272-3 0 0 0 0 0 0 0 1 0 0 0 0.5
O00292 0 0 0 0 0 0 0 1 0 0 0 0.5
Q9H773 0 0 0 0 1 0 0 0 0.5 0 0 0
M0QYZ9 1 0 0 0 0 0 0 0 0.5 0 0 0
F8W061 0 1 0 0 0 0 0 0 0 0.5 0 0
Q86VW2 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A075B6E 0 0 0 0 0 0 0 1 0 0 0 0.5
F8VVY9 0 0 0 0 0 1 0 0 0 0.5 0 0
C9IYI5 0 0 0 0 0 0 0 1 0 0 0 0.5
A6NFC9 0 0 0 0 0 1 0 0 0 0.5 0 0
P58005 0 0 0 0 0 1 0 0 0 0.5 0 0
Q6ZV70-2 1 0 0 0 0 0 0 0 0.5 0 0 0
P51878-3 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96BN2 1 0 0 0 0 0 0 0 0.5 0 0 0
E9PC90 0 0 0 0 1 0 0 0 0.5 0 0 0
Q15910 0 1 0 0 0 0 0 0 0 0.5 0 0
P46199 0 0 0 0 0 1 0 0 0 0.5 0 0
P78524 1 0 0 0 0 0 0 0 0.5 0 0 0
Q14093 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9NR48 0 0 0 0 1 0 0 0 0.5 0 0 0
F2Z388 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A0D9SF6 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A0A0MS 0 1 0 0 0 0 0 0 0 0.5 0 0
P09923 0 1 0 0 0 0 0 0 0 0.5 0 0
A0A087WU 1 0 0 0 0 0 0 0 0.5 0 0 0
B7ZBJ4 0 1 0 0 0 0 0 0 0 0.5 0 0
E9PF49 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A087WU 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A087WU 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9BTV7 0 1 0 0 0 0 0 0 0 0.5 0 0
Q7Z2Y5 1 0 0 0 0 0 0 0 0.5 0 0 0
A4UGR9-4 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0A0MR 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9Y4D7 0 1 0 0 0 0 0 0 0 0.5 0 0
F5GX86 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0A0MT 0 0 0 0 1 0 0 0 0.5 0 0 0
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Q9UKL4 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A0A0MT 0 0 0 0 1 0 0 0 0.5 0 0 0
P10412 1 0 0 0 0 0 0 0 0.5 0 0 0
F8WFC6 0 0 0 0 0 1 0 0 0 0.5 0 0
H7C4K7 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0A0MS 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9BY10 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9NQW5 0 0 0 0 0 1 0 0 0 0.5 0 0
G3V2R1 0 0 0 0 0 0 0 1 0 0 0 0.5
M0QZW4 0 0 0 0 0 1 0 0 0 0.5 0 0
Q16600 0 1 0 0 0 0 0 0 0 0.5 0 0
O14980 0 0 0 0 1 0 0 0 0.5 0 0 0
P78395 0 0 0 0 0 0 0 1 0 0 0 0.5
A0AUZ9 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A096LNV 0 0 0 0 0 1 0 0 0 0.5 0 0
A6NLC5 0 0 0 1 0 0 0 0 0 0 0 0.5
A6NNN8 0 0 0 0 1 0 0 0 0.5 0 0 0
LYSC_HUM 1 0 0 0 0 0 0 0 0.5 0 0 0
O00203 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A024R6X 0 0 0 0 1 0 0 0 0.5 0 0 0
O14529 1 0 0 0 0 0 0 0 0.5 0 0 0
O14640 0 0 0 0 1 0 0 0 0.5 0 0 0
G3V105 0 0 0 1 0 0 0 0 0 0 0 0.5
A4QPE4 0 0 0 1 0 0 0 0 0 0 0 0.5
H3BS03 0 0 0 0 1 0 0 0 0.5 0 0 0
O43347 0 0 0 0 1 0 0 0 0.5 0 0 0
O60503 0 0 0 0 1 0 0 0 0.5 0 0 0
O75159 0 0 0 0 1 0 0 0 0.5 0 0 0
O94776 0 0 0 1 0 0 0 0 0 0 0 0.5
C9JAT7 0 0 0 0 0 0 0 1 0 0 0 0.5
A8MUN2 0 0 0 0 1 0 0 0 0.5 0 0 0
P05109 1 0 0 0 0 0 0 0 0.5 0 0 0
P12273 1 0 0 0 0 0 0 0 0.5 0 0 0
P21817 0 0 0 1 0 0 0 0 0 0 0 0.5
P30048 0 0 0 0 1 0 0 0 0.5 0 0 0
H3BPE7 0 0 0 0 0 0 0 1 0 0 0 0.5
K7EKS1 0 0 0 0 1 0 0 0 0.5 0 0 0
P38606 1 0 0 0 0 0 0 0 0.5 0 0 0
C9JJ34 0 0 0 0 1 0 0 0 0.5 0 0 0
E9PI86 0 0 0 0 1 0 0 0 0.5 0 0 0
P49790 1 0 0 0 0 0 0 0 0.5 0 0 0
P49796-8 1 0 0 0 0 0 0 0 0.5 0 0 0
P51684 0 0 0 0 0 0 0 1 0 0 0 0.5
P52738 0 1 0 0 0 0 0 0 0 0.5 0 0
P53350 1 0 0 0 0 0 0 0 0.5 0 0 0
P58397 0 0 0 0 1 0 0 0 0.5 0 0 0
G5E9G7 0 0 0 0 1 0 0 0 0.5 0 0 0
B1AQK6 0 0 0 0 0 1 0 0 0 0.5 0 0
I6L8B7 1 0 0 0 0 0 0 0 0.5 0 0 0
F8VUA6 1 0 0 0 0 0 0 0 0.5 0 0 0
Q0ZLH3 1 0 0 0 0 0 0 0 0.5 0 0 0
Q13085 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A0A0MT 0 0 0 0 0 0 0 1 0 0 0 0.5
Q14643 1 0 0 0 0 0 0 0 0.5 0 0 0
Q15024 0 0 0 0 1 0 0 0 0.5 0 0 0
H0YLX2 0 0 0 0 1 0 0 0 0.5 0 0 0
Q3SXZ3 0 0 0 0 0 0 0 1 0 0 0 0.5
Q5BKY6 0 0 0 1 0 0 0 0 0 0 0 0.5
Q5T5P0 1 0 0 0 0 0 0 0 0.5 0 0 0
F6XA08 0 0 0 1 0 0 0 0 0 0 0 0.5
Q63HQ2 0 1 0 0 0 0 0 0 0 0.5 0 0
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Q6IA86 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0A0MS 0 0 0 0 1 0 0 0 0.5 0 0 0
Q6PL18 0 0 0 1 0 0 0 0 0 0 0 0.5
Q6UXQ4 0 1 0 0 0 0 0 0 0 0.5 0 0
Q6ZRI8 0 1 0 0 0 0 0 0 0 0.5 0 0
Q71F78 0 0 0 1 0 0 0 0 0 0 0 0.5
Q7Z4L9-2 0 0 0 1 0 0 0 0 0 0 0 0.5
Q8IXQ4-4 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8IZD9 0 1 0 0 0 0 0 0 0 0.5 0 0
Q8IZU8 0 0 0 1 0 0 0 0 0 0 0 0.5
Q8N1D0 0 0 0 0 0 0 0 1 0 0 0 0.5
K7EL42 0 0 0 1 0 0 0 0 0 0 0 0.5
Q8NA70 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8NEG0 0 0 0 1 0 0 0 0 0 0 0 0.5
H0Y6V6 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8WXF1 0 0 0 0 1 0 0 0 0.5 0 0 0
C9JA69 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A087X05 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96B26 0 0 0 0 1 0 0 0 0.5 0 0 0
Q96FS4 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96GW7 0 0 0 0 0 0 0 1 0 0 0 0.5
Q96J02 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96M60 1 0 0 0 0 0 0 0 0.5 0 0 0
Q96Q91 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96SQ9-2 0 0 0 1 0 0 0 0 0 0 0 0.5
E7ES68 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9BTY7 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9BVI0 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9C0B6 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9C0G6 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9H330 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9H3G5 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9H501 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9H6N6 0 0 0 0 0 0 0 1 0 0 0 0.5
H7C1U7 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9H7R0 0 0 0 0 0 0 0 1 0 0 0 0.5
A0A075B6H 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9H900 0 1 0 0 0 0 0 0 0 0.5 0 0
I3L139 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9HCD5 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9HCS5 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9NQW8 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9NRN7 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9NTZ6 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9NXG0 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9NYU2 0 0 0 0 0 0 0 1 0 0 0 0.5
K7EKM6 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9P2D3 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9P2I0 0 0 0 0 0 0 0 1 0 0 0 0.5
E9PMX7 0 0 0 1 0 0 0 0 0 0 0 0.5
G3V2W1 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9UKY3 0 0 0 0 0 1 0 0 0 0.5 0 0
H0YMN5 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9UP83 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0U1RQ 0 0 0 0 1 0 0 0 0.5 0 0 0
G8JLP4 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9Y6K8 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A087WW 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A1B0GU 0 0 0 1 0 0 0 0 0 0 0 0.5
F5H1Z8 0 0 0 1 0 0 0 0 0 0 0 0.5
F8VV97 1 0 0 0 0 0 0 0 0.5 0 0 0
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F8WDC4 0 0 0 0 1 0 0 0 0.5 0 0 0
H0YC36 0 1 0 0 0 0 0 0 0 0.5 0 0
H3BPN6 0 0 0 1 0 0 0 0 0 0 0 0.5
Q5SXN9 0 0 0 1 0 0 0 0 0 0 0 0.5
B5MDF5 1 0 0 0 0 0 0 0 0.5 0 0 0
A2AB06 1 0 0 0 0 0 0 0 0.5 0 0 0
C9J730 0 1 0 0 0 0 0 0 0 0.5 0 0
H7C121 0 0 0 1 0 0 0 0 0 0 0 0.5
J3QLI3 0 0 0 0 0 0 0 1 0 0 0 0.5
O43182 0 1 0 0 0 0 0 0 0 0.5 0 0
P07205 0 0 0 0 0 0 0 1 0 0 0 0.5
P13985 0 1 0 0 0 0 0 0 0 0.5 0 0
P20264 0 1 0 0 0 0 0 0 0 0.5 0 0
P49915 1 0 0 0 0 0 0 0 0.5 0 0 0
B4DXD0 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A0C4DG 0 0 0 0 0 1 0 0 0 0.5 0 0
Q6UXN9 0 0 0 0 1 0 0 0 0.5 0 0 0
I3L1V0 1 0 0 0 0 0 0 0 0.5 0 0 0
E9PMP7 0 0 0 1 0 0 0 0 0 0 0 0.5
Q96BJ8 0 1 0 0 0 0 0 0 0 0.5 0 0
H0Y7A5 0 0 0 0 0 0 0 1 0 0 0 0.5
Q9NX45 1 0 0 0 0 0 0 0 0.5 0 0 0
H0YC70 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A1B0GTR 0 0 0 1 0 0 0 0 0 0 0 0.5
K7EKP8 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A0A0MR 0 0 0 0 1 0 0 0 0.5 0 0 0
P14923 1 0 0 0 0 0 0 0 0.5 0 0 0
P46013 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A087WV 1 0 0 0 0 0 0 0 0.5 0 0 0
J3QT83 1 0 0 0 0 0 0 0 0.5 0 0 0
C9J8F4 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8NGJ4 1 0 0 0 0 0 0 0 0.5 0 0 0
C9JZB0 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A1B0GU 1 0 0 0 0 0 0 0 0.5 0 0 0
K7EQD1 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0C4DG 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0C4DG 0 0 0 0 0 0 0 1 0 0 0 0.5
B1AJY5 0 0 0 1 0 0 0 0 0 0 0 0.5
Q13127 0 0 0 0 0 1 0 0 0 0.5 0 0
B8ZZ87 0 0 0 0 0 1 0 0 0 0.5 0 0
F5GXW1 0 0 0 0 1 0 0 0 0.5 0 0 0
Q96PQ5 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9NY12 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9Y421-2 0 0 0 0 1 0 0 0 0.5 0 0 0
A6NJV1 0 1 0 0 0 0 0 0 0 0.5 0 0
P51511 0 1 0 0 0 0 0 0 0 0.5 0 0
F8VVT9 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0A6YYG 0 0 0 0 1 0 0 0 0.5 0 0 0
P08240 0 0 0 0 1 0 0 0 0.5 0 0 0
P34820-2 0 0 0 1 0 0 0 0 0 0 0 0.5
H0YLB9 0 0 0 0 1 0 0 0 0.5 0 0 0
K7ELC7 1 0 0 0 0 0 0 0 0.5 0 0 0
C9JKF1 0 0 0 0 1 0 0 0 0.5 0 0 0
A6PVH9 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9BTM9 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9H6T0 0 0 0 0 0 0 0 1 0 0 0 0.5
A6NCK2 1 0 0 0 0 0 0 0 0.5 0 0 0
B2RTY4 0 0 0 0 0 1 0 0 0 0.5 0 0
P0C853 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A087WW 0 1 0 0 0 0 0 0 0 0.5 0 0
C9JPI6 1 0 0 0 0 0 0 0 0.5 0 0 0
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A0A0A0MS 1 0 0 0 0 0 0 0 0.5 0 0 0
Q8N414 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0A0MQ 0 0 0 0 0 0 0 1 0 0 0 0.5
H0YFK7 0 0 0 0 0 0 0 1 0 0 0 0.5
H3BNW8 0 0 0 0 1 0 0 0 0.5 0 0 0
K7EK23 0 0 0 0 1 0 0 0 0.5 0 0 0
E7EMV8 0 0 0 0 0 1 0 0 0 0.5 0 0
A6NGW2 0 0 0 1 0 0 0 0 0 0 0 0.5
E5RG74 0 0 0 0 1 0 0 0 0.5 0 0 0
Q68DN1 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9NY15 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0A0MT 0 1 0 0 0 0 0 0 0 0.5 0 0
O75110 0 0 0 0 1 0 0 0 0.5 0 0 0
M0R1C8 0 0 0 1 0 0 0 0 0 0 0 0.5
P25391 1 0 0 0 0 0 0 0 0.5 0 0 0
J3KNB4 0 0 0 0 1 0 0 0 0.5 0 0 0
Q5M775 1 0 0 0 0 0 0 0 0.5 0 0 0
A0A087WT 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9H871 1 0 0 0 0 0 0 0 0.5 0 0 0
F5H026 0 0 0 0 0 1 0 0 0 0.5 0 0
Q6IEY1 0 0 0 0 1 0 0 0 0.5 0 0 0
Q5T3J3 0 0 0 0 0 1 0 0 0 0.5 0 0
Q86X59 0 0 0 0 1 0 0 0 0.5 0 0 0
Q8N5G2 0 0 0 0 1 0 0 0 0.5 0 0 0
A0A0C4DFU 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A087X07 0 0 0 0 1 1 0 0 0.5 0.5 0 0
Q9Y3Q8 0 0 0 0 0 1 0 0 0 0.5 0 0
H0YIZ1 0 0 0 0 0 1 0 0 0 0.5 0 0
Q86WV7 0 1 0 0 0 0 0 0 0 0.5 0 0
Q8TD57 0 0 0 0 0 1 0 0 0 0.5 0 0
O94907 0 1 0 0 0 0 0 0 0 0.5 0 0
Q14393 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0G2JM 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9H3C7 0 0 0 1 0 0 0 0 0 0 0 0.5
M0QYS1 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9BZF3 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9UMQ6 0 0 0 0 0 0 0 1 0 0 0 0.5
E5RIC9 1 0 0 0 0 0 0 0 0.5 0 0 0
C9JF14 0 1 0 0 0 0 0 0 0 0.5 0 0
J3KMY8 0 0 0 0 0 0 0 1 0 0 0 0.5
F8VWD7 0 0 0 0 1 0 0 0 0.5 0 0 0
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Q13541 1037 1085 607 643 2433 2252 1457 1357 1735 1668.5 1032 1000
TRYP_PIG 58 57 52 64 221 237 191 191 139.5 147 121.5 127.5
P11142 57 35 62 34 110 72 114 94 83.5 53.5 88 64
P42345 22 0 104 0 2 0 45 0 12 0 74.5 0
D6RBW1 68 70 61 72 76 64 79 68 72 67 70 70
P78347 37 25 36 27 74 78 102 92 55.5 51.5 69 59.5
P11021 44 43 44 22 85 64 72 79 64.5 53.5 58 50.5
P78527 40 0 66 6 11 0 31 3 25.5 0 48.5 4.5
P68363 31 24 43 49 24 14 50 53 27.5 19 46.5 51
P52272 1 1 26 20 1 0 58 39 1 0.5 42 29.5
A0A0G2JIW1 25 10 24 6 51 32 54 42 38 21 39 24
P07437 10 19 43 26 23 15 32 35 16.5 17 37.5 30.5
ALBU_BOVIN 53 50 51 84 14 17 20 11 33.5 33.5 35.5 47.5
Q13162 23 22 18 21 38 37 46 38 30.5 29.5 32 29.5
PRDX1_HUMAN 20 34 31 43 23 30 33 46 21.5 32 32 44.5
P04264 31 14 18 33 25 7 38 16 28 10.5 28 24.5
P13639 19 8 32 17 14 0 23 2 16.5 4 27.5 9.5
P17987 28 15 28 10 20 10 25 12 24 12.5 26.5 11
P49327 30 4 37 15 4 0 14 1 17 2 25.5 8
H0Y4R1 20 0 25 0 13 0 25 0 16.5 0 25 0
P68104 12 3 23 15 14 7 27 18 13 5 25 16.5
P30153 17 29 28 35 9 3 20 17 13 16 24 26
P50990 21 19 19 15 18 11 25 13 19.5 15 22 14
P13645 21 8 11 20 22 9 26 13 21.5 8.5 18.5 16.5
P35527 21 8 8 16 18 10 28 14 19.5 9 18 15
P60709 10 7 20 8 7 3 15 6 8.5 5 17.5 7
O14744 37 38 31 25 1 0 3 0 19 19 17 12.5
P63151 17 19 19 23 10 4 15 11 13.5 11.5 17 17
P08238 17 5 24 6 4 0 10 0 10.5 2.5 17 3
Q15393 14 15 22 14 6 1 12 5 10 8 17 9.5
Q8N122 21 21 25 18 6 1 8 3 13.5 11 16.5 10.5
P32119 10 17 18 22 11 13 15 13 10.5 15 16.5 17.5
E9PLK3 2 0 14 1 0 0 19 0 1 0 16.5 0.5
F5H5D3 0 0 19 22 0 0 14 0 0 0 16.5 11
Q9NUY8 0 0 18 0 0 0 15 0 0 0 16.5 0
P48643 17 6 14 7 14 3 17 8 15.5 4.5 15.5 7.5
P78371 13 3 12 6 15 7 19 14 14 5 15.5 10
Q99832 18 13 21 10 10 6 9 6 14 9.5 15 8
P10599 11 5 15 7 10 0 15 2 10.5 2.5 15 4.5
Q9BY77 1 3 1 1 12 12 28 22 6.5 7.5 14.5 11.5
P30041 15 10 14 10 12 3 14 3 13.5 6.5 14 6.5
P13797 13 0 12 1 5 0 16 0 9 0 14 0.5
Q16531 15 18 22 27 0 1 6 1 7.5 9.5 14 14
P68371 4 6 0 0 1 0 27 19 2.5 3 13.5 9.5
Q9BQA1 26 36 23 17 0 0 1 1 13 18 12 9
Q92598 16 3 18 0 3 0 6 0 9.5 1.5 12 0
P53396 12 2 16 2 6 0 8 0 9 1 12 1
P04350 4 0 23 24 0 0 0 0 2 0 11.5 12
Q9UJ70 3 0 15 0 1 0 8 0 2 0 11.5 0
Q15365 10 9 10 12 15 9 12 11 12.5 9 11 11.5
P11802 8 5 12 4 3 0 10 0 5.5 2.5 11 2
P22234 9 3 15 2 2 0 7 0 5.5 1.5 11 1
A0A0J9YVP6 13 9 9 12 7 8 11 10 10 8.5 10 11
F8W6I7 14 6 11 9 7 1 8 2 10.5 3.5 9.5 5.5
P40227 9 7 11 12 7 3 8 8 8 5 9.5 10
O60506 5 0 12 1 6 1 7 0 5.5 0.5 9.5 0.5
E9PB61 7 11 8 8 14 11 10 14 10.5 11 9 11
Replicate 1 PSMs Average PSMsReplicate 2 PSMs
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P49368 6 3 10 1 5 2 8 4 5.5 2.5 9 2.5
A0A0A0MQU4 9 12 9 10 4 2 8 2 6.5 7 8.5 6
Q9Y230 8 7 14 7 4 0 3 0 6 3.5 8.5 3.5
P62937 9 4 8 5 4 0 8 2 6.5 2 8 3.5
P46109 5 1 7 0 7 0 9 0 6 0.5 8 0
Q8TEX9 7 9 11 6 4 0 5 0 5.5 4.5 8 3
P07900 8 0 9 1 1 0 7 0 4.5 0 8 0.5
P07237 4 0 14 0 0 0 2 0 2 0 8 0
J3QRG6 3 2 5 4 5 0 10 1 4 1 7.5 2.5
Q71U36 0 0 0 0 0 0 15 5 0 0 7.5 2.5
O75190 0 0 6 7 0 0 9 8 0 0 7.5 7.5
P84090 5 5 8 9 9 5 6 8 7 5 7 8.5
Q15029 9 5 10 5 3 0 4 0 6 2.5 7 2.5
P62993 6 0 11 2 2 0 3 0 4 0 7 1
P13010 7 2 9 1 0 0 5 1 3.5 1 7 1
Q0VDG4 10 12 7 11 11 6 6 7 10.5 9 6.5 9
Q14011 7 6 5 4 7 4 8 7 7 5 6.5 5.5
P62714 6 0 13 25 5 4 0 0 5.5 2 6.5 12.5
P34932 10 2 11 1 0 0 2 0 5 1 6.5 0.5
P06748 7 1 7 1 0 1 6 1 3.5 1 6.5 1
P28482 5 7 10 10 1 0 3 2 3 3.5 6.5 6
P14618 3 1 12 10 3 0 1 0 3 0.5 6.5 5
Q5VWV2 1 0 5 1 1 0 8 1 1 0 6.5 1
A0A1C7CYX9 0 0 10 0 0 0 3 0 0 0 6.5 0
P52597 4 2 12 2 1 0 0 0 2.5 1 6 1
Q13085 1 0 11 0 0 0 1 0 0.5 0 6 0
Q14204 22 18 10 13 2 1 1 1 12 9.5 5.5 7
K22E_HUMAN 15 1 6 8 5 2 5 5 10 1.5 5.5 6.5
P19338 13 3 8 5 1 0 3 0 7 1.5 5.5 2.5
P67775 6 12 0 0 5 4 11 10 5.5 8 5.5 5
P00492 7 2 6 2 4 0 5 0 5.5 1 5.5 1
P98179 6 4 4 4 3 5 7 2 4.5 4.5 5.5 3
H0Y8C6 8 0 10 4 1 0 1 0 4.5 0 5.5 2
Q9HB71 5 0 5 0 3 0 6 0 4 0 5.5 0
P22314 6 1 9 4 1 0 2 0 3.5 0.5 5.5 2
A0A087WZT3 2 3 4 5 4 1 7 5 3 2 5.5 5
P30044 2 5 4 3 3 2 7 2 2.5 3.5 5.5 2.5
Q9P258 4 0 7 0 0 0 4 0 2 0 5.5 0
Q9BVC4 2 0 11 0 0 0 0 0 1 0 5.5 0
Q92616 2 0 10 0 0 0 1 0 1 0 5.5 0
A0A087WTP3 1 0 7 5 0 0 4 2 0.5 0 5.5 3.5
Q86X55 10 0 7 0 0 0 3 0 5 0 5 0
P50991 4 0 5 1 4 2 5 5 4 1 5 3
P22626 5 7 8 7 2 0 2 1 3.5 3.5 5 4
P27348 4 0 7 0 1 0 3 0 2.5 0 5 0
P63173 2 1 2 0 2 3 8 3 2 2 5 1.5
Q13395 4 0 8 1 0 0 2 0 2 0 5 0.5
E9PKG1 3 0 8 3 0 0 2 0 1.5 0 5 1.5
E9PCY7 8 7 4 6 1 0 5 1 4.5 3.5 4.5 3.5
A0A0A0MS07 2 2 5 4 6 6 4 6 4 4 4.5 5
G8JLD5 7 0 7 0 1 0 2 0 4 0 4.5 0
B0QY89 5 7 7 6 2 2 2 1 3.5 4.5 4.5 3.5
P55072 7 4 9 3 0 0 0 0 3.5 2 4.5 1.5
E7EUT5 2 2 3 0 2 0 6 2 2 1 4.5 1
A0A0U1RRM4 1 0 4 0 3 0 5 1 2 0 4.5 0.5
O60573 1 2 3 2 2 2 6 2 1.5 2 4.5 2
F8VPD4 3 0 9 6 0 0 0 0 1.5 0 4.5 3
P06733 1 2 4 2 2 1 5 1 1.5 1.5 4.5 1.5
Q9HA64 1 0 4 0 2 0 5 0 1.5 0 4.5 0
P17812 2 0 7 3 0 0 2 0 1 0 4.5 1.5
Q9HAV4 2 0 8 0 0 0 1 0 1 0 4.5 0
Q9BVA1 1 0 8 12 0 0 1 0 0.5 0 4.5 6
E9PL69 1 0 6 1 0 0 3 0 0.5 0 4.5 0.5
P09874 7 0 2 0 5 0 6 1 6 0 4 0.5
P60228 10 9 8 6 0 0 0 0 5 4.5 4 3
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P27694 2 1 1 1 8 8 7 4 5 4.5 4 2.5
A0A075B6S2 4 5 4 4 5 5 4 5 4.5 5 4 4.5
Q6P2Q9 6 4 7 5 2 0 1 0 4 2 4 2.5
B4DV12 2 2 3 3 5 1 5 4 3.5 1.5 4 3.5
I3L397 1 3 4 2 5 1 4 2 3 2 4 2
P12277 3 0 5 1 1 0 3 0 2 0 4 0.5
P26641 3 0 5 0 0 0 3 0 1.5 0 4 0
Q8NBS9 2 7 5 4 0 1 3 0 1 4 4 2
P17858 0 0 8 8 0 0 0 0 0 0 4 4
P17655 12 3 5 0 3 0 2 0 7.5 1.5 3.5 0
E9PK25 5 2 4 2 4 0 3 2 4.5 1 3.5 2
P19474 8 5 7 10 0 0 0 0 4 2.5 3.5 5
A0A0A0MRJ6 6 1 6 1 2 0 1 0 4 0.5 3.5 0.5
P78406 7 3 5 6 0 0 2 0 3.5 1.5 3.5 3
P02538 3 0 0 0 3 0 7 0 3 0 3.5 0
Q12906 3 3 5 3 2 0 2 0 2.5 1.5 3.5 1.5
O14980 4 4 6 1 1 0 1 0 2.5 2 3.5 0.5
E5RJR5 4 1 3 1 1 0 4 1 2.5 0.5 3.5 1
P08243 2 0 4 1 2 0 3 0 2 0 3.5 0.5
P61978 2 0 3 0 2 0 4 0 2 0 3.5 0
P08779 1 0 1 0 2 2 6 2 1.5 1 3.5 1
Q13838 2 2 5 6 1 0 2 1 1.5 1 3.5 3.5
P51991 3 1 5 1 0 0 2 0 1.5 0.5 3.5 0.5
P23246 2 0 2 0 1 0 5 0 1.5 0 3.5 0
E9PC52 0 6 7 3 2 0 0 1 1 3 3.5 2
J3KTA4 0 0 2 2 2 0 5 0 1 0 3.5 1
P23526 2 0 4 3 0 0 3 0 1 0 3.5 1.5
Q9Y265 2 1 5 1 0 0 2 0 1 0.5 3.5 0.5
P31689 1 0 6 3 0 0 1 0 0.5 0 3.5 1.5
Q6DKJ4 1 0 2 0 0 0 5 0 0.5 0 3.5 0
Q14257 0 0 5 3 0 0 2 4 0 0 3.5 3.5
P54136 0 0 7 4 0 0 0 0 0 0 3.5 2
Q9Y3I0 0 0 3 0 0 0 4 0 0 0 3.5 0
A0A087WW66 7 3 4 2 0 0 2 0 3.5 1.5 3 1
P14866 5 0 4 1 2 0 2 0 3.5 0 3 0.5
D6RAF8 5 2 4 2 1 0 2 0 3 1 3 1
Q99615 5 0 5 0 1 0 1 0 3 0 3 0
B1AHC9 3 0 2 0 3 0 4 0 3 0 3 0
P37802 3 0 4 1 2 0 2 0 2.5 0 3 0.5
Q9BQ67 4 2 5 4 0 0 1 0 2 1 3 2
O15067 3 0 6 1 0 0 0 0 1.5 0 3 0.5
P22102 3 0 6 0 0 0 0 0 1.5 0 3 0
J3KQ32 1 0 2 0 2 0 4 0 1.5 0 3 0
G5E9A6 2 2 5 5 0 0 1 0 1 1 3 2.5
P31948 2 0 4 1 0 0 2 0 1 0 3 0.5
Q93009 2 0 2 0 0 0 4 0 1 0 3 0
Q96CX2 1 0 5 0 1 0 1 0 1 0 3 0
Q8NI35 1 1 6 6 0 0 0 0 0.5 0.5 3 3
P55060 1 0 5 0 0 0 1 0 0.5 0 3 0
Q9Y224 0 0 2 0 1 0 4 0 0.5 0 3 0
Q9NPA8 1 1 1 3 7 3 4 4 4 2 2.5 3.5
Q9UMS4 4 4 3 4 3 1 2 1 3.5 2.5 2.5 2.5
B4DY09 6 2 4 4 0 0 1 0 3 1 2.5 2
P49458 4 2 2 3 2 0 3 0 3 1 2.5 1.5
A0A087WYT3 5 0 2 0 1 0 3 0 3 0 2.5 0
Q09028 3 6 1 3 2 0 4 1 2.5 3 2.5 2
Q00839 3 0 4 1 2 0 1 1 2.5 0 2.5 1
TRY1_BOVIN 1 1 1 0 3 3 4 2 2 2 2.5 1
J3QLE5 2 1 3 2 2 1 2 2 2 1 2.5 2
P35606 4 2 5 1 0 0 0 0 2 1 2.5 0.5
F5H365 3 2 3 0 1 0 2 0 2 1 2.5 0
B0QZ18 4 0 4 0 0 0 1 0 2 0 2.5 0
Q9Y3Y2 1 1 1 0 2 1 4 3 1.5 1 2.5 1.5
Q15233 1 0 2 0 2 0 3 1 1.5 0 2.5 0.5
Q9NZL4 3 0 4 1 0 0 1 0 1.5 0 2.5 0.5
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Q9Y3B4 1 0 3 0 2 0 2 1 1.5 0 2.5 0.5
J3KQ69 3 0 3 0 0 0 2 0 1.5 0 2.5 0
A0A087WTT1 2 4 2 3 0 0 3 0 1 2 2.5 1.5
C9J0J7 2 0 3 1 0 0 2 0 1 0 2.5 0.5
P62316 1 0 3 1 1 0 2 0 1 0 2.5 0.5
O75643 2 0 3 0 0 0 2 0 1 0 2.5 0
P38606 2 0 3 0 0 0 2 0 1 0 2.5 0
P45984 2 0 4 0 0 0 1 0 1 0 2.5 0
G5EA31 1 0 4 0 0 0 1 0 0.5 0 2.5 0
O95825 1 0 5 0 0 0 0 0 0.5 0 2.5 0
P12081 0 0 5 2 0 0 0 0 0 0 2.5 1
Q9H3U1 0 0 4 0 0 0 1 0 0 0 2.5 0
P02533 5 0 1 5 2 2 3 0 3.5 1 2 2.5
P62857 3 2 2 0 3 1 2 0 3 1.5 2 0
Q15208 6 1 4 1 0 0 0 0 3 0.5 2 0.5
O43390 5 4 3 1 0 0 1 0 2.5 2 2 0.5
P62913 2 0 2 0 3 1 2 2 2.5 0.5 2 1
Q16543 5 0 3 0 0 0 1 0 2.5 0 2 0
H3BLZ8 2 0 2 2 2 0 2 0 2 0 2 1
Q9BYB4 4 0 3 0 0 0 1 0 2 0 2 0
A0A087WVQ6 3 5 4 5 0 0 0 0 1.5 2.5 2 2.5
O43242 3 4 3 2 0 1 1 0 1.5 2.5 2 1
F8W079 3 1 4 5 0 0 0 0 1.5 0.5 2 2.5
P07195 3 0 4 0 0 0 0 1 1.5 0 2 0.5
P53602 3 0 4 0 0 0 0 0 1.5 0 2 0
Q08499-12 1 1 0 2 1 7 4 4 1 4 2 3
E9PDE8 2 0 4 0 0 0 0 0 1 0 2 0
J3QRS3 1 2 2 2 1 0 2 2 1 1 2 2
Q13200 2 2 3 2 0 0 1 0 1 1 2 1
Q13347 2 2 4 1 0 0 0 0 1 1 2 0.5
A0A087WWU8 2 0 4 0 0 0 0 0 1 0 2 0
P04080 1 0 1 0 1 0 3 0 1 0 2 0
P39019 0 0 0 0 2 0 4 0 1 0 2 0
Q13435 0 0 0 0 2 0 4 0 1 0 2 0
A0A0U1RR32 0 2 2 1 1 0 2 3 0.5 1 2 2
G3V1N2 1 0 4 2 0 0 0 0 0.5 0 2 1
H9KV75 1 0 3 1 0 0 1 0 0.5 0 2 0.5
P05387 1 0 2 0 0 0 2 0 0.5 0 2 0
P41250 1 0 2 0 0 0 2 0 0.5 0 2 0
Q93008 1 0 4 0 0 0 0 0 0.5 0 2 0
P55795 0 0 4 0 0 0 0 1 0 0 2 0.5
P51116 0 0 3 1 0 0 1 1 0 0 2 1
P61221 0 0 3 2 0 0 1 0 0 0 2 1
Q15773 0 0 2 2 0 0 2 0 0 0 2 1
Q6IA86 0 0 4 1 0 0 0 0 0 0 2 0.5
E9PJH4 0 0 1 0 0 0 3 0 0 0 2 0
P48147 0 0 3 0 0 0 1 0 0 0 2 0
Q14012 0 0 4 0 0 0 0 0 0 0 2 0
Q6PJG6 0 0 4 0 0 0 0 0 0 0 2 0
P23284 6 5 2 2 2 2 1 1 4 3.5 1.5 1.5
E9PMI6 5 6 3 2 0 0 0 0 2.5 3 1.5 1
P35244 3 2 0 2 2 1 3 1 2.5 1.5 1.5 1.5
Q9H4A4 4 1 3 4 0 0 0 0 2 0.5 1.5 2
P47813 2 0 1 1 2 1 2 3 2 0.5 1.5 2
Q7RTV0 1 1 2 3 3 1 1 0 2 1 1.5 1.5
E7EMB3 2 0 2 1 2 0 1 0 2 0 1.5 0.5
P62269 0 0 0 0 4 1 3 2 2 0.5 1.5 1
Q9UNE7 3 1 2 0 1 0 1 0 2 0.5 1.5 0
P35998 3 2 3 3 0 0 0 1 1.5 1 1.5 2
Q9UJ68 1 3 3 3 1 0 0 0 1 1.5 1.5 1.5
O00303 2 2 2 2 0 0 1 0 1 1 1.5 1
P61163 2 2 1 1 0 0 2 0 1 1 1.5 0.5
P62310 2 2 2 1 0 0 1 0 1 1 1.5 0.5
Q13561 1 1 2 1 1 0 1 1 1 0.5 1.5 1
Q13409-2 1 2 0 0 1 0 3 0 1 1 1.5 0
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P60842 2 0 1 1 0 0 2 0 1 0 1.5 0.5
CAS1_BOVIN 1 0 2 0 1 0 1 1 1 0 1.5 0.5
J3QT28 2 0 3 0 0 0 0 0 1 0 1.5 0
Q7KZF4 2 0 3 0 0 0 0 0 1 0 1.5 0
E7EX29 1 1 3 2 0 0 0 0 0.5 0.5 1.5 1
E5RHG8 1 2 3 2 0 0 0 0 0.5 1 1.5 1
K7ERF1 1 4 2 1 0 0 1 0 0.5 2 1.5 0.5
P62318 1 1 2 1 0 0 1 0 0.5 0.5 1.5 0.5
Q96J01 1 0 3 2 0 0 0 0 0.5 0 1.5 1
P61758 1 0 3 3 0 0 0 0 0.5 0 1.5 1.5
P62195 1 1 2 1 0 0 1 0 0.5 0.5 1.5 0.5
P04818 1 1 2 1 0 0 1 0 0.5 0.5 1.5 0.5
Q9BWJ5 1 1 3 1 0 0 0 0 0.5 0.5 1.5 0.5
O43175 0 0 3 2 1 0 0 0 0.5 0 1.5 1
A0A087X2I1 1 1 2 0 0 0 1 0 0.5 0.5 1.5 0
P13489 1 0 3 1 0 0 0 0 0.5 0 1.5 0.5
GSTP1_HUMAN 0 1 2 0 1 0 1 0 0.5 0.5 1.5 0
P52564 1 0 2 0 0 0 1 0 0.5 0 1.5 0
Q9BUF5 0 0 3 4 0 0 0 0 0 0 1.5 2
D6R9P3 0 0 3 0 0 0 0 0 0 0 1.5 0
H3BR35 0 0 3 3 0 0 0 0 0 0 1.5 1.5
O00170 0 0 3 3 0 0 0 0 0 0 1.5 1.5
Q9GZP4 0 0 3 3 0 0 0 0 0 0 1.5 1.5
E9PJM3 0 0 3 2 0 0 0 0 0 0 1.5 1
A0A0A6YY92 0 0 3 1 0 0 0 0 0 0 1.5 0.5
Q8N5X7 0 0 3 1 0 0 0 0 0 0 1.5 0.5
A0A0C4DGH5 0 0 2 0 0 0 1 0 0 0 1.5 0
A6NIH7 0 0 3 0 0 0 0 0 0 0 1.5 0
E9PLT0 0 0 3 0 0 0 0 0 0 0 1.5 0
H0Y650 0 0 3 0 0 0 0 0 0 0 1.5 0
K7EK33 0 0 3 0 0 0 0 0 0 0 1.5 0
P19623 0 0 2 0 0 0 1 0 0 0 1.5 0
P63167 0 0 2 0 0 0 1 0 0 0 1.5 0
Q8N3R9 0 0 3 0 0 0 0 0 0 0 1.5 0
Q9NRN7 0 0 3 0 0 0 0 0 0 0 1.5 0
P31151 3 4 2 1 2 0 0 0 2.5 2 1 0.5
P37108 2 0 1 0 2 0 1 0 2 0 1 0
Q8NC51 4 1 2 0 0 0 0 0 2 0.5 1 0
P43487 3 0 2 0 1 0 0 0 2 0 1 0
E7EQU1 1 0 0 0 2 1 2 0 1.5 0.5 1 0
P48556 2 3 1 3 1 0 1 0 1.5 1.5 1 1.5
P26639 3 0 2 1 0 0 0 0 1.5 0 1 0.5
E9PHA6 2 0 2 0 1 0 0 0 1.5 0 1 0
K7EN45 2 0 2 0 1 0 0 0 1.5 0 1 0
EFC4EBP1 1 1 0 2 1 3 2 1 1 2 1 1.5
A0A087WXI3 2 1 1 1 0 0 1 0 1 0.5 1 0.5
P01859 1 2 2 2 1 0 0 1 1 1 1 1.5
Q9Y383 2 1 2 1 0 0 0 0 1 0.5 1 0.5
D3YTI2 1 1 1 0 1 1 1 0 1 1 1 0
Q9UHV9 1 0 1 2 1 0 1 0 1 0 1 1
H3BQN4 2 1 2 0 0 0 0 0 1 0.5 1 0
O00232 2 1 1 0 0 0 1 0 1 0.5 1 0
O75131 2 0 0 0 0 0 2 0 1 0 1 0
P12955 2 0 1 0 0 0 1 0 1 0 1 0
Q14236 2 0 2 0 0 0 0 0 1 0 1 0
P68032 1 0 2 1 0 0 0 0 0.5 0 1 0.5
F8VZX2 0 0 0 1 1 0 2 0 0.5 0 1 0.5
F5H2F4 0 0 1 0 1 0 1 0 0.5 0 1 0
P62258 1 0 2 1 0 0 0 0 0.5 0 1 0.5
Q8N0Z9-2 1 0 1 2 0 0 1 0 0.5 0 1 1
Q9BW04 1 1 2 0 0 0 0 0 0.5 0.5 1 0
C9J381 1 0 2 0 0 0 0 0 0.5 0 1 0
Q9BTE3 1 0 2 2 0 0 0 0 0.5 0 1 1
J3QLI9 0 1 1 0 1 1 1 1 0.5 1 1 0.5
F5GX77 1 0 2 2 0 0 0 0 0.5 0 1 1
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P52907 1 0 2 0 0 0 0 0 0.5 0 1 0
Q8TF72 1 1 1 1 0 0 1 0 0.5 0.5 1 0.5
C9JIZ0 1 0 1 1 0 0 1 0 0.5 0 1 0.5
P11413 1 1 2 0 0 0 0 0 0.5 0.5 1 0
P08708 0 0 0 0 1 1 2 0 0.5 0.5 1 0
M0R0K9 1 0 2 0 0 0 0 0 0.5 0 1 0
P11172 1 0 2 0 0 0 0 0 0.5 0 1 0
Q5MNZ6 1 0 2 0 0 0 0 0 0.5 0 1 0
Q96QK1 1 0 2 0 0 0 0 0 0.5 0 1 0
Q9Y4C2 1 0 2 0 0 0 0 0 0.5 0 1 0
B1AHB1 0 0 2 0 1 0 0 0 0.5 0 1 0
B7Z6Z4 0 5 2 2 0 0 0 0 0 2.5 1 1
Q8NBF2 0 0 2 5 0 0 0 0 0 0 1 2.5
K7ERV3 0 2 1 1 0 0 1 0 0 1 1 0.5
P59025 0 0 1 1 0 0 1 0 0 0 1 0.5
B4DXZ6 0 0 0 0 0 0 2 1 0 0 1 0.5
P25398 0 2 2 0 0 0 0 0 0 1 1 0
Q13547 0 1 2 1 0 0 0 0 0 0.5 1 0.5
Q4G163 0 0 2 0 0 0 0 0 0 0 1 0
Q9Y5L4 0 0 2 2 0 0 0 0 0 0 1 1
B1AMS2 0 0 2 1 0 0 0 0 0 0 1 0.5
C9JZW3 0 0 2 1 0 0 0 0 0 0 1 0.5
G5E9W3 0 0 1 1 0 0 1 0 0 0 1 0.5
Q15024 0 0 2 1 0 0 0 0 0 0 1 0.5
A0A087WUW6 0 0 2 0 0 0 0 0 0 0 1 0
A0A087X2G1 0 0 0 0 0 0 2 0 0 0 1 0
A0A0C4DGX4 0 0 2 0 0 0 0 0 0 0 1 0
A0A1B0GTC3 0 0 2 0 0 0 0 0 0 0 1 0
C9JSQ1 0 0 1 0 0 0 1 0 0 0 1 0
E5RGS4 0 0 1 0 0 0 1 0 0 0 1 0
E7EPP6 0 0 1 0 0 0 1 0 0 0 1 0
F5H2T0 0 0 2 0 0 0 0 0 0 0 1 0
H0Y8B3 0 0 2 0 0 0 0 0 0 0 1 0
I3L2B0 0 0 1 0 0 0 1 0 0 0 1 0
J3KTM9 0 0 1 0 0 0 1 0 0 0 1 0
K7EIN2 0 0 2 0 0 0 0 0 0 0 1 0
M0R1M5 0 0 0 0 0 0 2 0 0 0 1 0
P11678 0 0 1 0 0 0 1 0 0 0 1 0
P14735 0 0 2 0 0 0 0 0 0 0 1 0
P26196 0 0 1 0 0 0 1 0 0 0 1 0
P56537 0 0 2 0 0 0 0 0 0 0 1 0
Q06330 0 0 2 0 0 0 0 0 0 0 1 0
Q8IXB1 0 0 2 0 0 0 0 0 0 0 1 0
Q8WUM4 0 0 2 0 0 0 0 0 0 0 1 0
Q9BPU6 0 0 0 0 0 0 2 0 0 0 1 0
B7Z9C2 2 1 1 0 2 0 0 0 2 0.5 0.5 0
H3BPE7 3 1 1 1 1 0 0 0 2 0.5 0.5 0.5
P29508 2 2 1 1 1 0 0 0 1.5 1 0.5 0.5
O60826 3 0 1 0 0 0 0 0 1.5 0 0.5 0
P31153 2 0 1 0 1 0 0 0 1.5 0 0.5 0
Q66LE6 2 1 1 3 0 0 0 1 1 0.5 0.5 2
P13647 2 0 0 2 0 0 1 0 1 0 0.5 1
CASB_BOVIN 2 0 1 2 0 0 0 0 1 0 0.5 1
P05204 2 1 1 0 0 1 0 2 1 1 0.5 1
E9PM69 2 2 0 1 0 0 1 0 1 1 0.5 0.5
H0YIE9 2 0 1 1 0 0 0 0 1 0 0.5 0.5
Q86YZ3 2 0 1 3 0 0 0 0 1 0 0.5 1.5
O00231 2 1 0 1 0 0 1 0 1 0.5 0.5 0.5
P62851 2 1 1 1 0 0 0 0 1 0.5 0.5 0.5
A0A087X2D0 1 1 0 1 1 0 1 0 1 0.5 0.5 0.5
A0A0B4J1R6 1 1 1 1 1 0 0 0 1 0.5 0.5 0.5
K7EKP8 2 0 1 1 0 0 0 0 1 0 0.5 0.5
P00338 2 0 1 1 0 0 0 0 1 0 0.5 0.5
D6RG13 1 0 0 0 1 0 1 1 1 0 0.5 0.5
B5MCX3 2 0 1 0 0 0 0 0 1 0 0.5 0
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E9PRH9 2 0 1 0 0 0 0 0 1 0 0.5 0
F8WCF6 2 0 1 0 0 0 0 0 1 0 0.5 0
Q9BTY7 2 0 1 0 0 0 0 0 1 0 0.5 0
Q9H773 2 0 1 0 0 0 0 0 1 0 0.5 0
H0YC04 1 0 1 0 1 0 0 0 1 0 0.5 0
P34931 1 2 1 1 0 0 0 0 0.5 1 0.5 0.5
A0A0C4DGB6 1 3 1 0 0 0 0 0 0.5 1.5 0.5 0
P27361 0 0 1 1 1 0 0 0 0.5 0 0.5 0.5
P62191 1 5 0 1 0 0 1 1 0.5 2.5 0.5 1
O76041 1 0 0 1 0 1 1 0 0.5 0.5 0.5 0.5
Q96JK2 1 4 1 2 0 0 0 0 0.5 2 0.5 1
C9JKF1 0 1 1 1 1 0 0 0 0.5 0.5 0.5 0.5
Q96DG6 1 4 1 1 0 0 0 0 0.5 2 0.5 0.5
D6RAX2 1 1 1 2 0 0 0 0 0.5 0.5 0.5 1
F6RFD5 1 0 1 0 0 0 0 0 0.5 0 0.5 0
O00487 1 1 0 2 0 0 1 0 0.5 0.5 0.5 1
Q96R54 1 0 0 0 0 1 1 0 0.5 0.5 0.5 0
Q9NZR2 0 0 0 1 1 0 1 0 0.5 0 0.5 0.5
A0A087WV05 1 2 1 0 0 0 0 0 0.5 1 0.5 0
A0A087WYS6 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
E9PMD7 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
H3BM60 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
O75037 1 1 1 1 0 0 0 0 0.5 0.5 0.5 0.5
O75348 1 0 1 0 0 0 0 0 0.5 0 0.5 0
P04004 1 2 1 0 0 0 0 0 0.5 1 0.5 0
Q9Y294 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
P14174 0 1 0 1 1 0 1 0 0.5 0.5 0.5 0.5
A0A087WX29 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
A0A0A0MSX9 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
A0A0C4DGL3 1 1 1 0 0 0 0 0 0.5 0.5 0.5 0
K7EPK0 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
O00483 1 0 0 0 0 1 1 0 0.5 0.5 0.5 0
O15085 1 0 1 0 0 0 0 1 0.5 0 0.5 0.5
O43592 1 0 1 1 0 0 0 0 0.5 0 0.5 0.5
B5MCP9 0 0 0 0 1 1 1 0 0.5 0.5 0.5 0
G3V1S7 0 0 0 0 1 0 1 1 0.5 0 0.5 0.5
H7C3G1 0 0 0 0 1 0 1 1 0.5 0 0.5 0.5
Q9UM47 0 0 1 0 1 1 0 0 0.5 0.5 0.5 0
Q9Y4R8 0 0 1 1 1 0 0 0 0.5 0 0.5 0.5
A0A087X027 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A087X1R4 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A0D9SFL3 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A0A0G2JIC2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
A8MWD9 1 0 1 0 0 0 0 0 0.5 0 0.5 0
B4E0K5 1 0 1 0 0 0 0 0 0.5 0 0.5 0
B8ZZU8 1 0 1 0 0 0 0 0 0.5 0 0.5 0
C9IZ80 1 0 1 0 0 0 0 0 0.5 0 0.5 0
C9JZD1 1 0 1 0 0 0 0 0 0.5 0 0.5 0
E9PF46 1 0 1 0 0 0 0 0 0.5 0 0.5 0
H0Y580 1 0 1 0 0 0 0 0 0.5 0 0.5 0
J3KPM9 1 0 1 0 0 0 0 0 0.5 0 0.5 0
K7ENA8 1 0 1 0 0 0 0 0 0.5 0 0.5 0
M0R261 1 0 1 0 0 0 0 0 0.5 0 0.5 0
P25705 1 0 1 0 0 0 0 0 0.5 0 0.5 0
P58546 1 0 0 0 0 0 1 0 0.5 0 0.5 0
P62306 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q05519 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q96DI7 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9BYN0 1 0 0 0 0 0 1 0 0.5 0 0.5 0
Q9H1R2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9H3P7 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9NSY0-2 1 0 1 0 0 0 0 0 0.5 0 0.5 0
Q9UPV7 1 0 1 0 0 0 0 0 0.5 0 0.5 0
O15397 0 0 1 0 1 0 0 0 0.5 0 0.5 0
Q5T3E1 0 0 1 0 1 0 0 0 0.5 0 0.5 0
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Q562R1 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A024QZP7 0 0 1 0 0 0 0 0 0 0 0.5 0
E7ESI2 0 0 1 0 0 0 0 0 0 0 0.5 0
O76003 0 1 1 4 0 0 0 0 0 0.5 0.5 2
P07996 0 0 0 0 0 1 1 0 0 0.5 0.5 0
P14625 0 0 1 0 0 0 0 0 0 0 0.5 0
P43686 0 2 0 0 0 1 1 0 0 1.5 0.5 0
P45983 0 0 0 0 0 1 1 0 0 0.5 0.5 0
P62829 0 0 1 3 0 0 0 0 0 0 0.5 1.5
Q01813 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NVP2 0 0 0 3 0 0 1 0 0 0 0.5 1.5
A0A087WT12 0 1 0 1 0 0 1 0 0 0.5 0.5 0.5
B1AKJ5 0 0 1 2 0 0 0 0 0 0 0.5 1
O60814 0 1 0 1 0 0 1 0 0 0.5 0.5 0.5
O75506 0 0 1 2 0 0 0 0 0 0 0.5 1
P08237 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P33993 0 0 1 2 0 0 0 0 0 0 0.5 1
Q13643 0 1 1 0 0 1 0 0 0 1 0.5 0
Q15181 0 0 1 2 0 0 0 0 0 0 0.5 1
Q6TFL3 0 1 0 0 0 0 1 1 0 0.5 0.5 0.5
Q6TFL3-3 0 0 0 1 0 0 1 1 0 0 0.5 1
Q8NBK3 0 0 1 2 0 0 0 0 0 0 0.5 1
Q9NUP9 0 1 1 1 0 0 0 0 0 0.5 0.5 0.5
A0A024RA52 0 1 1 0 0 0 0 0 0 0.5 0.5 0
A0A0B4J207 0 1 0 0 0 0 1 0 0 0.5 0.5 0
A2RRP1 0 0 1 0 0 0 0 1 0 0 0.5 0.5
B1AHE4 0 0 1 1 0 0 0 0 0 0 0.5 0.5
D6RCP9 0 1 1 0 0 0 0 0 0 0.5 0.5 0
F6TLX2 0 0 1 1 0 0 0 0 0 0 0.5 0.5
H3BN98 0 0 0 0 0 0 1 1 0 0 0.5 0.5
J3KNF4 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P07814 0 1 1 0 0 0 0 0 0 0.5 0.5 0
P12004 0 1 1 0 0 0 0 0 0 0.5 0.5 0
P14854 0 0 1 1 0 0 0 0 0 0 0.5 0.5
P31025 0 1 1 0 0 0 0 0 0 0.5 0.5 0
Q01581 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q04760 0 0 1 1 0 0 0 0 0 0 0.5 0.5
Q8N1N4 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9BUA3 0 0 1 1 0 0 0 0 0 0 0.5 0.5
A0A087WXX9 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A087X0B7 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0A0MTI9 0 0 1 0 0 0 0 0 0 0 0.5 0
A0A0U1RQC5 0 0 1 0 0 0 0 0 0 0 0.5 0
A3KFL1 0 0 0 0 0 0 1 0 0 0 0.5 0
B0QYA4 0 0 0 0 0 0 1 0 0 0 0.5 0
B1AK87 0 0 1 0 0 0 0 0 0 0 0.5 0
B3KQ25 0 0 1 0 0 0 0 0 0 0 0.5 0
B4DWH1 0 0 0 0 0 0 1 0 0 0 0.5 0
B4E3M2 0 0 1 0 0 0 0 0 0 0 0.5 0
B5MD17 0 0 1 0 0 0 0 0 0 0 0.5 0
C9J2Y4 0 0 1 0 0 0 0 0 0 0 0.5 0
C9J2Y9 0 0 1 0 0 0 0 0 0 0 0.5 0
C9J3R0 0 0 1 0 0 0 0 0 0 0 0.5 0
C9JUY3 0 0 1 0 0 0 0 0 0 0 0.5 0
C9JV77 0 0 1 0 0 0 0 0 0 0 0.5 0
D6RBM8 0 0 0 0 0 0 1 0 0 0 0.5 0
E3W980 0 0 0 0 0 0 1 0 0 0 0.5 0
E7EMG7 0 0 1 0 0 0 0 0 0 0 0.5 0
E7EMZ0 0 0 0 0 0 0 1 0 0 0 0.5 0
E7EWC5 0 0 1 0 0 0 0 0 0 0 0.5 0
E7EWD3 0 0 0 0 0 0 1 0 0 0 0.5 0
E9PFW2 0 0 1 0 0 0 0 0 0 0 0.5 0
E9PMM9 0 0 0 0 0 0 1 0 0 0 0.5 0
F5H6T1 0 0 1 0 0 0 0 0 0 0 0.5 0
F8W1B7 0 0 0 0 0 0 1 0 0 0 0.5 0
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G3V4T5 0 0 1 0 0 0 0 0 0 0 0.5 0
H0YCK3 0 0 1 0 0 0 0 0 0 0 0.5 0
H0YHR9 0 0 1 0 0 0 0 0 0 0 0.5 0
I3L106 0 0 1 0 0 0 0 0 0 0 0.5 0
M0R1Q8 0 0 1 0 0 0 0 0 0 0 0.5 0
M0R338 0 0 0 0 0 0 1 0 0 0 0.5 0
O00165 0 0 0 0 0 0 1 0 0 0 0.5 0
O14787-2 0 0 1 0 0 0 0 0 0 0 0.5 0
O14965 0 0 0 0 0 0 1 0 0 0 0.5 0
O43252 0 0 1 0 0 0 0 0 0 0 0.5 0
O43543 0 0 1 0 0 0 0 0 0 0 0.5 0
O75419 0 0 1 0 0 0 0 0 0 0 0.5 0
P15259 0 0 1 0 0 0 0 0 0 0 0.5 0
P23280 0 0 1 0 0 0 0 0 0 0 0.5 0
P28562 0 0 1 0 0 0 0 0 0 0 0.5 0
P32241-2 0 0 0 0 0 0 1 0 0 0 0.5 0
P49770 0 0 1 0 0 0 0 0 0 0 0.5 0
P59510-2 0 0 1 0 0 0 0 0 0 0 0.5 0
P60174 0 0 0 0 0 0 1 0 0 0 0.5 0
Q07973 0 0 1 0 0 0 0 0 0 0 0.5 0
Q08945 0 0 1 0 0 0 0 0 0 0 0.5 0
Q0VDF9 0 0 1 0 0 0 0 0 0 0 0.5 0
Q12852 0 0 1 0 0 0 0 0 0 0 0.5 0
Q13451 0 0 1 0 0 0 0 0 0 0 0.5 0
Q15084 0 0 0 0 0 0 1 0 0 0 0.5 0
Q52LJ0 0 0 0 0 0 0 1 0 0 0 0.5 0
Q5T1S4 0 0 1 0 0 0 0 0 0 0 0.5 0
Q5T6H7 0 0 1 0 0 0 0 0 0 0 0.5 0
Q5W0B1 0 0 1 0 0 0 0 0 0 0 0.5 0
Q6ZVT6-2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q7Z2T5 0 0 1 0 0 0 0 0 0 0 0.5 0
Q7Z6Z7 0 0 1 0 0 0 0 0 0 0 0.5 0
Q86Y25 0 0 1 0 0 0 0 0 0 0 0.5 0
Q8NFU7 0 0 0 0 0 0 1 0 0 0 0.5 0
Q8WXH2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q96P70 0 0 1 0 0 0 0 0 0 0 0.5 0
Q96PK6-5 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9BRX2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9BWD1 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9H069 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9NWU2 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9NX55 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9UBB9 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9UBF6 0 0 1 0 0 0 0 0 0 0 0.5 0
Q9UBQ7 0 0 0 0 0 0 1 0 0 0 0.5 0
Q9Y3Z3 0 0 1 0 0 0 0 0 0 0 0.5 0
S4R3T0 0 0 0 0 0 0 1 0 0 0 0.5 0
A0A0C4DGQ5 6 1 0 0 2 0 0 0 4 0.5 0 0
Q14344 1 1 0 1 3 1 0 0 2 1 0 0.5
E7EQ64 1 0 0 1 2 0 0 0 1.5 0 0 0.5
P05109 0 0 0 1 3 0 0 0 1.5 0 0 0.5
Q15008 2 1 0 1 1 0 0 0 1.5 0.5 0 0.5
F8W1S1 1 0 0 0 1 0 0 0 1 0 0 0
Q9H361 2 0 0 0 0 0 0 2 1 0 0 1
A0A0A0MRG9 0 0 0 1 2 0 0 3 1 0 0 2
A6PVX3 1 1 0 1 1 0 0 0 1 0.5 0 0.5
Q9NQ29 2 0 0 0 0 0 0 0 1 0 0 0
O14929 2 0 0 0 0 0 0 0 1 0 0 0
P62304 2 0 0 0 0 0 0 0 1 0 0 0
Q92572 2 0 0 0 0 0 0 0 1 0 0 0
Q9Y3F4 2 0 0 0 0 0 0 0 1 0 0 0
P81605 1 2 0 1 0 0 0 4 0.5 1 0 2.5
Q9Y657 1 2 0 1 0 0 0 0 0.5 1 0 0.5
Q15751 0 0 0 1 1 0 0 0 0.5 0 0 0.5
A0A087X0G5 1 0 0 0 0 2 0 0 0.5 1 0 0
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H0Y614 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
Q5D862 1 0 0 0 0 1 0 1 0.5 0.5 0 0.5
Q9UP83 1 1 0 1 0 0 0 0 0.5 0.5 0 0.5
A0A1B0GU80 0 0 0 1 1 1 0 0 0.5 0.5 0 0.5
M0R132 0 0 0 0 1 1 0 1 0.5 0.5 0 0.5
Q562F6 0 1 0 0 1 1 0 0 0.5 1 0 0
Q9Y5H6 0 0 0 0 1 0 0 2 0.5 0 0 1
E7EX17 1 1 0 0 0 0 0 0 0.5 0.5 0 0
E9PL10 1 1 0 0 0 0 0 0 0.5 0.5 0 0
H3BQH3 1 1 0 0 0 0 0 0 0.5 0.5 0 0
O95398-2 1 0 0 1 0 0 0 0 0.5 0 0 0.5
P49643 1 0 0 1 0 0 0 0 0.5 0 0 0.5
P49915 1 1 0 0 0 0 0 0 0.5 0.5 0 0
Q8NFC6 1 1 0 0 0 0 0 0 0.5 0.5 0 0
H3BSW0 0 0 0 0 1 0 0 1 0.5 0 0 0.5
Q99459 0 0 0 0 1 1 0 0 0.5 0.5 0 0
Q9P2P6 0 0 0 1 1 0 0 0 0.5 0 0 0.5
Q9UPU7 0 0 0 0 1 0 0 1 0.5 0 0 0.5
A0A0X1KG71 1 0 0 0 0 0 0 0 0.5 0 0 0
A8MT37 1 0 0 0 0 0 0 0 0.5 0 0 0
A8MTY9 1 0 0 0 0 0 0 0 0.5 0 0 0
B4DKY1 1 0 0 0 0 0 0 0 0.5 0 0 0
C9J5P6 1 0 0 0 0 0 0 0 0.5 0 0 0
E5RI99 1 0 0 0 0 0 0 0 0.5 0 0 0
E9PAV3 1 0 0 0 0 0 0 0 0.5 0 0 0
E9PHS0 1 0 0 0 0 0 0 0 0.5 0 0 0
F8W810 1 0 0 0 0 0 0 0 0.5 0 0 0
G3V3M6 1 0 0 0 0 0 0 0 0.5 0 0 0
G3V4W4 1 0 0 0 0 0 0 0 0.5 0 0 0
H0Y4E5 1 0 0 0 0 0 0 0 0.5 0 0 0
J3KNE3 1 0 0 0 0 0 0 0 0.5 0 0 0
O43172 1 0 0 0 0 0 0 0 0.5 0 0 0
P03891 1 0 0 0 0 0 0 0 0.5 0 0 0
P14923 1 0 0 0 0 0 0 0 0.5 0 0 0
Q09161 1 0 0 0 0 0 0 0 0.5 0 0 0
Q12874 1 0 0 0 0 0 0 0 0.5 0 0 0
Q15645 1 0 0 0 0 0 0 0 0.5 0 0 0
Q5SYB0-2 1 0 0 0 0 0 0 0 0.5 0 0 0
Q86U90 1 0 0 0 0 0 0 0 0.5 0 0 0
Q8N8D9 1 0 0 0 0 0 0 0 0.5 0 0 0
Q8N8L2 1 0 0 0 0 0 0 0 0.5 0 0 0
Q96GM8 1 0 0 0 0 0 0 0 0.5 0 0 0
Q9HB03 1 0 0 0 0 0 0 0 0.5 0 0 0
B2RPK0 0 0 0 0 1 0 0 0 0.5 0 0 0
B5ME19 0 0 0 0 1 0 0 0 0.5 0 0 0
E7ERC4 0 0 0 0 1 0 0 0 0.5 0 0 0
F8VQQ8 0 0 0 0 1 0 0 0 0.5 0 0 0
K7EKB9 0 0 0 0 1 0 0 0 0.5 0 0 0
O43379-2 0 0 0 0 1 0 0 0 0.5 0 0 0
O75934 0 0 0 0 1 0 0 0 0.5 0 0 0
P05412 0 0 0 0 1 0 0 0 0.5 0 0 0
P26678 0 0 0 0 1 0 0 0 0.5 0 0 0
P48751 0 0 0 0 1 0 0 0 0.5 0 0 0
P54296 0 0 0 0 1 0 0 0 0.5 0 0 0
Q7Z7K2 0 0 0 0 1 0 0 0 0.5 0 0 0
Q96HQ2 0 0 0 0 1 0 0 0 0.5 0 0 0
Q96NY8 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9NS62 0 0 0 0 1 0 0 0 0.5 0 0 0
Q9UJX2 0 0 0 0 1 0 0 0 0.5 0 0 0
Q05639 0 0 0 1 0 0 0 0 0 0 0 0.5
C9JUM1 0 0 0 1 0 0 0 0 0 0 0 0.5
Q8TEB1 0 9 0 4 0 0 0 0 0 4.5 0 2
A0A087WX41 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A087WUW9 0 0 0 3 0 0 0 0 0 0 0 1.5
P30048 0 1 0 2 0 0 0 0 0 0.5 0 1
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P54687 0 0 0 3 0 0 0 0 0 0 0 1.5
A0A087WWM6 0 2 0 0 0 0 0 0 0 1 0 0
C9J8P9 0 1 0 1 0 0 0 0 0 0.5 0 0.5
G3V3W4 0 1 0 1 0 0 0 0 0 0.5 0 0.5
H3BUZ6 0 1 0 1 0 0 0 0 0 0.5 0 0.5
K7ELC7 0 1 0 1 0 0 0 0 0 0.5 0 0.5
N0DVX5 0 1 0 1 0 0 0 0 0 0.5 0 0.5
O60884 0 0 0 2 0 0 0 0 0 0 0 1
Q5SY68 0 1 0 1 0 0 0 0 0 0.5 0 0.5
Q9Y3E2 0 0 0 2 0 0 0 0 0 0 0 1
Q9Y678 0 1 0 1 0 0 0 0 0 0.5 0 0.5
A0A087WTN8 0 1 0 0 0 0 0 0 0 0.5 0 0
A0A087WUB1 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A087WYC6 0 0 0 0 0 0 0 1 0 0 0 0.5
A0A087WYD6 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0A0MRV0 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0A0MSS2 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0A0MTS7 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0B4J1R5 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0B4J1X7 0 1 0 0 0 0 0 0 0 0.5 0 0
A0A0C4DFX2 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0C4DG21 0 0 0 0 0 0 0 1 0 0 0 0.5
A0A0C4DGF8 0 0 0 0 0 0 0 1 0 0 0 0.5
A0A0D9SFZ1 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A0G2JMX7 0 0 0 1 0 0 0 0 0 0 0 0.5
A0A0U1RRB6 0 0 0 0 0 1 0 0 0 0.5 0 0
A0A1B0GWD6 0 1 0 0 0 0 0 0 0 0.5 0 0
A1XBS5 0 0 0 0 0 0 0 1 0 0 0 0.5
A6NER6 0 0 0 1 0 0 0 0 0 0 0 0.5
B1AH59 0 0 0 0 0 0 0 1 0 0 0 0.5
B1AKR6 0 0 0 1 0 0 0 0 0 0 0 0.5
B1AQK6 0 1 0 0 0 0 0 0 0 0.5 0 0
B7Z4B8 0 0 0 0 0 0 0 1 0 0 0 0.5
B7Z4C8 0 0 0 0 0 0 0 1 0 0 0 0.5
C9J4I9 0 1 0 0 0 0 0 0 0 0.5 0 0
C9JK86 0 0 0 0 0 0 0 1 0 0 0 0.5
E9PC47 0 0 0 0 0 1 0 0 0 0.5 0 0
E9PM04 0 0 0 1 0 0 0 0 0 0 0 0.5
E9PMG9 0 1 0 0 0 0 0 0 0 0.5 0 0
E9PRF2 0 0 0 0 0 1 0 0 0 0.5 0 0
F8VVT9 0 0 0 1 0 0 0 0 0 0 0 0.5
F8W9P2 0 0 0 0 0 0 0 1 0 0 0 0.5
G5E9M4 0 0 0 1 0 0 0 0 0 0 0 0.5
H3BNW8 0 0 0 0 0 0 0 1 0 0 0 0.5
H7BZ54 0 0 0 1 0 0 0 0 0 0 0 0.5
H7C346 0 0 0 1 0 0 0 0 0 0 0 0.5
H7C5S0 0 0 0 1 0 0 0 0 0 0 0 0.5
H9KV93 0 0 0 0 0 1 0 0 0 0.5 0 0
I3L1D5 0 0 0 1 0 0 0 0 0 0 0 0.5
J3KNW5 0 0 0 0 0 0 0 1 0 0 0 0.5
K7EIK4 0 0 0 0 0 0 0 1 0 0 0 0.5
O14514 0 0 0 1 0 0 0 0 0 0 0 0.5
O15212 0 0 0 1 0 0 0 0 0 0 0 0.5
O60522 0 1 0 0 0 0 0 0 0 0.5 0 0
O60551 0 0 0 0 0 1 0 0 0 0.5 0 0
O75592 0 0 0 0 0 1 0 0 0 0.5 0 0
O95278 0 1 0 0 0 0 0 0 0 0.5 0 0
P01037 0 1 0 0 0 0 0 0 0 0.5 0 0
P01570 0 0 0 1 0 0 0 0 0 0 0 0.5
P05386 0 0 0 1 0 0 0 0 0 0 0 0.5
P15927 0 1 0 0 0 0 0 0 0 0.5 0 0
P20618 0 1 0 0 0 0 0 0 0 0.5 0 0
P21399 0 0 0 1 0 0 0 0 0 0 0 0.5
P41212 0 0 0 1 0 0 0 0 0 0 0 0.5
P55884 0 1 0 0 0 0 0 0 0 0.5 0 0
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Q15056 0 1 0 0 0 0 0 0 0 0.5 0 0
Q3KQV3 0 0 0 0 0 1 0 0 0 0.5 0 0
Q4J6C6 0 1 0 0 0 0 0 0 0 0.5 0 0
Q502W7 0 1 0 0 0 0 0 0 0 0.5 0 0
Q5TB80 0 0 0 0 0 1 0 0 0 0.5 0 0
Q5VU13-2 0 1 0 0 0 0 0 0 0 0.5 0 0
Q5VUC0 0 0 0 0 0 0 0 1 0 0 0 0.5
Q5VYS8 0 0 0 0 0 0 0 1 0 0 0 0.5
Q6NSW5 0 0 0 0 0 0 0 1 0 0 0 0.5
Q6P0N0 0 1 0 0 0 0 0 0 0 0.5 0 0
Q6WRI0 0 0 0 0 0 0 0 1 0 0 0 0.5
Q7L0X2 0 0 0 0 0 1 0 0 0 0.5 0 0
Q8IWV7 0 1 0 0 0 0 0 0 0 0.5 0 0
Q8TB03 0 0 0 1 0 0 0 0 0 0 0 0.5
Q92674 0 1 0 0 0 0 0 0 0 0.5 0 0
Q96BQ3 0 1 0 0 0 0 0 0 0 0.5 0 0
Q96N38-2 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9BPW9 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9BRF8 0 0 0 1 0 0 0 0 0 0 0 0.5
Q9BU76 0 0 0 0 0 1 0 0 0 0.5 0 0
Q9NP61 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9NP77 0 1 0 0 0 0 0 0 0 0.5 0 0
Q9NTX9 0 0 0 0 0 0 0 1 0 0 0 0.5
Q9Y219 0 0 0 0 0 1 0 0 0 0.5 0 0














































Eukaryotic translation initiation factor 4E-bindin        2264 2405 2220 2584
sp TRYP_PIG 204 214 224 299
Keratin, type II cytoskeletal 1 OS=Homo sapiens   44 30 169 40
Keratin, type I cytoskeletal 10 OS=Homo sapien    30 30 136 27
Isoform of P06730, Eukaryotic translation initia        126 147 113 134
Heat shock cognate 71 kDa protein OS=Homo s    136 119 108 88
Keratin, type II cytoskeletal 2 epidermal OS=Ho     18 14 85 11
78 kDa glucose-regulated protein OS=Homo sap    102 97 80 97
General transcription factor II-I OS=Homo sapie    43 50 71 36
Isoform of P0DMV9, Heat shock 70 kDa protein      36 38 48 22
Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 P  53 43 46 37
Tubulin alpha-1B chain OS=Homo sapiens GN=T   29 25 41 32
Tubulin beta chain OS=Homo sapiens GN=TUBB  36 22 39 30
sp PRDX1_HUMAN 39 33 26 42
T-complex protein 1 subunit theta OS=Homo sa    27 24 26 23
T-complex protein 1 subunit alpha OS=Homo sa    23 16 25 14
Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV 12 1 22 3
Elongation factor 2 OS=Homo sapiens GN=EEF2  11 1 17 1
Poly(rC)-binding protein 1 OS=Homo sapiens GN   11 17 16 13
T-complex protein 1 subunit beta OS=Homo sap    14 11 16 5
Keratin, type II cytoskeletal 1b OS=Homo sapien    0 0 16 0
Elongation factor 1-alpha 1 OS=Homo sapiens G   14 8 15 10
sp ALBU_BOVIN 28 71 14 34
Isoform of Q9BY77, Polymerase delta-interactin        8 10 14 10
T-complex protein 1 subunit eta OS=Homo sapi    12 8 14 5
Keratin, type II cytoskeletal 5 OS=Homo sapiens   0 0 14 0
Keratin, type I cytoskeletal 9 OS=Homo sapiens   22 17 13 15
Isoform of Q86V81, THO complex subunit 4 OS=     10 10 13 6
Cytoplasmic dynein 1 heavy chain 1 OS=Homo s    4 6 13 7
DNA-dependent protein kinase catalytic subuni      6 1 13 1
Poly [ADP-ribose] polymerase 1 OS=Homo sapie    6 0 13 0
Keratinocyte proline-rich protein OS=Homo sap    0 0 13 0
Tubulin beta-4B chain OS=Homo sapiens GN=TU   2 0 11 0
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 P  12 10 11 11
Isoform of P48643, T-complex protein 1 subuni       13 11 11 5
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACT   12 6 11 7
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 P  11 6 11 8
T-complex protein 1 subunit zeta OS=Homo sap    12 7 10 4
PSMs
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Serine/threonine-protein phosphatase 2A 65 kD           11 7 10 5
Enhancer of rudimentary homolog OS=Homo sa    10 9 9 10
Isoform of Q9UHX1, Poly(U)-binding-splicing fac        11 12 9 7
Isoform of P13797, Plastin-3 OS=Homo sapiens   8 0 9 0
Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV 3 4 9 0
Keratin, type I cytoskeletal 14 OS=Homo sapien    3 0 8 3
Isoform of P01857, Ig gamma-1 chain C region (      8 6 8 10
Cold-inducible RNA-binding protein OS=Homo s    5 6 8 10
Splicing factor 3B subunit 3 OS=Homo sapiens G   5 4 8 7
Peptidyl-prolyl cis-trans isomerase A OS=Homo    11 3 8 2
Isoform of P12268, Inosine-5_-monophosphate        16 0 8 0
Regulatory-associated protein of mTOR OS=Hom     6 1 8 2
T-complex protein 1 subunit gamma OS=Homo    3 2 8 2
Isoform of P49327, Fatty acid synthase OS=Hom     7 0 8 0
Isoform of P22234, Multifunctional protein ADE       5 1 8 1
Serine/threonine-protein phosphatase 2A catal         6 4 7 6
T-complex protein 1 subunit delta OS=Homo sa    1 2 7 2
Heat shock protein HSP 90-beta OS=Homo sapi    4 1 7 1
Isoform of P63241, Eukaryotic translation initia         3 1 7 2
Serine/threonine-protein phosphatase 2A 55 kD           8 4 6 5
RNA-binding protein 3 OS=Homo sapiens GN=R   6 5 6 6
Isoform of P09651, Heterogeneous nuclear ribo       6 5 6 6
Heterogeneous nuclear ribonucleoprotein R OS     3 0 6 1
Calpain-2 catalytic subunit OS=Homo sapiens G   4 0 6 0
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 1 0 6 3
ATP-citrate synthase OS=Homo sapiens GN=AC   3 0 6 0
Isoform of P05783, Keratin, type I cytoskeletal 1      8 5 5 7
Isoform of Q08499, Isoform 12 of cAMP-specifi       5 7 5 5
Peroxiredoxin-5, mitochondrial OS=Homo sapie    5 3 5 3
Cyclin-dependent kinase 4 OS=Homo sapiens G   4 0 5 2
Isoform of Q14103, Heterogeneous nuclear ribo        3 1 5 2
Crk-like protein OS=Homo sapiens GN=CRKL PE  4 0 5 0
Isoform of Q92598, Heat shock protein 105 kDa     3 0 5 1
Heterogeneous nuclear ribonucleoprotein L OS     3 1 5 0
Non-POU domain-containing octamer-binding p      3 0 5 0
Keratin, type II cytoskeletal 78 OS=Homo sapien    0 0 5 0
Isoform of P05090, Apolipoprotein D (Fragment      0 0 5 0
DNA damage-binding protein 1 OS=Homo sapie    3 3 4 6
Secernin-3 OS=Homo sapiens GN=SCRN3 PE=1 S 5 3 4 3
Eukaryotic translation initiation factor 3 subunit      3 2 4 4
Isoform of P23528, Cofilin-1 OS=Homo sapiens   3 4 4 2
Signal recognition particle 9 kDa protein OS=Ho     4 2 4 2
Heterogeneous nuclear ribonucleoproteins A2/      1 1 4 6
Nucleophosmin OS=Homo sapiens GN=NPM1 P  3 0 4 0
RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=  2 2 4 1
Heterogeneous nuclear ribonucleoprotein F OS     1 0 4 0
Synaptic functional regulator FMR1 OS=Homo s    1 1 4 1
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Histone-arginine methyltransferase CARM1 OS=     1 0 4 0
Isoform of P14618, Pyruvate kinase OS=Homo s    1 0 4 0
Actin, alpha cardiac muscle 1 OS=Homo sapiens   1 0 3 0
Isoform of Q9H3K6, BolA-like protein 2 OS=Hom     7 3 3 3
Histone-binding protein RBBP4 OS=Homo sapie    6 3 3 2
Isoform of Q16576, Histone-binding protein RB      0 0 3 2
sp TRY1_BOVIN 3 3 3 3
Isoform of Q96I15, Selenocysteine lyase OS=Ho     3 2 3 4
Transcription and mRNA export factor ENY2 OS     4 3 3 2
Peptidyl-prolyl cis-trans isomerase B OS=Homo    4 1 3 3
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV 4 0 3 3
Low molecular weight phosphotyrosine protein      3 1 3 2
Heterogeneous nuclear ribonucleoprotein K OS     4 0 3 0
Isoform of P22061, Protein-L-isoaspartate O-me      4 0 3 0
Hypoxanthine-guanine phosphoribosyltransfera      3 0 3 1
Elongation factor 1-gamma OS=Homo sapiens G   1 0 3 1
Isoform of P19484, Transcription factor EB (Fra      1 0 3 1
Isoform of P04406, Glyceraldehyde-3-phosphat       2 0 3 0
Mitogen-activated protein kinase 1 OS=Homo s    0 0 3 2
X-ray repair cross-complementing protein 5 OS=     1 0 3 0
Serpin B12 OS=Homo sapiens GN=SERPINB12 P  0 0 3 0
Specifically androgen-regulated gene protein O     0 0 3 0
Isoform of P25311, Zinc-alpha-2-glycoprotein O     0 0 3 0
Isoform of Q15366, Poly(rC)-binding protein 2 (      0 0 2 0
Pre-mRNA-processing factor 19 OS=Homo sapie    3 3 2 2
PHD finger-like domain-containing protein 5A O     3 2 2 3
Band 3 anion transport protein OS=Homo sapie    4 4 2 0
116 kDa U5 small nuclear ribonucleoprotein co      3 1 2 1
Isoform of P0CG47, Polyubiquitin-B OS=Homo s    1 3 2 3
Isoform of P63162, Small nuclear ribonucleopro         2 1 2 2
14-3-3 protein epsilon OS=Homo sapiens GN=Y   2 1 2 1
Serine/threonine-protein kinase mTOR OS=Hom     3 0 2 0
Eukaryotic translation initiation factor 1A, X-chr      2 1 2 0
Protein S100-A7 OS=Homo sapiens GN=S100A7  1 0 2 2
40S ribosomal protein S28 OS=Homo sapiens G   3 0 2 0
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV= 1 1 2 1
Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 3 0 2 0
Isoform of O15372, Eukaryotic translation initia          2 0 2 1
26S protease regulatory subunit 7 OS=Homo sa    1 0 2 1
Isoform of P27348, 14-3-3 protein theta (Fragm      2 0 2 0
Growth factor receptor-bound protein 2 OS=Ho     2 0 2 0
Isoform of Q99829, Copine-1 OS=Homo sapiens   2 0 2 0
Chromatin target of PRMT1 protein OS=Homo s    0 1 2 1
Isoform of Q99615, DnaJ homolog subfamily C        2 0 2 0
26S protease regulatory subunit 6B OS=Homo s    1 0 2 1
Caspase recruitment domain-containing protein      1 0 2 1
Eukaryotic translation initiation factor 3 subunit      1 1 2 0
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Isoform of Q9UJ70, N-acetyl-D-glucosamine kin      0 0 2 0
Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE  1 0 2 0
Isoform of P52272, Heterogeneous nuclear ribo       1 0 2 0
Macrophage migration inhibitory factor OS=Ho     1 0 2 0
Ribonuclease P protein subunit p38 OS=Homo s    0 1 2 0
Plasminogen activator inhibitor 1 RNA-binding p      1 0 2 0
Isoform of P26599, Polypyrimidine tract-bindin        1 0 2 0
Isoform of Q92841, Probable ATP-dependent R        0 0 2 0
Isoform of P17844, Probable ATP-dependent RN        0 0 2 0
Filaggrin OS=Homo sapiens GN=FLG PE=1 SV=3 0 0 2 0
Asparagine synthetase [glutamine-hydrolyzing]     0 0 2 0
Splicing factor, proline- and glutamine-rich OS=     0 0 2 0
Heterogeneous nuclear ribonucleoprotein A3 O     0 0 2 0
Isoform of P25205, DNA replication licensing fa       0 0 2 0
Caspase-14 OS=Homo sapiens GN=CASP14 PE=  0 0 2 0
Isoform of Q96DR8, Mucin-like protein 1 OS=Ho     0 0 2 0
Isoform of Q13867, Bleomycin hydrolase (Fragm      0 0 2 0
U5 small nuclear ribonucleoprotein 200 kDa he      0 0 2 0
Isoform of P15170, Eukaryotic peptide chain re           0 0 2 0
Tubulin beta-2A chain OS=Homo sapiens GN=TU   0 0 1 0
Keratin, type I cytoskeletal 27 OS=Homo sapien    0 0 1 0
sp EFC4EBP1 2 2 1 4
sp GSTP1_HUMAN 2 3 1 3
Isoform of Q7RTS7, Keratin, type II cytoskeletal      0 0 1 0
Heterogeneous nuclear ribonucleoprotein Q OS     3 1 1 1
Isoform of Q03431, Parathyroid hormone/para          4 3 1 1
Isoform of P31943, Heterogeneous nuclear ribo       5 0 1 0
Isoform of P63173, 60S ribosomal protein L38 (      3 3 1 1
Isoform of P60660, Myosin light polypeptide 6 O     3 1 1 2
Isoform of P63208, S-phase kinase-associated p       4 1 1 0
Isoform of Q15185, Prostaglandin E synthase 3     6 0 1 0
Isoform of P19105, Myosin regulatory light cha       2 2 1 2
Non-histone chromosomal protein HMG-17 OS     3 1 1 1
Isoform of Q15370, Elongin-B OS=Homo sapien    3 0 1 0
Thioredoxin domain-containing protein 5 OS=H     0 1 1 4
Isoform of Q8TAT6, Nuclear protein localization        1 1 1 0
Eukaryotic translation initiation factor 3 subunit      2 1 1 2
Isoform of P42771, Cyclin-dependent kinase inh       3 0 1 1
26S proteasome non-ATPase regulatory subunit      1 1 1 2
Isoform of P84103, Serine/arginine-rich-splicing       1 1 1 2
Isoform of O94952, F-box only protein 21 (Frag      2 0 1 2
Isoform of Q9UKF6, Cleavage and polyadenylat            2 1 1 1
Isoform of P17980, 26S protease regulatory sub       2 0 1 2
Isoform of Q9H0R5, Guanylate binding protein        2 0 1 1
Isoform of Q9H2I8, Leucine-rich repeat-contain        1 1 1 1
Isoform of P20929, Nebulin OS=Homo sapiens G   1 1 1 0
Isoform of Q92945, Far upstream element-bind        2 0 1 0
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BTB/POZ domain-containing protein KCTD12 OS     2 0 1 0
Isoform of Q9UBQ5, Eukaryotic translation initi          1 0 1 1
Isoform of P02724, Glycophorin OS=Homo sapi    0 1 1 1
FRAS1-related extracellular matrix protein 3 OS     0 1 1 1
Replication protein A 70 kDa DNA-binding subu      1 1 1 0
Isoform of P55884, Eukaryotic translation initia           1 0 1 1
Isoform of Q15008, 26S proteasome non-ATPas          1 0 1 1
Histone H2B type 1-K OS=Homo sapiens GN=HI   1 1 1 0
Isoform of P06576, ATP synthase subunit beta,       1 0 1 1
Calcyclin-binding protein OS=Homo sapiens GN   2 0 1 0
Isoform of O00429, Dynamin-1-like protein (Fra      2 0 1 0
Isoform of P04632, Calpain small subunit 1 (Fra      2 0 1 0
Isoform of P06753, Tropomyosin alpha-3 chain     2 0 1 0
Isoform of O95757, Heat shock 70 kDa protein      2 0 1 0
Dynein light chain 1, cytoplasmic OS=Homo sap    1 0 1 0
Trifunctional purine biosynthetic protein adeno      0 0 1 1
Stress-induced-phosphoprotein 1 OS=Homo sap    1 0 1 0
Isoform of Q9NTJ3, Structural maintenance of c       1 0 1 0
Isoform of Q13148, TAR DNA-binding protein 4       0 0 1 1
Immunoglobulin heavy constant gamma 2 OS=H     1 0 1 0
Coatomer subunit beta_ OS=Homo sapiens GN=   1 0 1 0
Isoform of Q6L8Q7, 2_,5_-phosphodiesterase 1      0 0 1 1
Isoform of Q9BYB4, Guanine nucleotide-binding           1 0 1 0
Prefoldin subunit 2 OS=Homo sapiens GN=PFDN   1 0 1 0
Isoform of P05114, Non-histone chromosomal       1 0 1 0
Esterase OVCA2 OS=Homo sapiens GN=OVCA2  0 1 1 0
StAR-related lipid transfer protein 9 OS=Homo s    1 0 1 0
Isoform of Q9Y678, Coatomer subunit gamma-1      0 1 1 0
Small nuclear ribonucleoprotein Sm D3 OS=Hom     0 1 1 0
Isoform of P35080, Profilin OS=Homo sapiens G   1 0 1 0
Isoform of P15880, 40S ribosomal protein S2 OS     1 0 1 0
Isoform of Q9HA64, Ketosamine-3-kinase (Frag      1 0 1 0
Putative annexin A2-like protein OS=Homo sapi    0 0 1 0
sp ANXA5_HUMAN 0 0 1 0
Eukaryotic translation initiation factor 3 subunit       0 0 1 0
Isoform of O00410, Importin-5 (Fragment) OS=     0 0 1 0
Isoform of O95336, 6-phosphogluconolactonas      0 0 1 0
Isoform of O95447, Lebercilin-like protein (Frag      0 0 1 0
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=   0 0 1 0
Cystathionine beta-synthase-like protein OS=Ho     0 0 1 0
Isoform of P11940, Polyadenylate-binding prote      0 0 1 0
Prolactin-inducible protein OS=Homo sapiens G   0 0 1 0
Fibrillin-1 OS=Homo sapiens GN=FBN1 PE=1 SV= 0 0 1 0
Histidine ammonia-lyase OS=Homo sapiens GN   0 0 1 0
Isoform of P53992, Protein transport protein Se       0 0 1 0
Isoform of Q14240, Eukaryotic initiation factor      0 0 1 0
Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=  0 0 1 0
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Synaptic vesicular amine transporter OS=Homo    0 0 1 0
Isoform of Q13526, Peptidyl-prolyl cis-trans iso       0 0 1 0
Isoform of Q15436, Protein transport protein S      0 0 1 0
KN motif and ankyrin repeat domain-containing       0 0 1 0
Isoform of Q6DKJ4, Nucleoredoxin OS=Homo sa    0 0 1 0
Isoform of Q6H8Q1, Actin-binding LIM protein 2      0 0 1 0
Suprabasin OS=Homo sapiens GN=SBSN PE=1 SV 0 0 1 0
BRCA1-associated protein OS=Homo sapiens GN   0 0 1 0
DnaJ homolog subfamily C member 10 OS=Hom     0 0 1 0
Isoform of Q8N9I9, Probable E3 ubiquitin-prote         0 0 1 0
Arrestin domain-containing protein 2 OS=Homo    0 0 1 0
Mucin-16 OS=Homo sapiens GN=MUC16 PE=1 S 0 0 1 0
Isoform of Q9Y383, Putative RNA-binding prote        0 0 1 0
Conserved oligomeric Golgi complex subunit 5 O     0 0 1 0
1-phosphatidylinositol 3-phosphate 5-kinase OS     0 0 1 0
Isoform of Q96FF7, Uncharacterized protein MI       0 0 1 0
Isoform of P08493, Isoform 2 of Matrix Gla prot    0 0 1 0
Pre-B-cell leukemia transcription factor 2 OS=H     0 0 1 0
Isoform of P58546, Myotrophin OS=Homo sapie    0 0 1 0
Isoform of P62316, Small nuclear ribonucleopro        0 0 1 0
Eukaryotic translation initiation factor 3 subunit      0 0 1 0
Isoform of Q8TAC2, Josephin-2 (Fragment) OS=     0 0 1 0
Isoform of Q96SN8, CDK5 regulatory subunit-as        0 0 1 0
Splicing factor 3B subunit 5 OS=Homo sapiens G   0 0 1 0
dCTP pyrophosphatase 1 OS=Homo sapiens GN   0 0 1 0
CMP-N-acetylneuraminate-beta-galactosamide       0 0 1 0
Uncharacterized protein OS=Homo sapiens GN=   0 0 1 0
Isoform of Q9H9A5, CCR4-NOT transcription co         0 0 1 0
Isoform of P26368, Splicing factor U2AF 65 kDa       0 0 1 0
Isoform of Q86YA3, HCG21296, isoform CRA_a     0 0 1 0
Isoform of O15197, Ephrin type-B receptor 6 OS     0 0 1 0
Isoform of Q6MZP7, Isoform 2 of Protein lin-54    0 0 1 0
Isoform of Q8NA56, Tetratricopeptide repeat p       0 0 1 0
Ubiquitin carboxyl-terminal hydrolase 40 OS=Ho     0 0 1 0
ADM2 OS=Homo sapiens GN=ADM2 PE=2 SV=1 0 0 1 0
Isoform of Q8TB05, UBA-like domain-containing       0 0 1 0
Isoform of P55209, Nucleosome assembly prote        0 0 1 0
60S ribosomal protein L11 OS=Homo sapiens G   0 0 1 0
Claudin-8 OS=Homo sapiens GN=CLDN8 PE=1 SV 0 0 1 0
E3 ubiquitin-protein ligase UBR3 OS=Homo sap    0 0 1 0
Isoform of Q9NZI2, Kv channel-interacting prote       0 0 1 0
Retinoblastoma-like protein 2 OS=Homo sapien    0 0 1 0
Paraneoplastic antigen-like protein 5 OS=Homo    0 0 1 0
Isoform of Q9UFE4, Coiled-coil domain-contain         0 0 1 0
Zinc finger protein 648 OS=Homo sapiens GN=Z   0 0 1 0
Isoform of Q9GZM8, Nuclear distribution prote        0 0 1 0
Isoform of Q9BXK5, Bcl-2-like protein 13 OS=Ho     0 0 1 0
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Titin OS=Homo sapiens GN=TTN PE=1 SV=1 0 0 1 0
Protein pelota homolog OS=Homo sapiens GN=   0 0 1 0
Isoform of Q9NPH5, NADPH oxidase 4 OS=Hom     0 0 1 0
Isoform of Q6P4R8, Nuclear factor-related to ka        0 0 1 0
Isoform of P53602, Diphosphomevalonate deca       0 0 1 0
Isoform of O75821, Eukaryotic translation initia           0 0 1 0
Isoform of Q13509, HCG1983504, isoform CRA_      0 0 0 1
Immunoglobulin kappa variable 2D-29 OS=Hom     6 4 0 3
Isoform of Q7Z4L5, Tetratricopeptide repeat pr        0 4 0 1
Heat shock protein HSP 90-alpha OS=Homo sap    4 0 0 1
Isoform of Q8N1B3, Cyclin-related protein FAM      0 2 0 2
Isoform of M0R082, Uncharacterized protein O    3 4 0 0
Isoform of Q9BUL8, Programmed cell death 10,       1 1 0 1
Isoform of Q96N23, Cilia- and flagella-associate         0 0 0 3
Isoform of P24941, Cyclin-dependent kinase 2 O     1 0 0 0
Serine/threonine-protein kinase MAK OS=Homo    0 2 0 0
Isoform of P33316, Deoxyuridine 5_-triphospha        1 3 0 1
Isoform of Q99460, 26S proteasome non-ATPas         2 1 0 2
Isoform of P08670, Vimentin (Fragment) OS=Ho     1 2 0 1
Dynactin subunit 2 OS=Homo sapiens GN=DCTN   3 1 0 0
Isoform of P36941, Tumor necrosis factor recep         1 1 0 0
Peptidyl-prolyl cis-trans isomerase OS=Homo sa    1 0 0 0
Solute carrier family 2, facilitated glucose trans        1 2 0 0
Pre-mRNA-processing-splicing factor 8 OS=Hom     1 1 0 1
Protein arginine N-methyltransferase 5 OS=Hom     2 0 0 1
26S proteasome non-ATPase regulatory subunit      2 1 0 0
Probable maltase-glucoamylase 2 OS=Homo sa    0 0 0 3
Isoform of Q92839, Hyaluronan synthase 1 OS=     2 1 0 0
Creatine kinase B-type OS=Homo sapiens GN=C   3 0 0 0
26S protease regulatory subunit 8 OS=Homo sa    1 0 0 1
Cytoplasmic dynein 1 intermediate chain 2 OS=     1 1 0 0
Bifunctional glutamate/proline--tRNA ligase OS     0 1 0 1
Isoform of P27708, CAD protein (Fragment) OS=     1 0 0 1
Isoform of Q8N3X6, Ligand-dependent nuclear        0 1 0 1
26S proteasome non-ATPase regulatory subunit      1 0 0 1
Isoform of P00441, Superoxide dismutase [Cu-Z      2 0 0 0
Isoform of A0A0U1RRH7, Histone H2A OS=Hom     0 1 0 1
Isoform of P62333, 26S protease regulatory sub       0 0 0 2
Interleukin enhancer-binding factor 3 OS=Homo    1 0 0 1
Isoform of Q3ZCQ8, Isoform 2 of Mitochondrial         0 0 0 2
Isoform of Q9HCF6, TRPM3 protein OS=Homo s    0 0 0 2
DNA-directed RNA polymerases I, II, and III subu       1 1 0 0
Fer-1-like protein 6 OS=Homo sapiens GN=FER1   1 0 0 1
Heat shock 70 kDa protein 4 OS=Homo sapiens   2 0 0 0
U11/U12 small nuclear ribonucleoprotein 35 kD       1 1 0 0
Isoform of Q5JVF3, Isoform 4 of PCI domain-con      2 0 0 0
Isoform of O60232, Sjoegren syndrome/sclerod        1 1 0 0
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Isoform of Q96MR6, Cilia- and flagella-associate        0 2 0 0
Isoform of P61247, 40S ribosomal protein S3a (      1 1 0 0
Transmembrane protein 239 OS=Homo sapiens   1 1 0 0
Isoform of Q8WZA1, Protein O-linked-mannose       0 2 0 0
Isoform of P51991, Heterogeneous nuclear ribo        1 0 0 0
Phosphoribosylformylglycinamidine synthase O     2 0 0 0
Sphingosine-1-phosphate lyase 1 OS=Homo sap    1 0 0 1
26S proteasome non-ATPase regulatory subunit      2 0 0 0
sp CAS1_BOVIN 0 0 0 1
sp K2M2_SHEEP 0 0 0 1
Laminin subunit alpha-5 OS=Homo sapiens GN=   0 1 0 0
Isoform of O15294, UDP-N-acetylglucosamine--           0 0 0 1
Endonuclease domain-containing 1 protein OS=     0 1 0 0
Isoform of O95819, Mitogen-activated protein          0 0 0 1
Aspartate aminotransferase, mitochondrial OS=     0 0 0 1
Protein S100-A8 OS=Homo sapiens GN=S100A8  0 0 0 1
Phosphoglycerate mutase 2 OS=Homo sapiens   1 0 0 0
Isoform of P18754, Regulator of chromosome c       1 0 0 0
Isoform of P24394, Interleukin-4 receptor subu        0 1 0 0
Isoform of P31995, Low affinity immunoglobuli           0 1 0 0
Glycerol kinase OS=Homo sapiens GN=GK PE=1 0 1 0 0
Isoform of P35244, Replication protein A 14 kD       0 1 0 0
Isoform of P35637, RNA-binding protein FUS OS     0 1 0 0
Isoform of P45984, Mitogen-activated protein k      0 1 0 0
Isoform of P47756, Capping protein (Actin filam           1 0 0 0
Vacuolar protein sorting-associated protein 41      0 0 0 1
Coatomer subunit beta OS=Homo sapiens GN=C   0 1 0 0
LIM domain kinase 2 OS=Homo sapiens GN=LIM   0 0 0 1
Uncharacterized protein (Fragment) OS=Homo   1 0 0 0
Isoform of P60981, Destrin OS=Homo sapiens G   1 0 0 0
Isoform of P62888, 60S ribosomal protein L30 O     1 0 0 0
Isoform of Q00978, Interferon regulatory facto       0 1 0 0
ATP-dependent 6-phosphofructokinase, platele       0 0 0 1
Isoform of Q12768, WASH complex subunit 5 O     0 0 0 1
Isoform of Q12769, Nuclear pore complex prote        0 0 0 1
26S proteasome non-ATPase regulatory subunit      0 0 0 1
Isoform of Q13459, Unconventional myosin-IXb     0 1 0 0
Protein Tob2 OS=Homo sapiens GN=TOB2 PE=1 0 1 0 0
Unhealthy ribosome biogenesis protein 2 homo      0 0 0 1
Calponin-3 OS=Homo sapiens GN=CNN3 PE=1 S 1 0 0 0
ELAV-like protein 1 OS=Homo sapiens GN=ELAV   1 0 0 0
Zinc finger protein 425 OS=Homo sapiens GN=Z   0 0 0 1
PDZ domain-containing RING finger protein 4 O     1 0 0 0
Zinc finger protein 467 OS=Homo sapiens GN=Z   0 1 0 0
Isoform of Q86XX4, Extracellular matrix protein       1 0 0 0
Hornerin OS=Homo sapiens GN=HRNR PE=1 SV= 0 0 0 1
Isoform of Q8IXL7, Methionine-R-sulfoxide redu        0 1 0 0
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pre-rRNA processing protein FTSJ3 OS=Homo sa    1 0 0 0
Uncharacterized protein C17orf53 OS=Homo sa    1 0 0 0
Isoform of Q8N5X7, Eukaryotic translation initia           1 0 0 0
Olfactory receptor 52E4 OS=Homo sapiens GN=   0 0 0 1
AP-3 complex subunit sigma-1 OS=Homo sapien    1 0 0 0
Isoform of Q92608, Dedicator of cytokinesis pro       0 0 0 1
Isoform of Q92736, Ryanodine receptor 2 OS=H     0 1 0 0
Glomulin OS=Homo sapiens GN=GLMN PE=1 SV 1 0 0 0
Isoform of Q93009, Ubiquitin carboxyl-termina        1 0 0 0
Isoform of Q96G01, BICD1 protein OS=Homo sa    1 0 0 0
Isoform of Q96K80, Zinc finger CCCH domain-co         0 1 0 0
Probable G-protein coupled receptor 101 OS=H     0 0 0 1
Isoform of Q99497, Protein deglycase DJ-1 OS=     1 0 0 0
Membrane-associated phosphatidylinositol tran        0 0 0 1
Isoform of Q9UBW7, Zinc finger MYM-type pro        0 1 0 0
Isoform of Q9UI30, Multifunctional methyltrans         1 0 0 0
Isoform of Q9UKV5, E3 ubiquitin-protein ligase       0 0 0 1
Isoform of Q9UL40, Zinc finger protein 346 OS=     1 0 0 0
Isoform of Q9UPR5, Sodium/calcium exchanger      1 0 0 0
Carbohydrate sulfotransferase 2 OS=Homo sap    1 0 0 0
FACT complex subunit SPT16 OS=Homo sapiens   1 0 0 0
CD2-associated protein OS=Homo sapiens GN=C   0 0 0 1
Uncharacterized protein OS=Homo sapiens PE=  1 0 0 0
Sjoegren syndrome nuclear autoantigen 1 OS=H     1 0 0 0
Isoform of Q9ULX6, A-kinase anchor protein 8-l       1 0 0 0
Isoform of O15519, CASP8 and FADD-like apopt        0 1 0 0
Putative small nuclear ribonucleoprotein G-like       1 0 0 0
Isoform of O60610, Protein diaphanous homolo       0 1 0 0
Low-density lipoprotein receptor-related prote       1 0 0 0
Solute carrier family 22 member 3 OS=Homo sa    0 0 0 1
Isoform of P07203, Glutathione peroxidase OS=     0 0 0 1
TFIIH basal transcription factor complex helicas        0 1 0 0
Isoform of P41252, Isoleucine--tRNA ligase, cyto      1 0 0 0
Arfaptin-1 OS=Homo sapiens GN=ARFIP1 PE=1 S 0 1 0 0
Isoform of Q02297, Isoform 10 of Pro-neuregul      1 0 0 0
Isoform of Q58DX5, Isoform 2 of Inactive N-ace        0 0 0 1
Osteoclast stimulatory transmembrane protein     1 0 0 0
Zinc finger protein 407 OS=Homo sapiens GN=Z   1 0 0 0
Protocadherin-18 OS=Homo sapiens GN=PCDH1   1 0 0 0
Isoform of Q8NBL1, Protein O-glucosyltransfera       1 0 0 0
Isoform of Q8N2M8, CLK4-associating serine/ar       0 0 0 1
Isoform of P23381, Tryptophan--tRNA ligase, cy       0 0 0 1
Isoform of P12110, Collagen alpha-2(VI) chain (      1 0 0 0
KN motif and ankyrin repeat domain-containing       0 0 0 1
Isoform of Q5U5Z8, Cytosolic carboxypeptidase      0 0 0 1
Immunoglobulin superfamily member 2 OS=Ho     1 0 0 0
Isoform of Q9P267, Methyl-CpG-binding domai        1 0 0 0
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Isoform of Q6ZRI0, Isoform 2 of Otogelin OS=Ho   1 0 0 0
Peroxidasin-like protein OS=Homo sapiens GN=   1 0 0 0
Isoform of P38159, RNA-binding motif protein,        0 1 0 0
Isoform of Q00532, Cyclin-dependent kinase-lik       0 0 0 1
Isoform of Q92599, Septin-8 OS=Homo sapiens   1 0 0 0
Isoform of Q86YC2, Partner and localizer of BRC      0 0 0 1
Protein bicaudal D homolog 2 OS=Homo sapien    0 0 0 1
Isoform of Q6ZPD9, Probable C-mannosyltransf        1 0 0 0
Isoform of Q9NQ69, LIM/homeobox protein Lh      0 0 0 1
Receptor-transporting protein 1 OS=Homo sapi    0 0 0 1
Zinc finger protein 468 OS=Homo sapiens GN=Z   1 0 0 0
Isoform of Q8WVK7, Spindle and kinetochore-a        1 0 0 0
Sorting nexin-9 OS=Homo sapiens GN=SNX9 PE  1 0 0 0
Zinc finger protein 491 OS=Homo sapiens GN=Z   0 0 0 1
Isoform of P13725, Oncostatin-M OS=Homo sap    0 1 0 0
Transcription factor SOX-11 OS=Homo sapiens G   0 1 0 0
Isoform of P47755, F-actin-capping protein sub       1 0 0 0
40S ribosomal protein S25 OS=Homo sapiens G   1 0 0 0
Isoform of Q99426, Tubulin-folding cofactor B O     1 0 0 0
Isoform of P20290, Transcription factor BTF3 (F      0 0 0 1
Isoform of P32929, Isoform 2 of Cystathionine g    1 0 0 0
Nuclear pore complex protein Nup107 OS=Hom     0 0 0 1
Solute carrier family 22 member 12 OS=Homo s    0 0 0 1
DNA replication factor Cdt1 OS=Homo sapiens G   1 0 0 0
Thyroid transcription factor 1-associated protei       0 1 0 0
Protein sel-1 homolog 1 OS=Homo sapiens GN=   0 0 0 1
Dual oxidase 1 OS=Homo sapiens GN=DUOX1 P  0 1 0 0
B-cell lymphoma/leukemia 11A OS=Homo sapie    1 0 0 0
E3 ubiquitin-protein ligase TRIM71 OS=Homo sa    1 0 0 0
Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 S 1 0 0 0
Acetylcholine receptor subunit delta OS=Homo    0 1 0 0
2_-5_-oligoadenylate synthase-like protein OS=     1 0 0 0
Zinc finger and BTB domain-containing protein      0 1 0 0
Isoform of Q9Y4E5, Isoform 3 of E3 SUMO-prot      0 1 0 0
Transmembrane 6 superfamily member 2 OS=H     0 0 0 1
Structural maintenance of chromosomes flexib          0 0 0 1
ATP-binding cassette sub-family C member 9 OS     1 0 0 0
Isoform of P35443, Thrombospondin-4 OS=Hom     1 0 0 0
Isoform of Q96HE7, ERO1-like protein alpha OS     0 0 0 1
Actin-like protein 8 OS=Homo sapiens GN=ACTL   1 0 0 0
Follistatin-related protein 3 OS=Homo sapiens G   1 0 0 0
Nucleolar pre-ribosomal-associated protein 1 O     1 0 0 0
Guanine nucleotide-binding protein subunit alp      0 0 0 1
Isoform of P62158, Calmodulin OS=Homo sapie    0 1 0 0
Ubiquitin-like-conjugating enzyme ATG3 OS=Ho     0 0 0 1
Protein Shroom4 OS=Homo sapiens GN=SHROO   0 0 0 1
Isoform of P60891, Ribose-phosphate pyrophos       1 0 0 0
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Nestin OS=Homo sapiens GN=NES PE=1 SV=2 1 0 0 0
Immunoglobulin superfamily member 10 OS=H     0 0 0 1
Isoform of Q9BYT3, Serine/threonine-protein k       0 0 0 1
Isoform of Q9NVF9, Ethanolamine kinase 2 (Fra      0 1 0 0
Tripeptidyl-peptidase 1 OS=Homo sapiens GN=T   0 1 0 0
Isoform of Q5K651, Sterile alpha motif domain-         1 0 0 0
Isoform of Q8WV37, Zinc finger protein 480 (Fr      0 0 0 1
Isoform of O94916, Isoform A of Nuclear factor       1 0 0 0
Inorganic pyrophosphatase OS=Homo sapiens G   1 0 0 0
Isoform of Q92887, Canalicular multispecific or         1 0 0 0
Isoform of Q14938, Isoform 2 of Nuclear factor     1 0 0 0
Isoform of O75334, Liprin-alpha-2 (Fragment) O     1 0 0 0
Ankyrin repeat domain-containing protein 61 O     1 0 0 0
Isoform of P16112, Aggrecan core protein OS=H     1 0 0 0
Transcription elongation factor A protein 1 OS=     1 0 0 0
Isoform of P35241, Radixin OS=Homo sapiens G   0 1 0 0
Cysteine/serine-rich nuclear protein 1 OS=Hom     0 1 0 0
Isoform of O95180, Voltage-dependent T-type c          0 0 0 1
Myomesin-2 OS=Homo sapiens GN=MYOM2 PE  0 1 0 0
Putative zinc finger protein 840 OS=Homo sapie    0 1 0 0
Isoform of Q674X7, Kazrin OS=Homo sapiens G   1 0 0 0
Elongation factor 1-beta OS=Homo sapiens GN=   1 0 0 0
Heart- and neural crest derivatives-expressed p       0 0 0 1
Calsyntenin-2 OS=Homo sapiens GN=CLSTN2 PE  0 1 0 0
Alpha-mannosidase 2 OS=Homo sapiens GN=M   1 0 0 0
Isoform of O75095, Multiple epidermal growth         0 0 0 1
Isoform of Q8IZF3, Adhesion G protein-coupled       0 1 0 0
Protein bassoon OS=Homo sapiens GN=BSN PE=  0 0 0 1
Isoform of Q8TES7, Fas-binding factor 1 (Fragm      1 0 0 0















































































Q13541 Eukaryotic translation initiation factor 4E-bind        2396 2556 1803 1764
TRYP_PIG sp TRYP_PIG 228 255 255 246
P06730-3 Isoform of P06730, Isoform 3 of Eukaryotic tr       64 73 92 75
P78347 General transcription factor II-I OS=Homo sap    61 55 75 56
P11142 Heat shock cognate 71 kDa protein OS=Homo    36 13 75 23
ALBU_BOV sp ALBU_BOVIN 33 34 53 47
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=   23 25 46 53
P42345 Serine/threonine-protein kinase mTOR OS=Ho     7 0 45 0
PRDX1_HU sp PRDX1_HUMAN 33 22 44 32
A0A0G2JIWIsoform of P0DMV9, Heat shock 70 kDa prote       26 5 39 14
P52272 Heterogeneous nuclear ribonucleoprotein M     0 0 38 33
K1C10_HUMsp K1C10_HUMAN 16 23 35 22
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapie    12 40 34 34
Q13162 Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4  25 29 31 31
P50990 T-complex protein 1 subunit theta OS=Homo    14 13 29 15
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=   2 1 28 27
P68104 Elongation factor 1-alpha 1 OS=Homo sapiens   6 3 27 10
P78527 DNA-dependent protein kinase catalytic subu      6 0 27 2
P07437 Tubulin beta chain OS=Homo sapiens GN=TUB   21 9 26 21
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapien    21 26 24 23
H0Y4R1 Isoform of P12268, Inosine-5_-monophospha         7 0 24 0
P30153 Serine/threonine-protein phosphatase 2A 65           10 2 23 10
Q71U36 Tubulin alpha-1A chain OS=Homo sapiens GN   0 0 22 0
Q14204 Cytoplasmic dynein 1 heavy chain 1 OS=Homo    15 12 22 13
P17987 T-complex protein 1 subunit alpha OS=Homo    11 9 20 11
K22E_HUMsp K22E_HUMAN 3 13 19 13
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 12 1 17 3
P11021 78 kDa glucose-regulated protein OS=Homo s    10 18 16 12
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=AC   11 6 15 9
Q15393 Splicing factor 3B subunit 3 OS=Homo sapiens   7 8 15 9
Q0VDG4 Secernin-3 OS=Homo sapiens GN=SCRN3 PE=  7 9 14 10
P48643 T-complex protein 1 subunit epsilon OS=Hom     0 5 14 3
F6VRR5 Isoform of Q9BY77, Polymerase delta-interact        19 10 13 15
Q15365 Poly(rC)-binding protein 1 OS=Homo sapiens G   8 7 13 14
P63151 Serine/threonine-protein phosphatase 2A 55           9 3 13 6
P67775 Serine/threonine-protein phosphatase 2A cat         3 4 13 8
P08238 Heat shock protein HSP 90-beta OS=Homo sa    9 1 13 3
Q9Y230 RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE  5 4 13 3
A0A0U1RQ Isoform of P49327, Fatty acid synthase OS=Ho     1 0 13 0
PSMs
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A0A0J9YVPIsoform of Q9UHX1, Poly(U)-binding-splicing f        8 10 12 8
P30041 Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6  7 7 12 4
A0A087WTIsoform of Q92945, Far upstream element-bin        3 0 12 3
Q9NUY8 TBC1 domain family member 23 OS=Homo sa    0 0 12 1
E9PB61 Isoform of Q86V81, THO complex subunit 4 O     13 12 11 11
P40227 T-complex protein 1 subunit zeta OS=Homo s    4 4 11 5
O75190 DnaJ homolog subfamily B member 6 OS=Hom     0 0 11 7
P14866 Heterogeneous nuclear ribonucleoprotein L O     4 0 11 0
P46109 Crk-like protein OS=Homo sapiens GN=CRKL P  3 0 11 0
E9PLK3 Isoform of P55786, Puromycin-sensitive amin      0 0 11 0
F8W6I7 Isoform of P09651, Heterogeneous nuclear ri       10 8 10 5
P62937 Peptidyl-prolyl cis-trans isomerase A OS=Hom     9 5 10 7
Q99832 T-complex protein 1 subunit eta OS=Homo sa    5 1 10 5
P13639 Elongation factor 2 OS=Homo sapiens GN=EEF   6 1 10 1
P32119 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2  2 12 9 7
Q09028 Histone-binding protein RBBP4 OS=Homo sap    6 7 9 8
P84090 Enhancer of rudimentary homolog OS=Homo    6 7 9 6
A0A087WZ Isoform of Q9H3K6, BolA-like protein 2 OS=Ho     3 2 9 5
F5GWF6 Isoform of P78371, T-complex protein 1 subu       6 4 9 5
Q9Y265 RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE  2 0 9 1
B4DUR8 Isoform of P49368, T-complex protein 1 subu       0 0 9 0
P07900 Heat shock protein HSP 90-alpha OS=Homo sa    1 1 7 0
P63173 60S ribosomal protein L38 OS=Homo sapiens   5 4 7 2
Q8N122 Regulatory-associated protein of mTOR OS=H     7 2 7 1
O60506 Heterogeneous nuclear ribonucleoprotein Q O     3 1 7 2
P12956 X-ray repair cross-complementing protein 6 O     1 0 7 1
E9PCY7 Isoform of P31943, Heterogeneous nuclear ri       1 0 7 0
Q9UMS4 Pre-mRNA-processing factor 19 OS=Homo sap    8 9 6 8
P22626 Heterogeneous nuclear ribonucleoproteins A2      10 6 6 0
B4DV12 Isoform of P0CG47, Polyubiquitin-B OS=Homo    6 6 6 4
Q9Y3Y2 Chromatin target of PRMT1 protein OS=Homo    4 6 6 3
A0A0A0MQIsoform of Q96I15, Selenocysteine lyase OS=H     3 2 6 5
H3BLZ8 Isoform of Q92841, Probable ATP-dependent        6 1 6 0
Q13838 Spliceosome RNA helicase DDX39B OS=Homo    0 0 6 6
J3KTA4 Isoform of P17844, Probable ATP-dependent        2 1 6 0
E9PBS1 Isoform of P22234, Multifunctional protein AD       2 0 6 0
P11802 Cyclin-dependent kinase 4 OS=Homo sapiens   1 0 6 0
P62993 Growth factor receptor-bound protein 2 OS=H     1 0 6 0
Q9HA64 Ketosamine-3-kinase OS=Homo sapiens GN=F   1 0 6 0
J3KQ32 Isoform of Q9NTK5, Obg-like ATPase 1 OS=Ho     1 0 6 0
A0A1C7CYXIsoform of Q16555, Dihydropyrimidinase-rela        0 0 6 0
Q9Y3I0 tRNA-splicing ligase RtcB homolog OS=Homo    0 0 6 0
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapie    8 4 5 4
Q14011 Cold-inducible RNA-binding protein OS=Homo    4 5 5 7
TRY1_BOVI sp TRY1_BOVIN 5 4 5 3
D6W5Y5 Isoform of Q14011, Cold inducible RNA bindin         0 0 5 0
Q9NPA8 Transcription and mRNA export factor ENY2 O     5 3 5 6
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A0A0A0MSIsoform of P01857, Ig gamma-1 chain C region      5 3 5 0
Q7RTV0 PHD finger-like domain-containing protein 5A     2 3 5 2
H3BPE7 Isoform of P35637, RNA-binding protein FUS O     1 2 5 3
Q13435 Splicing factor 3B subunit 2 OS=Homo sapiens   2 1 5 3
E9PM69 Isoform of P17980, 26S protease regulatory s       1 2 5 1
P00492 Hypoxanthine-guanine phosphoribosyltransfe      1 1 5 1
P13010 X-ray repair cross-complementing protein 5 O     1 1 5 0
P26641 Elongation factor 1-gamma OS=Homo sapiens   1 0 5 1
A0A0A0MSIsoform of P13797, Plastin-3 OS=Homo sapien    2 0 5 0
P42771 Cyclin-dependent kinase inhibitor 2A OS=Hom     1 0 5 0
Q92598 Heat shock protein 105 kDa OS=Homo sapien    1 0 5 0
P31689 DnaJ homolog subfamily A member 1 OS=Hom     0 0 5 0
O43175 D-3-phosphoglycerate dehydrogenase OS=Ho     0 0 5 0
Q13885 Tubulin beta-2A chain OS=Homo sapiens GN=   0 0 4 0
A0A075B6SImmunoglobulin kappa variable 2D-29 OS=Ho     3 6 4 4
H0Y6E7 Isoform of P38159, RNA-binding motif protein         4 4 4 3
P62857 40S ribosomal protein S28 OS=Homo sapiens   7 1 4 2
P62913 60S ribosomal protein L11 OS=Homo sapiens   4 1 4 3
Q13409-2 Isoform of Q13409, Isoform 2B of Cytoplasmi         3 4 4 0
P50991 T-complex protein 1 subunit delta OS=Homo s    3 1 4 1
GSTP1_HUMsp GSTP1_HUMAN 1 2 4 2
P09874 Poly [ADP-ribose] polymerase 1 OS=Homo sap    5 0 4 0
P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 P  1 1 4 2
E7EMB3 Isoform of P62158, Calmodulin OS=Homo sap    2 1 4 1
P52597 Heterogeneous nuclear ribonucleoprotein F O     1 0 4 0
Q9UJ70 N-acetyl-D-glucosamine kinase OS=Homo sap    1 0 4 0
Q9HB71 Calcyclin-binding protein OS=Homo sapiens G   2 0 4 0
P53396 ATP-citrate synthase OS=Homo sapiens GN=A   1 0 4 0
Q9BVC4 Target of rapamycin complex subunit LST8 OS     1 0 4 0
H3BND8 Isoform of Q93009, Ubiquitin carboxyl-termin         0 0 4 0
O14744 Protein arginine N-methyltransferase 5 OS=Ho     0 0 4 0
Q9BUF5 Tubulin beta-6 chain OS=Homo sapiens GN=T   0 0 3 2
E7EQ64 Isoform of P07477, Trypsin-1 OS=Homo sapie    3 5 3 3
E9PC52 Isoform of Q16576, Histone-binding protein R      0 0 3 1
P98179 RNA-binding protein 3 OS=Homo sapiens GN=   6 4 3 4
P23284 Peptidyl-prolyl cis-trans isomerase B OS=Hom     4 6 3 3
O43390 Heterogeneous nuclear ribonucleoprotein R O     3 1 3 2
Q08499-12 Isoform of Q08499, Isoform 12 of cAMP-spec       4 3 3 3
E9PK25 Isoform of P23528, Cofilin-1 OS=Homo sapien    3 2 3 4
Q99459 Cell division cycle 5-like protein OS=Homo sap    3 4 3 1
P62269 40S ribosomal protein S18 OS=Homo sapiens   3 3 3 1
P09661 U2 small nuclear ribonucleoprotein A_ OS=Ho     0 4 3 2
Q16531 DNA damage-binding protein 1 OS=Homo sap    1 2 3 3
A0A087X2DIsoform of P84103, Serine/arginine-rich-splici        1 3 3 2
Q9Y383 Putative RNA-binding protein Luc7-like 2 OS=H     2 2 3 2
P51991 Heterogeneous nuclear ribonucleoprotein A3     3 1 3 2
C9J4W5 Isoform of Q9GZV4, Eukaryotic translation ini         3 1 3 2
206
J3QLE5 Isoform of P63162, Small nuclear ribonucleop         2 1 3 2
P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV 2 1 3 2
P05204 Non-histone chromosomal protein HMG-17 O     3 1 3 1
Q15029 116 kDa U5 small nuclear ribonucleoprotein c      1 0 3 2
P35998 26S protease regulatory subunit 7 OS=Homo s    1 1 3 2
A0A0A0MRIsoform of Q12905, Interleukin enhancer-bind        1 1 3 2
D6RAF8 Isoform of Q14103, Heterogeneous nuclear ri        2 1 3 1
Q12874 Splicing factor 3A subunit 3 OS=Homo sapiens   2 1 3 1
A0A087WYIsoform of Q15185, Prostaglandin E synthase      3 1 3 0
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Ho     0 1 3 2
O00483 Cytochrome c oxidase subunit NDUFA4 OS=H     0 2 3 1
G3V4N7 Isoform of P12277, Creatine kinase B-type (Fr      0 1 3 1
P28482 Mitogen-activated protein kinase 1 OS=Homo    0 1 3 1
P37802 Transgelin-2 OS=Homo sapiens GN=TAGLN2 P  2 0 3 0
A0A0A0MRIsoform of P22061, Protein-L-isoaspartate O-m      2 0 3 0
O75934 Pre-mRNA-splicing factor SPF27 OS=Homo sap    2 0 3 0
P30044 Peroxiredoxin-5, mitochondrial OS=Homo sap    0 0 3 1
P02765 Alpha-2-HS-glycoprotein OS=Homo sapiens G   0 0 3 1
P31948 Stress-induced-phosphoprotein 1 OS=Homo s    1 0 3 0
E7EUT5 Isoform of P04406, Glyceraldehyde-3-phosph       1 0 3 0
K7EPP7 Isoform of Q99615, DnaJ homolog subfamily C       1 0 3 0
P23280 Carbonic anhydrase 6 OS=Homo sapiens GN=   1 0 3 0
Q16543 Hsp90 co-chaperone Cdc37 OS=Homo sapiens   0 0 3 0
Q13395 Probable methyltransferase TARBP1 OS=Hom     0 0 3 0
ALBU_HUMsp ALBU_HUMAN 0 0 2 0
A0A087WUIsoform of Q8N1B3, Cyclin-related protein FA      2 5 2 4
H7C3G1 Isoform of Q9H8V3, Protein ECT2 (Fragment)     2 2 2 1
O14602 Eukaryotic translation initiation factor 1A, Y-c      3 3 2 2
CAS1_BOVIsp CAS1_BOVIN 2 3 2 2
A0A087WTIsoform of P11940, Polyadenylate-binding pro      4 2 2 1
P01859 Immunoglobulin heavy constant gamma 2 OS     2 2 2 2
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain      3 2 2 1
A0A087WVIsoform of Q00610, Clathrin heavy chain OS=H     1 4 2 0
P62318 Small nuclear ribonucleoprotein Sm D3 OS=Ho     3 1 2 1
A0A087WZ Isoform of O15372, Eukaryotic translation init          0 1 2 3
B7Z6Z4 Isoform of P60660, Myosin light polypeptide 6     2 1 2 1
Q15233 Non-POU domain-containing octamer-binding      3 1 2 0
M0QXL5 Isoform of P22087, rRNA 2_-O-methyltransfe        0 2 2 1
P43686 26S protease regulatory subunit 6B OS=Homo    1 1 2 1
P14174 Macrophage migration inhibitory factor OS=H     2 1 2 0
P11678 Eosinophil peroxidase OS=Homo sapiens GN=   0 0 2 0
P61163 Alpha-centractin OS=Homo sapiens GN=ACTR   1 0 2 1
B5ME19 Eukaryotic translation initiation factor 3 subu        1 1 2 0
A0A087WWIsoform of P21333, Filamin-A OS=Homo sapie    1 0 2 1
J3QRS3 Isoform of P19105, Myosin regulatory light ch       1 1 2 0
Q8NBS9 Thioredoxin domain-containing protein 5 OS=     1 0 2 1
F8W883 Isoform of Q9Y6X6, Unconventional myosin-X      1 1 2 0
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Q12906 Interleukin enhancer-binding factor 3 OS=Hom     1 1 2 0
E9PQ57 Isoform of P78406, mRNA export factor OS=H     2 0 2 0
P31153 S-adenosylmethionine synthase isoform type-      2 0 2 0
P06748 Nucleophosmin OS=Homo sapiens GN=NPM1  2 0 2 0
B0QY89 Isoform of Q9Y262, Eukaryotic translation init          0 0 2 1
B5MCA4 Isoform of P16422, Epithelial cell adhesion mo      0 0 2 1
Q8NBF2 NHL repeat-containing protein 2 OS=Homo sa    0 0 2 1
Q9UHV9 Prefoldin subunit 2 OS=Homo sapiens GN=PFD   0 0 2 1
Q5JZ02 Isoform of Q96S44, TP53-regulating kinase OS     0 0 2 1
P17812 CTP synthase 1 OS=Homo sapiens GN=CTPS1  1 0 2 0
A0A087WWIsoform of P06753, Tropomyosin alpha-3 chai      1 0 2 0
F5H365 Isoform of Q15436, Protein transport protein      1 0 2 0
I3L0J9 Isoform of Q6P2Q9, Pre-mRNA-processing-sp         1 0 2 0
O75643 U5 small nuclear ribonucleoprotein 200 kDa h      1 0 2 0
P13489 Ribonuclease inhibitor OS=Homo sapiens GN=   0 0 2 0
A0A0U1RR Isoform of P26599, Polypyrimidine tract-bind        0 0 2 0
P04080 Cystatin-B OS=Homo sapiens GN=CSTB PE=1 S 0 0 2 0
E5RJR5 Isoform of P63208, S-phase kinase-associated       0 0 2 0
Q13263 Transcription intermediary factor 1-beta OS=H     0 0 2 0
E9PEB5 Isoform of Q96AE4, Far upstream element-bin        0 0 2 0
B1ALA9 Isoform of P60891, Ribose-phosphate pyroph       0 0 2 0
E7EWB4 Isoform of Q9BPU6, Dihydropyrimidinase-rela         0 0 2 0
P23526 Adenosylhomocysteinase OS=Homo sapiens G   0 0 2 0
Q13129 Zinc finger protein Rlf OS=Homo sapiens GN=   0 0 2 0
Q9H773 dCTP pyrophosphatase 1 OS=Homo sapiens G   0 0 2 0
Q92896 Golgi apparatus protein 1 OS=Homo sapiens G   0 0 2 0
Q00839 Heterogeneous nuclear ribonucleoprotein U O     0 0 2 0
Q9NP60 X-linked interleukin-1 receptor accessory prot       0 0 2 0
H0Y8C6 Isoform of O00410, Importin-5 (Fragment) OS     0 0 2 0
G8JLD5 Isoform of O00429, Dynamin-1-like protein O     0 0 2 0
E7EQB9 Isoform of O15160, DNA-directed RNA polym           0 0 2 0
O95373 Importin-7 OS=Homo sapiens GN=IPO7 PE=1 0 0 2 0
P00338 L-lactate dehydrogenase A chain OS=Homo sa    0 0 2 0
P05386 60S acidic ribosomal protein P1 OS=Homo sap    0 0 2 0
H7BZ94 Isoform of P07237, Protein disulfide-isomeras      0 0 2 0
P62714 Serine/threonine-protein phosphatase 2A cat         3 0 1 0
P30154 Serine/threonine-protein phosphatase 2A 65           0 0 1 0
O75190-2 Isoform of O75190, Isoform B of DnaJ homolo        0 0 1 4
EFC4EBP1 sp EFC4EBP1 1 1 1 0
O75909 Cyclin-K OS=Homo sapiens GN=CCNK PE=1 SV 1 4 1 2
P62195 26S protease regulatory subunit 8 OS=Homo s    2 3 1 1
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 S 2 2 1 2
P60228 Eukaryotic translation initiation factor 3 subu       3 1 1 2
P55036 26S proteasome non-ATPase regulatory subu       2 2 1 1
P57081 tRNA (guanine-N(7)-)-methyltransferase non-        2 0 1 1
P62851 40S ribosomal protein S25 OS=Homo sapiens   2 2 1 1
D6RG13 Isoform of P61247, 40S ribosomal protein S3a      1 2 1 1
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Q2TAM9 Tumor suppressor candidate gene 1 protein O     2 1 1 1
A6NFY0 Isoform of Q00013, 55 kDa erythrocyte memb        0 0 1 1
Q13347 Eukaryotic translation initiation factor 3 subu       0 2 1 1
O43660 Pleiotropic regulator 1 OS=Homo sapiens GN=   0 1 1 0
A0A024QZPIsoform of P06493, Cell division cycle 2, G1 to            1 0 1 0
P27694 Replication protein A 70 kDa DNA-binding sub      1 1 1 1
P07814 Bifunctional glutamate/proline--tRNA ligase O     1 0 1 1
A0A0A0MSIsoform of P41252, Isoleucine--tRNA ligase, cy      1 1 1 1
Q16650 T-box brain protein 1 OS=Homo sapiens GN=T   1 1 1 1
A0A1B0GTTIsoform of P08670, Vimentin (Fragment) OS=H     2 1 1 0
P08579 U2 small nuclear ribonucleoprotein B__ OS=H     0 2 1 0
P00519 Tyrosine-protein kinase ABL1 OS=Homo sapie    0 1 1 1
P62258 14-3-3 protein epsilon OS=Homo sapiens GN=   0 0 1 2
A0A087X2I Isoform of P62333, 26S protease regulatory s       0 1 1 1
E5RFI6 Isoform of Q92769, Histone deacetylase 2 (Fr      0 1 1 1
A0A0A0MSIsoform of P51531, Probable global transcript         0 0 1 2
K7ERY7 Isoform of P61353, 60S ribosomal protein L27     1 1 1 0
J3KP15 Isoform of Q01130, Serine/arginine-rich-splici         1 1 1 0
G3V1D4 Isoform of Q9NUP9, Lin-7 homolog C (C. elega        1 0 1 1
J3KRI4 Isoform of O43237, Cytoplasmic dynein 1 ligh          1 1 1 0
H3BSW0 Isoform of Q8N9N7, Leucine-rich repeat-cont         1 1 1 0
Q9NRC6 Spectrin beta chain, non-erythrocytic 5 OS=Ho     1 0 1 1
A0A087WVIsoform of Q9UBQ5, Eukaryotic translation in          1 1 1 0
Q9UKZ4 Teneurin-1 OS=Homo sapiens GN=TENM1 PE=  1 1 1 0
E7EQG2 Isoform of Q14240, Eukaryotic initiation facto       2 0 1 0
A0A087WWIsoform of Q99460, 26S proteasome non-ATP         2 0 1 0
Q9P258 Protein RCC2 OS=Homo sapiens GN=RCC2 PE=  2 0 1 0
C9J381 Isoform of P20839, Inosine-5_-monophospha       0 0 1 0
Q8TBZ5 Zinc finger protein 502 OS=Homo sapiens GN=   0 1 1 0
A8MUF7 Isoform of P02100, Hemoglobin subunit epsilo       0 0 1 1
J3QRY4 Isoform of O00231, 26S proteasome non-ATP          0 0 1 1
O00232 26S proteasome non-ATPase regulatory subu       0 1 1 0
A0A087WZ Isoform of Q03938, Zinc finger protein 90 OS=     0 0 1 1
Q00577 Transcriptional activator protein Pur-alpha OS     0 1 1 0
A0A087WWIsoform of Q06033, Inter-alpha-trypsin inhibit         0 0 1 1
Q13200 26S proteasome non-ATPase regulatory subu       0 0 1 1
H0YCQ8 Isoform of Q7L2H7, Eukaryotic translation init           0 0 1 1
Q96M95 Coiled-coil domain-containing protein 42 OS=     0 0 1 1
K7EJT5 Isoform of P35268, 60S ribosomal protein L22      0 1 1 0
H0Y7R1 Isoform of Q8TBZ2, MYCBP-associated protei       0 1 1 0
Q8WTU2 Scavenger receptor cysteine-rich domain-con         0 0 1 1
F8WA32 Isoform of Q9BZW7, Testis-specific gene 10 p       0 1 1 0
Q12767-2 Isoform of Q12767, Isoform 2 of Transmembr      0 0 1 1
H0YKH9 Isoform of P49641, Alpha-mannosidase 2x (Fr      0 0 1 1
F5GWN5 Isoform of O00750, Phosphatidylinositol 4-ph           0 0 1 1
Q86VD1 MORC family CW-type zinc finger protein 1 OS     0 1 1 0
Q9BYB4 Guanine nucleotide-binding protein subunit b        1 0 1 0
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C9JZD1 Isoform of O15145, Actin-related protein 2/3         1 0 1 0
O43143 Pre-mRNA-splicing factor ATP-dependent RNA       1 0 1 0
B8ZZL3 Isoform of O60573, Eukaryotic translation init          1 0 1 0
A0A0U1RR Isoform of A0A0U1RRH7, Histone H2A OS=Ho     1 0 1 0
P08243 Asparagine synthetase [glutamine-hydrolyzing      1 0 1 0
A0A0B4J1RIsoform of P29401, Transketolase OS=Homo s    1 0 1 0
A0A0D9SETIsoform of P47755, F-actin-capping protein su       1 0 1 0
P61978 Heterogeneous nuclear ribonucleoprotein K O     1 0 1 0
H0YA86 Isoform of A6NEF3, Golgin subfamily A memb          1 0 1 0
Q9Y2V2 Calcium-regulated heat-stable protein 1 OS=H     0 0 1 0
O00165 HCLS1-associated protein X-1 OS=Homo sapie    0 0 1 0
O00170 AH receptor-interacting protein OS=Homo sap    0 0 1 0
O14980 Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 0 0 1 0
O15371 Eukaryotic translation initiation factor 3 subu       0 0 1 0
O75306-2 Isoform of O75306, Isoform 2 of NADH dehyd         0 0 1 0
C9JIZ0 Isoform of O95777, LSM8 homolog, U6 small            0 0 1 0
O95881 Thioredoxin domain-containing protein 12 OS     0 0 1 0
A0A075B71Isoform of P08708, 40S ribosomal protein S17     0 0 1 0
P0DN76 Splicing factor U2AF 35 kDa subunit-like prote      0 0 1 0
P12955 Xaa-Pro dipeptidase OS=Homo sapiens GN=PE   0 0 1 0
B4DNK4 Isoform of P14618, Pyruvate kinase OS=Homo    0 0 1 0
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo    0 0 1 0
P22102 Trifunctional purine biosynthetic protein aden      0 0 1 0
E9PJH4 Isoform of P23396, 40S ribosomal protein S3     0 0 1 0
J3KQ69 Isoform of P25205, DNA replication licensing       0 0 1 0
P25398 40S ribosomal protein S12 OS=Homo sapiens   0 0 1 0
A0A0C4DG Isoform of P33316, DUTP pyrophosphatase, is       0 0 1 0
C9J0J7 Isoform of P35080, Profilin OS=Homo sapiens   0 0 1 0
B5MC59 Isoform of P35244, Replication protein A 14 k       0 0 1 0
P41227 N-alpha-acetyltransferase 10 OS=Homo sapie    0 0 1 0
H3BUM9 Isoform of P41240, Tyrosine-protein kinase CS       0 0 1 0
J3KPM9 Isoform of P42224, Signal transducer and acti        0 0 1 0
P42285 Superkiller viralicidic activity 2-like 2 OS=Hom     0 0 1 0
B1AK85 Isoform of P47756, F-actin-capping protein su       0 0 1 0
B4DXZ6 Isoform of P51114, Fragile X mental retardati         0 0 1 0
A8MU27 Isoform of P55854, Small ubiquitin-related mo       0 0 1 0
P55884 Eukaryotic translation initiation factor 3 subu       0 0 1 0
A0A0U1RQ Uncharacterized protein (Fragment) OS=Hom    0 0 1 0
C9JL85 Isoform of P58546, Myotrophin OS=Homo sap    0 0 1 0
A0A0A6YYGProtein ARPC4-TTLL3 OS=Homo sapiens GN=A   0 0 1 0
D6R9I9 Isoform of P61221, ATP-binding cassette sub-         0 0 1 0
B4DWR3 Isoform of P61758, Prefoldin subunit 3 OS=Ho     0 0 1 0
P62310 U6 snRNA-associated Sm-like protein LSm3 O     0 0 1 0
P62701 40S ribosomal protein S4, X isoform OS=Hom     0 0 1 0
E9PR30 Isoform of P35544, 40S ribosomal protein S30     0 0 1 0
A0A0A0MSIsoform of Q14192, Four and a half LIM doma        0 0 1 0
Q14566 DNA replication licensing factor MCM6 OS=Ho     0 0 1 0
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Q15056 Eukaryotic translation initiation factor 4H OS=     0 0 1 0
Q15717 ELAV-like protein 1 OS=Homo sapiens GN=ELA   0 0 1 0
B5MCZ9 Isoform of Q16769, Glutaminyl-peptide cyclot       0 0 1 0
Q3KQU3 MAP7 domain-containing protein 1 OS=Homo    0 0 1 0
Q52LJ0 Protein FAM98B OS=Homo sapiens GN=FAM9   0 0 1 0
J3QTJ6 Isoform of Q5CZC0, Fibrous sheath-interacting       0 0 1 0
C9JKF1 Isoform of Q5K651, Sterile alpha motif domai         0 0 1 0
B4DEH8 Isoform of Q86U42, Polyadenylate-binding pr       0 0 1 0
K7EQA8 Isoform of Q86X55, Histone-arginine methyltr        0 0 1 0
B1AP52 Isoform of Q8TEW0, Partitioning defective 3 h      0 0 1 0
Q8WXX5 DnaJ homolog subfamily C member 9 OS=Hom     0 0 1 0
A0A087X2GIsoform of Q92499, ATP-dependent RNA helic       0 0 1 0
K7EIN2 Isoform of Q9BRJ7, Protein syndesmos (Fragm      0 0 1 0
Q96M86 Dynein heavy chain domain-containing protei       0 0 1 0
A0A1B0GU Isoform of Q96N23, Cilia- and flagella-associa         0 0 1 0
M0QX71 Isoform of Q9BQ67, Glutamate-rich WD repea         0 0 1 0
Q9BQA1 Methylosome protein 50 OS=Homo sapiens G   0 0 1 0
Q9BYX2 TBC1 domain family member 2A OS=Homo sa    0 0 1 0
E9PJP1 Isoform of Q9H7C9, Mth938 domain-containi       0 0 1 0
F6TLX2 Isoform of Q9HC38, Glyoxalase domain-conta        0 0 1 0
Q9P2Q2 FERM domain-containing protein 4A OS=Hom     0 0 1 0
C9JHK9 Isoform of Q9UG63, ATP-binding cassette sub          0 0 1 0
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohyd       0 0 1 0
H0Y4N6 Isoform of O14786, Neuropilin-1 (Fragment) O     0 0 1 0
K9M1A9 Isoform of K9M1U5, Interferon lambda-4 OS=     0 0 1 0
E7EQB2 Isoform of P02788, Lactotransferrin (Fragmen      0 0 1 0
C9J712 Isoform of P35080, Profilin OS=Homo sapiens   0 0 1 0
O15294 UDP-N-acetylglucosamine--peptide N-acetylg         0 0 1 0
O75348 V-type proton ATPase subunit G 1 OS=Homo s    0 0 1 0
P41250 Glycine--tRNA ligase OS=Homo sapiens GN=G   0 0 1 0
P53350 Serine/threonine-protein kinase PLK1 OS=Hom     0 0 1 0
Q86VV8 Rotatin OS=Homo sapiens GN=RTTN PE=1 SV= 0 0 1 0
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding      0 0 1 0
H0Y339 Isoform of Q8NHY2, E3 ubiquitin-protein ligas        0 0 1 0
P20618 Proteasome subunit beta type-1 OS=Homo sa    0 0 1 0
M0QXK4 Isoform of P39019, 40S ribosomal protein S19      0 0 1 0
A0A0A0MRIsoform of Q8IW50, Protein FAM219A OS=Ho     0 0 1 0
Q9UBB9 Tuftelin-interacting protein 11 OS=Homo sapi    0 0 1 0
F2Z388 Isoform of P42766, 60S ribosomal protein L35     0 0 1 0
Q9BWJ5 Splicing factor 3B subunit 5 OS=Homo sapiens   0 0 1 0
K7EL89 Isoform of P19623, Spermidine synthase (Frag      0 0 1 0
H7BZU1 Isoform of P41091, Eukaryotic translation init           0 0 1 0
Q53F19 Nuclear cap-binding protein subunit 3 OS=Ho     0 0 1 0
Q9GZP4 PITH domain-containing protein 1 OS=Homo s    0 0 1 0
Q9UQE7 Structural maintenance of chromosomes prot       0 0 1 0
E9PKN4 Isoform of O75534, Cold shock domain-conta         0 0 1 0
C9JM43 Isoform of Q6ZSS3, Zinc finger protein 621 (Fr      0 0 1 0
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A0A096LP1Isoform of Q8ND56, Protein LSM14 homolog       0 0 1 0
A8MW50 Isoform of P07195, L-lactate dehydrogenase (      0 0 1 0
Q9P2P6 StAR-related lipid transfer protein 9 OS=Homo    0 0 1 0
A6NMZ7 Collagen alpha-6(VI) chain OS=Homo sapiens   0 0 1 0
B1ALD9 Isoform of Q15063, Periostin OS=Homo sapie    0 0 1 0
H0YCK3 Isoform of P55265, Double-stranded RNA-spe         0 0 1 0
F8WDP8 Isoform of Q8N841, Tubulin polyglutamylase       0 0 1 0
Q8TB03 Uncharacterized protein CXorf38 OS=Homo sa    0 0 1 0
F8VPD4 Isoform of P27708, CAD protein OS=Homo sa    0 0 1 0
O00479 High mobility group nucleosome-binding dom        0 0 1 0
P0DN79 Cystathionine beta-synthase-like protein OS=     0 0 1 0
A0A0C4DG Isoform of Q86VP6, Cullin-associated NEDD8-         0 0 1 0
Q8TE59 A disintegrin and metalloproteinase with thro        0 0 1 0
Q9HAV4 Exportin-5 OS=Homo sapiens GN=XPO5 PE=1 0 0 1 0
Q14674 Separin OS=Homo sapiens GN=ESPL1 PE=1 SV 0 0 1 0
J3KTM9 Isoform of Q14974, Importin subunit beta-1 (      0 0 1 0
A0A087X1NIsoform of P20929, Nebulin OS=Homo sapien    0 0 1 0
D6R9P3 Isoform of Q99729, Heterogeneous nuclear ri       0 0 1 0
C9K0F9 Isoform of Q92794, Histone acetyltransferase      0 0 1 0
O94826 Mitochondrial import receptor subunit TOM7      0 0 1 0
P20023 Complement receptor type 2 OS=Homo sapie    0 0 1 0
E7ENZ3 Isoform of P48643, T-complex protein 1 subu       11 5 0 3
P68032 Actin, alpha cardiac muscle 1 OS=Homo sapie    0 3 0 0
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapie    0 4 0 4
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapi    0 0 0 4
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapie    0 1 0 1
Q6NUN7 Uncharacterized protein C11orf63 OS=Homo    1 1 0 5
A6NIJ5 Putative protein FAM90A20P OS=Homo sapie    3 7 0 0
F8VXH9 Isoform of Q15366, Poly(rC)-binding protein 2      0 0 0 0
Q9NZL6 Ral guanine nucleotide dissociation stimulato       0 0 0 3
Q8NFD2 Ankyrin repeat and protein kinase domain-co        3 0 0 0
F8W1S1 Isoform of Q7RTS7, Keratin, type II cytoskelet       0 1 0 0
O95470 Sphingosine-1-phosphate lyase 1 OS=Homo sa    1 2 0 0
F8W079 Isoform of P06576, ATP synthase subunit beta        1 2 0 2
P23246-2 Isoform of P23246, Isoform Short of Splicing f       3 1 0 0
P54296 Myomesin-2 OS=Homo sapiens GN=MYOM2 P  1 2 0 1
A0A0A0MTIsoform of Q6ZN11, Zinc finger protein 793 OS     1 0 0 1
E9PGM7 Isoform of O94988, Protein FAM13A OS=Hom     0 0 0 3
D6R9A6 Isoform of P26583, High mobility group prote        2 0 0 0
S4R3T0 Isoform of M0R082, Uncharacterized protein    2 0 0 1
Q4ZG55 Protein GREB1 OS=Homo sapiens GN=GREB1  1 2 0 0
A0A0D9SFI Isoform of Q8TAT6, Nuclear protein localizatio         1 2 0 0
Q9UPU7 TBC1 domain family member 2B OS=Homo sa    1 2 0 0
P62191 26S protease regulatory subunit 4 OS=Homo s    0 1 0 0
A0A0D9SF5Isoform of O00571, ATP-dependent RNA helic       0 0 0 1
E5RHG6 Isoform of O75347, Tubulin-specific chaperon       0 1 0 1
H0YBW5 Isoform of Q8WVK2, U4/U6.U5 small nuclear          0 2 0 0
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J3QL71 Isoform of Q96FV2, Secernin-2 OS=Homo sap    0 1 0 1
E9PDH4 Isoform of Q9Y2I7, 1-phosphatidylinositol 3-p        0 1 0 1
O43506 Disintegrin and metalloproteinase domain-co        0 1 0 1
G3V1N2 Isoform of P69905, HCG1745306, isoform CRA      0 0 0 2
G3V198 Isoform of Q12769, Nuclear pore complex pro        0 2 0 0
K7EJS6 Isoform of Q92918, Mitogen-activated protei            0 1 0 1
P63167 Dynein light chain 1, cytoplasmic OS=Homo sa    2 0 0 0
Q9ULD9 Zinc finger protein 608 OS=Homo sapiens GN=   1 1 0 0
D6RFZ2 Isoform of Q0IIM8, TBC1 domain family mem       2 0 0 0
B2RPK0 Putative high mobility group protein B1-like 1     2 0 0 0
A0A087X0QIsoform of Q9BVV2, Fibronectin type III doma         1 0 0 1
C9J808 Isoform of Q9BYG3, MKI67 FHA domain-inter         1 0 0 1
P53803 DNA-directed RNA polymerases I, II, and III su       1 1 0 0
F8WBW2 Isoform of Q9UFE4, Coiled-coil domain-conta        1 1 0 0
Q96HU1 Small G protein signaling modulator 3 OS=Hom     1 0 0 1
K7EN45 Isoform of Q13526, Peptidyl-prolyl cis-trans is       2 0 0 0
A0A0A0MRIsoform of Q96SN8, CDK5 regulatory subunit-        2 0 0 0
E9PFE2 Isoform of Q9UHL9, General transcription fac           1 0 0 1
O60519 cAMP-responsive element-binding protein-lik       0 0 0 1
P11441 Ubiquitin-like protein 4A OS=Homo sapiens G   0 1 0 0
B4DQ67 Isoform of P49590, Probable histidine--tRNA l       0 0 0 1
Q15427 Splicing factor 3B subunit 4 OS=Homo sapiens   0 0 0 1
Q5T280 Putative methyltransferase C9orf114 OS=Hom     0 0 0 1
A0A0D9SG Isoform of Q6P1N9, Putative deoxyribonuclea       0 1 0 0
Q7L1I2 Synaptic vesicle glycoprotein 2B OS=Homo sa    0 1 0 0
Q86U38 Nucleolar protein 9 OS=Homo sapiens GN=NO   0 0 0 1
Q8IVB5 LIX1-like protein OS=Homo sapiens GN=LIX1L  0 1 0 0
H0YD40 Isoform of Q8IZC6, Collagen alpha-1(XXVII) ch       0 0 0 1
C9J5X9 Isoform of Q8NB91, Fanconi anemia group B       0 0 0 1
A0A1B0GX6Isoform of Q969T4, Ubiquitin-conjugating enz         0 0 0 1
F5GWH4 Isoform of Q96EP1, E3 ubiquitin-protein ligase       0 1 0 0
Q9NVP2 Histone chaperone ASF1B OS=Homo sapiens G   0 0 0 1
Q9P109 Beta-1,3-galactosyl-O-glycosyl-glycoprotein b       0 1 0 0
Q9P227 Rho GTPase-activating protein 23 OS=Homo s    0 1 0 0
J3QQJ0 Isoform of Q9UHR5, SAP30-binding protein (F      0 1 0 0
B3KPX4 Isoform of Q9UJ83, 2-hydroxyacyl-CoA lyase 1     0 1 0 0
Q9UKN8 General transcription factor 3C polypeptide 4     0 1 0 0
Q9Y3B4 Splicing factor 3B subunit 6 OS=Homo sapiens   0 1 0 0
F8WDC4 Isoform of Q8NBL1, Protein O-glucosyltransfe       0 0 0 1
Q8N3T6 Transmembrane protein 132C OS=Homo sapi    0 1 0 0
Q96PQ1 Sialic acid-binding Ig-like lectin 12 OS=Homo s    0 0 0 1
Q99543 DnaJ homolog subfamily C member 2 OS=Hom     0 0 0 1
Q9HC44 Vasculin-like protein 1 OS=Homo sapiens GN=   0 0 0 1
Q14344 Guanine nucleotide-binding protein subunit a      0 1 0 0
Q99962 Endophilin-A1 OS=Homo sapiens GN=SH3GL2  0 1 0 0
Q9UKS7-5 Isoform of Q9UKS7, Isoform 5 of Zinc finger p     0 1 0 0
Q9Y5B6 PAX3- and PAX7-binding protein 1 OS=Homo    0 0 0 1
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A0A0B4J25 Isoform of P61626, Lysozyme C OS=Homo sap    0 1 0 0
D6RGK3 Isoform of Q16594, Transcription initiation fa          0 0 0 1
A0A0A0MSIsoform of Q9Y6M7, Anion exchange protein     0 1 0 0
A4D2P6 Delphilin OS=Homo sapiens GN=GRID2IP PE=3 0 1 0 0
K7EPW3 Isoform of P10072, Krueppel-related zinc fing        0 0 0 1
Q9NXL6 SID1 transmembrane family member 1 OS=Ho     0 1 0 0
H7C319 Isoform of Q9UHB7, AF4/FMR2 family membe        0 0 0 1
H3BUU9 Isoform of P55287, Cadherin-11 OS=Homo sa    0 0 0 1
H3BPG7 Isoform of Q6FI81, Anamorsin OS=Homo sapi    0 0 0 1
K7EKB9 Isoform of P15923, Transcription factor E2-alp       0 1 0 0
Q13136 Liprin-alpha-1 OS=Homo sapiens GN=PPFIA1 P  0 0 0 1
O00443 Phosphatidylinositol 4-phosphate 3-kinase C2        0 0 0 1
Q9P2F8 Signal-induced proliferation-associated 1-like       0 1 0 0
G3V295 Isoform of P60900, Proteasome subunit alpha      0 0 0 1
Q5TA15 Isoform of O15056, Synaptojanin-2 (Fragment      0 1 0 0
Q9Y2W2 WW domain-binding protein 11 OS=Homo sap    0 0 0 1
U3KQH8 Isoform of P24310, Cytochrome c oxidase sub        0 1 0 0
O96004 Heart- and neural crest derivatives-expressed       0 1 0 0
Q7RTY3 Serine protease 45 OS=Homo sapiens GN=PRS   0 0 0 1
P11498 Pyruvate carboxylase, mitochondrial OS=Hom     0 1 0 0
H0Y607 Isoform of Q96BN6, Protein FAM149B1 (Fragm      0 1 0 0
A6NNM8 Tubulin polyglutamylase TTLL13P OS=Homo s    0 1 0 0
P25445-7 Isoform of P25445, Isoform 7 of Tumor necro         0 0 0 1
A2VEC9-2 Isoform of A2VEC9, Isoform 2 of SCO-spondin   1 0 0 0
O95400 CD2 antigen cytoplasmic tail-binding protein 2     1 0 0 0
D3YTI2 Isoform of P24666, Low molecular weight pho        1 0 0 0
E9PS50 Isoform of P62277, 40S ribosomal protein S13      1 0 0 0
E9PKU4 Isoform of P62917, 60S ribosomal protein L8      1 0 0 0
D6RER2 Isoform of Q13634, Cadherin-18 OS=Homo sa    1 0 0 0
Q15034 Probable E3 ubiquitin-protein ligase HERC3 O     1 0 0 0
C9IZX4 Isoform of Q6P9H4, Connector enhancer of ki          1 0 0 0
E7ENR6 Isoform of Q8TBG4, Ethanolamine-phosphate      1 0 0 0
A2A304 Isoform of Q96NH3, Protein broad-minded (F      1 0 0 0
Q96QD8 Sodium-coupled neutral amino acid transport       1 0 0 0
Q9BU76 Multiple myeloma tumor-associated protein 2     1 0 0 0
Q9H5V9 UPF0428 protein CXorf56 OS=Homo sapiens G   1 0 0 0
Q9NR30 Nucleolar RNA helicase 2 OS=Homo sapiens G   1 0 0 0
F5GX77 Isoform of Q9UI30, Multifunctional methyltra         1 0 0 0
Q9UKP5 A disintegrin and metalloproteinase with thro        1 0 0 0
Q9Y2S6 Translation machinery-associated protein 7 O     1 0 0 0
A0A182DWZinc finger protein 812, pseudogene OS=Hom     1 0 0 0
E9PJP2 Isoform of Q5TF21, Protein SOGA3 OS=Homo    1 0 0 0
P17655 Calpain-2 catalytic subunit OS=Homo sapiens   1 0 0 0
B5MD17 Isoform of P83916, Chromobox protein homo        1 0 0 0
H0YAE2 Isoform of Q0JRZ9, F-BAR domain only protei        1 0 0 0
Q14938-2 Isoform of Q14938, Isoform 2 of Nuclear facto      1 0 0 0
Q6P3R8 Serine/threonine-protein kinase Nek5 OS=Ho     1 0 0 0
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Q6UXC1 Apical endosomal glycoprotein OS=Homo sap    1 0 0 0
Q70JA7 Chondroitin sulfate synthase 3 OS=Homo sapi    1 0 0 0
P55060 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 1 0 0 0
A0A087WZ Isoform of Q8N162, Olfactory receptor 8H2 O     1 0 0 0
P51571 Translocon-associated protein subunit delta O     1 0 0 0
A0A087WXIsoform of Q06787, Synaptic functional regula       1 0 0 0
Q8WZ82 Esterase OVCA2 OS=Homo sapiens GN=OVCA   1 0 0 0
Q08211 ATP-dependent RNA helicase A OS=Homo sap    1 0 0 0
Q16739 Ceramide glucosyltransferase OS=Homo sapie    1 0 0 0
E7ER45 Isoform of O43451, Maltase-glucoamylase, in      1 0 0 0
A8MXE2 Putative UDP-GlcNAc:betaGal beta-1,3-N-acet      1 0 0 0
P14410 Sucrase-isomaltase, intestinal OS=Homo sapie    1 0 0 0
A0A087WVIsoform of Q8IVF4, Dynein heavy chain 10, ax      1 0 0 0
Q96JW4 Solute carrier family 41 member 2 OS=Homo    1 0 0 0
P09619 Platelet-derived growth factor receptor beta O     1 0 0 0
B1AHC5 Isoform of Q96EK2, PHD finger protein 21B O     1 0 0 0
E7ETF4 Isoform of O60701, UDP-glucose 6-dehydroge       1 0 0 0
Q9H568 Actin-like protein 8 OS=Homo sapiens GN=AC   1 0 0 0
215
